<SEC-DOCUMENT>0001178879-20-000023.txt : 20200507
<SEC-HEADER>0001178879-20-000023.hdr.sgml : 20200507
<ACCEPTANCE-DATETIME>20200507163037
ACCESSION NUMBER:		0001178879-20-000023
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20200331
FILED AS OF DATE:		20200507
DATE AS OF CHANGE:		20200507

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		20856949

	BUSINESS ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		(609) 662-2000

	MAIL ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMICUS THERAPEUTICS INC
		DATE OF NAME CHANGE:	20020729
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>fold-20200331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:d7d83936-4003-4695-9e73-95a98e869b39,g:49308d12-68e9-469e-b9d5-8a5a2cc3db36,d:37a61778173840fc811d567d8624cfac--><html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:fold="http://www.amicustherapeutics.com/20200331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>fold-20200331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180L2ZyYWc6ZTk0NGM4MTVlMThkNDJjOGJhODdlMzAxNmQ5MGJmNDMvdGFibGU6MDEzMzI1MTVmZTg5NGI5NmFhMTk1YzdlZTdiZmVmNjgvdGFibGVyYW5nZTowMTMzMjUxNWZlODk0Yjk2YWExOTVjN2VlN2JmZWY2OF8zLTEtMS0xLTA_54a13a3b-132c-4082-b6d6-6b83663e1231">0001178879</ix:nonNumeric><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180L2ZyYWc6ZTk0NGM4MTVlMThkNDJjOGJhODdlMzAxNmQ5MGJmNDMvdGFibGU6MDEzMzI1MTVmZTg5NGI5NmFhMTk1YzdlZTdiZmVmNjgvdGFibGVyYW5nZTowMTMzMjUxNWZlODk0Yjk2YWExOTVjN2VlN2JmZWY2OF80LTEtMS0xLTA_f4df3328-e9b0-4bf0-bfbf-4936c6ec5142">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180L2ZyYWc6ZTk0NGM4MTVlMThkNDJjOGJhODdlMzAxNmQ5MGJmNDMvdGFibGU6MDEzMzI1MTVmZTg5NGI5NmFhMTk1YzdlZTdiZmVmNjgvdGFibGVyYW5nZTowMTMzMjUxNWZlODk0Yjk2YWExOTVjN2VlN2JmZWY2OF81LTEtMS0xLTA_dd2fec19-23ae-4b78-81cd-211640c2e13d">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180L2ZyYWc6ZTk0NGM4MTVlMThkNDJjOGJhODdlMzAxNmQ5MGJmNDMvdGFibGU6MDEzMzI1MTVmZTg5NGI5NmFhMTk1YzdlZTdiZmVmNjgvdGFibGVyYW5nZTowMTMzMjUxNWZlODk0Yjk2YWExOTVjN2VlN2JmZWY2OF83LTEtMS0xLTA_e21418f0-bcd4-438e-9025-8b382c02a0c5">2020</ix:nonNumeric><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180L2ZyYWc6ZTk0NGM4MTVlMThkNDJjOGJhODdlMzAxNmQ5MGJmNDMvdGFibGU6MDEzMzI1MTVmZTg5NGI5NmFhMTk1YzdlZTdiZmVmNjgvdGFibGVyYW5nZTowMTMzMjUxNWZlODk0Yjk2YWExOTVjN2VlN2JmZWY2OF84LTEtMS0xLTA_ef39271a-681e-4523-a76a-a3daf9880331">Q1</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMy0xLTEtMS0w_266a35b8-1c26-4c76-b874-18ce15c059a6">6,260</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMy0yLTEtMS0w_2562b098-113a-4dbf-a353-469d5ff5bbe4">5,342</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfNi0xLTEtMS0w_467b7ade-6ba8-40e1-99b8-de2dce227898">19,260</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfNi0yLTEtMS0w_71e7e7e7-ef34-482e-aad0-ce6bc4b813e5">17,604</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfOS0xLTEtMS0w_5b06617e-3037-4e4c-858e-45007eb54b2c">0.01</ix:nonFraction><ix:nonFraction unitRef="usdPerShare" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfOS0yLTEtMS0w_3dcd4003-c980-4ced-8ddb-85e2f0d8da07">0.01</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMTAtMS0xLTEtMA_d20a9205-e17d-48dc-b38a-6cb31098a4a6">500,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMTAtMi0xLTEtMA_0956017f-f4ab-4ef3-8048-c327ac4d42b2">500,000,000</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMTEtMS0xLTEtMA_214578af-d8a2-4017-91e7-e5f9b6de87fe">257,449,955</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMTEtMi0xLTEtMA_9821553b-4eea-4f8b-ac83-f768ae0b1ecf">255,417,869</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMTItMS0xLTEtMA_f072800a-e9d5-4108-aa86-7b70d4631749">257,449,955</ix:nonFraction><ix:nonFraction unitRef="shares" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMTItMi0xLTEtMA_7d79e806-098f-4642-8ed4-2c0e5c316841">255,417,869</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zMS9mcmFnOmNiMGM4OTI4Njg1ZDQ4YTg5MmY3ZmY4MDIzMTVjMDU1L3RhYmxlOjBjMmFiNWYyNjMzYjQzYzFhMjAzOWMzN2RiNWFiYjRkL3RhYmxlcmFuZ2U6MGMyYWI1ZjI2MzNiNDNjMWEyMDM5YzM3ZGI1YWJiNGRfMi0xLTEtMS0w_bdf5b18d-e2f7-4c47-9df4-0a6f75296461">1,536</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zMS9mcmFnOmNiMGM4OTI4Njg1ZDQ4YTg5MmY3ZmY4MDIzMTVjMDU1L3RhYmxlOjBjMmFiNWYyNjMzYjQzYzFhMjAzOWMzN2RiNWFiYjRkL3RhYmxlcmFuZ2U6MGMyYWI1ZjI2MzNiNDNjMWEyMDM5YzM3ZGI1YWJiNGRfMi0zLTEtMS0w_673d9174-550f-4834-97ab-bcadb9e23a5c">&#8212;</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zMS9mcmFnOmNiMGM4OTI4Njg1ZDQ4YTg5MmY3ZmY4MDIzMTVjMDU1L3RhYmxlOjBjMmFiNWYyNjMzYjQzYzFhMjAzOWMzN2RiNWFiYjRkL3RhYmxlcmFuZ2U6MGMyYWI1ZjI2MzNiNDNjMWEyMDM5YzM3ZGI1YWJiNGRfMy0xLTEtMS0w_35091da9-3eca-49ab-845b-fe49b3307327">56</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zMS9mcmFnOmNiMGM4OTI4Njg1ZDQ4YTg5MmY3ZmY4MDIzMTVjMDU1L3RhYmxlOjBjMmFiNWYyNjMzYjQzYzFhMjAzOWMzN2RiNWFiYjRkL3RhYmxlcmFuZ2U6MGMyYWI1ZjI2MzNiNDNjMWEyMDM5YzM3ZGI1YWJiNGRfMy0zLTEtMS0w_95f3be2e-190f-43a8-ab2e-171d76e929e4">&#8212;</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ie0ba4a524aed416486913ea7a9dba98f_I20200331" decimals="2" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183Ni9mcmFnOmM1ZGNjNTZlMmMzYjQ3NTg4Y2JhN2Q4MzU0NzQ1OTI2L3RleHRyZWdpb246YzVkY2M1NmUyYzNiNDc1ODhjYmE3ZDgzNTQ3NDU5MjZfMTg_e46e8f55-bb7d-4f1c-afca-a18978b6f096">75</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i9feff19608a147b4a577c14d3cd15368_I20200331" decimals="2" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183Ni9mcmFnOmM1ZGNjNTZlMmMzYjQ3NTg4Y2JhN2Q4MzU0NzQ1OTI2L3RleHRyZWdpb246YzVkY2M1NmUyYzNiNDc1ODhjYmE3ZDgzNTQ3NDU5MjZfMjQ_3871914a-e2a2-4a19-9ee4-061f41bb8817">78</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="fold-20200331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i99ffeda6d436452d9771eb87cc47254e_I20200427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i196c9221c6d643fdaa0ea733f27450c9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec6b6ea5594b4731a877338c089938f3_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ab7b2af443045e981707c6d83e68f71_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic617e48d8a10423db3184a6dfab2b3bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7607f8134f5b416d9727cf6788be5ff0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d497ab4f2c34411849a9c0b7f6ad148_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibac1144c427c4ab28f9978dedda26866_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f01de7d9dd44ea8b91087aef6dc8069_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia98f9eda9405487aa88f7722bcf90c06_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c53c43e07c4745bc497b9834079c0a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4281d64af2d427b85cef94416b0a885_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if69166eb2b574a688fba8c17a396ddc1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c8339ddd7df40d5a162d23e286d54ae_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf2972e46bfc4f359a17c8f36be0ac34_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26248ac6987b40c48626b19b6e0c9195_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05bc9b3b7144464c88b636e60eedf49a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcbb93cbfad34e7d97f71f16ddd6c611_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96c0a7cbb6b3472bb1e2424eaa5e6177_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibba94963ffeb42d08d8d600f49ecd905_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idadd57a0cda848479ab4cb0f85af2845_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icab07bfc15ea4b0a9b2e3d5dfe987d2a_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a73b1ec2ad049afa1945e4ac428aa91_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i727363bd8bbd43adae093805b3e3a8eb_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab7bd98c579140b5b443d931338863c7_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9528373dcfb944969e8d059bcea89906_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5491ffc350124a71b70a57e9a6ea8c72_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9251812ad7e4ed885bebff24390dfb9_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5462b45a2d554a69b26d20db9f69d769_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d09871cf6ad4200a92e067dd3180699_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia85c7d4cee774ba29ddedfa2ec518587_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31b61ba1de064ab9a35f6ea596b4cac0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6665e4e8d56945d6a3eb5b178eed1e42_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e9b6c86da6148bc9f33450341bbd731_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i713aa7461f474212a79f6fbf3e5b8ce4_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie299466a221248989d0654e27aa2fa15_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i76dd233dc95c43edb284968ccf887232_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79d9f3582ceb4f39b144041e9d62cd8f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e582d44c1854742ab6c8ed5ee290d43_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14951a04eb4e4b7b9d35f47bed16e634_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef63e91418e4383b7ebde0b9c4cffe0_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i555c0f48291d4b38b8d561d915768eff_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69bfb02d155d46d7a1e1ec0c33f195ca_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i780f97fa745c46f2a97bd268ba15bc18_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1cd03431da34173829810953c60ca83_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87a274e586cf4c16a08587c4031550b4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if972968827f048e9b40900a185eca935_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaae514757a6c44d4a4b8a4a9a318e979_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i140e72212c4a4bfb81bf6148fb2aa0a6_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3674ca7debaf4f0aafd63c83f885edf1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb44be7fb6564606a0f40b69c09e76c5_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b34927c8eaa48f08e87f87c3ed7a95c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ic6b8135fdb4c48c0a197d684b3bef8b9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44debd31ac6748d0a90567edb19522f6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="day"><xbrli:measure>fold:day</xbrli:measure></xbrli:unit><xbrli:context id="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe7c67f71a114f90ae76db8af5fe4c45_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3357c282064f406dac5037a4c2b21d13_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b6358ff594f435b8c28ece99c733032_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id011b45be10140f38519fd2adf3253d2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16020fa576b847e0be1314bfb846de53_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i086ab493f15f4e6680cd436cde171e07_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie57efb8719074ac89dbe8b6a28e6d637_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bddcfce942349258e4cb92f5ce02164_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0c9afa9ca0b4b35bab63830db5c839b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc1a4e6d9264abd9af1dd18a8a59526_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69ecdce58c8e44a7b7446b787e6b5571_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib14953c89ea842048d571e925165ae39_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd85987fc9fb44248ab3d5d19af0664e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic98cbd8bf78c4e479a4b68211ebe7595_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9850e46e79c9490ca6d79c93c720720b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if74e828956b7436da5162de1eb41377f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i975aba94542c4c2988e78b6ee343ef08_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a2116def0d444d1b2c560065e4d05c1_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41235f69acc344c2ab91f52c5639a874_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00deaed1957b488787cdaa82dc50e59b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65b648c925e740579dcae60193ae3051_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa313342b3241bba30e7d90a90214b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5ecdd9caab3473cb281d4bc13e0eca9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e7a3776ad894ab5b362c7b3cf1a371c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1230a6c7511406892e2964d9334d607_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55f9cd444bfc49af80a93225821ade9c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib43a922550c542ecb66e87e81bc9113b_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44733de43da34221b7d954e41f00c039_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0ba4a524aed416486913ea7a9dba98f_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9feff19608a147b4a577c14d3cd15368_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia053dc80670e4de08f203297971a38ee_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd00e196fb5248c38c3a76f7e124b8ff_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic483241cafdd4ff19dea8e3ded6ae7c9_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9fe2af9630e470c8859c9adef1e1816_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i208a59305dc0405a95804c555ac42287_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2456a772e9a5467790859303b3e7e057_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8d7af76424f479fa3108e53610e4c9a_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41dc54a86052461baed38b6ea6e9142a_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001178879</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i37a61778173840fc811d567d8624cfac_1"></div><div style="height:40.5pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">RL </span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #000000;border-bottom:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Washington, D.C. 20549</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;">FORM&#160;<ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMDk4_798761d4-1399-4814-99ad-e48d022834d1">10-Q</ix:nonNumeric> </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(Mark One)</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:18pt;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMDk5_30cc9af9-d6a4-4905-a0d1-69a905f0c2e9">&#9746;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the quarterly period ended <ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMzU_f25d6a6c-6a6a-4e62-9566-fc58b51834eb">March 31, 2020</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OR</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">        </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMTAw_0946edb2-c16f-409c-bac2-03c82b8f022c">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#160;&#160;&#160;&#160;&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Commission file number <ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMTAx_fb1d3f03-17ae-47b3-9355-26f7666b93a4">001-33497</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%;"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMTAy_2f4f2ed0-3f8c-486b-bab3-d5f8f0496e22">Amicus Therapeutics,&#160;Inc.</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:24.315%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.210%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.654%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.102%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN18wLTAtMS0xLTA_fdfe448d-1460-4809-9bd2-96569a9f9bd0">Delaware</ix:nonNumeric></span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN18wLTQtMS0xLTA_be1cc0b5-0d28-495e-8bd9-9b4a4b4d7d5a">71-0869350</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or Other Jurisdiction of</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer</span></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Incorporation or Organization)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Identification Number)</span></td></tr><tr><td colspan="9" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN180LTAtMS0xLTA_3c0b2937-5cd2-4be0-b569-041ffc20781a">1 Cedar Brook Drive,</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN180LTEtMS0xLTA_58c34d63-b821-4867-aa99-be0e783c437a">Cranbury,</ix:nonNumeric></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN180LTItMS0xLTA_f2d64f29-45c9-4292-bb76-43116dc73887">NJ</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN180LTQtMS0xLTA_bff9e0b9-9fc9-4147-a890-debb54e9f1d2">08512</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of Principal Executive Offices)</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Zip Code)</span></td></tr><tr><td colspan="9" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN183LTAtMS0xLTA_8c3204f7-d9ac-43cd-a81a-f902a13838ea">(609)</ix:nonNumeric></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN183LTMtMS0xLTA_a2f94321-c0fa-4674-b509-32c14995316f">662-2000</ix:nonNumeric></span></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">(Registrant's Telephone Number,&#160;Including Area Code)</span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center;margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:35.704%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:22.590%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:35.706%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YjYxZTEyZTQ4YzdjNGI3OTg3MGI4N2VkZjhkZjIzZDcvdGFibGVyYW5nZTpiNjFlMTJlNDhjN2M0Yjc5ODcwYjg3ZWRmOGRmMjNkN18xLTAtMS0xLTA_6fac4170-1d5f-440f-90c4-60283b12e7ce">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YjYxZTEyZTQ4YzdjNGI3OTg3MGI4N2VkZjhkZjIzZDcvdGFibGVyYW5nZTpiNjFlMTJlNDhjN2M0Yjc5ODcwYjg3ZWRmOGRmMjNkN18xLTEtMS0xLTA_1eadf553-8b96-4c7b-b124-63cc207f8859">FOLD</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YjYxZTEyZTQ4YzdjNGI3OTg3MGI4N2VkZjhkZjIzZDcvdGFibGVyYW5nZTpiNjFlMTJlNDhjN2M0Yjc5ODcwYjg3ZWRmOGRmMjNkN18xLTItMS0xLTA_0c1d6c73-3d8a-4a92-b969-f4ebf20d8f49">NASDAQ Global Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160; <ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMTAz_90577830-3b59-45af-a84b-e324ea0c75b8">Yes</ix:nonNumeric> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">No </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160; <ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMTA0_e31530a7-2a89-41e8-a2d3-ce87d59df547">Yes</ix:nonNumeric> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> No </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:25.046%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.947%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:14.520%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:2.532%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:27.239%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:1.947%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.039%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6MGI1Yzk4ODk1ZjI5NGUwOGJjN2ZlODliYmNiZWE4OTkvdGFibGVyYW5nZTowYjVjOTg4OTVmMjk0ZTA4YmM3ZmU4OWJiY2JlYTg5OV8wLTAtMS0xLTA_88481743-66d6-4a9f-afbd-31a8c7371bd0">Large accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9746;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accelerated filer</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-accelerated filer </span></td><td colspan="3" style="display:none;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#9744;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Smaller reporting company</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6MGI1Yzk4ODk1ZjI5NGUwOGJjN2ZlODliYmNiZWE4OTkvdGFibGVyYW5nZTowYjVjOTg4OTVmMjk0ZTA4YmM3ZmU4OWJiY2JlYTg5OV8xLTctMS0xLTA_017c6bc3-9af4-4e38-b879-17a1ce11245b">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="12" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Emerging growth company</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Arial Unicode MS',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6MGI1Yzk4ODk1ZjI5NGUwOGJjN2ZlODliYmNiZWE4OTkvdGFibGVyYW5nZTowYjVjOTg4OTVmMjk0ZTA4YmM3ZmU4OWJiY2JlYTg5OV8yLTctMS0xLTA_af9126ec-9155-4b90-b07b-b9305a6cb625">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9744;</span></div><div style="padding-left:18pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMDk3_bcb1ae70-cd72-47f1-b9e8-b0196e5f3ad0">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> No </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#9746;</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">The number of shares outstanding of the registrant's common stock, $0.01 par value per share, as of April&#160;27, 2020 was <ix:nonFraction unitRef="shares" contextRef="i99ffeda6d436452d9771eb87cc47254e_I20200427" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8xNjQ5MjY3NDQzODUz_3afefa32-2be1-4850-b7c6-8ff53f03bf5b">257,664,403</ix:nonFraction> shares.</span></div><div style="margin-top:6pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:2pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="margin-top:6pt;"><span><br/></span></div><div style="position:relative;width:100%;height:27pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_7"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">AMICUS THERAPEUTICS,&#160;INC.</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Form&#160;10-Q for the Quarterly Period Ended March 31, 2020 </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:2.538%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.516%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.067%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:36.067%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:7.812%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Page</span></td></tr><tr><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_13">PART&#160;I.&#160;&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_13">3</a></span></div></td></tr><tr><td colspan="12" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1.</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_16">Consolidated Financial Statements and Notes (unaudited)</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_16">3</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_19">Consolidated Balance Sheets as of March 31, 2020 and December 31, 2019</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_19">3</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_25">Consolidated Statements of Operations for the Three Months Ended March 31, 2020 and 2019</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_25">4</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_28">Consolidated Statements of Comprehensive Loss for the Three Months Ended March 31, 2020 and 2019</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_28">5</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_34">Consolidated Statements of Changes in Stockholders' Equity for the Three Months Ended March 31, 2020 and 2019</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_34">6</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_37">Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_37">7</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_40">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_40">8</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2.</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_85">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_85">21</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 3.</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_97">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_97">30</a></span></div></td></tr><tr><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 4.</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_100">Controls and Procedures</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_100">30</a></span></div></td></tr><tr><td colspan="12" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:3pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_103">PART&#160;II.&#160;&#160;&#160;&#160;&#160;OTHER INFORMATION</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_103">31</a></span></div></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1.</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_106">Legal Proceedings</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_106">31</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 1A.</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_109">Risk Factors</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_109">31</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 2.</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_112">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_112">31</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 3.</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_115">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_115">31</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 4.</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_118">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_118">31</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 5.</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_121">Other Information</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_121">31</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Item 6.</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_124">Exhibits</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_124">32</a></span></div></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_127">SIGNATURES</a></span></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:right;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;" href="#i37a61778173840fc811d567d8624cfac_127">33</a></span></div></td></tr><tr><td colspan="12" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="12" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:18pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We have filed applications to register certain trademarks in the United States and abroad, including AMICUS THERAPEUTICS and design, AMICUS ASSIST and design, CHART and design, AT THE FOREFRONT OF THERAPIES FOR RARE AND ORPHAN DISEASES, HEALING BEYOND DISEASE, OUR GOOD STUFF, and Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and design. </span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">i</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_10"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">This Quarterly Report on Form&#160;10-Q contains forward-looking statements that involve risks, uncertainties, and assumptions.&#160; Forward-looking statements are all statements, other than statements of historical facts, that discuss our current expectation and projections relating to our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans, and objectives of management. These statements may be preceded by, followed by, or include the words "aim," "anticipate," "believe," "can," "could," "estimate," "expect," "forecast," "intend," "likely," "may," "outlook," "plan," "potential," "predict," "project," "seek," "should," "will," "would," the negatives or plurals thereof, and other words and terms of similar meaning, although not all forward-looking statements contain these identifying words.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that our assumptions made in connection with the forward-looking statements are reasonable, we cannot assure you that the assumptions and expectations will prove to be correct. You should understand that the following important factors could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements: </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the progress and results of our preclinical and clinical trials of our drug candidates and gene therapy candidates, including but not limited to AT-GAA, CLN6 and CLN3;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the cost of manufacturing drug supply for our clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme Replacement Therapy ("ERT" or "ATB200") and gene therapies;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the scope, progress, results, and costs of preclinical development, laboratory testing, and clinical trials for our product candidates including those testing the use of a pharmacological chaperone co-administered with ERT for the treatment of Pompe disease ("AT-GAA") and gene therapies for the treatment of rare genetic metabolic diseases;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the future results of on-going preclinical research and subsequent clinical trials for cyclin-dependent kinase-like 5 ("CDKL5") deficiency, Pompe gene therapy, Fabry gene therapy, Niemann- Pick Type C ("NPC"), Mucopolysaccharidosis Type IIIB ("MPSIIIB") and next generation Mucopolysaccharidosis Type IIIA ("MPSIIIA"), including our ability to obtain regulatory approvals and commercialize these gene therapies and obtain market acceptance for such therapies;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs, timing, and outcome of regulatory review of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any changes in regulatory standards relating to the review of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the number and development requirements of other product candidates that we pursue;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs of commercialization activities, including product marketing, sales, and distribution;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the emergence of competing technologies and other adverse market developments;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to successfully commercialize Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> ("migalastat HCl");</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to manufacture or supply sufficient clinical or commercial products, including Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, AT-GAA and our gene therapy candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain reimbursement for Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain market acceptance of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the extent to which we acquire or invest in businesses, products, and technologies;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to successfully integrate our acquired products and technologies into our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to establish collaborations, partnerships or other similar arrangements and to obtain milestone, royalty, or other payments from any such collaborators;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to adjust to changes in the European and United Kingdom markets in the wake of the United Kingdom leaving the European Union; </span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the extent to which our business could be adversely impacted by the effects of the novel coronavirus ("COVID-19") outbreak, including due to actions by us, governments, our customers or suppliers or other third parties to control the spread of COVID-19, or by other health epidemics or pandemics;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">fluctuations in foreign currency exchange rates; and </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in accounting standards.&#160;</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In light of these risks and uncertainties, we may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in Part&#160;I Item 1A &#8212; Risk Factors of the Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2019, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make.&#160;Those factors and the other risk factors described therein are not necessarily all of the important factors that could cause actual results or developments to differ materially from those expressed in any of our forward-looking statements. Other unknown or unpredictable factors also could harm our results. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, collaborations, or investments we may make. Consequently, there can be no assurance that actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, us. Given these uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">You should read this Quarterly Report on Form&#160;10-Q in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2019 completely and with the understanding that our actual future results may be materially different from what we expect. These forward-looking statements speak only as of the date of this report. We undertake no obligation, and specifically decline any obligation, to publicly update or revise any forward-looking statements, even if experience or future developments make it clear that projected results expressed or implied in such statements will not be realized, except as may be required by law.&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_13"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART&#160;I.&#160;FINANCIAL INFORMATION</span></div><div id="i37a61778173840fc811d567d8624cfac_16"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 1.&#160;CONSOLIDATED FINANCIAL STATEMENTS AND NOTES (UNAUDITED)</span></div><div id="i37a61778173840fc811d567d8624cfac_19"></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Balance Sheets</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share amounts)</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:74.754%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:9.257%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.259%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMy0xLTEtMS0w_d8ca31d5-3f3b-446a-9957-4d0d7593675a">123,231</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMy0zLTEtMS0w_568bb4b8-2271-4129-a92b-0fcfc09c4f7e">142,837</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investments in marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNC0xLTEtMS0w_39df2fc1-91ad-405f-a956-21f10145945c">215,642</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNC0zLTEtMS0w_ecceb39a-c9b8-408f-90e7-d0ee3275613b">309,903</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNS0xLTEtMS0w_9100607f-08d9-4273-8cc6-43b7d4770c67">40,555</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNS0zLTEtMS0w_e3500550-32ae-4af1-b1ff-fc48b5f6b3f1">33,284</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNi0xLTEtMS0w_25a4e6b8-5fc0-460c-be8d-25c054fb793a">12,831</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNi0zLTEtMS0w_8eeeee6a-5173-44c3-8a7c-5b324101565e">14,041</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNy0xLTEtMS0w_882d1c3c-b59f-44c0-a56d-5b2763136596">15,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNy0zLTEtMS0w_648d95bc-eeea-41d2-a50b-f51c6e97b801">20,008</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfOC0xLTEtMS0w_e2169321-7e41-45c3-bf4a-45ffe5a8f82e">407,949</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfOC0zLTEtMS0w_11a991a2-bf9b-4409-a653-0acc04f24825">520,073</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease right-of-use assets, less accumulated amortization of $6,260 and $5,342 at March 31, 2020 and December 31, 2019, respectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfOS0xLTEtMS0w_dcc03a0a-9b95-4712-aab2-1a29504444b0">32,501</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfOS0zLTEtMS0w_8d92e676-6239-49e3-b88d-524e61066d8c">33,315</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Property and equipment, less accumulated depreciation of $19,260 and $17,604 at March 31, 2020 and December 31, 2019, respectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTAtMS0xLTEtMA_46724608-9493-4c20-9257-90fdcce95d1f">47,688</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTAtMy0xLTEtMA_148c56f5-0042-41a4-b1e5-bbee84571f02">47,705</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">In-process research&#160;&amp; development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTEtMS0xLTEtMA_d021d95a-74c1-4700-b7fd-3b0c45c1444e">23,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTEtMy0xLTEtMA_cdba57d9-2d65-4633-b610-345580ebc6df">23,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Goodwill</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTItMS0xLTEtMA_8fe125a0-058d-45b0-81d8-705b2d375b80">197,797</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTItMy0xLTEtMA_86d890cf-e521-4f5e-a1e8-9e6efa76338a">197,797</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTMtMS0xLTEtMA_6ee1814d-c520-4dcf-a183-758900c5f1cc">29,414</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTMtMy0xLTEtMA_270fcbc7-a82e-4039-8cfc-a0827eeabe3a">28,317</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Assets</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTQtMS0xLTEtMA_99e85bd6-eeb5-46e4-a3a3-5573f0c6534d">738,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTQtMy0xLTEtMA_6dacf2a1-1380-4739-991f-2e40c4bebc9c">850,207</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTctMS0xLTEtMA_91f8b1a1-d3ae-47df-b81c-9cdd821054a9">16,239</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTctMy0xLTEtMA_3ef41925-2985-4aed-b014-711afcdee549">21,722</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accrued expenses and other current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTgtMS0xLTEtODY0_d8e4233b-0d58-427e-9035-e504dd0fb641">66,722</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTgtMy0xLTEtODY0_04592105-65b0-4ed5-9113-c2b49d3a713d">98,651</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred reimbursements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTgtMS0xLTEtMA_11a807f5-33f8-4473-be94-42c002a08ab9">1,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTgtMy0xLTEtMA_c6308a7c-08ef-4fdc-8905-e5465cb4a057">1,250</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTktMS0xLTEtMA_a6b100af-ff26-4035-8cdc-e904be49ec44">7,503</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTktMy0xLTEtMA_7ff3108e-089b-4940-a0b4-ca71344f61e6">7,189</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjAtMS0xLTEtMA_f24f6411-5605-4e21-97f2-d03345beb789">91,714</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjAtMy0xLTEtMA_3d54b11f-29c2-4dd0-8eb5-09605af9334c">128,812</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred reimbursements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjEtMS0xLTEtMA_ae113134-5385-410d-87ab-63df5006e1a4">8,906</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjEtMy0xLTEtMA_08206f49-c6a4-45ac-9a91-692f767b57bf">8,906</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjItMS0xLTEtMA_2d95a5b9-bf15-4b70-a07f-e85a3784fe5f">2,167</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjItMy0xLTEtMA_a45f0370-cfc7-40c1-a088-05aa2376f3c8">2,131</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Senior secured term loan</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecuredLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjMtMS0xLTEtMA_30d09906-66eb-4647-a010-896805858077">147,569</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecuredLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjMtMy0xLTEtMA_097067a3-5bae-4ade-a9b6-277fcbc834c8">147,374</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjQtMS0xLTEtMA_a9e945f1-285a-444b-8416-18acc71acf7b">23,612</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjQtMy0xLTEtMA_f6d62cb5-888a-4701-a434-da3747260fa2">22,681</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income taxes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjUtMS0xLTEtMA_02b6ed96-3905-4bd7-b0c8-4954554ea0d3">5,051</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjUtMy0xLTEtMA_35328afb-e6f0-48f8-b651-4e9c164a8c13">5,051</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating lease liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjYtMS0xLTEtMA_a3e7a986-23ea-4f02-aa17-3241d1666ab5">52,522</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjYtMy0xLTEtMA_c637f8e5-f0aa-4991-a9a8-7f089630e0ad">53,531</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjctMS0xLTEtMA_f7554b0b-cfbf-4482-8606-345e1bebfe02">4,214</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjctMy0xLTEtMA_9eaa902a-76c6-471e-b966-7613b04e1a10">5,296</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjgtMS0xLTEtMA_6b7efecb-a75a-4477-bc3a-e236944d616f">335,755</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjgtMy0xLTEtMA_567f1c47-cec2-4ceb-9067-0bf2493ce793">373,782</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commitments and contingencies</span></td><td colspan="2" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjktMS0xLTEtMA_e6f9ff73-2a0d-4703-bf86-819b4de13859"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjktMy0xLTEtMA_5c39323e-6b1b-45fc-b48b-7dd0e980e79b"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common stock, $0.01 par value, 500,000,000 shares authorized, 257,449,955 and 255,417,869 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzEtMS0xLTEtMA_dcc5de39-118b-4ba9-98f8-d572a198c346">2,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzEtMy0xLTEtMA_9a829223-5feb-44f0-9e5b-00f7cb04dea7">2,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional paid-in capital</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzItMS0xLTEtMA_91ecc778-1e0e-4fbf-bb5e-cdf35b8e96bb">2,238,346</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzItMy0xLTEtMA_35b9dc24-4045-479d-96f2-988000fab1a5">2,227,225</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzQtMS0xLTEtMA_3858cf78-fc20-40c4-b3aa-ddafaa777a8a">6,981</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzQtMy0xLTEtMA_49f6edbb-3528-40bd-9c46-2887442fbeac">2,785</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized (loss) gain on available-for-sale securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzUtMS0xLTEtMA_a65ebe06-0cd5-4992-a52f-d37e04339aeb">169</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzUtMy0xLTEtMA_6d44e2af-b543-443e-881e-fb6ec957402f">40</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzYtMS0xLTEtMA_11c093f6-1502-4012-8f62-7adb4abece1f">12,387</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzYtMy0xLTEtMA_2557b782-34c9-4d8e-9a0a-ff180a3e8f3d">12,387</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated deficit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzctMS0xLTEtMA_768e0604-6441-4341-885a-60bc09da59ee">1,857,558</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzctMy0xLTEtMA_82483467-ae3e-4c6c-8e5c-d32ef568adda">1,768,610</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total stockholders&#8217; equity</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzgtMS0xLTEtMA_36673c06-86d6-4a34-8daa-6231b17df492">402,594</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzgtMy0xLTEtMA_063db597-dc5f-4e5e-94c7-de98b9f91dd3">476,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzktMS0xLTEtMA_69f30971-afbc-4d9e-ac1f-edbc0486e778">738,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzktMy0xLTEtMA_9270e85a-774e-42c2-99a9-8a27dafef9d8">850,207</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Consolidated Financial Statements</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_25"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Statements of Operations</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share and per share amounts)</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.710%;"><tr><td style="width:1.0%;"></td><td style="width:70.238%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:11.517%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.526%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.519%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net product sales</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMi0xLTEtMS0w_992918da-861e-41a2-84cc-8b9342c00b5c">60,525</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMi0zLTEtMS0w_1fe533f2-2cc5-48df-bd88-9eb34cbbb6d8">34,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods sold</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMy0xLTEtMS0w_e6af2db3-c364-4518-af86-2a04859fa374">6,552</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMy0zLTEtMS0w_31be2956-8225-4aad-80cc-e73ca5fe6c7e">4,055</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross profit</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfNC0xLTEtMS0w_885d82e6-7948-41e5-bc8f-b4540f3901d0">53,973</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfNC0zLTEtMS0w_f3876c14-4678-46ee-a9f7-a3cc5196450a">29,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfNi0xLTEtMS0w_5ccc2742-e2db-4ae0-9edc-bc226c337cc9">89,120</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfNi0zLTEtMS0w_b677c440-8167-46fc-bca4-3779d14e03cf">64,593</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general, and administrative</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfNy0xLTEtMS0w_5e050faf-ca75-44fb-915a-5666c6680f82">40,215</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfNy0zLTEtMS0w_3cdbd0e3-57c0-4b30-92ed-73652c94c8f8">44,303</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in fair value of contingent consideration payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfOC0xLTEtMS0w_713d3f8c-10ff-4ffb-9fd1-73295650e17e">931</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfOC0zLTEtMS0w_fdb61de1-7aef-4926-80d8-4c8775d5e1e0">1,383</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfOS0xLTEtMS0w_f4ff83aa-0974-43cb-a258-0def82137c24">1,764</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfOS0zLTEtMS0w_11397961-5956-4168-aebc-829472503516">991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total operating expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTAtMS0xLTEtMA_87d1609e-9c35-4942-a875-c03c34ac1222">132,030</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTAtMy0xLTEtMA_eaf573c7-3f6a-4f09-a41a-8528b6c8e4da">111,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss from operations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTEtMS0xLTEtMA_7b91b131-8d46-41ab-8ede-345605cd00fe">78,057</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTEtMy0xLTEtMA_ce4b4438-68e3-4e80-83da-dff12078f7ca">81,279</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTMtMS0xLTEtMA_7b6d5cae-4b32-4faf-9906-a716450a0b2a">1,515</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTMtMy0xLTEtMA_3c3bbc0e-03b7-445a-99fd-1134549ddd13">2,639</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTQtMS0xLTEtMA_eae3b091-b8e5-4dc4-9bc1-cc7e84c42644">3,729</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTQtMy0xLTEtMA_97a1fd5a-9fad-450c-9f7f-fadea0cd2260">6,454</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on exchange of convertible notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTUtMS0xLTEtMA_c82ea145-5f90-49ed-a1fd-79683bfe4a88">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTUtMy0xLTEtMA_1625c83f-791b-47bc-98a9-9dee2d10d503">36,123</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (expense) income</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTctMS0xLTEtMA_f3375a79-2853-4797-9441-d384447e698b">8,316</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTctMy0xLTEtMA_671aa4c9-36b6-44fb-915b-c3e24989b3a5">1,086</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss before income tax </span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTgtMS0xLTEtMA_f4587935-24f3-4c7c-904b-ca9a21c70f44">88,587</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTgtMy0xLTEtMA_011c4b57-5501-47b7-841d-8ed0cec2ece2">120,131</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTktMS0xLTEtMA_13f77cfc-79be-4677-a65b-5627bd768f07">361</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTktMy0xLTEtMA_f59cb45a-6765-4d7d-9bf8-c20f93dd45c7">168</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to common stockholders</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMjAtMS0xLTEtMA_f974a23b-36b5-45b2-80dd-2d4f651a5d2e">88,948</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMjAtMy0xLTEtMA_bdc8ae54-83f8-4bd4-af50-d7a599cebfa6">120,299</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to common stockholders per common share&#160;&#8212; basic and diluted</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMjEtMS0xLTEtMA_ca29e06d-432d-43b5-8b61-1c66f19f8036">0.35</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usdPerShare" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMjEtMy0xLTEtMA_ddfe25f1-d4b0-4d1d-9256-e82fa2c35b9f">0.56</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted-average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMjItMS0xLTEtMA_068caca2-9a3f-48ea-94f1-9924af0a46e4">256,968,248</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMjItMy0xLTEtMA_a9c85cb2-c198-4069-8441-8cccf533ab61">213,519,287</ix:nonFraction></span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_28"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Statements of Comprehensive Loss </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:72.340%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.463%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.464%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfMi0xLTEtMS0w_b6367402-c938-4b0e-a672-ef58984a3d30">88,948</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfMi0zLTEtMS0w_ab9cdcbb-6c4c-4456-9663-c7cb60e75cd7">120,299</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive gain (loss):</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment gain (loss), net of tax impact of $1,536 and $0, respectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNC0xLTEtMS0w_c822256a-d199-4f7e-8fde-11dcd63c167d">4,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNC0zLTEtMS0w_cf02fa09-8133-4152-9909-41f7be721193">1,804</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:11.25pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized (loss) gain on available-for-sale securities, net of tax impact of $(56) and $0, respectively</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNS0xLTEtMS0w_e6870bc4-eef2-4c48-88b0-31fa31b83b0e">209</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNS0zLTEtMS0w_aec299f3-bc81-4a56-9b78-fc51a80f7ca6">584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other comprehensive income </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNi0xLTEtMS0w_d1f90a98-e146-4197-bf05-7058f6ac353f">3,987</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNi0zLTEtMS0w_bb5e24c1-5824-4f49-b9aa-5b84efe8b680">1,220</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Comprehensive loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNy0xLTEtMS0w_5e8a524b-fae1-48eb-b51f-c2c8eaabc9e0">84,961</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNy0zLTEtMS0w_7525ab83-fbf2-4219-a952-ca018f5557f9">121,519</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Consolidated Financial Statements</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_34"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Statements of Changes in Stockholders' Equity</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands, except share amounts)</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Three Months Ended March 31, 2020</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:24.872%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.572%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.782%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.957%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.782%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.187%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.425%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.019%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other<br/>Comprehensive<br/>Gain (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iec6b6ea5594b4731a877338c089938f3_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi0xLTEtMS0w_06f1b3bd-5329-4c0a-9dbe-a00d709291bb">255,417,869</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="iec6b6ea5594b4731a877338c089938f3_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi0zLTEtMS0w_590cd324-fe4f-4e1f-a53f-ed5c100ce68b">2,598</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9ab7b2af443045e981707c6d83e68f71_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi01LTEtMS0w_cd94a986-2bf5-48bb-8be1-840ee09196e2">2,227,225</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic617e48d8a10423db3184a6dfab2b3bf_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi03LTEtMS0w_687279d9-a0ca-4794-a2c5-23f1807f6ec2">12,387</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7607f8134f5b416d9727cf6788be5ff0_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi05LTEtMS0w_e380e8b3-88cf-4f5a-904e-8b33266fec2b">2,825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9d497ab4f2c34411849a9c0b7f6ad148_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi0xMS0xLTEtMA_62ff0e0c-b033-4f7e-bf32-ff30c6d844c2">1,768,610</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi0xMy0xLTEtMA_3f49de86-d271-4b1d-ac16-1590bbc3b2fa">476,425</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock issued from exercise of stock options, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibac1144c427c4ab28f9978dedda26866_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMy0xLTEtMS0w_816c3561-f580-47f1-bce0-ad32a650e909">958,947</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibac1144c427c4ab28f9978dedda26866_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMy0zLTEtMS0w_f223533d-8bcf-4ee2-892d-1e5fae49c699">9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f01de7d9dd44ea8b91087aef6dc8069_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMy01LTEtMS0w_b6c69fae-0f64-4142-ad9d-0e60a660ad4b">6,068</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMy0xMy0xLTEtMA_c60b2229-7c03-4dfb-bece-6c968c3b95a5">6,077</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock tax vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibac1144c427c4ab28f9978dedda26866_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNC0xLTEtMS0w_4f1c60c6-4825-4cc4-85f5-700f8ebb575f">1,073,139</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7f01de7d9dd44ea8b91087aef6dc8069_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNC01LTEtMS0w_d21e5e6e-bd9d-47aa-802b-e5235f565668">7,543</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNC0xMy0xLTEtMA_93d20842-0326-4803-bf33-52992e341eee">7,543</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7f01de7d9dd44ea8b91087aef6dc8069_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNS01LTEtMS0w_56288ae7-ecb9-4f13-b35b-d62431e958c3">12,596</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNS0xMy0xLTEtMA_347a6206-62d4-4b30-b2d3-837b9a855178">12,596</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized holding loss on available-for-sale securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia98f9eda9405487aa88f7722bcf90c06_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNi05LTEtMS0w_9c402005-e0c5-497b-8122-65d32c825189">209</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNi0xMy0xLTEtMA_df4617f4-8dda-4455-ad92-dd3607683125">209</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia98f9eda9405487aa88f7722bcf90c06_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNy05LTEtMS0w_cc5ff978-6155-4ef5-b83c-0728f5c85b85">4,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNy0xMy0xLTEtMA_b97ea330-93ad-45fd-bdf7-92082690ea59">4,196</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i03c53c43e07c4745bc497b9834079c0a_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOC0xMS0xLTEtMA_cf4ed3fe-5243-46e6-b02d-3df38da55f51">88,948</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOC0xMy0xLTEtMA_abafded7-ac97-4245-9e61-2e96275eab29">88,948</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="if4281d64af2d427b85cef94416b0a885_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS0xLTEtMS0w_f507029d-8da4-4211-8798-6e77bff9fb6e">257,449,955</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if4281d64af2d427b85cef94416b0a885_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS0zLTEtMS0w_942f6ec9-e68f-47ca-8977-4969891d3ae7">2,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if69166eb2b574a688fba8c17a396ddc1_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS01LTEtMS0w_10d4f46d-d4e1-4833-b22d-5a17665cc818">2,238,346</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3c8339ddd7df40d5a162d23e286d54ae_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS03LTEtMS0w_d4aa656a-0bae-4db3-9474-8b400d2cf238">12,387</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibf2972e46bfc4f359a17c8f36be0ac34_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS05LTEtMS0w_71eb14d5-ee76-4a9f-86fd-66deeaebb5a2">6,812</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i26248ac6987b40c48626b19b6e0c9195_I20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS0xMS0xLTEtMA_68d4d71b-d3f9-4354-93ba-1a604b649be8">1,857,558</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS0xMy0xLTEtMA_c9038627-5706-4029-893b-0378c163d356">402,594</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;margin-top:24pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%;">Three Months Ended March 31, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> </span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:24.872%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:8.572%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.782%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:6.957%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:5.782%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.187%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.425%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.019%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Common Stock</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other<br/>Comprehensive<br/>Gain (Loss)</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" rowspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amount</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at December 31, 2018</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i05bc9b3b7144464c88b636e60eedf49a_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi0xLTEtMS0w_95bc5ec2-df88-49ea-b6e6-f559d42d3a32">189,383,924</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i05bc9b3b7144464c88b636e60eedf49a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi0zLTEtMS0w_2de5a27d-1ee4-415c-9943-993872bcc665">1,942</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifcbb93cbfad34e7d97f71f16ddd6c611_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi01LTEtMS0w_4fe46d83-bd3b-4d92-a450-648f94ecabc2">1,740,061</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i96c0a7cbb6b3472bb1e2424eaa5e6177_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi03LTEtMS0w_571e1f90-6a6e-4da2-baf9-aa344656c9f5">13,063</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ibba94963ffeb42d08d8d600f49ecd905_I20181231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi05LTEtMS0w_8cdc92c1-aacb-474a-a2c2-b858f76db81b">68</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="idadd57a0cda848479ab4cb0f85af2845_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi0xMS0xLTEtMA_3e33e286-7f18-4ca5-833f-b04716a99b7e">1,412,222</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icab07bfc15ea4b0a9b2e3d5dfe987d2a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi0xMy0xLTEtMA_12086ebd-959d-4aab-a447-870b3da17cf2">342,912</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock issued from exercise of stock options, net</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMy0xLTEtMS0w_ab4028c9-eec7-4132-8e4b-281ac7c14e2e">578,451</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMy0zLTEtMS0w_a9bad4f6-c063-4b17-a6a9-cc6c58f8767d">6</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMy01LTEtMS0w_05a875c7-ca35-471c-82bb-a319739dcecc">3,947</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMy0xMy0xLTEtMA_6ef8924e-9ba3-44fb-ae04-13aea26e5799">3,953</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted stock tax vesting</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNC0xLTEtMS0w_cf42c359-1305-419e-b862-8840de9c9bb7">301,058</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNC01LTEtMS0w_1f3dc95f-ac97-491a-bf2f-5c835f99f40b">1,940</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNC0xMy0xLTEtMA_37813d3f-7faa-4560-aa4b-5bb009325cf1">1,940</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock issued for contingent consideration</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="fold:StockIssuedDuringPeriodSharesContingentConsideration" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNS0xLTEtMS0w_52830030-f071-4e22-b190-907ab1d64a93">771,804</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331" decimals="-3" name="fold:StockIssuedDuringPeriodValueContingentConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNS0zLTEtMS0w_42d7cc04-e695-4cab-98b9-0fa547e5b11e">8</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="fold:StockIssuedDuringPeriodValueContingentConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNS01LTEtMS0w_41b29e10-4120-4241-94c7-73e1522fe98a">9,308</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="fold:StockIssuedDuringPeriodValueContingentConsideration" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNS0xMy0xLTEtMTI5MA_b5f27325-aac6-45c5-9f91-1890e44fbea2">9,316</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNi01LTEtMS0w_498f689b-3408-4b41-a91e-22dab309ff60">12,744</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNi0xMy0xLTEtMA_a4faf784-2e2e-4d84-8873-473ae6984320">12,744</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Warrants exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="fold:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNy0xLTEtMS0w_a7941284-4a0c-445e-b003-e9ab6e434b0b">101,787</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNy0zLTEtMS0w_37eb9500-0723-48c5-ac67-2d7d29d38280">1</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNy01LTEtMS0w_c2397472-4ff8-4690-b6fe-9435e40dace8">1,487</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i4a73b1ec2ad049afa1945e4ac428aa91_D20190101-20190331" decimals="-3" sign="-" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNy03LTEtMS0w_873f4a6d-5fe6-4fff-ba9d-8e848f03e216">676</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" name="fold:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNy0xMy0xLTEtMA_12983161-076e-48f3-99fa-70f9287c5959">812</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity component of the convertible notes</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfOC0xLTEtMS0w_389eed30-e4ab-4760-b917-adca6957e099">39,043,690</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfOC0zLTEtMS0w_e77707d4-06f3-4ca7-bb84-287e55c9f8c9">390</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfOC01LTEtMS0w_c1579afa-ea70-41e9-a322-79dceef0aa78">190,368</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfOC0xMy0xLTEtMTI5Mg_a4de2464-707f-475e-826a-4817a3ae9812">190,758</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Termination of capped call confirmations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfOS01LTEtMS0w_f6971f85-8285-4390-bb19-acb1ae39254c">14,632</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfOS0xMy0xLTEtMTI5NA_a3366de2-c29f-4797-88fb-8536f6125e00">14,632</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unrealized holding gain on available-for-sale securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i727363bd8bbd43adae093805b3e3a8eb_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTAtOS0xLTEtMA_11825845-7a00-4766-b5d7-a07080af5287">584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTAtMTMtMS0xLTA_c0bec97c-583a-4b92-8256-56888e2a06b2">584</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency translation adjustment</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i727363bd8bbd43adae093805b3e3a8eb_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTEtOS0xLTEtMA_15fc0f18-85b3-4f9c-82b4-20460e419e79">1,804</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTEtMTMtMS0xLTA_beb09a88-1117-440b-8440-6d55d059dc3a">1,804</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="iab7bd98c579140b5b443d931338863c7_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTItMTEtMS0xLTA_51292a7f-748d-4a93-a49f-a56c956fa502">120,299</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTItMTMtMS0xLTA_40e7e32a-4293-41ec-ac16-94e036ffccc5">120,299</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance at March 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i9528373dcfb944969e8d059bcea89906_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtMS0xLTEtMA_73cee19d-2c51-4867-a1f4-f82540ab849f">230,180,714</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9528373dcfb944969e8d059bcea89906_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtMy0xLTEtMA_c5ae57f6-1d53-47ea-b1e7-d0fc05fa27d4">2,347</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i5491ffc350124a71b70a57e9a6ea8c72_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtNS0xLTEtMA_30dbe9ae-ae4e-4b95-b6e3-6ae7320acb86">1,970,607</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="id9251812ad7e4ed885bebff24390dfb9_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtNy0xLTEtMA_b49137be-2be5-4731-bd72-8785abc4e4c1">12,387</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i5462b45a2d554a69b26d20db9f69d769_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtOS0xLTEtMA_69214e82-9bf5-4a21-bf4d-6ad0294054f3">1,152</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i9d09871cf6ad4200a92e067dd3180699_I20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtMTEtMS0xLTA_5986fce3-2456-4fa5-9de0-bf89c9d7198d">1,532,521</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtMTMtMS0xLTA_1b1c9918-33ad-4c33-8282-e86c63946742">451,668</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Consolidated Financial Statements</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">6</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_37"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Statements of Cash Flows</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(Unaudited)</span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(in thousands)</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMy0xLTEtMS0w_68d77885-0308-4342-8af9-12cc4d20390b">88,948</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMy0zLTEtMS0w_4c2b06c6-5f90-4b62-b56b-3de3b1efebc2">120,299</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount and deferred financing</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfNS0xLTEtMS0w_e1375b84-fa97-4ce9-b8c4-1a3286939027">231</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfNS0zLTEtMS0w_cbfc51e9-eb2c-40cb-8c1b-2112e999c2ea">1,649</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfNi0xLTEtMS0w_3262ae03-eee7-460b-9829-8523da184f41">1,764</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfNi0zLTEtMS0w_9fe8655a-a31d-46db-b098-d47ff84604c6">991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Stock-based compensation</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfNy0xLTEtMS0w_5f59e031-efe0-423a-bd39-5245b6fa6ec3">12,596</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfNy0zLTEtMS0w_d8def44a-df4d-4ffb-a323-764c2d93da2d">12,744</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on exchange of convertible debt</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfOC0xLTEtMS0w_ee627fec-3cff-41cf-b5f0-7d5891847d1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfOC0zLTEtMS0w_c00f1468-16ea-42c8-91bb-3f11840df404">36,123</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-cash changes in the fair value of contingent consideration payable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfOS0xLTEtMS0w_056917c4-ca0a-4b8a-b66c-761b09a18ecd">931</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfOS0zLTEtMS0w_1d8a3e4e-3073-4e19-8464-f1a1ce22acaa">1,383</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Foreign currency remeasurement loss</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTAtMS0xLTEtMA_5656bcb2-c5c6-4421-ad4c-8ef684d2beec">10,662</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" name="fold:ForeignCurrencyRemeasurementGainLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTAtMy0xLTEtMA_0a9de204-11cf-40fb-baca-04474f5e9442">325</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:middle;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts receivable</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTMtMS0xLTEtMA_1e40781c-d4ca-47a0-8ef0-5395b25384f8">8,358</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTMtMy0xLTEtMA_ad6c1053-305f-4dca-b0f0-f81f9cdc0792">1,001</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inventories</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTQtMS0xLTEtMA_fbbcedfc-6ba9-4b6e-a321-84218219599f">251</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTQtMy0xLTEtMA_abc65449-9fb6-4edc-b7bd-5ee9cfc8b47e">345</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Prepaid expenses and other current assets</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTUtMS0xLTEtMA_f79255ad-c379-4d2d-8b1f-19f0da8e2785">4,016</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTUtMy0xLTEtMA_020682f9-36eb-4b4f-9e5b-fe977a0accfd">3,059</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Accounts payable and accrued expenses</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTYtMS0xLTEtMA_4a33217f-0a7e-4ed9-be3f-570de96864f4">35,251</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTYtMy0xLTEtMA_efaee182-07ea-4cb4-8e3f-4cde773c9528">8,858</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other non-current assets and liabilities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTctMS0xLTEtMA_d8784d87-73f4-4b22-9a97-8efcc453a0f8">5,334</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="fold:IncreaseDecreaseInNoncurrentOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTctMy0xLTEtMA_13a62bb0-474e-4ce6-8eb6-f6042d61be60">3,507</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred reimbursements</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="fold:IncreaseDecreaseInDeferredReimbursements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTgtMS0xLTEtMA_e6087293-3488-46bd-8501-c59c0dc49e16">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="fold:IncreaseDecreaseInDeferredReimbursements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTgtMy0xLTEtMA_6bafb3a8-62f6-438c-acb1-2b109e04be2a">1,500</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash used in operating activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTktMS0xLTEtMA_e369d2f0-3c70-4a97-8683-78b36a13e303">107,942</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTktMy0xLTEtMA_9451b23c-8669-461b-a28e-eb3129550ba7">78,546</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Sale and redemption of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjEtMS0xLTEtMA_f7003280-94d1-4935-8ce0-815af7758ef2">106,140</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjEtMy0xLTEtMA_1652e8a7-b90d-4548-978c-a65fc38b69aa">135,187</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchases of marketable securities</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjItMS0xLTEtMA_757afa68-0a96-4e05-b3c9-6913f36ec2fc">12,088</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjItMy0xLTEtMA_291bad1a-ba05-48ad-adb1-90c958f5a0fa">52,178</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital expenditures</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjMtMS0xLTEtMA_bf1c1386-4d9d-42f7-9002-b72098a4184b">806</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjMtMy0xLTEtMA_5ad9fb4a-a708-4684-9ac3-9f04e26cf392">2,944</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash provided by investing activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjQtMS0xLTEtMA_4d5b4844-e8d3-4815-ad94-3abff1ffad61">93,246</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjQtMy0xLTEtMA_3464ea43-e893-46bf-93e4-55b8fdcee288">80,065</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Payment of finance leases</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjYtMS0xLTEtMA_493d928a-69f1-475d-af47-2f1545a4cba5">21</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjYtMy0xLTEtMA_d7bb520c-f0b2-448f-9dd7-da6825949d0a">75</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Purchase of vested restricted stock units</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="fold:PaymentsForRepurchaseOfRestrictedStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjctMS0xLTEtMA_f223c8a3-e087-474b-9ea2-0ca38180ba85">7,543</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="fold:PaymentsForRepurchaseOfRestrictedStockUnits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjctMy0xLTEtMA_22196f43-5171-4292-a9f5-930c124a758f">1,938</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from termination of capped call confirmations</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjgtMS0xLTEtMA_e6f6dc51-fa51-4c51-a978-416c5f794eb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjgtMy0xLTEtMA_33096a50-69d8-4323-b12f-5f7c1db889bb">14,632</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds from exercise of stock options</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjktMS0xLTEtMA_943f7c98-3307-4cd1-9b00-3975bdb6677c">6,077</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjktMy0xLTEtMA_1d36bb28-aa62-45e5-9194-b5bbd589b54d">3,953</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Proceeds of exercise of warrants</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzAtMS0xLTEtMA_8c79c40c-15c4-4f86-a3e6-e85dc85dad73">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzAtMy0xLTEtMA_24be7b6c-d40b-447c-bbe3-dfe1bffbd951">812</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net cash (used in) provided by financing activities</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzEtMS0xLTEtMA_16335d61-3bda-473a-a6cb-08e4fd1e2664">1,487</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzEtMy0xLTEtMA_f6f8e74d-d4fe-4d31-a2f0-272f51d921e0">17,384</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzItMS0xLTEtMA_391fb534-eaf8-4852-a55a-98e534d5256c">4,265</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzItMy0xLTEtMA_c1756038-87bf-4183-94fc-95490bfce3cc">2,350</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net (decrease) increase in cash, cash equivalents, and restricted cash at the end of the period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzMtMS0xLTEtMA_90ff90dc-d4b4-4d17-9fb1-b4f0a3e204a8">20,448</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzMtMy0xLTEtMA_7a38fef8-aa4f-4cfb-904e-c89460663eb8">16,553</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzQtMS0xLTEtMA_589ed14a-e59c-4c61-8ba5-795e94c0d27c">146,341</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icab07bfc15ea4b0a9b2e3d5dfe987d2a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzQtMy0xLTEtMA_a7487938-d12b-4062-9f36-18d0c521c0d3">82,375</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents, and restricted cash at the end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzUtMS0xLTEtMA_f6b5b814-0091-4cbe-baeb-ba0486d84660">125,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzUtMy0xLTEtMA_7b01fc10-ef79-4068-8274-50ed4d4884ea">98,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Supplemental disclosures of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Tenant improvements paid through lease incentives</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzctMS0xLTEtMTEw_09afcbee-e485-403e-a2cc-218456188aaa">254</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsForTenantImprovements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzctMy0xLTEtMTEw_813e0e8d-5099-46fe-a251-3f9a60f209fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash paid during the period for interest </span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzctMS0xLTEtMA_2212d51e-425e-40b7-859b-411597cdfa38">3,693</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzctMy0xLTEtMA_f2c2bd2f-ab75-4737-ad06-33174652f0b8">4,846</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration paid in shares</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="fold:ContingentConsiderationPaidInStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzktMS0xLTEtMTMwNA_beff6829-18e8-4242-b91e-6f55cc2d836b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="fold:ContingentConsiderationPaidInStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzktMy0xLTEtMTMwNg_7152cb4b-d99e-4c76-9c10-c7fbcb729e39">9,316</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Capital expenditures unpaid at the end of period</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzgtMS0xLTEtMA_b5cd8d53-d7aa-4d43-ae5d-69f209903c56">589</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzgtMy0xLTEtMA_7f10c3c5-a757-4c0b-9de4-f53a55e5e911">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">See accompanying Notes to Consolidated Financial Statements</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">7</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_40"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Amicus Therapeutics,&#160;Inc.</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(Unaudited)</span></div><div id="i37a61778173840fc811d567d8624cfac_43"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 1. <ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180My9mcmFnOmRhZDZiZTAwMWM3OTRkNmY4YjUzNzY2YWE0OWJiM2M5L3RleHRyZWdpb246ZGFkNmJlMDAxYzc5NGQ2ZjhiNTM3NjZhYTQ5YmIzYzlfMTA0NDUzNjA0NjkxNjg_bcf4a323-960d-4499-9353-6cc4dad43fd7" continuedAt="i6bec5410886548e8a2143454cc7c9277" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="i6bec5410886548e8a2143454cc7c9277"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities led by the first, oral monotherapy for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease in the clinic, and an industry leading rare disease gene therapy portfolio. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The cornerstone of the Company's portfolio is Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several other geographies around the world. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. In February 2019, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In the first quarter of 2020, the British Medicines and Healthcare Products Regulatory Agency issued a Promising Innovative Medicine designation for AT-GAA for the treatment of late-onset Pompe disease. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has established an industry leading gene therapy portfolio of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital ("Nationwide Children's") and an expanded collaboration with the University of Pennsylvania ("Penn"). The Company's pipeline includes gene therapy programs in rare, neurologic lysosomal disorders ("LDs"), specifically: CLN6, CLN3, and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), Niemann-Pick Type C (&#8220;NPC&#8221;), Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). This expanded collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies In the first quarter of 2020, the FDA granted Fast Track designation to the CLN3 Batten disease gene therapy, AT-GTX-502, for the treatment of pediatric patients less than 18 years of age. </span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company's operations have not yet been significantly impacted from the novel coronavirus (&#8220;COVID-19&#8221;) pandemic. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, and maintained its clinical trials, with minimal disruption. The Company believes its ability to continue to operate without any significant disruptions will depend on the continued health of its employees, the ongoing demand for Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and the continued operation of its global supply chain. The Company has continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of its global workforce. However, the Company's results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-8" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180My9mcmFnOmRhZDZiZTAwMWM3OTRkNmY4YjUzNzY2YWE0OWJiM2M5L3RleHRyZWdpb246ZGFkNmJlMDAxYzc5NGQ2ZjhiNTM3NjZhYTQ5YmIzYzlfMzU4Nw_b75c25dc-fd47-4805-86f8-e059b963dfbd">1.9</ix:nonFraction> billion as of March 31, 2020 and anticipates incurring losses through the fiscal year ending December 31, 2020 and beyond. The Company has historically funded its operations through stock offerings, debt issuances, Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> revenues, collaborations, and other financing arrangements. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The current cash position, including expected Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> revenues, is sufficient to fund ongoing Fabry, Pompe, and gene therapy program operations well into the second half of 2022. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">8</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_46"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="margin-top:12pt;margin-bottom:12pt;"><span><br/></span></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 2. <ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNzE_12be4865-a151-4271-9f79-6add5f4bd99b" continuedAt="i6b0b96a76f4a4b50883f0302f3ab754e" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i6b0b96a76f4a4b50883f0302f3ab754e" continuedAt="ibe74678d3f7d4bf1821a2b098dd1e2d8"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyMzc_68ecc617-a80e-4ea2-a800-b98288aa97c8" continuedAt="ib8293ac582ff4cbea99a94f5ff34faf2" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.</span></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ib8293ac582ff4cbea99a94f5ff34faf2">The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2019.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2019.</ix:continuation> </span></div><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNjk_489d504f-a47f-4c09-8690-12c46b736687" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Consolidation</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyMTQ_dcd07184-f2a6-41a1-b8bb-62303a5c26bd" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Transactions</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNDk_ca70bc75-005a-4479-bc22-c3330582cb2e" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of March 31, 2020 and through the issuance of this report. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div></ix:nonNumeric><div style="text-indent:18pt;"><span><br/></span></div><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyMjQ_7926f5dd-ad0f-4b76-8a73-a744228f43dd" continuedAt="ib51f9a874fcc4787a87f6e7203155074" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="ib51f9a874fcc4787a87f6e7203155074">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company's Consolidated Balance Sheets.</ix:continuation> </span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">9</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><ix:continuation id="ibe74678d3f7d4bf1821a2b098dd1e2d8" continuedAt="ia413a0299cfd4a16b6937d7c221b576e"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNjA_b671912f-2e9c-46bd-a0fe-bf447cd2c540" continuedAt="i90b84ee957f64b2ca0e4d899a0d40df1" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;"><ix:continuation id="i90b84ee957f64b2ca0e4d899a0d40df1" continuedAt="i687f74c0d80e41c3a1bbcdcaa8786ba3"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"><ix:continuation id="i687f74c0d80e41c3a1bbcdcaa8786ba3">. The Company's accounts receivable at March 31, 2020 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers and the geographic economic environments and conditions to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.</ix:continuation> As of March 31, 2020, the Company recorded an allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfNDg2NA_b7dcf3ec-de49-4c23-bb43-be94af94a029">0.1</ix:nonFraction> million.</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNjY_6f89e176-55bf-47cf-bad5-9b6a5408a0cf" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's net product sales consist of sales of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> are generally received from distributors and pharmacies with the ultimate payor often a government authority. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the sale of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNjE_b463424d-a52b-46a1-916f-f40f04c1fb6c" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company's net product sales from Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> disaggregated by geographic area:</span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:71.900%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.316%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.318%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i31b61ba1de064ab9a35f6ea596b4cac0_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RhYmxlOjFkZmU2MTlhM2ExZDRkMGViNmVjZjUxYzEzMWNlZjVjL3RhYmxlcmFuZ2U6MWRmZTYxOWEzYTFkNGQwZWI2ZWNmNTFjMTMxY2VmNWNfMi0yLTEtMS0w_90f6ab7f-4021-4b6a-bbfb-a4f38a83095c">17,772</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6665e4e8d56945d6a3eb5b178eed1e42_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RhYmxlOjFkZmU2MTlhM2ExZDRkMGViNmVjZjUxYzEzMWNlZjVjL3RhYmxlcmFuZ2U6MWRmZTYxOWEzYTFkNGQwZWI2ZWNmNTFjMTMxY2VmNWNfMi00LTEtMS0w_fd7d8fb1-8f2d-4d43-b034-447ee679ac5e">9,068</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ex-U.S.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4e9b6c86da6148bc9f33450341bbd731_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RhYmxlOjFkZmU2MTlhM2ExZDRkMGViNmVjZjUxYzEzMWNlZjVjL3RhYmxlcmFuZ2U6MWRmZTYxOWEzYTFkNGQwZWI2ZWNmNTFjMTMxY2VmNWNfMy0yLTEtMS0w_6467ee1b-c67f-4dcc-a06c-f6f5721062d1">42,753</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i713aa7461f474212a79f6fbf3e5b8ce4_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RhYmxlOjFkZmU2MTlhM2ExZDRkMGViNmVjZjUxYzEzMWNlZjVjL3RhYmxlcmFuZ2U6MWRmZTYxOWEzYTFkNGQwZWI2ZWNmNTFjMTMxY2VmNWNfMy00LTEtMS0w_a30d795a-508a-40bc-9ddc-f31f3403596c">24,978</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RhYmxlOjFkZmU2MTlhM2ExZDRkMGViNmVjZjUxYzEzMWNlZjVjL3RhYmxlcmFuZ2U6MWRmZTYxOWEzYTFkNGQwZWI2ZWNmNTFjMTMxY2VmNWNfNC0yLTEtMS0w_6885a132-58ba-4ede-ab37-080db877f2a2">60,525</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RhYmxlOjFkZmU2MTlhM2ExZDRkMGViNmVjZjUxYzEzMWNlZjVjL3RhYmxlcmFuZ2U6MWRmZTYxOWEzYTFkNGQwZWI2ZWNmNTFjMTMxY2VmNWNfNC00LTEtMS0w_9cebf099-9765-4d1a-83b1-ca12ebbfebc9">34,046</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:InventoryCostsForContractsOrProgramsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyMzM_e1b729b7-3267-427f-b8a7-47e444452d9e" continuedAt="i353523ee63d449ad8c5ca49b8f7d2057" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Inventories and Cost of Goods Sold</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i353523ee63d449ad8c5ca49b8f7d2057">Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.</ix:continuation> </span></div><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNDg_ac8e4271-d185-46b9-97e4-faf4a14c2cff" continuedAt="i595ce94f02be4da1ab9b34973441c5ec" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. </span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">10</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><ix:continuation id="ia413a0299cfd4a16b6937d7c221b576e" continuedAt="i633e395f080648b9864f5d819c633004"><ix:continuation id="i595ce94f02be4da1ab9b34973441c5ec" continuedAt="i8f69491f55a4487ebb843e775745f173"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lease term for all of the Company's leases include the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. </span></div></ix:continuation><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i8f69491f55a4487ebb843e775745f173">Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</ix:continuation> </span></div><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyMzQ_2361916e-1c4e-4b41-bb4d-03ac610181e6" continuedAt="i55549edf08cd43adb0f1e81de28ea0d8" escape="true"><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Developments - Guidance Adopted in 2020</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2018-15 - In August 2018, the Financial Accounting Standards Board ("FASB") issued&#160;Accounting Standards Update ("ASU") 2018-15,&#160;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): ("ASU 2018-15"), relating to a customer&#8217;s accounting for implementation, set-up, and other upfront costs incurred in a&#160;cloud computing&#160;arrangement that is hosted by a vendor. Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance does not affect the accounting for the service element of a hosting arrangement that is a service contract. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized software costs and related amortization expense and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for public companies. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2018-13 - In August 2018, the FASB issued ASU 2018-03, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on (i) changes in unrealized gains and losses, (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and (iii) the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2017-04 - In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2016-13 - In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected and amends guidance on the impairment of financial instruments. ASU 2016-13 is effective for public companies who are SEC filers for fiscal years beginning after December 15, 2019, including interim periods within those years. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">11</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><ix:continuation id="i633e395f080648b9864f5d819c633004"><ix:continuation id="i55549edf08cd43adb0f1e81de28ea0d8"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Developments - Guidance Not Yet Adopted</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2019-12 - In December 2019, the FASB issued ASU 2019-15, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following apply in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#8217; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted for public business entities for periods for which financial statements have not yet been issued. The Company is currently assessing the impact that this standard will have on the Company's Consolidated Financial Statements upon adoption.</span></div></ix:continuation></ix:continuation><div id="i37a61778173840fc811d567d8624cfac_52"></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 3.&#160;<ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMjY0NA_ece4b62d-7e7d-4228-9fde-7169f6d24abe" continuedAt="id0f3a15e9e88404dab5f05c2ddf09881" escape="true">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</ix:nonNumeric></span></div><ix:continuation id="id0f3a15e9e88404dab5f05c2ddf09881" continuedAt="ibeff4e8f0ad44ef8bbdff47dfc83f59a"><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of March 31, 2020, the Company held $<ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMTA4_9c29018c-aa9e-42de-b621-575acd2d67c7">123.2</ix:nonFraction> million in cash and cash equivalents and $<ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMTQ2_1ecae38d-d3b8-4c83-9dea-f354c4b48a7a">215.6</ix:nonFraction> million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within accumulated other comprehensive loss in the Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#8217;s fair value is determined to less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss the Company would recognize an allowance and the corresponding credit loss would be included in earnings.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">12</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><ix:continuation id="ibeff4e8f0ad44ef8bbdff47dfc83f59a" continuedAt="i18b1e53403754c138519735692feb5ae"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfODI0NjMzNzIxMTIxNQ_891cf6ba-d209-44cb-a57b-d8e115ef34b3" continuedAt="ib708f7f6a96b46b0a46035319e2d0297" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: </span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:44.198%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.719%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.725%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31, 2020</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMi0yLTEtMS0w_85bfa4f7-10d1-4d51-84e3-31d711cdd9e2">123,231</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMi04LTEtMS0w_35603d1b-d313-4061-a500-4f9cb075c150">123,231</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie299466a221248989d0654e27aa2fa15_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMy0yLTEtMS0w_2ea2c522-d9db-4ff5-82ed-871af3ae3ee8">107,152</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie299466a221248989d0654e27aa2fa15_I20200331" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMy00LTEtMS0w_77b73d06-a681-4815-8f35-c7364a2607f8">65</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ie299466a221248989d0654e27aa2fa15_I20200331" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMy02LTEtMS0w_012b35a7-0b7c-4d3c-9757-328c978fd360">119</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie299466a221248989d0654e27aa2fa15_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMy04LTEtMS0w_c1005547-4e80-40a7-bd92-c1eb6b5ec314">107,098</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76dd233dc95c43edb284968ccf887232_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNC0yLTEtMS0w_6355260f-de4d-4943-83ed-413d1d6eecb3">35,248</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76dd233dc95c43edb284968ccf887232_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNC00LTEtMS0w_7338bb3a-d313-4701-99b2-f42ed972b4bd">100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76dd233dc95c43edb284968ccf887232_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNC02LTEtMS0w_2da51c30-d4e8-4738-a800-cdb3ef1d5617">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76dd233dc95c43edb284968ccf887232_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNC04LTEtMS0w_19c7a407-5646-4b21-ade9-df109b3cd300">35,348</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79d9f3582ceb4f39b144041e9d62cd8f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNS0yLTEtMS0w_fcbb2cf0-3563-4744-bcfb-c25ba66264d0">68,812</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79d9f3582ceb4f39b144041e9d62cd8f_I20200331" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNS00LTEtMS0w_34887a56-6d5b-450e-96ef-ea23c4885988">25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i79d9f3582ceb4f39b144041e9d62cd8f_I20200331" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNS02LTEtMS0w_34c22f33-9a5e-4d8a-a4dd-baf17fbd223e">42</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79d9f3582ceb4f39b144041e9d62cd8f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNS04LTEtMS0w_74feb5d3-4ebf-4da8-a4f8-7b69a0c7c77f">68,795</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e582d44c1854742ab6c8ed5ee290d43_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNi0yLTEtMS0w_3c0531d6-f277-4b1a-8a28-57b923bdfd79">4,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e582d44c1854742ab6c8ed5ee290d43_I20200331" decimals="-3" format="ixt:zerodash" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNi00LTEtMS0w_ec9acbcf-c823-4e30-addb-ab586adb0329">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e582d44c1854742ab6c8ed5ee290d43_I20200331" decimals="-3" format="ixt:zerodash" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNi02LTEtMS0w_30d06b2f-d673-47e6-a5da-75ed5eb0b1ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e582d44c1854742ab6c8ed5ee290d43_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNi04LTEtMS0w_bcf6bc94-684e-4c30-812c-ac8fce8efa77">4,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14951a04eb4e4b7b9d35f47bed16e634_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNy0yLTEtMS0w_22769555-ec42-4b9e-8aff-ee28ba18a0fc">350</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14951a04eb4e4b7b9d35f47bed16e634_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNy00LTEtMS0w_798a7505-da94-4c3f-9c52-e9d004f19b30">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14951a04eb4e4b7b9d35f47bed16e634_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNy02LTEtMS0w_724fc1a2-56e7-4fa7-b185-bf0922fa25d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14951a04eb4e4b7b9d35f47bed16e634_I20200331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNy04LTEtMS0w_dd8016d7-1c5a-49b0-9e28-8c3f0aa7339f">350</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ef63e91418e4383b7ebde0b9c4cffe0_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOC0yLTEtMS0w_653c5999-4c6c-4095-ad0f-6e44530f5390">51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ef63e91418e4383b7ebde0b9c4cffe0_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOC00LTEtMS0w_aca4ccc7-0977-4377-98e8-219939f6a345">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ef63e91418e4383b7ebde0b9c4cffe0_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOC02LTEtMS0w_1e4b43f1-8347-4c81-bfe6-6a0eaae80100">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3ef63e91418e4383b7ebde0b9c4cffe0_I20200331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOC04LTEtMS0w_99a18386-05be-4c61-a538-2cb7abe1f18f">51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOS0yLTEtMS0w_3265eef3-d5f3-4f9f-82a4-e08975cd1ef3">338,844</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOS00LTEtMS0w_75d5046c-d256-4513-b2cd-fec4a321bcb4">190</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOS02LTEtMS0w_34927268-9d13-4a73-9394-243085884225">161</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOS04LTEtMS0w_5ebe1d79-48c1-4ed9-97bb-375b78876c6f">338,873</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTAtMi0xLTEtMA_ade16c0d-02d7-4c23-95f1-cb08a8627c1c">123,231</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTAtOC0xLTEtMA_be5fd57d-2c53-4737-9564-f64089ff4ad8">123,231</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Included in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTEtMi0xLTEtMA_236e9615-fdb2-4a37-8919-16679d2416a7">215,613</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTEtNC0xLTEtMA_83881467-1274-4ea3-a901-b969e67a379b">190</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTEtNi0xLTEtMA_100620b7-6d15-4a1a-bc0b-bcde85862f6d">161</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTEtOC0xLTEtMA_ab799070-c49d-405a-bc9e-0f5f2f360149">215,642</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTItMi0xLTEtMA_c8518b48-839f-48ce-b981-597a13992221">338,844</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTItNC0xLTEtMA_e1f3b87b-aa1a-4946-b50a-a16ccf5bbfec">190</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTItNi0xLTEtMA_348c14b9-a25d-4b64-a031-ec0c95c60d78">161</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTItOC0xLTEtMA_4ba24fb6-4761-437c-9d6f-91570c12a900">338,873</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:44.120%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMi0yLTEtMS0w_8317968b-dc57-4f11-9b16-9cd6b9e2f0ac">142,837</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMi04LTEtMS0w_1099c751-00b7-40c5-9556-01260e1ab351">142,837</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i555c0f48291d4b38b8d561d915768eff_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMy0yLTEtMS0w_2627fb3e-9a2d-4178-9459-43fcd38cd2ed">145,875</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i555c0f48291d4b38b8d561d915768eff_I20191231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMy00LTEtMS0w_53e4b64a-7477-4c43-8b83-77e7bee2846d">121</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i555c0f48291d4b38b8d561d915768eff_I20191231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMy02LTEtMS0w_eac929ee-082e-437d-a5ab-42abff31babf">5</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i555c0f48291d4b38b8d561d915768eff_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMy04LTEtMS0w_bbea5b33-41fc-489f-8dc8-b76017289606">145,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69bfb02d155d46d7a1e1ec0c33f195ca_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNC0yLTEtMS0w_2f1a8b58-4ba4-48d9-b765-64167e2d8db5">73,659</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69bfb02d155d46d7a1e1ec0c33f195ca_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNC00LTEtMS0w_ebc5433b-9dc0-4f18-bd18-0fdbabf84ac4">53</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i69bfb02d155d46d7a1e1ec0c33f195ca_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNC02LTEtMS0w_d232e621-f8eb-4c46-a953-cb3bbd4a0b76">2</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69bfb02d155d46d7a1e1ec0c33f195ca_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNC04LTEtMS0w_bad0aad4-6b07-402e-b08d-52be6f9318d1">73,710</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i780f97fa745c46f2a97bd268ba15bc18_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNS0yLTEtMS0w_9ec543d8-0dde-4d95-9432-ab0a8838b61c">77,731</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i780f97fa745c46f2a97bd268ba15bc18_I20191231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNS00LTEtMS0w_80c3a5e0-997f-45b1-ab0c-a24428200220">79</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i780f97fa745c46f2a97bd268ba15bc18_I20191231" decimals="-3" format="ixt:zerodash" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNS02LTEtMS0w_52e76dc8-7ed1-46ee-9593-8c3d5df772ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i780f97fa745c46f2a97bd268ba15bc18_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNS04LTEtMS0w_09a37801-d4da-402a-a116-22d90534bf7c">77,810</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1cd03431da34173829810953c60ca83_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNi0yLTEtMS0w_2ebbc635-bf2e-41fc-b531-a045259bb793">11,999</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1cd03431da34173829810953c60ca83_I20191231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNi00LTEtMS0w_e5310d11-f15b-46e3-9bbf-de0d08eab492">2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="ia1cd03431da34173829810953c60ca83_I20191231" decimals="-3" name="fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNi02LTEtMS0w_50fd97d1-5925-4417-8ad0-7b814f038a7e">10</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1cd03431da34173829810953c60ca83_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNi04LTEtMS0w_88f5ac96-f368-41f3-baa9-b4114862778e">11,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87a274e586cf4c16a08587c4031550b4_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNy0yLTEtMS0w_55219b0d-57fb-42d6-8922-e0406321eeae">350</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87a274e586cf4c16a08587c4031550b4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNy00LTEtMS0w_43d9b376-82cb-4ddb-bc71-eb41e79ef4a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87a274e586cf4c16a08587c4031550b4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNy02LTEtMS0w_1c6c62a1-f273-4ac4-8443-60fbde736e3d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87a274e586cf4c16a08587c4031550b4_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNy04LTEtMS0w_64cad344-2fa2-490d-93e5-84b2b71a2152">350</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if972968827f048e9b40900a185eca935_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOC0yLTEtMS0w_032be3d9-a5c6-4e14-9e32-f6aa9ffb2b03">51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if972968827f048e9b40900a185eca935_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOC00LTEtMS0w_15b32a2c-e183-4d45-b874-6820c6664eed">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if972968827f048e9b40900a185eca935_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOC02LTEtMS0w_5f84e12a-1e3f-4aae-88bb-ac05e31c365b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if972968827f048e9b40900a185eca935_I20191231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOC04LTEtMS0w_2750830b-8efa-43d4-9b5b-836d9d644989">51</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOS0yLTEtMS0w_4923a47d-dd53-4cec-bf78-f1ddede26f66">452,502</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOS00LTEtMS0w_b39fc1b4-4252-4152-91e2-412e6cd47125">255</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOS02LTEtMS0w_0cf2080d-5242-40e5-b36b-1937b5b2f076">17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOS04LTEtMS0w_1b48e9c9-cf5b-4182-ac51-0c151b9da98d">452,740</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTAtMi0xLTEtMA_3ec4aefc-249a-4c90-a0b3-c3593c882771">142,837</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTAtOC0xLTEtMA_5fe347ad-e7a8-461a-b786-635af9d5751f">142,837</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Included in marketable securities</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTEtMi0xLTEtMA_b30af807-da81-46ee-bd00-05c9138d75e8">309,665</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTEtNC0xLTEtMA_6e3a6755-cf95-44f1-96db-50408a312e93">255</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTEtNi0xLTEtMA_7381f057-f2ec-4f66-b8e3-98aa27208996">17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTEtOC0xLTEtMA_fc0f61d9-6261-4159-a728-6568c96386dd">309,903</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTItMi0xLTEtMA_1dbbb68d-8509-4abb-a80f-d9e7f2b0e97d">452,502</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTItNC0xLTEtMA_46d49b2e-4ac5-466a-b8cc-8f14d8d93036">255</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTItNi0xLTEtMA_caa88a3e-a472-49d8-ba14-32685ffabd28">17</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTItOC0xLTEtMA_bfc455f4-82d4-436c-bf38-40b14c4a59d0">452,740</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________________________</span></div></ix:nonNumeric><div style="text-align:justify;margin-bottom:12pt;"><ix:continuation id="ib708f7f6a96b46b0a46035319e2d0297" continuedAt="if9499c9931ae44e98b3a74e91f17e3a2"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">As of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">December 31, 2019</span></ix:continuation><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"><ix:continuation id="if9499c9931ae44e98b3a74e91f17e3a2">, $<ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMTY3MQ_6a80f878-f332-4508-9fc2-4cc47645c5b2">9.5</ix:nonFraction> million of marketable securities have maturity dates greater than 12 months and are available to convert into cash, if needed.</ix:continuation>&#160;</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2020 there were <ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMTgzNA_b02bf94a-6c93-4ff8-9e41-59fa4634fafa">no</ix:nonFraction>minal realized gains. For the fiscal year ended December 31, 2019, there were <ix:nonFraction unitRef="usd" contextRef="iaae514757a6c44d4a4b8a4a9a318e979_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesRealizedGainLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMTkwNQ_b24b5e76-7b81-4a50-99f4-b9f971121dd0">no</ix:nonFraction> realized gains or losses. The cost of securities sold is based on the specific identification method.</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Unrealized loss positions in the marketable securities as of March 31, 2020 and December 31, 2019 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized in other comprehensive gain (loss). The fair value of these marketable securities in unrealized loss positions was $<ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMjM0Mg_c6b13708-4668-4fb6-83ef-206d9eddd64c">99.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMjM1MA_4e25378e-9686-4f4f-889f-13ccffaddfe6">42.6</ix:nonFraction> million as of March 31, 2020 and December 31, 2019, respectively.&#160; </span></div></ix:continuation><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">13</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><ix:continuation id="i18b1e53403754c138519735692feb5ae"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMjYzNA_9282eb89-b77e-438b-b391-6b5cd9f9d99e" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:68.175%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.181%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.530%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.184%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjc1MWI4ZjgxOWViMjQ5ZmNiZmMyMTE1MjhhOGY4OWIxL3RhYmxlcmFuZ2U6NzUxYjhmODE5ZWIyNDlmY2JmYzIxMTUyOGE4Zjg5YjFfMS0yLTEtMS0w_f97bd11a-7640-4099-8f8a-edde3dd024ae">123,231</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjc1MWI4ZjgxOWViMjQ5ZmNiZmMyMTE1MjhhOGY4OWIxL3RhYmxlcmFuZ2U6NzUxYjhmODE5ZWIyNDlmY2JmYzIxMTUyOGE4Zjg5YjFfMS02LTEtMS0w_cd921979-27ab-4b96-9881-a0afbb9cb831">96,349</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjc1MWI4ZjgxOWViMjQ5ZmNiZmMyMTE1MjhhOGY4OWIxL3RhYmxlcmFuZ2U6NzUxYjhmODE5ZWIyNDlmY2JmYzIxMTUyOGE4Zjg5YjFfMi0yLTEtMS0w_5f628b7a-8a9e-49fa-8a14-2d3a2d2f6fb7">2,662</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjc1MWI4ZjgxOWViMjQ5ZmNiZmMyMTE1MjhhOGY4OWIxL3RhYmxlcmFuZ2U6NzUxYjhmODE5ZWIyNDlmY2JmYzIxMTUyOGE4Zjg5YjFfMi02LTEtMS0w_ee7f5a22-124e-461c-9632-c4a970c413eb">2,579</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjc1MWI4ZjgxOWViMjQ5ZmNiZmMyMTE1MjhhOGY4OWIxL3RhYmxlcmFuZ2U6NzUxYjhmODE5ZWIyNDlmY2JmYzIxMTUyOGE4Zjg5YjFfMy0yLTEtMS0w_8247003d-4ef6-4332-a097-8d63eb2fcc94">125,893</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjc1MWI4ZjgxOWViMjQ5ZmNiZmMyMTE1MjhhOGY4OWIxL3RhYmxlcmFuZ2U6NzUxYjhmODE5ZWIyNDlmY2JmYzIxMTUyOGE4Zjg5YjFfMy02LTEtMS0w_3ff1b3d6-fb1e-49de-a4e0-8a49088b22a0">98,928</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div id="i37a61778173840fc811d567d8624cfac_55"></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 4.&#160;<ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RleHRyZWdpb246NzFkNzA4ZTFiZTBlNGJlNmJmZTI0MDI1NTk5ZmFjZjBfMjgw_713baf54-0e14-46cd-b2b7-f67e73c886ef" continuedAt="i3468ffdb6e8b4f7ea5fde6e6b941049e" escape="true">Inventories</ix:nonNumeric></span></div><ix:continuation id="i3468ffdb6e8b4f7ea5fde6e6b941049e" continuedAt="i1e25673fecb44c378651526dd8d65d22"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories consist of raw materials, work-in-process, and finished goods related to the manufacture of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. <ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RleHRyZWdpb246NzFkNzA4ZTFiZTBlNGJlNmJmZTI0MDI1NTk5ZmFjZjBfMjgz_56894f5c-b0da-4b3e-a6cc-984127a8e647" continuedAt="i11369ffd1cda467aa6177d889ebd74dd" escape="true">The following table summarizes the components of inventories: </ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:15pt;"><ix:continuation id="i11369ffd1cda467aa6177d889ebd74dd"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:67.648%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.809%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.077%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfMS0yLTEtMS0w_48f9c47e-6d38-4032-8525-0bd387929b64">5,322</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfMS00LTEtMS0w_855695b6-3a6f-4fed-a15d-15f5deda91d3">6,544</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfMi0yLTEtMS0w_19c194ef-d2da-40d1-ba01-e8699faad7b1">2,900</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfMi00LTEtMS0w_bd6ff3bc-98b1-4a7c-84df-d2c1d16bf842">3,660</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfMy0yLTEtMS0w_e9688249-d45c-4f3d-9fa0-bf3b6ca8f1c0">4,609</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfMy00LTEtMS0w_f0975bff-b4ac-4825-b6da-c7f631d5ee4e">3,837</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfNC0yLTEtMS0w_5ef91bc6-e587-4171-b797-d6542ed899fc">12,831</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfNC00LTEtMS0w_80427761-fce0-4699-9acb-bb423e4407b6">14,041</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div></ix:continuation><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"><ix:continuation id="i1e25673fecb44c378651526dd8d65d22">The Company recorded a reserve for inventory of $<ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RleHRyZWdpb246NzFkNzA4ZTFiZTBlNGJlNmJmZTI0MDI1NTk5ZmFjZjBfMjU0_52a568ed-089c-4280-80ad-48faf13c4f25"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryValuationReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RleHRyZWdpb246NzFkNzA4ZTFiZTBlNGJlNmJmZTI0MDI1NTk5ZmFjZjBfMjU0_5d1f35e8-2341-453f-8361-9a5f20a9892d">0.2</ix:nonFraction></ix:nonFraction> million as of March 31, 2020 and December 31, 2019.</ix:continuation>&#160;</span></div><div id="i37a61778173840fc811d567d8624cfac_61"></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">14</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 5.&#160;<ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfNzA5NQ_423c5aaf-3a82-4098-9bc2-1552fd09f824" continuedAt="i853bbb67bd734ff4b7ff9a797bda58a4" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="i853bbb67bd734ff4b7ff9a797bda58a4"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ConvertibleDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NzU1NQ_041acc10-2206-4216-8814-768cee5ccd82" continuedAt="i4768a8bda6354ca8a9de98aef1f22ad7" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's debt consists of the following: </span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:67.208%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.662%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.664%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Senior Secured Term Loan due 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i140e72212c4a4bfb81bf6148fb2aa0a6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMS0yLTEtMS0xNTQ4_e6f093e5-ba3a-4ba8-a725-1eb10dfe11ac">150,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3674ca7debaf4f0aafd63c83f885edf1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMS00LTEtMS0xNTQ4_2503493e-d784-4420-b999-285f035f8597">150,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Less: debt discount </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i140e72212c4a4bfb81bf6148fb2aa0a6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMi0yLTEtMS0xNTQ4_22a1f5fc-5500-4815-8954-8fbd1a56e694">2,142</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3674ca7debaf4f0aafd63c83f885edf1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMi00LTEtMS0xNTQ4_c7d09e6f-cc3e-4bca-aaf5-6b1e14d75759">2,315</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Less: deferred financing </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i140e72212c4a4bfb81bf6148fb2aa0a6_I20200331" decimals="-3" name="us-gaap:DeferredOfferingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMy0yLTEtMS0xNTQ4_6a36cd3f-9b40-4652-9b99-db84d597684f">289</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i3674ca7debaf4f0aafd63c83f885edf1_I20191231" decimals="-3" name="us-gaap:DeferredOfferingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMy00LTEtMS0xNTQ4_5c28a506-6ecd-4ff3-a6fa-ac8295b507d4">311</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net carrying value of the Senior Secured Term Loan</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i140e72212c4a4bfb81bf6148fb2aa0a6_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfNS0yLTEtMS0xODY4_18dee782-024e-4ff0-92c0-cc1b3df49e32">147,569</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3674ca7debaf4f0aafd63c83f885edf1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfNS00LTEtMS0xODcx_a950364c-894b-4e08-aab4-ee7e8ce7730c">147,374</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Convertible Notes due 2023 </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb44be7fb6564606a0f40b69c09e76c5_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfOC0yLTEtMS0xNTg3_1b23aa7a-8b3b-46c5-a3f3-ce80012d3243">2,825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b34927c8eaa48f08e87f87c3ed7a95c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfOC00LTEtMS0xNTg3_a45b2876-5c2f-4d43-baa9-65d7ce09ed44">2,825</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Less: debt discount </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb44be7fb6564606a0f40b69c09e76c5_I20200331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfOS0yLTEtMS0xNTg3_371904bf-bdaa-4b07-9572-1175b5379e1d">625</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b34927c8eaa48f08e87f87c3ed7a95c_I20191231" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfOS00LTEtMS0xNTg3_be423ecd-6045-4635-9c7f-d293df6aa061">659</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Less: deferred financing </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="icb44be7fb6564606a0f40b69c09e76c5_I20200331" decimals="-3" name="us-gaap:DeferredOfferingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMTAtMi0xLTEtMTU4Nw_2c4365b6-86d5-422f-b4c1-5e581185f34e">33</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i0b34927c8eaa48f08e87f87c3ed7a95c_I20191231" decimals="-3" name="us-gaap:DeferredOfferingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMTAtNC0xLTEtMTU4Nw_0582d845-0417-4bcb-9f24-063cebb17f73">35</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net carrying value of the Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icb44be7fb6564606a0f40b69c09e76c5_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMTEtMi0xLTEtMTg3NQ_fe575413-c583-4288-9d31-9c9a3879286e">2,167</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"></span></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i0b34927c8eaa48f08e87f87c3ed7a95c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMTEtNC0xLTEtMTg3Nw_0b5cb4b9-b805-4c86-a69d-595bdaffe7d9">2,131</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________________________</span></div><div style="text-align:justify;margin-top:3pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> Included in the Consolidated Balance Sheets within Convertible Notes and Senior Secured Term Loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</span></div></ix:nonNumeric><div style="text-align:justify;margin-top:3pt;margin-bottom:15pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"><ix:continuation id="i4768a8bda6354ca8a9de98aef1f22ad7" continuedAt="i2816193106164ab7a85aa9dc738e1343">(2)</ix:continuation></sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"><ix:continuation id="i2816193106164ab7a85aa9dc738e1343"> The Convertible Notes are currently convertible as the last reported sale price of the Company's common stock was equal to or more than <ix:nonFraction unitRef="number" contextRef="ic6b8135fdb4c48c0a197d684b3bef8b9_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTgwOQ_05de4854-adec-404f-972a-1ceac3ff5a0c">130</ix:nonFraction>% of the conversion price for at least <ix:nonNumeric contextRef="i44debd31ac6748d0a90567edb19522f6_D20200101-20200331" format="ixt-sec:durday" name="fold:DebtInstrumentsConvertibleThresholdTradingDays" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTgxOA_074e3aa5-40b5-4b50-9324-36632e187b96">20</ix:nonNumeric> trading days of the <ix:nonFraction unitRef="day" contextRef="ic6b8135fdb4c48c0a197d684b3bef8b9_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTgxNA_8d4802c0-0140-4522-ac0c-84f904e7603b">30</ix:nonFraction> consecutive trading days ending on the last day of the quarter.</ix:continuation> </span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">During the first quarter of 2019, the Company entered into separate, privately negotiated Exchange Agreements with a limited number of holders ("the Holders") of the unsecured Convertible Senior Notes due in 2023 ("the Convertible Notes"). Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331" decimals="-5" format="ixt:numdotdecimal" name="fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTgyNA_c1a36763-9044-42dd-905d-ac4b11afe670">219.3</ix:nonFraction>&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately <ix:nonFraction unitRef="shares" contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331" decimals="-5" format="ixt:numdotdecimal" name="fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NzQzMA_260a698c-0dd5-4db1-823f-e4a2c16e27be">39.0</ix:nonFraction>&#160;million shares of Company common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTg3NQ_dd3b03f6-622b-4056-8697-d22a038c068c">0.01</ix:nonFraction> per share. In addition, pursuant to the Exchange Agreements, the Company made aggregate cash payments of $<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="fold:DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NzQ1Nw_c3edef25-4151-4a94-a5be-3c4ac29dacc8">1.0</ix:nonFraction>&#160;million to the Holders to satisfy accrued and unpaid interest to the closing date of the transactions, along with cash in lieu of fractional shares. These transactions resulted in $<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="fold:GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NzQ4Ng_ec83c8af-9333-49e9-979d-14dab2833a81">190.4</ix:nonFraction>&#160;million in additional paid-in-capital and common stock of $<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="fold:GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTg0NA_7888916e-8638-40e6-97ed-b395cc0eddca">0.4</ix:nonFraction>&#160;million on the Consolidated Balance Sheets as of March 31, 2019. Additionally, the Company recognized a net loss on the exchange of debt of $<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTkxNA_9976abf7-ed7b-4690-94ba-c5661cc65add">36.1</ix:nonFraction>&#160;million on the Consolidated Statements of Operations for the three months ended March 31, 2019. </span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:1pt;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">During the first quarter of 2019, the Company terminated the Capped Call Confirmations related to the exchange of the Convertible Notes for proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NzQwMg_07f25940-3dac-4880-be72-8ebca00a7c84"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-5" format="ixt:numdotdecimal" name="fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NzQwMg_b51394c2-cd4f-403c-86a6-230530bf6b95">14.6</ix:nonFraction></ix:nonFraction>&#160;million.  </span></div><div style="text-indent:22.5pt;"><span><br/></span></div><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfNzA5MA_257a8583-0a43-416d-bf2b-cad01ee827c1" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth interest expense recognized related to the Company's debt for the three months ended March 31, 2020 and 2019, respectively:</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:70.140%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.049%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.826%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:11.052%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOmRiODY5OTE3NDg1ZDQ1Y2RiZjY0ODNiYWI5NDExMzY0L3RhYmxlcmFuZ2U6ZGI4Njk5MTc0ODVkNDVjZGJmNjQ4M2JhYjk0MTEzNjRfMi0yLTEtMS0w_f90051bd-d381-4613-ada4-9775570d02c5">3,585</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOmRiODY5OTE3NDg1ZDQ1Y2RiZjY0ODNiYWI5NDExMzY0L3RhYmxlcmFuZ2U6ZGI4Njk5MTc0ODVkNDVjZGJmNjQ4M2JhYjk0MTEzNjRfMi00LTEtMS0w_0592166e-6668-4e69-993d-7d877f9866dc">4,813</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOmRiODY5OTE3NDg1ZDQ1Y2RiZjY0ODNiYWI5NDExMzY0L3RhYmxlcmFuZ2U6ZGI4Njk5MTc0ODVkNDVjZGJmNjQ4M2JhYjk0MTEzNjRfMy0yLTEtMS0w_67835fbf-b59d-40d4-96ca-6952bbeb0b5d">206</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOmRiODY5OTE3NDg1ZDQ1Y2RiZjY0ODNiYWI5NDExMzY0L3RhYmxlcmFuZ2U6ZGI4Njk5MTc0ODVkNDVjZGJmNjQ4M2JhYjk0MTEzNjRfMy00LTEtMS0w_8d4859f3-6a4a-4e97-ba46-f15731a0ca5c">1,559</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" name="fold:AmortizationDeferredFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOmRiODY5OTE3NDg1ZDQ1Y2RiZjY0ODNiYWI5NDExMzY0L3RhYmxlcmFuZ2U6ZGI4Njk5MTc0ODVkNDVjZGJmNjQ4M2JhYjk0MTEzNjRfNC0yLTEtMS0w_3cfd38a5-c349-4e0c-9f83-cd9c8a89493d">25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" name="fold:AmortizationDeferredFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOmRiODY5OTE3NDg1ZDQ1Y2RiZjY0ODNiYWI5NDExMzY0L3RhYmxlcmFuZ2U6ZGI4Njk5MTc0ODVkNDVjZGJmNjQ4M2JhYjk0MTEzNjRfNC00LTEtMS0w_c37a4188-c375-4a54-8ca1-2a3d913d5892">83</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">15</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_70"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-indent:2.25pt;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 6. <ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMjgzOA_41c66156-8d80-4333-a2a6-5f08d02434a3" continuedAt="if1f05f773fca46efaa152f3df75ab630" escape="true">Share-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="if1f05f773fca46efaa152f3df75ab630" continuedAt="ice12b91e23e844768d688242a87d16ef"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's Equity Incentive Plans consist of the Amended and Restated 2007 Equity Incentive Plan (the "Plan") and the 2007 Director Option Plan (the "2007 Director Plan"). The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock Option Grants</span></div><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMjgyOA_7a8148b7-fb05-4911-a6c7-e52ac5935af0" continuedAt="ief0a7171e02d4a57a7b98b9b787fa509" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.792%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected stock price volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfMi0xLTEtMS0w_eefd62d2-21b1-45ea-a99c-266a1401d6fb">75.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ibe7c67f71a114f90ae76db8af5fe4c45_D20190101-20190331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfMi0zLTEtMS0w_a06fce9b-ebc1-4977-ae36-bbc4d88f2e18">74.2</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfMy0xLTEtMS0w_5b29e8ed-31f5-4a0a-82c2-676fed00f0cf">1.7</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ibe7c67f71a114f90ae76db8af5fe4c45_D20190101-20190331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfMy0zLTEtMS0w_d0a92e46-b1d9-4d5b-9100-191363697c0b">2.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Expected life of options (years)</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfNC0xLTEtMS0w_0f80a3d6-80f2-44a4-8e1b-3265d3d9f6c8">5.67</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ibe7c67f71a114f90ae76db8af5fe4c45_D20190101-20190331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfNC0zLTEtMS0w_5292e98e-ae6f-4b29-83ed-2875b44099fb">5.68</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected annual dividend per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" decimals="INF" format="ixt:zerodash" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfNS0xLTEtMS0w_3aa0e066-09e4-4e22-8234-83ebe556867a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe7c67f71a114f90ae76db8af5fe4c45_D20190101-20190331" decimals="INF" format="ixt:zerodash" name="fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfNS0zLTEtMS0w_2860d561-a07f-4ad8-905b-cf2129aa6ce8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;______________________________</span></div></ix:nonNumeric><div style="text-align:justify;margin-bottom:15pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"><ix:continuation id="ief0a7171e02d4a57a7b98b9b787fa509" continuedAt="i9a6a3c0c748847faa41f3497d8a839e0">(1)</ix:continuation></sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"><ix:continuation id="i9a6a3c0c748847faa41f3497d8a839e0"> The average expected life is determined using actual historical data.</ix:continuation> </span></div><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMjgzMA_9f99352e-16ee-4759-b167-dcdc2ce17ce9" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the Company's stock options for the three months ended March 31, 2020 were as follows:</span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:44.852%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.741%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise&#160;<br/>Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining <br/>Years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3357c282064f406dac5037a4c2b21d13_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfMi0xLTEtMS0w_df430cb9-a2fd-4644-bbfb-43cf0a95db0f">16,724</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i3357c282064f406dac5037a4c2b21d13_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfMi0zLTEtMS0w_3573c2bd-febb-4021-8a4b-484b6f63706f">9.15</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfMy0xLTEtMS0w_24ccacd1-bf03-4e90-a6f8-1a23d1369b33">3,944</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfMy0zLTEtMS0w_dfe5c22f-4445-46e4-9dba-c9ae34b4cf52">9.57</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNC0xLTEtMS0w_dc89c84c-94ec-4e0e-a6e5-5d32ac71f9db">968</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNC0zLTEtMS0w_f61a4750-ae16-4c25-b92d-2712f63804e3">6.28</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNS0xLTEtMS0w_fdf645b9-3937-4e26-a98a-ca438bea5cd6">355</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNS0zLTEtMS0w_8370fe45-6e05-4b52-b763-a866912fee74">10.40</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNi0xLTEtMS0w_a4e1fcc2-a1d9-4c2a-815b-c2d55b48a587">259</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNi0zLTEtMS0w_c35d9e92-bd37-454f-96c4-6bf15553a7d6">13.08</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNy0xLTEtMS0w_1a20d2e7-c9c4-4436-b76e-69ad40280b6d">19,086</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNy0zLTEtMS0w_2148bd22-ca59-4619-be53-0752d310dab3">9.30</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNy01LTEtMS0w_07b431ea-a9ee-4467-8a5e-9066297cec1d">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNy03LTEtMS0w_1c08cb53-8cab-43f7-948e-e7aecbbc3caa">23.5</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and unvested expected to vest, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOC0xLTEtMS0w_568883d0-64bf-4bc1-a8ce-2015d95e211e">17,629</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOC0zLTEtMS0w_746f9897-c0e0-4c96-a9c4-9b38c15ddcab">9.23</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOC01LTEtMS0w_5fb009e3-0393-4fce-b381-4efb1000c086">6.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOC03LTEtMS0w_d2d7211e-a082-4bdc-be01-d7936ad99e2c">23.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOS0xLTEtMS0w_bcc93c4b-501c-4d34-ad46-1ea912ef8e81">10,808</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOS0zLTEtMS0w_6c4e5a4b-436a-48ae-ad3b-cd5c3dc02ecd">8.59</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOS01LTEtMS0w_a556446a-d670-4090-922c-0be4dd557302">5.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOS03LTEtMS0w_b05db707-a4c2-4bb8-a691-006e8f6dc8d5">21.4</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, the total unrecognized compensation cost related to non-vested stock options granted was $<ix:nonFraction unitRef="usd" contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMTYwMw_2acdcdf0-d4ee-4245-9ee8-e211753e502e">42.8</ix:nonFraction> million and is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMzg0ODI5MDcwMDI3OQ_e3ebdd5a-1953-421a-b0cf-30ffe2ad6455">three years</ix:nonNumeric>.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">16</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><ix:continuation id="ice12b91e23e844768d688242a87d16ef"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restricted Stock Units</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">and Performance-Based Restricted Stock Units (collectively "RSUs")</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. <ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMjg1MQ_904474bf-5c0b-4558-8acd-d7c555994f2e" continuedAt="i12a1747d2c164a08aed1015d1116d35a" escape="true">A summary of non-vested RSU activity under the Plan for the three months ended March 31, 2020 is as follows:</ix:nonNumeric></span></div><div style="text-align:center;margin-bottom:15pt;"><ix:continuation id="i12a1747d2c164a08aed1015d1116d35a"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.029%;"><tr><td style="width:1.0%;"></td><td style="width:39.076%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.384%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.569%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.384%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.569%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.384%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.569%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:8.465%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of&#160;Shares<br/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted <br/>Average Grant  <br/>Date Fair  <br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted&#160;<br/>Average<br/>Remaining&#160;<br/>Years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id011b45be10140f38519fd2adf3253d2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfMi0xLTEtMS0w_4cd8c5f2-fd2c-45f5-a663-cf434d434921">5,792</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="id011b45be10140f38519fd2adf3253d2_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfMi0zLTEtMS0w_423b6eef-9832-4bfb-88ce-779a0fd46434">11.18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfMy0xLTEtMS0w_460d0f7c-32c3-465e-9b0e-829d6beee274">3,600</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfMy0zLTEtMS0w_ccc2ffa8-26a7-413e-ae03-a652e78f7699">10.25</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNC0xLTEtMS0w_1bb347af-bb01-4e3e-81c8-ada271047c94">1,600</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNC0zLTEtMS0w_879be6be-893e-4d96-b329-4fa5d173b596">8.94</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="shares" contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNS0xLTEtMS0w_b5347ed2-d6f2-4a62-a2f3-3c9d177c75ed">230</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNS0zLTEtMS0w_57db7763-3488-462b-89d3-9291ddac34a3">10.67</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested units as of March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i086ab493f15f4e6680cd436cde171e07_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNi0xLTEtMS0w_6c9d1e8b-cb99-456b-afe9-be6a5f15c9cf">7,562</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usdPerShare" contextRef="i086ab493f15f4e6680cd436cde171e07_I20200331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNi0zLTEtMS0w_da33bae7-5f45-440a-90a2-32c9a9e450fd">11.18</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNi01LTEtMS0w_82af1f4f-ae7b-41f6-8d23-8f66084e9b17">2.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i086ab493f15f4e6680cd436cde171e07_I20200331" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNi03LTEtMS0w_9cad8159-49e3-4d26-aa41-2665bbf157a3">69.9</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></ix:continuation></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All non-vested units are expected to vest over their normal term. As of March 31, 2020, there was $<ix:nonFraction unitRef="usd" contextRef="i086ab493f15f4e6680cd436cde171e07_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMzg0ODI5MDcwMDI4NQ_b2d06d45-53d7-4396-a639-0e68701e3811">73.4</ix:nonFraction> million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331" format="ixt-sec:durwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMzg0ODI5MDcwMDMwMQ_8dfe4dbb-5ee9-474d-a6da-afe17dd7e05f">three years</ix:nonNumeric>.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Compensation Expense Related to Equity Awards</span></div><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMjgzNA_fbfac799-1332-4ae9-a9dd-b38c8a13b2a5" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.060%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity compensation expense recognized in:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ie57efb8719074ac89dbe8b6a28e6d637_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmFlNjZlOGIwNzg2NTQ5OGE5ZWQxZTM5MzhlY2VjYzU2L3RhYmxlcmFuZ2U6YWU2NmU4YjA3ODY1NDk4YTllZDFlMzkzOGVjZWNjNTZfMy0yLTEtMS0w_8da76768-7bcb-4897-adac-4d1eb2e20194">5,253</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1bddcfce942349258e4cb92f5ce02164_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmFlNjZlOGIwNzg2NTQ5OGE5ZWQxZTM5MzhlY2VjYzU2L3RhYmxlcmFuZ2U6YWU2NmU4YjA3ODY1NDk4YTllZDFlMzkzOGVjZWNjNTZfMy00LTEtMS0w_c4cc99d1-85ce-45b0-9018-d98d108a4b59">5,032</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib0c9afa9ca0b4b35bab63830db5c839b_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmFlNjZlOGIwNzg2NTQ5OGE5ZWQxZTM5MzhlY2VjYzU2L3RhYmxlcmFuZ2U6YWU2NmU4YjA3ODY1NDk4YTllZDFlMzkzOGVjZWNjNTZfNC0yLTEtMS0w_7405b71b-5293-435c-8579-267cdcf85ee5">7,343</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i1dc1a4e6d9264abd9af1dd18a8a59526_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmFlNjZlOGIwNzg2NTQ5OGE5ZWQxZTM5MzhlY2VjYzU2L3RhYmxlcmFuZ2U6YWU2NmU4YjA3ODY1NDk4YTllZDFlMzkzOGVjZWNjNTZfNC00LTEtMS0w_59ecb9c5-db41-4b6d-8178-6be02e9b873e">7,712</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity compensation expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmFlNjZlOGIwNzg2NTQ5OGE5ZWQxZTM5MzhlY2VjYzU2L3RhYmxlcmFuZ2U6YWU2NmU4YjA3ODY1NDk4YTllZDFlMzkzOGVjZWNjNTZfNS0yLTEtMS0w_9ddbdb44-6738-4e22-807f-782caf59de53">12,596</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmFlNjZlOGIwNzg2NTQ5OGE5ZWQxZTM5MzhlY2VjYzU2L3RhYmxlcmFuZ2U6YWU2NmU4YjA3ODY1NDk4YTllZDFlMzkzOGVjZWNjNTZfNS00LTEtMS0w_29e02b5f-41a7-470b-a7fc-425551702732">12,744</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div id="i37a61778173840fc811d567d8624cfac_73"></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Note 7.&#160;<ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RleHRyZWdpb246MWUyYzhmMjE0MzQ4NGIyODkxODg4YTViOGM2YWVhMDBfNTYxNw_01811006-6a97-47b7-84b0-3c10ef37eb4d" continuedAt="i5c3534f475a842c4aca792b94af5c23e" escape="true">Assets and Liabilities Measured at Fair Value</ix:nonNumeric></span></div><ix:continuation id="i5c3534f475a842c4aca792b94af5c23e" continuedAt="i4c7ac2d0a6f44831ba0df18e3f4e3883"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows:</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Inputs that are unobservable for the asset or liability.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">17</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><ix:continuation id="i4c7ac2d0a6f44831ba0df18e3f4e3883" continuedAt="i9db0ed1dd1c04a8587098d593db1a846"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RleHRyZWdpb246MWUyYzhmMjE0MzQ4NGIyODkxODg4YTViOGM2YWVhMDBfNTYxOA_57c2d3dd-83e8-43fa-b2a7-7129f1611ad1" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of March 31, 2020 are identified in the following table:</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.060%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands) </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69ecdce58c8e44a7b7446b787e6b5571_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfMi0yLTEtMS0w_ef703aff-c724-4ddf-bad9-c41648099ae4">35,348</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i76dd233dc95c43edb284968ccf887232_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfMi00LTEtMS0w_af7e8dfc-676c-4ee5-aa84-b4d374e267b6">35,348</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib14953c89ea842048d571e925165ae39_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfMy0yLTEtMS0w_4bed404c-81d2-4a8c-80f4-a8a0afe6344f">68,795</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i79d9f3582ceb4f39b144041e9d62cd8f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfMy00LTEtMS0w_edd1eea0-8228-45dc-893a-1c423fb758c9">68,795</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ifd85987fc9fb44248ab3d5d19af0664e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNC0yLTEtMS0w_a455e2c3-8be6-4545-9e5c-78221150c971">107,098</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ic98cbd8bf78c4e479a4b68211ebe7595_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNC00LTEtMS0w_d901e0f3-3f42-4a9f-8e10-7971d99a55bd">107,098</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i9850e46e79c9490ca6d79c93c720720b_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNS0yLTEtMS0w_f381f781-1e22-423c-86db-4b982f054f30">4,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i6e582d44c1854742ab6c8ed5ee290d43_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNS00LTEtMS0w_d37f4241-5a05-4f81-bde3-ea3e2dfb54d2">4,000</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="if74e828956b7436da5162de1eb41377f_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNi0yLTEtMS0w_317ea01e-0ffe-45ba-8671-2280e7757d34">3,378</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i14951a04eb4e4b7b9d35f47bed16e634_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNi00LTEtMS0w_cb2f79fa-edc3-4908-929c-d9628ea86066">3,378</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i975aba94542c4c2988e78b6ee343ef08_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNy0yLTEtMS0w_2e89e1d4-5a84-4e65-9894-e7700d1f43d9">218,619</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNy00LTEtMS0w_410d3ca3-b717-4f66-9aae-16bd56e9d009">218,619</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:58.058%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.481%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.775%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.484%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands) </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i975aba94542c4c2988e78b6ee343ef08_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfMi0yLTEtMS0w_a3c2e703-38bd-449d-8de4-e9f6205398b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a2116def0d444d1b2c560065e4d05c1_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfMi00LTEtMS0w_0399c9d7-3333-4c0d-96d0-bbe551663f20">23,612</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfMi02LTEtMS0w_3822536a-fb74-4398-88cd-131b36ec9c6b">23,612</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i975aba94542c4c2988e78b6ee343ef08_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfMy0yLTEtMS0w_dbc87e55-e15a-415d-bdc3-fea84a0d3c62">3,055</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a2116def0d444d1b2c560065e4d05c1_I20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfMy00LTEtMS0w_7a0caf99-b8d2-4e7d-a4fe-7746646716c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfMy02LTEtMS0w_36e28429-081b-4a13-8154-fb0d80614efd">3,055</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i975aba94542c4c2988e78b6ee343ef08_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfNC0yLTEtMS0w_68861b7f-ed1b-4a7d-944e-9e64f4c58e8f">3,055</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i4a2116def0d444d1b2c560065e4d05c1_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfNC00LTEtMS0w_2e7b6a2e-1777-4606-8611-191435696f43">23,612</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfNC02LTEtMS0w_b2a5f13f-5cd9-4218-961d-6a32e8f5efcf">26,667</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2019 are identified in the following table:</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.060%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i41235f69acc344c2ab91f52c5639a874_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfMi0yLTEtMS0w_6a37de9f-8308-4fa7-a347-c895c6365d02">73,710</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i69bfb02d155d46d7a1e1ec0c33f195ca_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfMi00LTEtMS0w_a56cff80-cdab-46a5-bf9e-c8354d2d3c76">73,710</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i00deaed1957b488787cdaa82dc50e59b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfMy0yLTEtMS0w_fe5538af-4b8b-45ae-8d8e-b9454e264f76">77,810</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i780f97fa745c46f2a97bd268ba15bc18_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfMy00LTEtMS0w_84bd759d-9420-4ec1-9fe8-95c3716151da">77,810</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i65b648c925e740579dcae60193ae3051_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNC0yLTEtMS0w_dffdb00c-2b5a-445a-bb3a-856cbc33c1cb">145,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7fa313342b3241bba30e7d90a90214b9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNC00LTEtMS0w_b3e0e405-8a15-4986-9b2b-f7dfbc32ed0d">145,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ib5ecdd9caab3473cb281d4bc13e0eca9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNS0yLTEtMS0w_7028d06f-7abc-4c04-a1b6-8110e39fce97">11,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1cd03431da34173829810953c60ca83_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNS00LTEtMS0xMzk0_c288d20e-ab55-4e39-a36c-0de56263a934">11,991</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i2e7a3776ad894ab5b362c7b3cf1a371c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNi0yLTEtMS0w_fc42ed4e-79c8-4080-937a-f1359ea8cba1">4,768</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i87a274e586cf4c16a08587c4031550b4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNi00LTEtMS0w_ab5bc5f3-ea6d-4135-9342-7fab65889851">4,768</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1230a6c7511406892e2964d9334d607_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNy0yLTEtMS0w_3608c32d-ef4e-4c57-a75e-979a193a6123">314,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNy00LTEtMS0w_ba333d2a-4879-4a9b-9b96-87ed3ae52458">314,270</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:61.876%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.306%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.306%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:9.310%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1230a6c7511406892e2964d9334d607_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfMi0yLTEtMS0w_c770a46e-20d0-44c6-9e0f-7eb8e91365fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55f9cd444bfc49af80a93225821ade9c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfMi00LTEtMS0w_e291a435-cca1-45d8-9a04-5c642e9a2264">22,681</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfMi02LTEtMS0w_4b940054-7252-4c1a-b930-eae125903ef1">22,681</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1230a6c7511406892e2964d9334d607_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfMy0yLTEtMS0w_551bfa9a-7d1c-4046-9800-d05544a2f4ec">4,419</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55f9cd444bfc49af80a93225821ade9c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfMy00LTEtMS0w_9f80545a-4cea-40e4-b307-62a515b0d47f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfMy02LTEtMS0w_1b9ef1be-acb4-430c-a0ac-265089d1fab5">4,419</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia1230a6c7511406892e2964d9334d607_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfNC0yLTEtMS0w_cd60df51-7967-474a-9b10-b3fccaa4f032">4,419</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i55f9cd444bfc49af80a93225821ade9c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfNC00LTEtMS0w_f2690a29-7575-4bac-85e7-867498aaad69">22,681</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfNC02LTEtMS0w_b251fc2d-9e83-4eaa-ae2e-9834933ee152">27,100</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's Convertible Notes fall into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. The fair value of the Convertible Notes at March 31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="i975aba94542c4c2988e78b6ee343ef08_I20200331" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ConvertibleDebtFairValueDisclosures" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RleHRyZWdpb246MWUyYzhmMjE0MzQ4NGIyODkxODg4YTViOGM2YWVhMDBfMTI0NQ_fe5b20bc-eef4-43af-855f-b6118ab58342">4.7</ix:nonFraction> million.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's Senior Secured Term Loan fall into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan approximates the fair value.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not have any Level 3 assets as of March 31, 2020 or December 31, 2019.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">18</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><ix:continuation id="i9db0ed1dd1c04a8587098d593db1a846"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Money Market Funds, and Marketable Securities</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingent Consideration Payable</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. ("Callidus") in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration payable for Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market.&#160;If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. </span></div><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RleHRyZWdpb246MWUyYzhmMjE0MzQ4NGIyODkxODg4YTViOGM2YWVhMDBfNTYyMQ_7ccd3f27-0b5d-4b66-9594-cb12929a9be6" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program: </span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.567%;"><tr><td style="width:1.0%;"></td><td style="width:18.625%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:13.468%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.625%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.625%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.581%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.533%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent&#160;Consideration<br/>Liability</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value as of March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation&#160;Technique</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable&#160;Input</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="number" contextRef="ib43a922550c542ecb66e87e81bc9113b_I20200331" decimals="3" name="fold:ContingentConsiderationMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmU5MjEzNzRjOTZiZTRmZDQ5NzU4YTRjMjhhNTBmYWQyL3RhYmxlcmFuZ2U6ZTkyMTM3NGM5NmJlNGZkNDk3NThhNGMyOGE1MGZhZDJfMy04LTEtMS0w_af2ce1a8-e5eb-40bd-b7fa-a8312c78836d">9.4</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i44733de43da34221b7d954e41f00c039_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmU5MjEzNzRjOTZiZTRmZDQ5NzU4YTRjMjhhNTBmYWQyL3RhYmxlcmFuZ2U6ZTkyMTM3NGM5NmJlNGZkNDk3NThhNGMyOGE1MGZhZDJfNS0yLTEtMS0w_1f5ca1cc-62e4-4727-a869-1b1373e94317">22,985</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability weighted discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability of achievement of milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75% - 78%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021 - 2022</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.</span></div><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RleHRyZWdpb246MWUyYzhmMjE0MzQ4NGIyODkxODg4YTViOGM2YWVhMDBfNTYyNw_9581939f-ca73-4e3b-8cec-9df11f1529bf" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows the change in the balance of contingent consideration payable for the three months ended March 31, 2020 and March 31, 2019, respectively:</span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.060%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfMi0yLTEtMS0w_100c73c6-ffff-4d5e-af41-178438bffae2">22,681</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="icab07bfc15ea4b0a9b2e3d5dfe987d2a_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfMi00LTEtMS0w_bac453c8-19f6-445f-9850-942f388d3a41">19,700</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in fair value during the period, included in the Consolidated Statements of Operations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfNC0yLTEtMS0w_3b0b7a16-4c7c-4028-ae9f-684ff0695812">931</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfNC00LTEtMS0w_0e00226d-18dd-47d4-a167-c56193de086b">1,383</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment for contingent consideration paid in stock </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="fold:ContingentConsiderationPaidInStockAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfNS0yLTEtMS0w_ab2012f7-588b-4c97-8009-8e6c9adfcc69">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" name="fold:ContingentConsiderationPaidInStockAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfNS00LTEtMS0w_d23c1713-491e-4175-861c-243ccf40e4f9">316</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, end of the period</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfNi0yLTEtMS0w_ffe22b93-1352-4fcb-b020-6e70e188b2c3">23,612</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="usd" contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfNi00LTEtMS0w_09ae966e-9c78-4f20-9273-61f2f7c5e99d">20,767</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Deferred Compensation Plan - Investment and Liability</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Deferred Compensation Plan (the "Deferral Plan") provides certain key employees and members of the Board of Directors with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. Deferral Plan assets are classified as trading securities and recorded at fair value with changes in the investment's fair value recognized in the period they occur. The asset investments consist of market exchanged mutual funds. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and related liability within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these securities.</span></div></ix:continuation><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">19</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_82"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;"> Note 8.&#160;<ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RleHRyZWdpb246ZWZiYTIwNTc1YTRlNDUwNGEwYTE1ZDI5YTE2MmJiODBfNzMy_e8a05faf-0bc4-4365-9c2c-b3070a41cbf3" continuedAt="iab28a9d785ef4a4f991e82a39179d20a" escape="true">Basic and Diluted Net Loss per Common Share</ix:nonNumeric></span></div><ix:continuation id="iab28a9d785ef4a4f991e82a39179d20a"><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RleHRyZWdpb246ZWZiYTIwNTc1YTRlNDUwNGEwYTE1ZDI5YTE2MmJiODBfNzI4_5e8d29c2-0e0e-46d6-aa13-3a3745b13c93" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"></td><td style="width:71.568%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.481%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.534%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.483%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjEwZDk0YTdiMDA0YzQxMTNhOTY5MmVkOGE3OTkwMWFlL3RhYmxlcmFuZ2U6MTBkOTRhN2IwMDRjNDExM2E5NjkyZWQ4YTc5OTAxYWVfMy0yLTEtMS0w_f2a176be-4499-4379-b40d-e7e500746d09">88,948</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(<ix:nonFraction unitRef="usd" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjEwZDk0YTdiMDA0YzQxMTNhOTY5MmVkOGE3OTkwMWFlL3RhYmxlcmFuZ2U6MTBkOTRhN2IwMDRjNDExM2E5NjkyZWQ4YTc5OTAxYWVfMy00LTEtMS0w_94e82d8c-02ee-4739-b976-bf47dcd3a508">120,299</ix:nonFraction>)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjEwZDk0YTdiMDA0YzQxMTNhOTY5MmVkOGE3OTkwMWFlL3RhYmxlcmFuZ2U6MTBkOTRhN2IwMDRjNDExM2E5NjkyZWQ4YTc5OTAxYWVfNS0yLTEtMS0w_0e3b1d5d-9e82-4845-9439-7f823a1104fc">256,968,248</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjEwZDk0YTdiMDA0YzQxMTNhOTY5MmVkOGE3OTkwMWFlL3RhYmxlcmFuZ2U6MTBkOTRhN2IwMDRjNDExM2E5NjkyZWQ4YTc5OTAxYWVfNS00LTEtMS0w_36072e4a-ba19-4933-a774-fcda33e14f27">213,519,287</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs, and warrants for common stock equivalents.&#160;Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect.</span></div><ix:nonNumeric contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RleHRyZWdpb246ZWZiYTIwNTc1YTRlNDUwNGEwYTE1ZDI5YTE2MmJiODBfNzM2_1395b538-9e39-4188-9119-f5d5bea87e17" escape="true"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:71.060%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.739%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ia053dc80670e4de08f203297971a38ee_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfMi0yLTEtMS0w_a0144aeb-7111-4ec9-bf56-58256543f79d">19,086</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ibd00e196fb5248c38c3a76f7e124b8ff_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfMi00LTEtMS0w_883dbcbb-b89c-4b78-81db-41dbd43f32c3">18,331</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible notes</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ic483241cafdd4ff19dea8e3ded6ae7c9_D20200101-20200331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfMy0yLTEtMS0w_7074614a-aefe-4b46-92ae-e1d90a933e2b">462</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="ie9fe2af9630e470c8859c9adef1e1816_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfMy00LTEtMS0w_6d4a7d45-b5a0-40c6-ba39-94b1928a64d2">5,017</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding warrants, convertible to common stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i208a59305dc0405a95804c555ac42287_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfNC0yLTEtMS0w_075f1557-6e6d-4e42-bbe6-0b74ecc911fc">2,554</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i2456a772e9a5467790859303b3e7e057_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfNC00LTEtMS0w_35d6f150-dbaf-4642-85be-a82c28679090">2,554</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="id8d7af76424f479fa3108e53610e4c9a_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfNS0yLTEtMS0w_f085e826-8afd-49ac-bc6c-9fdc560c88a6">7,562</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i41dc54a86052461baed38b6ea6e9142a_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfNS00LTEtMS0w_4980bdfb-3f22-4718-8949-7498a3f47dc1">6,010</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfNy0yLTEtMS0w_ed4ed9e5-b412-4eb3-8dd8-25da1347e1e4">29,664</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonFraction unitRef="shares" contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfNy00LTEtMS0w_0350b0dd-266b-435e-92fd-eec0fad722f3">31,912</ix:nonFraction>&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">20</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_85"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Overview</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. We have a portfolio of product opportunities led the first, oral monotherapy for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease in the clinic, and an industry leading rare disease gene therapy portfolio.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The cornerstone of our portfolio is Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several geographies around the world. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lead biologics program of our pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. In February 2019, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We have established an industry leading gene therapy portfolio of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital ("Nationwide Children&#8217;s") and an expanded collaboration with the University of Pennsylvania ("Penn"). Our pipeline includes gene therapy programs in rare, neurologic lysosomal disorders ("LDs"), specifically: CLN6, CLN3, and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), Niemann-Pick Type C ("NPC"), Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). Our expanded collaboration with Penn also provides us with exclusive disease-specific access and the option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies. In the first quarter of 2020, the FDA granted Fast Track designation to the CLN3 Batten disease gene therapy, AT-GTX-502, for the treatment of pediatric patients less than 18 years of age.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Strategy</span></div><div style="text-indent:20.25pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our strategy is to create, manufacture, test, and deliver the highest quality medicines for people living with rare metabolic diseases through internally developed, acquired, or in-licensed products and product candidates that have the potential to obsolete current treatments, provide significant benefits to patients, and be first- or best-in-class. In addition to our programs in Fabry and Pompe, we are leveraging our global capabilities to develop and expand our robust pipeline in genomic medicine. We have made significant progress toward fulfilling our vision of building a leading global biotechnology company focused on rare metabolic diseases. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Our operations have not yet been significantly impacted from the novel coronavirus (&#8220;COVID-19&#8221;) pandemic. We have maintained operations in all geographies, secured our global supply chain for our commercial and clinical products, and maintained our clinical trials, with minimum disruptions. Our ability to continue to operate without any significant disruptions will depend on the continued health of our employees, the ongoing demand for Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and the continued operation of our global supply chain. We have continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of our global workforce. However, our results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.</span></div><div style="text-indent:20.25pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Highlights of our progress include:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Commercial and regulatory success in Fabry disease.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> For the three months ended March 31, 2020, Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> revenue totaled $60.5 million, an increase of $26.5 million compared to the same period in the prior year, with minimal impact from changes in ordering patterns related to the COVID-19 pandemic. We continue to see strong commercial momentum and expansion into additional geographies. In countries we have been operating the longest, such as Germany and the U.K., we see an increasing proportion of previously untreated patients come onto Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. In the U.S., we continue to see a significant increase in patients from a growing and very wide prescriber base. Across all markets, we see a high rate of compliance and adherence to this oral treatment option.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">21</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt;">Pompe clinical program milestones.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> We completed enrollment in our global Phase 3 pivotal study of AT-GAA (ATB200-03, also known as "PROPEL") with 123 participants at 59 global sites. The U.S. FDA  granted BTD for AT-GAA for the treatment of late-onset Pompe disease. Additionally, the British Medicines and Healthcare Products Regulatory Agency issued a Promising Innovative Medicine designation ("PIM") for AT-GAA for the treatment of late-onset Pompe disease. Currently, we have not experienced any significant changes to the study as a result of the COVID-19 pandemic. </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;">Pipeline advancement and growth.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> We have established an industry leading gene therapy portfolio of medicines for people living with rare metabolic diseases through a license with Nationwide Children&#8217;s and an expanded collaboration with Penn. During the first quarter of 2020, we initiated the long-term follow-up of the initial participants in the CLN6 Phase 1/2 study. In 2019, we reported positive interim clinical results for the first eight patients in our ongoing CLN6 clinical study. Additionally, in 2019 the research collaboration with Penn was expanded to pursue research and development of novel gene therapies for Pompe disease, Fabry disease, CDD, NPC, MPSIIIB, as well as a next generation program in MPSIIIA. Amicus has rights for additional collaborative research programs in rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy and select other muscular dystrophies. </span></div><div><span><br/></span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:12.53pt;">Manufacturing. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">We continue to manufacture our Pompe biologic at commercial scale (1,000L) for our pivotal PROPEL study and early commercial inventory. Our supply agreement with WuXi Biologics and current capacity are expected to produce sufficient quantities to support commercial needs after receipt of applicable regulatory approvals if obtained. For gene therapy, we are working closely with our strategic partners at Catalent Biologics and Thermo Fisher Scientific to support our clinical manufacturing capabilities for our active preclinical lysosomal disorder programs in development at Penn and the Amicus intrathecal AAV Batten disease gene therapy programs. Through the first quarter of 2020, our global supply chains have not been interrupted and we have thus far maintained our ability to manufacture Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> as well as our Pompe biologic, AT-GAA, during the COVID-19 pandemic.</span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;padding-left:14.5pt;">Financial strength</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. Total cash, cash equivalents, and marketable securities as of March 31, 2020 was $338.9 million. The current cash position, considering the COVID-19 pandemic and including expected Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174; </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">revenues, is sufficient to fund ongoing Fabry, Pompe, and gene therapy program operations well into the second half of 2022; this assumes the current minimal impact to operations, supply chain and revenue of the COVID-19 pandemic. Potential future impact of the COVID-19 pandemic, future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.</span></div><div><span><br/></span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Our Commercial Product and Product Candidates</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;vertical-align:top;">&#174; </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">(Migalastat HCl) for Fabry Disease</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our oral precision medicine Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> was granted accelerated approval by the FDA in August 2018 under the brand name Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene ("GLA") variant based on in vitro assay data. The FDA approved Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for 348 amenable GLA variants. Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> was approved in the E.U. and U.K. in May 2016 as a first-line therapy for long-term treatment of adults and adolescents, aged 16 years and older, with a confirmed diagnosis of Fabry disease and who have an amenable mutation (variant). The approved E.U. and U.K. labels include 367 Fabry-causing mutations, which represent up to half of all patients with Fabry disease. Approvals have also been granted in over 40 countries around the world, including the U.S., E.U., U.K., Japan, and others. We plan to continue to launch Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in additional countries during 2020. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As an orally administered monotherapy, Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is designed to bind to and stabilize an endogenous alpha-galactosidase A ("alpha-Gal A") enzyme in those patients with genetic variants identified as amenable in a GLP cell-based amenability assay. Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is an oral precision medicine intended to treat Fabry disease in patients who have amenable genetic variants, and at this time, it is not intended for concomitant use with ERT.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Gene Therapy for Fabry Disease</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are committed to continued innovation for all people living with Fabry disease. For people living with Fabry disease who have non-amenable variants, which are not suitable for Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> as a monotherapy, our strategy is to develop a Fabry gene therapy. In October 2018, we expanded our gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies, including Fabry disease, and other indications. In October 2019, we disclosed preliminary data from a Fabry AAV gene therapy using an Amicus-engineered transgene that demonstrated high levels of GLA activity and robust GL-3 reduction in a mouse model of Fabry disease.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">22</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Novel ERT for Pompe Disease</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are leveraging our biologics capabilities to develop AT-GAA, a novel treatment paradigm for Pompe disease. AT-GAA consists of a uniquely engineered rhGAA enzyme, ATB200, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with a pharmacological chaperone, AT2221, to improve activity and stability. We initiated a global Phase 3 clinical study of AT-GAA, ATB200-03, or PROPEL in adult patients with late onset Pompe disease in December 2018.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The pharmacological chaperone, AT2221 is not an active ingredient that contributes directly to GAA substrate reduction but instead acts to stabilize ATB200. The small molecule pharmacological chaperone AT2221 binds and stabilizes ATB200 in circulation to improve the uptake of active enzyme in key disease-relevant tissues, resulting in increased clearance of accumulated substrate, glycogen.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our strategy is to enhance the body of clinical data for AT-GAA in ongoing clinical studies. Based on regulatory feedback from both the U.S. FDA and the European Medicines Agency ("EMA"), the Phase 3 PROPEL study is expected to support approval for a broad indication, including ERT-switch and treatment-na&#239;ve patients, if the results are favorable. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> In October 2019, we reported additional interim data from our clinical study ATB200-02 at the 24th International Annual Congress of the World Muscle Society. Highlights included muscle function, safety, and tolerability data in patients as well as pharmacodynamic data (muscle damage biomarker, creatine kinase, disease substrate biomarker, and urine hexose tetrasaccharide). Muscle function improved in 16 out of 18 patients at 24 months. Mean six-minute walk test ("6MWT") distance  improved in both ERT-na&#239;ve and ERT-switch patients with continued benefit observed out to month 24. All five ERT-naive patients showed increases from baseline in 6MWT distance at all time points out to month 24. To date, adverse events have been generally mild and transient. AT-GAA has resulted in a low rate of infusion-associated reactions ("IARs") following over 1,500+ infusions (28 events of IARs in eight patients). The clinical pharmacokinetic profile has been consistent with previously reported preclinical data. Treatment with AT-GAA resulted in persistent and durable reductions in creatine kinase and urine hexose tetrasaccharide across all patient cohorts up to month 24.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Gene Therapy for Pompe Disease</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As part of our long-term commitment to provide multiple solutions to address the significant unmet needs of the Pompe community, we are also advancing a next-generation gene therapy treatment for Pompe disease. In October 2018, we expanded our gene therapy portfolio through a collaboration agreement with Penn to pursue research and development of novel gene therapies for Pompe disease and other indications. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In April 2019, we presented initial preclinical data from our investigational adeno-associated viral ("AAV") gene therapy program for Pompe disease. This initial preclinical study in Pompe knockout mice administered a single high dose of AAV gene therapy with either unmodified wild-type hGAA ("unmodified hGAA") or an Amicus/Penn engineered hGAA transgene with a Lysosomal-Targeting Cell receptor binding motif ("engineered hGAA"). The Amicus/Penn engineered hGAA AAV gene therapy demonstrated more robust and consistent glycogen reduction compared to unmodified hGAA AAV gene therapy, in all key tissues assessed in a Pompe mouse model. In the central nervous system, the engineered hGAA AAV gene therapy also showed robust glycogen reduction in neuronal cells, suggesting this may be an effective way to address neuronal aspects of Pompe disease. Unmodified hGAA AAV gene therapy showed minimal glycogen reduction in neuronal cells. This preclinical study provides initial validation for combining Amicus-engineered transgenes with Penn's AAV gene therapy technologies.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Gene Therapy for Various Types of Batten Disease</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Through our license with Nationwide Children&#8217;s, we are researching potential first-in-class gene therapies for multiple forms of Batten disease. Batten disease is the common name for a broad class of rare, fatal, inherited disorders of the nervous system also known as neuronal ceroid lipofuscinoses ("NCLs"). In these diseases, a defect in a specific gene triggers a cascade of problems that interferes with a cell's ability to recycle certain molecules. Each gene is called ceroid lipofuscinosis, neuronal ("CLN") and given a different number designation as its subtype. There are 13 known forms of Batten disease often referred to as CLN1-8; 10-14. The various types of Batten disease have similar features and symptoms but vary in severity and age of onset.</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have two clinical programs in CLN6 and CLN3 Batten disease, and several preclinical programs including CLN1 and other types of Batten disease.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">23</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Our Phase 1/2 study in CLN6 Batten disease completed target enrollment, with thirteen patients receiving a single administration of adeno-associated virus serotype 9 AAV-CLN6 gene therapy. In August 2019, we reported positive interim clinical data from the first eight patients in the study. The AAV-CLN6 gene therapy demonstrated a positive impact on motor and language function. Seven out of eight patients maintained stable Hamburg Motor and Language scores or had an initial change (+1 to -1 points) followed by stabilization. In October 2019, we reported additional interim clinical data further supporting the impact of one-time intrathecal AAV gene therapy in children with CLN6 Batten disease.&#160; This interim data suggested stabilization of various components of the Hamburg Motor, Language, Seizure, and Vision scores in most patients from baseline to month 12 or 24, in particular those patients treated at a younger age, compared to the progression expected in matched untreated patients. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In the fourth quarter of 2018, we announced the initiation of a Phase 1/2 study to evaluate the safety and efficacy of a single intrathecal administration of adeno-associated virus serotype 9 AAV-CLN3 gene therapy in children with CLN3 Batten disease. In the Phase 1/2 study, a total of three patients were dosed in the low dose group, and based on the safety profile to date, the data safety monitoring board cleared us to begin enrollment in the high dose cohort of up to three additional patients. One high dose patient has been dosed, with no serious adverse events to date following a single administration of AAV-CLN3 gene therapy. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">CDKL5 Deficiency Disorder</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are researching a potential first-in-class protein replacement therapy approach for CDD, as well as researching a gene therapy for CDD through our collaboration with Penn. CDKL5 is a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of several essential proteins for normal brain development. Genetic mutations in the CDKL5 gene result in CDKL5 protein deficiency and CDD. This disorder manifests clinically as persistent seizures starting in infancy, followed by severe impairment in neurological development. Most children affected by CDD cannot walk or care for themselves and may also suffer from scoliosis, visual impairment, sensory issues, and gastrointestinal complications. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Other Preclinical Gene Therapies</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We have a number of additional gene therapies in active preclinical development, including gene therapies for NPC, MPSIIIB, as well as a next generation program in MPSIIIA. Our strategy is to develop first or best in class AAV gene therapies for these rare devastating pediatric neurological lysosomal storage diseases.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Strategic Alliances and Arrangements</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We will continue to evaluate business development opportunities as appropriate that build stockholder value and provide us with access to the financial, technical, clinical, and commercial resources necessary to develop and market technologies or products with a focus on rare metabolic diseases. We are exploring potential collaborations, alliances, and other business development opportunities on a regular basis. These opportunities may include the acquisition of preclinical-stage, clinical-stage, or marketed products so long as such transactions are consistent with our strategic plan to develop and provide therapies to patients living with rare and orphan diseases.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">24</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_88"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Consolidated Results of Operations</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Three Months Ended March 31, 2020 compared to March 31, 2019 </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides selected financial information for the Company:</span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"></td><td style="width:57.590%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.737%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.532%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:10.740%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="15" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Change</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net product sales</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,479&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods sold</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,552&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,497&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of goods sold as a percentage of net product sales</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.8&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.1)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Operating expenses:</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,593&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,527&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general, and administrative</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">40,215&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">44,303&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,088)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in fair value of contingent consideration payable</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">931&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,383&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(452)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Depreciation and amortization</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,764&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">773&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,515&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,639&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,124)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,729)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(6,454)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,725&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss on exchange of convertible notes</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(36,123)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">36,123&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other (expense) income</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(8,316)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,402)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(361)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(168)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(193)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(88,948)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(120,299)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,351&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Net Product Sales.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Net product sales increased $26.5 million during the three months ended March 31, 2020 compared to the same period in the prior year. The increase was primarily due to continued growth in the Europe, US, and Japan markets. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Cost of Goods Sold.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Cost of goods sold includes manufacturing costs as well as royalties associated with sales of our product. Cost of goods sold as a percentage of net product sales was 10.8% during the three months ended March 31, 2020 compared to 11.9% during the same period in the prior year, primarily due to the proportion of sales in countries subject to a higher royalty burden. </span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Research and Development Expense.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The following table summarizes our principal product development programs for each product candidate in development, and the out-of-pocket, third party expenses incurred with respect to each product candidate:</span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.198%;"><tr><td style="width:1.0%;"></td><td style="width:67.148%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.559%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.589%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.559%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.745%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projects</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Third party direct project expenses</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6.75pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"> (Fabry Disease)</span></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,761&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,356&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AT-GAA (Pompe Disease)</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,907&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">28,286&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gene therapy programs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,995&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,192&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Pre-clinical and other programs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,205&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">460&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total third-party direct project expenses</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,868&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,294&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other project costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Personnel costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,718&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,634&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,534&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total other project costs</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,252&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,299&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total research and development costs</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">89,120&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">64,593&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">25</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The $24.5 million increase in research and development costs was primarily due to increases in gene therapy programs driven by the pipeline growth and clinical research and manufacturing costs with the advancement and enrollment of clinical studies in the Pompe program, partially offset by a decrease in expense associated with the ongoing regulatory requirements, approval in new geographies, and pediatric and other studies to support label expansion of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. There were also increases in personnel costs associated with the advancement and enrollment of clinical studies and investments in manufacturing.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Selling, General, and Administrative Expense.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> Selling, general, and administrative expense decreased $4.1 million, mainly driven by reduction in third-party professional fees and travel.</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Loss on exchange of convertible notes. </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the first quarter of 2019, the Company entered into separate, privately negotiated exchange agreements with a limited number of holders of the Convertible Notes. As a result of this exchange, the Company recognized a loss on exchange of debt of $36.1 million in the Consolidated Statement of Operations, and $190.4 million in additional paid-in-capital and common stock of $0.4 million in the Consolidated Balance Sheets for the three months ended March 31, 2019.</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"> Other (Expense) Income.&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The $9.4 million variance was primarily driven by foreign exchange losses in the remeasurement of our intercompany transactions.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Income Tax Expense.</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The income tax expense for the first quarter of 2020 was $0.4 million. We are subject to income taxes in various jurisdictions. Our tax liabilities are largely dependent on the distribution of pre-tax earnings among the many jurisdiction in which we operate. </span></div><div id="i37a61778173840fc811d567d8624cfac_91"></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Liquidity and Capital Resources</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of our significant research and development expenditures, as well as expenditures to build a commercial organization to support the launch of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, we have not been profitable and have generated operating losses since we were incorporated in 2002. We have historically funded our operations through stock offerings, debt issuances, Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> revenues, collaborations, and other financing arrangements.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash Flow Discussion</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, we had cash, cash equivalents, and marketable securities of $338.9 million. We invest cash in excess of our immediate requirements in regard to liquidity and capital preservation in a variety of interest-bearing instruments, including obligations of U.S. government agencies and money market accounts. Wherever possible, we seek to minimize the potential effects of concentration and degrees of risk. Although we maintain cash balances with financial institutions in excess of insured limits, we do not anticipate any losses with respect to such cash balances. For more details on the cash, cash equivalents, and marketable securities, refer to "&#8212;Note 3.&#160; Cash, Cash Equivalents, Marketable Securities, and Restricted Cash," in our Notes to Consolidated Financial Statements.</span></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Cash Used in Operating Activities</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operations for the three months ended March 31, 2020 was $107.9 million. The components of net cash used in operations included the net loss for the three months ended March 31, 2020 of $88.9 million and the net change in operating assets and liabilities of $45.2 million. The change in operating assets was primarily due to an increase in accounts receivable by $8.4 million due to increased commercial sales of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174; </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">and a decrease in prepaid and other current assets of $4.0 million to support the commercial activities for Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The net cash used in operations was also impacted by a decrease in accounts payable and accrued expenses of $35.3 million, mainly related to the payment of contract manufacturing and research costs, program expenses and personnel costs.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in operations for the three months ended March 31, 2019 was $78.5 million. The components of net cash used in operations included the net loss for the three months ended March 31, 2019 of $120.3 million and the net change in operating assets and liabilities of $11.5 million. The change in operating assets was primarily due to increases in accounts receivable by $1.0 million, partially offset by decrease in prepaid and other current assets of $3.1 million for spending to support commercial activities for Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> launch and decrease in inventory of $0.3 million due to increased commercial sales of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The net cash used in operations was also impacted by decrease in accounts payable and accrued expenses of $8.9 million, mainly related to program expenses and support for the commercial launch of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, and a decrease in deferred reimbursement of $1.5 million due to payment of a milestone.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">26</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Cash Provided by Investing Activities</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by investing activities for the three months ended March 31, 2020 was $93.2 million. Our investing activities have consisted primarily of purchases and sales and maturities of investments and capital expenditures. Net cash provided by investing activities reflects $106.1 million for the sale and redemption of marketable securities, partially offset by $12.1 million for the purchase of marketable securities and $0.8 million for the acquisition of property and equipment.&#160;</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by investing activities for the three months ended March 31, 2019 was $80.1 million. Our investing activities have consisted primarily of purchases and sales and maturities of investments and capital expenditures. Net cash provided by investing activities reflects $135.2 million for the sale and redemption of marketable securities, partially offset by $52.2 million for the purchase of marketable securities, and $2.9 million for the acquisition of property and equipment.</span></div><div style="padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Net Cash (Used in) Provided by Financing Activities</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash used in financing activities for the three months ended March 31, 2020 was $1.5 million. Net cash used in financing activities primarily reflects $7.5 million from the purchase of vested restricted stock units, partially offset by&#160;$6.1 million from the exercise of stock options.&#160;</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Net cash provided by financing activities for the three months ended March 31, 2019 was $17.4 million. Net cash provided by financing activities primarily reflects $14.6 million from partial termination of capped call and $4.8 million from the exercise of stock options and warrants, partially offset by $1.9 million from the purchase of vested restricted stock units.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Funding Requirements</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We expect to incur losses from operations for the foreseeable future primarily due to research and development expenses, including expenses related to conducting clinical trials.&#160;Our future capital requirements will depend on a number of factors, including:</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the progress and results of our preclinical and clinical trials of our drug candidates and gene therapy candidates, including but not limited to AT-GAA, CLN6 and CLN3;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the cost of manufacturing drug supply for our clinical and preclinical studies, including the cost of manufacturing Pompe Enzyme Replacement Therapy ("ERT" or "ATB200") and gene therapies;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the scope, progress, results, and costs of preclinical development, laboratory testing, and clinical trials for our product candidates, including those testing the use of a pharmacological chaperone co-administered with ERT for the treatment of Pompe disease ("AT-GAA") and gene therapies for the treatment of rare genetic metabolic diseases;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the future results of on-going preclinical research and subsequent clinical trials for CDD, Pompe gene therapy, Fabry gene therapy, NPC, MPSIIIB and next generation MPSIIIA, including our ability to obtain regulatory approvals and commercialize these gene therapies and obtain market acceptance for such therapies;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs, timing, and outcome of regulatory review of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">any changes in regulatory standards relating to the review of our product candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the number and development requirements of other product candidates that we pursue;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs of commercialization activities, including product marketing, sales, and distribution;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the emergence of competing technologies and other adverse market developments;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to successfully commercialize Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> ("migalastat HCl");</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to manufacture or supply sufficient clinical or commercial products, including Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">, AT-GAA and our gene therapy candidates;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain reimbursement for Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to satisfy post-marketing commitments or requirements for continued regulatory approval of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to obtain market acceptance of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the costs of preparing, filing, and prosecuting patent applications and maintaining, enforcing, and defending intellectual property-related claims;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">27</span></div></div></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">the extent to which we acquire or invest in businesses, products, and technologies;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to successfully integrate our acquired products and technologies into our business, including the possibility that the expected benefits of the transactions will not be fully realized by us or may take longer to realize than expected; </span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to establish collaborations, partnerships, or other similar arrangements and to obtain milestone, royalty, or other payments from any such collaborators;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">our ability to adjust to changes in the European and U.K. markets in the wake of the U.K. leaving the E.U.;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">the extent to which our business could be adversely impacted by the effects of the novel coronavirus  ("COVID-19") outbreak, including due to actions by us, governments, our customers or suppliers or other third parties to control the spread of COVID-19, or by other health epidemics or pandemics;</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt;">fluctuations in foreign currency exchange rates; and</span></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;margin-top:6pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#8226;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;">changes in accounting standards.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">While we continue to generate revenue from product sales, in the absence of additional funding, we expect our continuing operating losses to result in increases in our cash used in operations over the next several quarters and years.&#160;We may seek additional funding through public or private financings of debt or equity. We believe that our current cash position, including expected Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> revenues, is sufficient to fund ongoing Fabry, Pompe, and gene therapy program operations well into the second half of 2022 Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact our future capital requirements.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Financial Uncertainties Related to Potential Future Payments</span></div><div style="text-indent:-13.5pt;padding-left:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Milestone Payments / Royaltie</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">s</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Celenex</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> - With our acquisition of Celenex in 2018, we agreed to pay up to an additional $15 million in connection with the achievement of certain development milestones, $262 million in connection with the achievement of certain regulatory approval milestones across multiple programs and up to $75 million in tiered sales milestone payments.</span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;">Nationwide Children&#8217;s</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> - Celenex has an exclusive license agreement with Nationwide Children&#8217;s. Under this license agreement, Nationwide Children&#8217;s is eligible to receive development and sales-based milestones of up to $7.8 million from us for each product.</span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Penn</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> - Under our expanded collaboration agreement with Penn, Penn is eligible to receive certain milestone, royalty and discovery research payments with respect to licensed products for each indication. Milestone payments are payable following the achievement of certain development and commercial milestone events in each indication, up to an aggregate of $88.0 million per indication. Royalty payments are based on net sales of licensed products on a licensed product-by-licensed product and country-by-country basis. We will provide $10.0 million each year during the five-year agreement to fund the discovery research program.</span></div><div style="text-indent:22.5pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">GlaxoSmithKline</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> - In November&#160;2013, we entered into the Revised Agreement (the "Revised Agreement") with GlaxoSmithKline ("GSK"), pursuant to which we have obtained global rights to develop and commercialize migalastat as a monotherapy and in combination with ERT for Fabry disease. The Revised Agreement amends and replaces in its entirety the earlier agreement entered into between us and GSK in July&#160;2012 (the "Original Collaboration Agreement"). Under the terms of the Revised Agreement, there was no upfront payment from us to GSK. For migalastat monotherapy, GSK is eligible to receive post-approval and sales-based milestones up to $40 million, as well as tiered royalties in the mid-teens in eight major markets outside the U.S. In addition, because we reacquired worldwide rights to migalastat, we are no longer eligible to receive any milestones or royalties we would have been eligible to receive under the Original Collaboration Agreement.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">28</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_94"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Critical Accounting Policies and Significant Judgments</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The discussion and analysis of our financial condition and results of operations are based on our financial statements, which we have prepared in accordance with U.S.&#160;GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">There were no significant changes during the three months ended March 31, 2020 to the items that we disclosed as our significant accounting policies and estimates described in "&#8212;Note 2. Summary of Significant Accounting Policies" to the Company's financial statements as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December&#160;31, 2019.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Pronouncements</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Please refer to "&#8212;Note 2. Summary of Significant Accounting Policies," in our Notes to Consolidated Financial Statements.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">29</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_97"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Market risk is the risk of change in fair value of a financial instrument due to changes in interest rates, equity prices, creditworthiness, financing, exchange rates, or other factors. Our primary market risk exposure relates to changes in interest rates in our cash, cash equivalents, and marketable securities. We place our investments in high-quality financial instruments, primarily money market funds, corporate debt securities, asset backed securities, and U.S. government agency notes with maturities of less than one year, which we believe are subject to limited interest rate and credit risk. The securities in our investment portfolio are not leveraged, are classified as available-for-sale and, due to the short-term nature, are subject to minimal interest rate risk. We believe that a 1% (100 basis points) change in average interest rates would either increase or decrease the market value of our investment portfolio by $0.7 million as of March 31, 2020. We currently do not hedge interest rate exposure and consistent with our investment policy, we do not use derivative financial instruments in our investment portfolio. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are exposed to interest rate risk with respect to variable rate debt. At March 31, 2020, we had a $150 million Senior Secured Term Loan that bears interest at a rate equal to the 3-month LIBOR plus 7.50% per year. We do not currently hedge our variable interest rate debt. The annual average variable interest rate for our variable rate debt as of March 31, 2020 was 9.7%. A hypothetical 100 basis point increase or decrease in the average interest rate on our variable rate debt would  result in a $0.4 million change in the interest expense as of March 31, 2020. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Financial Conduct Authority has announced the intent to phase out the use of LIBOR by the end of 2021. If LIBOR is discontinued, we may need to renegotiate the terms of the Senior Secured Term Loan in order to replace LIBOR with the new standard that is established. As a result, we may incur incremental costs in transitioning to a new standard, and interest rates on our current or future indebtedness may be adversely affected by the new standard. There is currently no definitive information regarding the future utilization of LIBOR or of any particular replacement rate. As such, the potential effect of any such event on our cost of capital cannot yet be determined, but we do not expect it to have a material impact on our consolidated financial condition, results of operations, or cash flows.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We face foreign exchange risk as a result of entering into transactions denominated in currencies other than U.S. dollars. We are not currently engaged in any foreign currency hedging activities. The current exposures arise primarily from cash, accounts receivable, intercompany receivables and payables, and net product sales denominated in foreign currencies. Both positive and negative impacts to our international product sales from movements in foreign currency exchange rates may be partially mitigated by the natural, opposite impact that foreign currency exchange rates have on our international operating expenses. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have had a material impact on our Consolidated Financial Statements.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;For information regarding our exposure to certain market risks, see Item 7A, Quantitative and Qualitative Disclosures About Market Risk, in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019. There have been no material changes in our financial instrument portfolio or market risk exposures since our fiscal year ended December 31, 2019.</span></div><div id="i37a61778173840fc811d567d8624cfac_100"></div><div style="margin-top:12pt;margin-bottom:12pt;"><span><br/></span></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of the end of the period covered by this Quarterly Report on Form&#160;10-Q, an evaluation of the effectiveness of our disclosure controls and procedures (pursuant to Rule&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended (the "Exchange Act") was carried out under the supervision of our Principal Executive Officer and Principal Financial Officer, with the participation of our management.&#160;Based on that evaluation, the Principal Executive Officer and the Principal Financial Officer concluded that, as of the end of such period, our disclosure controls and procedures are effective in recording, processing, summarizing and reporting, on a timely basis, information required to be disclosed by us in the reports that we file or submit under the Exchange Act and are effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">During the fiscal quarter covered by this report, there has been no change in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act) that occurred during the last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">30</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_103"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PART&#160;II.&#160; OTHER INFORMATION</span></div><div id="i37a61778173840fc811d567d8624cfac_106"></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="text-indent:18pt;text-align:justify;margin-top:12pt;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">We are not currently a party to any legal proceedings.</span></div><div style="text-indent:18pt;text-align:justify;margin-top:3pt;margin-bottom:6pt;"><span><br/></span></div><div id="i37a61778173840fc811d567d8624cfac_109"></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 1A.&#160;RISK FACTORS</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">       The following risk factor should be considered in addition to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019.</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%;">       The novel coronavirus ("COVID-19") pandemic and efforts to reduce its spread may negatively impact our business and operations.</span></div><div><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">      The COVID-19 pandemic has substantially burdened healthcare systems worldwide which may impact progression of our clinical trials. Required inspections and reviews by regulatory agencies may also be delayed due to the focus of resources on COVID-19 as well as travel and other restrictions. Significant delays in the timing of our clinical trials and in regulatory reviews could adversely affect our ability to commercialize some assets in our product pipeline. Lack of normal access by patients to the healthcare system, along with concern about the continued supply of medications, may result in changes in buying patterns throughout the supply chain, including by patients, which could increase or decrease demand for our products. Similarly, we have temporarily halted in-person interactions by our employees with healthcare providers, which may decrease demand for our products. COVID-19 could also have an adverse impact on our supply chain and distribution systems, which could impact our ability to distribute our products and the ability of third parties on which we rely to fulfill their obligations to us, and could increase our expenses. In addition, the conditions created by the pandemic may intensify other risks inherent in our business, including, among other things, risks related to drug pricing and access, intellectual property protection, product safety and efficacy concerns, product liability and other litigation, and the impact of adverse global and local economic conditions. </span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">     As a result, while the financial impact on us has not been material to date, given the rapid and evolving nature of the virus, COVID-19 could negatively affect our results of operations, financial condition, liquidity and cash flows in future periods, perhaps materially. The degree to which COVID-19 affects us will depend on developments that are highly uncertain and beyond our knowledge or control, including, but not limited to, the duration and severity of the pandemic, the actions taken to reduce its transmission, and the speed with which, and extent to which, more stable economic and operating conditions resume. Should the COVID-19 pandemic and any associated recession or depression continue for a prolonged period, our results of operations, financial condition, liquidity, and cash flows could be materially impacted by lower revenues and profitability and a lower likelihood of effectively and efficiently developing and launching new medicines.</span></div><div style="margin-bottom:12pt;"><span><br/></span></div><div id="i37a61778173840fc811d567d8624cfac_112"></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Recent Sales of Unregistered Securities</span></div><div style="text-indent:20.25pt;text-align:justify;margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Issuer Purchases of Equity Securities</span></div><div style="text-indent:20.25pt;text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i37a61778173840fc811d567d8624cfac_115"></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i37a61778173840fc811d567d8624cfac_118"></div><div style="text-align:justify;margin-top:12pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div id="i37a61778173840fc811d567d8624cfac_121"></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 5. OTHER INFORMATION</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">None.</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">31</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_124"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="margin-bottom:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">ITEM 6. EXHIBITS</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:8.117%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.533%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:87.150%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exhibit<br/>Number</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Description</span></td></tr><tr><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:5pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">++10.1</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit101.htm">First Amendment to the Amended and Restated Research, Collaboration &amp; License Agreement dated December 20, 2019 by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania.</a></span></div></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">++10.2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit102.htm">Second Amendment to  the Amended and Restated Research, Collaboration &amp; License Agreement dated </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit102.htm">March 26, 2020</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="exhibit102.htm"> by and between Amicus Therapeutics, Inc. and the Trustees of the University of Pennsylvania.</a></span></div></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="fold-03312020xex311.htm">Certification of Principal Executive Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated pursuant to the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.2</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="fold-03312020xex312.htm">Certification of Principal Financial Officer pursuant to Rules&#160;13a-14 and 15d-14 promulgated pursuant to the Securities Exchange Act of 1934, as amended</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.1</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="fold-03312020xex321.htm">Certification of Principal Executive Officer and Principal Financial </a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="fold-03312020xex321.htm">Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="fold-03312020xex321.htm"> pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.INS</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;margin-bottom:8pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document </span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.SCH </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.CAL </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.LAB </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.PRE </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">101.DEF </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">104</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cover Page Interactive Data File (formatted in Inline XBRL and included in Exhibit 101)</span></td></tr></table></div><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">++               Subject to confidential treatment request.&#160;</span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">32</span></div></div></div><div id="i37a61778173840fc811d567d8624cfac_127"></div><hr style="page-break-after:always"/><div style="height:42.75pt;width:100%;"><div style="text-align:right;"><span><br/></span></div></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:3.425%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:46.826%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.278%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:38.471%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">AMICUS THERAPEUTICS,&#160;INC.</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 7, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ John F. Crowley</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">John F. Crowley</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chairman and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Executive Officer)</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">May 7, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By:</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">/s/ Daphne Quimi</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Daphne Quimi</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:1pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Principal Financial Officer)</span></td></tr></table></div><div style="text-align:center;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">33</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i11f9c24c9ba54adba2a10e3f06b6bb5e_1"></div><div style="height:1pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">PORTIONS HEREIN IDENTIFIED BY &#91;***&#93; HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div><div><font><br></font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="padding-left:331.65pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;">CONFIDENTIAL</font></div><div style="padding-left:330.3pt;margin-top:0.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%;">Execution Version</font></div><div><font><br></font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:1pt;padding-left:141.85pt;padding-right:147.55pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">FIRST AMENDMENT TO AMENDED AND RESTATED</font></div><div style="padding-left:45.95pt;padding-right:51.55pt;text-align:center;margin-top:0.15pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">RESEARCH, COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-top:0.3pt;"><font><br></font></div><div style="text-indent:35.15pt;padding-left:11.05pt;padding-right:15.3pt;text-align:justify;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">This FIRST AMENDMENT (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%;">&#34;Amendment&#34;), </font><font style="background-color:rgb(255,255,255, 0.0);color:#161616;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">dated </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">December 20, 2019 (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%;">&#34;Amendment Date&#34;), </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">is entered into by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%;">(&#34;Penn&#34;), </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">and Amicus Therapeutics, Inc., a corporation organized under the laws of the state of Delaware </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%;">(&#34;Licensee&#34;). </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">Penn and Licensee may be referred to herein as a </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%;">&#34;Party&#34; </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">or, collectively, as </font><font style="background-color:rgb(255,255,255, 0.0);color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%;">&#34;Parties&#34;.</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:35.35pt;padding-left:10.8pt;padding-right:15.5pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">WHEREAS, the Parties entered into a Research, Collaboration &#38; License Agreement dated October 8, 2018, which was later amended pursuant to the Amended and Restated Research, Collaboration &#38; License Agreement dated May 28, 2019 (the </font><font style="background-color:rgb(255,255,255, 0.0);color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%;">&#34;Collaboration </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%;">Agreement&#34;), </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">pursuant to which, among other things, Penn and Licensee are conducting a research program for the pre-clinical development of ce1iain gene therapy products intended to treat certain specified indications&#59; and</font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="text-indent:35pt;padding-left:11.15pt;padding-right:16.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">WHEREAS, the Pa1iies now wish to amend certain provisions of the Collaboration Agreement as set forth in this Amendment.</font></div><div style="margin-top:0.35pt;"><font><br></font></div><div style="text-indent:34.65pt;padding-left:11.1pt;padding-right:15.75pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="text-indent:0.3pt;padding-left:11.1pt;padding-right:15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:16.35pt;">The Research Plan and timeline contained in </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%;">Exhibit B </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">of the Agreement for the &#91;***&#93; programs is hereby amended </font><font style="background-color:rgb(255,255,255, 0.0);color:#161616;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">to </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">include the additional work and timeline outlined in the updated </font><font style="background-color:rgb(255,255,255, 0.0);color:#3d3d3d;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">Exhibit </font><font style="background-color:rgb(255,255,255, 0.0);color:#161616;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">B </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">to this First Amendment.</font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="text-indent:-0.1pt;padding-left:11.1pt;padding-right:15.3pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:16.75pt;">The Research Program Budget contained in </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:122%;">Exhibit C </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">of the Agreement for the &#91;***&#93; is hereby amended </font><font style="background-color:rgb(255,255,255, 0.0);color:#161616;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">to </font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">include the new Research Program Budget contained in Exhibit C to this First Amendment. The payment schedule contained in Exhibit C of the Agreement is amended and restated in its entirety as set forth in Exhibit C to this First Amendment.</font></div><div style="margin-top:0.15pt;"><font><br></font></div><div style="text-indent:0.2pt;padding-left:10.85pt;padding-right:15.45pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:122%;padding-left:16.7pt;">This First Amendment and the Agreement contains the entire understanding between the Pa1iies and supersedes any and all prior agreements, understandings and arrangements whether written or oral between the Patties with respect to the matters contained in the Agreement and this First Amendment. No amendments, changes, modifications or alterations of the terms and conditions of this First Amendment shall be binding upon any Patty, unless in writing and signed by an authorized representative of each Party.</font></div><div><font><br></font></div><div style="text-indent:0.1pt;padding-left:10.7pt;padding-right:16.7pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#262626;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:16.95pt;">All terms and conditions of the Agreement not changed by this First Amendment shall remain in full force and effect.</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:67pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="i11f9c24c9ba54adba2a10e3f06b6bb5e_4"></div><hr style="page-break-after:always"><div style="height:0pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.4pt;"><font><br></font></div><div style="text-indent:0.3pt;padding-left:11.4pt;padding-right:15.3pt;text-align:justify;margin-top:4.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#232323;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#232323;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;padding-left:16.05pt;">Signatures on this First Amendment may be communicated by facsimile or e-mail transmission and shall be binding upon the Parties  upon  receipt  by transmitting  the same by facsimile or e-mail, which signatures shall be deemed originals. </font><font style="background-color:rgb(255,255,255, 0.0);color:#232323;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:118%;">If </font><font style="background-color:rgb(255,255,255, 0.0);color:#232323;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:118%;">executed in counterparts, the Amendment shall be effective as if simultaneously executed.</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:50.2pt;padding-right:51.55pt;text-align:center;margin-top:9.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#232323;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%;">&#91;Remainder of the page intentionally left blank&#59; signature page follows.&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.15pt;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:67pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="i11f9c24c9ba54adba2a10e3f06b6bb5e_7"></div><hr style="page-break-after:always"><div style="height:1pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:33.05pt;padding-left:25.85pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:135%;">IN WITNESS WHEREOF, </font><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:135%;">duly authorized representatives of the Parties have executed this Agreement as of the Amendment Date.</font></div><div style="text-indent:33.05pt;padding-left:25.85pt;margin-top:0.05pt;"><font><br></font></div><div style="margin-top:0.15pt;"><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="i11f9c24c9ba54adba2a10e3f06b6bb5e_10"></div><hr style="page-break-after:always"><div style="height:1pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:25.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THE TRUSTEES OF THE UNIVERSITY</font></div><div style="text-indent:25.9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">OF PENNSYLVANIA</font></div><div style="text-indent:25.85pt;margin-top:4.8pt;"><font><br></font></div><div style="text-indent:25.85pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">By&#58;      </font><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; John S. Swartley., PhD</font></div><div style="text-indent:25.85pt;padding-right:49.25pt;margin-top:0.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;">Name&#58; John S. Swartley, PhD</font></div><div style="padding-left:25.85pt;padding-right:49.25pt;margin-top:0.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;">Title&#58;   Associate Vice Provost for           </font></div><div style="padding-left:58.85pt;padding-right:49.25pt;margin-top:0.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;">Research and Managing Director, Penn Center for Innovation</font></div><div style="text-indent:25.85pt;margin-top:4.8pt;"><font><br></font></div><div style="margin-top:0.1pt;"><font><br></font></div><div style="padding-left:36pt;padding-right:19.45pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:124%;">&#14;</font><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:124%;">AMICUS&#160;THERAPEUTICS, INC.</font></div><div><font><br></font></div><div style="padding-left:41.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">By&#58;&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; John F. Crowley</font></div><div style="text-indent:-0.05pt;padding-left:41.35pt;padding-right:49.25pt;margin-top:0.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;">Name&#58; John F. Crowley</font></div><div style="text-indent:-0.05pt;padding-left:41.35pt;padding-right:49.25pt;margin-top:0.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:122%;">Title&#58; Chairman and CEO</font></div><div><font><br></font></div><div id="i11f9c24c9ba54adba2a10e3f06b6bb5e_13"></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.2pt;"><font><br></font></div><div style="padding-left:25.35pt;margin-top:4.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Read and Acknowledged&#58;</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div><font><br></font></div><div id="i11f9c24c9ba54adba2a10e3f06b6bb5e_16"></div><div style="text-indent:-0.05pt;padding-left:25pt;padding-right:-40.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">By&#58;       </font><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;text-decoration: underline;">&#47;s&#47; Dr. James M. Wilson</font></div><div style="text-indent:-0.05pt;padding-left:25pt;padding-right:-0.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">Name&#58;  Dr. James Wilson</font></div><div style="text-indent:-0.05pt;padding-left:25pt;padding-right:-0.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#1f1f1f;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:138%;">Title&#58;    Director, Gene Therapy Program</font></div><div style="padding-left:11.75pt;"><font><br></font></div><div id="i11f9c24c9ba54adba2a10e3f06b6bb5e_19"></div><div style="padding-right:221.15pt;margin-top:4.5pt;"><font><br></font></div><div style="position:relative;width:100%;height:67pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="i11f9c24c9ba54adba2a10e3f06b6bb5e_22"></div><hr style="page-break-after:always"><div style="height:3pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:50pt;padding-right:51.55pt;text-align:center;margin-top:4.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit B</font></div><div style="text-align:center;"><font><br></font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;***&#93;</font></div><div style="position:relative;width:100%;height:91pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="i11f9c24c9ba54adba2a10e3f06b6bb5e_25"></div><hr style="page-break-after:always"><div style="height:2pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:0.3pt;"><font><br></font></div><div style="margin-top:0.3pt;"><font><br></font></div><div style="margin-top:0.3pt;"><font><br></font></div><div style="margin-top:0.3pt;"><font><br></font></div><div style="padding-left:50.2pt;padding-right:51.45pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">Exhibit </font><font style="background-color:rgb(255,255,255, 0.0);color:#282828;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">C</font></div><div style="padding-left:50.2pt;padding-right:51.45pt;text-align:center;"><font><br></font></div><div style="padding-left:50.2pt;padding-right:51.45pt;text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#91;***&#93;</font></div><div style="position:relative;width:100%;height:91pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exhibit102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie14a6327fdc2419494b8e4449751e33a_1"></div><div style="height:40pt;width:100%;"><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">PORTIONS HEREIN IDENTIFIED BY &#91;***&#93; HAVE BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE EXCLUDED INFORMATION IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div></div><div style="padding-left:381.35pt;margin-top:3.15pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">CONFIDENTIAL</font></div><div style="padding-left:379.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%;">Execution Version</font></div><div><font><br></font></div><div style="text-indent:0.05pt;padding-left:164.6pt;padding-right:163.55pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SECOND AMENDMENT TO AMENDED AND RESTATED</font></div><div style="padding-left:68.1pt;padding-right:67.25pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">RESEARCH, COLLABORATION AND LICENSE AGREEMENT</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:35.95pt;padding-left:10pt;padding-right:8.75pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">This SECOND AMENDMENT (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), dated March 26, 2020 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amendment Date</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), is entered into by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Penn</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), and Amicus Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Licensee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Penn and Licensee may be referred to herein as a &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Party</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; or, collectively, as &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Parties</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:35.95pt;padding-left:10pt;padding-right:8.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, the Parties entered into that certain Amended and Restated Research, Collaboration &#38; License Agreement dated May 28, 2019, as amended through a first amendment dated December 20, 2019 (collectively, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Collaboration Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), pursuant to which, among other things, Penn and Licensee are conducting a research program for the pre-clinical development of certain gene therapy products intended to treat certain specified indications&#59; and</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:35.95pt;padding-left:10pt;padding-right:8.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, the Parties entered in to that certain Process Development Research &#38; License Agreement dated March 26, 2020 (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PD Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), pursuant to which, among other things, Penn and Licensee are conducting a research program for the development and&#47;or optimization of manufacturing technology for gene therapy products&#59;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:35.95pt;padding-left:10pt;padding-right:8.9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">WHEREAS, the Parties now wish to further amend certain provisions of the Collaboration Agreement as set forth in this Amendment.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:35.95pt;padding-left:10pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:28pt;padding-right:8.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;">Defined Terms</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Capitalized terms used in this Amendment and not defined herein shall have the meaning given to such terms in the Collaboration Agreement, unless otherwise specified herein.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:28pt;padding-right:8.85pt;text-align:justify;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;">Joint Steering Committee</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Sections 4.1.2(j) and 4.1.2(k) of the Collaboration Agreement are hereby deleted in their entirety and replaced with the following&#58;</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:46pt;padding-right:26.75pt;text-align:justify;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;(j)  endeavor to resolve any disagreement between the Parties arising at the JIPC,  the JMC (as defined in the PD Agreement) established pursuant to the PD Agreement or any other subcommittee established under this Agreement or the PD Agreement&#59;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:46pt;padding-right:26.75pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.7pt;">establish such additional subcommittees as it deems necessary to achieve the objectives and intent of each Research Program, the Discovery Program and&#47;or the PD Research Program (as defined in the PD Agreement)&#59; and</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:46pt;padding-right:27pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.02pt;">conduct such other activities as specifically assigned to the JSC under this Agreement or the PD Agreement.</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_4"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:46pt;padding-right:8.95pt;text-align:justify;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">As used in this Agreement, &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">PD Agreement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means that certain Process Development Research &#38; License Agreement entered into by and between Penn and Licensee dated March 26, 2020.&#8221;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:28pt;padding-right:8.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;">Additional Financial Provisions</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The following is hereby added as Section 6.14 of the Collaboration Agreement&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:28pt;padding-right:8.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;In the event that a Licensed Product is Covered by a Penn PD Patent Right or a Joint PD Patent Right (each, as defined in the PD Agreement) in a particular country, and such Licensed Product is not Covered by any Penn Patent Rights, Joint Patent Rights, or Licensed Know- How, the royalty and milestone payments under this Agreement shall apply to such Licensed Product as follows&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:17.95pt;padding-left:28pt;padding-right:8.9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.75pt;">Solely with respect to such Licensed Product and such country and solely for purposes of subsections (b) and (c) below, the definition of &#8220;Program Valid Claim&#8221; shall be deemed to refer to such Penn PD Patent Rights or Joint PD Patent Rights (each, as defined in the PD Agreement) instead of Penn Patent Rights A or Penn Patent Rights B&#59;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-36.05pt;padding-left:82pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.07pt;">Licensee will pay Penn milestone payments in accordance with the terms of Section</font></div><div style="padding-left:28pt;padding-right:9.2pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.2 upon the achievement of the corresponding milestone event by such Licensed Product&#59; provided that such milestones have not previously been achieved by a Licensed Product for the same Indication&#59;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:17.95pt;padding-left:28pt;padding-right:9.15pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.75pt;">Licensee will pay Penn royalties in accordance with the terms of Section 6.3 on Net Sales of such Licensed Product.&#8221;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-18.05pt;padding-left:28pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9.05pt;">Amendments</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:50.55pt;padding-right:9.2pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">a.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt;">Section 1.19 of the Collaboration Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:82pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;1.19 &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Discovery Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; &#91;***&#93;.&#8221;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:50.55pt;padding-right:49.7pt;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">b.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">Section 1.30 of the Collaboration Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:82pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;1.30 &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DRG Technology</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means &#91;***&#93;&#8221;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:71pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">2</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_7"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:50.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt;">Section 1.32 of the Collaboration Agreement is hereby amended by the deletion of&#58;</font></div><div style="padding-left:50.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;***&#93;.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18.65pt;padding-left:50.55pt;padding-right:9.35pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.65pt;">Section 1.50 of the Collaboration Agreement is hereby amended by adding the following to the end of Section 1.50&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:82pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;For clarity, Licensed Discovery Know-How does not include any DRG Technology.&#8221;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:50.55pt;padding-right:8.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">e.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt;">Section 1.93 of the Collaboration Agreement is hereby amended by adding the following to the end of Section 1.93&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:82pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;&#91;***&#93;&#8221;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:50.55pt;padding-right:9.2pt;margin-top:10.85pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">f.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.01pt;">Section 1.99 of the Collaboration Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:82pt;padding-right:8.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;1.99 &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Wilson Lab</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means Dr. James M. Wilson and all individuals who are under the direct supervision or control of Dr. James M. Wilson or his successor as Director of the Wilson Gene Therapy Program at Penn</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">provided that the Service Center Cores are not included in the Wilson Lab, including any personnel of the Service Center Cores. For clarity, and notwithstanding the foregoing sentence, Vector Operations is a department of the Wilson Lab and is included in the Wilson Lab, but the performance of Vector Core activities are specifically excluded from the Wilson Lab. It is understood that the activities of the Wilson Lab and&#47;or Vector Operations in the performance of a Research Program are not Vector Core activities.&#8221;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:50.55pt;padding-right:8.75pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">For clarity, references to the Wilson Lab in the Collaboration Agreement, including in Sections 1.19, 1.47, 1.51, 1.57, 1.61, 1.67, 1.68, 1.69, 1.86 and 2.5.5 of the Collaboration Agreement, shall be deemed to refer to the Wilson Lab and&#47;or Vector Operations.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-18.05pt;padding-left:50.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">g.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.05pt;">The following sections are hereby added to Article 1 of the Collaboration Agreement&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:50.55pt;padding-right:8.9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;1.101&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Vector Core</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the performance of the following activities by Vector Operations for and on behalf of personnel and departments of Penn (including the Wilson Lab) and&#47;or for other Third Parties&#58; (a) vector production services, and (b)</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">3</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_10"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:50.55pt;padding-right:9.1pt;text-align:justify;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">characterization, release and stability testing of vectors, small scale through large scale, including for use in support of toxicology studies.&#8221;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:50.55pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;1.102&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Vector Operations</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a laboratory at Penn that reports to Dr. James</font></div><div style="padding-left:50.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">M. Wilson and focuses on the development of AAV and other parvovirus vector manufacturing processes.&#8221;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:50.55pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;1.103&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DRG Exclusivity Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means &#91;***&#93;.&#34;</font></div><div><font><br></font></div><div style="padding-left:50.55pt;padding-right:8.5pt;text-align:justify;margin-top:10.85pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;1.104&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DRG Patent Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (a) &#91;***&#93; and (b) any continuations, provisionals,  continued   prosecution   applications,  substitutions,   extensions   and term  restorations,  registrations,   confirmations,   reexaminations,   renewals   or reissues of any of the Patent Rights in (a), including divisions, but excluding continuations-in-part except to the extent of claims solely supported in the specification and entitled to the priority date of  the  parent  application  for  any  of  the foregoing, and (c) any corresponding foreign Patent Rights to the foregoing&#59; provided, however, that the foregoing shall not include &#91;***&#93;.&#8221;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:50.55pt;padding-right:8.55pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;1.105&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exclusive DRG Technology Indications</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means (a) CDKL5 Deficiency Disorder, (b) Pompe Disease, (c) Fabry Disease, (d) NPC, (e) MPS IIIA, (f) MPS IIIB, and (g) &#91;***&#93;, as each of the foregoing indications are defined in Sections 1.32 and 1.46.&#8221;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:50.55pt;text-align:justify;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;1.106&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exploratory DRG Technology Indications</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means, &#91;***&#93;.&#8221;</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:50.55pt;padding-right:8.55pt;text-align:justify;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;1.107&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Licensee Product</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means a gene therapy product, other than a Licensed Product or Designated Product, for which Licensee has rights with respect to the research, development or commercialization of the gene therapy product, itself or with or through any Third Party, for a Licensee Product Option Indication.&#8221;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:50.55pt;padding-right:8.55pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;1.108&#160;&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Licensee Product Option Indications</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221; means the following specific disease or condition&#58; &#91;***&#93;.&#8221;</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:50.55pt;padding-right:9.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">h.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">The Collaboration Agreement is hereby amended by the addition of the following Section 2.5.5&#58;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">4</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_13"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:50.55pt;padding-right:5.75pt;text-align:justify;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;2.5.5 In the event Penn desires to grant a for-profit, commercial entity (other than such an entity controlled (as such term is defined in Section 1.3) or formed by Tom Hamilton or the Cure FA Foundation) a license for the indication &#91;***&#93; under Patent Rights Controlled by Penn and conceived and reduced to practice by the Wilson Lab,  Penn  shall provide Licensee written notice and provide Licensee a right of first negotiation     to negotiate with Penn terms for such license. Upon written notification from Penn (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ROFN Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), Licensee will have &#91;***&#93; from the date of such Offer Notice to provide written notice of exercise to Penn that Licensee desires to negotiate terms for such license with Penn (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exercise Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Upon Penn&#8217;s receipt of such Exercise Notice, Penn and Licensee shall negotiate in good faith for a period of up to &#91;***&#93; for such license agreement (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Negotiation Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). For clarity, the foregoing shall not restrict Penn from negotiating terms for, or granting such license to, (a) a non-profit or non-commercial entity, or (b) any Third Party in the event (i) Licensee does not provide an Exercise Notice within such &#91;***&#93; period from the date of such Offer Notice, (ii) Penn and Licensee are unable to agree to the terms of such license, or (iii) Penn and Licensee are unable to enter into an agreement for such license after good faith negotiations during the Negotiation Period.&#8221;</font></div><div><font><br></font></div><div style="text-indent:-18pt;padding-left:50.55pt;padding-right:8.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">i.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt;">Section 2.9 of the Collaboration Agreement is hereby amended by the addition of the following sentence at the end of Section 2.9&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:50.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;&#91;***&#93;.&#8221;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:50.55pt;padding-right:8.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">j.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.67pt;">The Collaboration Agreement is hereby amended by the addition of the following Section 2.13&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:50.55pt;padding-right:8.55pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;2.13 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Non-Exclusive DRG Technology License Option</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. During the period beginning on the Amendment Date until expiration of the Discovery Term (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Non-Exclusive DRG Option Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), Penn hereby grants to Licensee an option (the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Non-Exclusive DRG Option</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) to obtain, on a Licensee Product Option Indication-by-Licensee Product Option Indication basis, a non-exclusive, worldwide, royalty-bearing right and license, with the right to sublicense only in conjunction with a license to a Licensee Product and subject to the provisions of Section 5.6, under the DRG Patent Rights and the Know-How within the DRG Technology, to make, have made, use, sell, offer for sale, and import Licensee Products for such Licensee Product Option Indication. Licensee may exercise the Non- Exclusive DRG Option by providing written notice to Penn of exercise of such Non- Exclusive DRG Option during the Non-Exclusive DRG Option Period identifying the specific Licensee Product Option Indication subject to such exercise. Licensee shall only disclose such Licensee Product Option Indication in such exercise notice and shall not disclose to Penn additional information relating to any Licensee Product. If Licensee exercises such Non-Exclusive DRG Option, then the license grant set forth in Section 5.8.1(d) shall come into effect upon Penn&#8217;s receipt of payment of the Non-Exclusive DRG Option Fee with respect to such Licensee Product Option Indication. The option set forth in this Section 2.13 shall terminate upon early termination of the Agreement.&#8221;</font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div style="text-indent:-18.05pt;padding-left:50.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">k.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.05pt;">Section 3.3.2 is hereby deleted in its entirety.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">6</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_16"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:-18.05pt;padding-left:50.55pt;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">l.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.72pt;">Section 5.1(b) is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:50.55pt;padding-right:8.8pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;(b)(i) an exclusive, worldwide, royalty-bearing right and license, with the right to sublicense (subject to the provisions of Section 5.6), under Penn Patent Rights B and (ii) a non-exclusive, world-wide royalty-bearing right and license, with the right to sublicense (subject to the provisions of Section 5.6), under Licensed Discovery Know-How, in each case ((i) and (ii)), to make, have made, use, sell, offer for sale, and import Designated Products for the Indications in the Field of Use during the Term&#59;&#8221;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:50.3pt;padding-right:39pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">m.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:5.67pt;">Section 5.4 of the Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:50.55pt;padding-right:68.4pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Retained Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Notwithstanding the License or DRG Technology License, Penn retains the right under the Penn Patent Rights and the DRG Patent Rights to (a) conduct educational, research and clinical &#47; patient care activities itself (including sponsored research) and (b) authorize non- commercial third parties to conduct education, non- commercial research and clinical &#47; patient activities, in each case of subpart (a) and (b) related to the Indications in the Field of Use&#59; provided however that Penn shall not have the right to use or authorize the use of any Licensed Product for an Indication that is under active clinical testing or being sold by Licensee in the conduct of clinical or patient care activities without Licensee&#8217;s consent.&#8221;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:50.3pt;padding-right:39.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">n.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">Section 5.5 of the Agreement is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-top:0.15pt;"><font><br></font></div><div style="padding-left:50.55pt;padding-right:68.4pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">U.S. Government Rights</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The License and the DRG Technology License are expressly subject to all applicable provisions of any license to the United States Government executed by Penn and is subject to any overriding obligations to the United States Federal Government under 35 U.S.C. &#167;&#167;200- 212, applicable governmental implementing regulations, and the U.S. Government sponsored research agreement or other guidelines, including that products that result from intellectual property funded by the United States Federal Government that are sold in the United States be substantially manufactured in the United States. If so requested by Licensee, Penn shall reasonably cooperate with and assist Licensee to seek and obtain a waiver from the appropriate Regulatory Authorities with respect to such manufacturing requirement.&#8221;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:50.55pt;padding-right:9.1pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">o.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;">The Collaboration Agreement is hereby amended by the addition of the following Section 5.8&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:50.55pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;5.8    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DRG Technology License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:25.07pt;padding-left:50.55pt;padding-right:8.8pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">i.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:26.05pt;">Grant of DRG Technology License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160;Subject to the terms and conditions of this Agreement, Penn hereby grants to Licensee (the below rights, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DRG Technology License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#58;</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">8</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_19"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:31.4pt;padding-left:50.55pt;padding-right:8.75pt;text-align:justify;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.75pt;">(i) an exclusive, worldwide, royalty-bearing (solely to the extent provided in Section 6.3) right and license, with the right to sublicense only in conjunction with a Designated Product for such Exclusive DRG Technology Indication subject to the provisions Section 5.6, under the DRG Patent Rights and (ii) a non-exclusive, worldwide, royalty-bearing right and license, with the right to sublicense only in conjunction with a Designated Product subject to the provisions Section 5.6 under the DRG Technology, in each case ((i) and (ii)), to make, have made, use, sell, offer for sale, and import Designated Products for the Exclusive DRG Technology Indications in the Field of Use for the Exclusivity Period. Following the expiration of the Exclusivity Period, the DRG Technology License granted under this Section 5.8.1(a)(i) shall convert to a non- exclusive, worldwide, royalty-bearing right and license with the right to sublicense only in conjunction with a Designated Product subject to the provisions Section 5.6&#59;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:31.4pt;padding-left:50.55pt;padding-right:8.65pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.07pt;">a non-exclusive, worldwide, royalty-bearing (solely to the extent provided in Section 6.3) right and license, with the right to sublicense only in conjunction with a Designated Product for such Exploratory DRG Technology Indication subject to the provisions of Section 5.6, under DRG Patent Rights and the DRG Technology to make, have made, use, sell, offer for sale, and import Designated Products for the Exploratory Indications&#59;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:31.4pt;padding-left:50.55pt;padding-right:8.7pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.75pt;">a non-exclusive, worldwide, royalty-bearing (solely to the extent provided in Section 6.3) right and license, with the right to sublicense only in conjunction with a Licensed Product for such Exclusive DRG Technology Indication subject to the provisions of Section 5.6, under DRG Patent Rights and the DRG Technology to make, have made, use, sell, offer for sale, and import Licensed Products for the Exclusive DRG Technology Indications&#59; and</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:31.4pt;padding-left:50.55pt;padding-right:8.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.07pt;">on a Licensee Product Option Indication-by-Licensee Product Option Indication basis and subject to Licensee&#8217;s exercise of the Non-Exclusive DRG Option and payment of the Non-Exclusive DRG Option Fee, a non-exclusive, worldwide, royalty- bearing right and license, with the right to sublicense only in conjunction with a Licensee Product, under the DRG Patent Rights and DRG Technology to make, have made, use, sell, offer for sale, and import Licensee Products for the Licensee Product Option Indication.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:21.74pt;padding-left:50.55pt;padding-right:8.65pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.72pt;">Limited Exclusivity</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. The exclusive license grant set forth in Section 5.8.1(a) is subject to any applicable requirement, order, specific written request or decree by a Regulatory Authority to Penn to make such DRG Technology available to a Third Party on a non-exclusive basis for a specified Exclusive DRG Technology Indication. In such event, Penn shall provide written notice to Licensee of the foregoing, and any exclusive license grant set forth in Section 5.8.1(a) during the DRG Exclusivity Period shall convert to a non-exclusive license grant with respect to such Exclusive DRG Technology Indication to the extent necessary to accommodate Penn&#8217;s compliance with such requirement, order, specific written request or decree.</font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:18.41pt;padding-left:50.55pt;padding-right:8.8pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">iii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.72pt;">Diligence</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. In the event an IND is filed for a Designated Product for an Exclusive DRG Technology Indication and such Designated Product does not utilize the</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">10</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_22"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:50.55pt;padding-right:8.8pt;text-align:justify;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">DRG Technology, upon written notification by Penn, the exclusive license grant under Section 5.8.1(a) with respect to such Exclusive DRG Technology Indication shall convert to a non-exclusive, worldwide, royalty-bearing right and license without the right to sublicense (except in conjunction with a sublicense to a Licensed Product subject to the provisions Section 5.6).</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:19.07pt;padding-left:50.55pt;padding-right:8.95pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">iv.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:20.05pt;">Indication Restriction</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Subject to Section 5.8.3 and Penn&#8217;s retained rights set forth in Section 5.4 and Section 5.8.2, during the DRG Exclusivity Period, Penn shall not license to any Third Party the DRG Patent Rights for a product for an Exclusive DRG Technology Indication.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:50.55pt;padding-right:9.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">e.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.68pt;">The Collaboration Agreement is hereby amended by the addition of the following Section 6.15&#58;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="padding-left:50.55pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;6.15 </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Financials Related to the DRG Technology License</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-42.38pt;padding-left:154.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">i.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:36.05pt;">Financials Related to License Granted Pursuant to Section</font></div><div style="padding-left:50.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">5.8.1(d)</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-72.1pt;padding-left:190.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:63.1pt;">Upfront   Payment</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.&#160;On   a   Licensee   Product   Option</font></div><div style="padding-left:50.55pt;padding-right:8.6pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Indication-by-Licensee Product Option Indication basis, within &#91;***&#93; of Licensee&#8217;s exercise of the Non-Exclusive DRG Option with respect to such Licensee Product Option Indication, Licensee shall pay Penn a non-refundable and non-creditable license issue fee of&#58; (a) &#91;***&#93; if Licensee exercises such Non-Exclusive DRG Option for such Licensee Product Option Indication prior to the first dosing of the first patient in a Clinical  Study  of  a  Licensee  Product  for  such Licensee Product Option Indication or</font></div><div style="padding-left:50.55pt;padding-right:8.6pt;text-align:justify;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b) &#91;***&#93; if Licensee exercises such Non-Exclusive DRG Option for such Licensee Product Option Indication after the first dosing of the first patient in a Clinical Study of a Licensee Product for such Licensee Product Option Indication.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:67.4pt;padding-left:50.55pt;padding-right:8.6pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:17.05pt;">Milestones</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. In addition, and as additional consideration for the DRG Technology License set  forth  in  Section 5.8.1(d),  Licensee will pay Penn  the following milestone payments upon  the  achievement  of  the  first  Licensee Product to achieve the corresponding milestone for each Licensee Product Option Indication, whether achieved by Licensee or an  Affiliate  or  Sublicensee.  Licensee shall promptly notify Penn in writing of the achievement of any such milestone and Licensee shall pay Penn in  full  the  corresponding  milestone  payment  within  &#91;***&#93;  of such achievement. For clarity, each milestone payment set forth below is non- refundable, non-creditable and is not an advance against Royalties due to Penn or any other amounts due to Penn.</font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:71pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:81.776%;"><tr><td style="width:1.0%;"></td><td style="width:70.316%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.684%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bdbdbd;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.65pt;padding-right:1.95pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:109%;">Milestone</font></div><div style="padding-left:2.9pt;padding-right:1.95pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:103%;">(payable once per Licensee Product Option Indication)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bdbdbd;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="padding-left:5.6pt;margin-top:0.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%;">Milestone Payment (in U.S. dollars)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$&#91;***&#93;</font></td></tr></table></div><div style="position:relative;width:100%;height:71pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">12</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_25"></div><hr style="page-break-after:always"><div style="height:72pt;width:100%;"><div><font><br></font></div></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:81.776%;"><tr><td style="width:1.0%;"></td><td style="width:70.316%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:25.684%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bdbdbd;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:2.65pt;padding-right:1.95pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:110%;">Milestone</font></div><div style="padding-left:2.9pt;padding-right:1.95pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:104%;">(payable once per Licensee Product Option Indication)</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#bdbdbd;text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><div style="padding-left:5.6pt;margin-top:0.7pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%;">Milestone Payment (in U.S. dollars)</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#91;***&#93;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$&#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-0.85pt;padding-left:5.6pt;margin-top:0.45pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:105%;">Total Milestone Payments per Licensee Product Option Indication</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:top;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$&#91;***&#93;</font></td></tr></table></div><div style="padding-left:118pt;padding-right:8.65pt;text-align:justify;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:17pt;">Royalty</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. In addition, and as further consideration for the DRG Technology License set forth in Section 5.8.1(d), on a Licensee Product-by-Licensee Product basis for each Licensee Product Option Indication and during the applicable Licensee Product Royalty Period, Licensee shall pay to Penn a non-refundable, non-creditable royalty of &#91;***&#93; of worldwide Net Sales of Licensee Product for such Licensee Product Option Indication. Licensee&#8217;s obligation to pay Penn such royalty will continue on a country-by-country and  Licensee  Product-by- Licensee Product basis from the date of First Commercial Sale of such Licensee Product for such Licensee Product Option Indication in a country until the latest of (a) the expiration or abandonment of the last Valid  Claim within the DRG Patent Rights covering such Licensee Product in such country, (b) &#91;***&#93; after First Commercial Sale of such Licensee Product in such country, (c) the expiration of the Regulatory Exclusivity with respect to such Licensee Product&#59; &#91;***&#93; (such royalty period, the &#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Licensee Product Royalty Period</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). In addition, the royalty under this Section 6.15.1.3 shall be subject to the royalty reductions set forth in Section 6.3.3, applied </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">mutatis mutandis</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. For the avoidance of doubt, no additional royalty shall be due under this Section 6.15 with respect to Net Sales of any Licensed Product, including  any  Designated Product. For  the avoidance of doubt, such products are subject to royalty obligations solely pursuant to Section 6.3.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="padding-left:118pt;padding-right:8.65pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17pt;">As used in this Section 6.15.1, (a) &#8220;Net Sales&#8221; shall have the meaning ascribed to such term as set forth in Section  1.59, substituting Licensee Product for each reference to Licensed Product in such section and (b) &#8220;Valid Claim&#8221; shall have the meaning ascribed to such term as set forth</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">13</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_28"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:118pt;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">in Section 1.98, substituting DRG Patent Rights for each reference to Penn Patent Rights in such section.&#8221;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:50.55pt;padding-right:9.1pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">f.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.01pt;">The Collaboration Agreement is hereby amended by the addition of the following Section 8.7&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:50.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;8.7&#160;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DRG Patent Filing Prosecution and Maintenance, Patent Costs, Infringement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-42.38pt;padding-left:118pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">i.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:36.05pt;">Patent Filing Prosecution and Maintenance</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:82pt;padding-right:8.75pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.7pt;">Penn will use diligent efforts to file, and thereafter prosecute in good faith and maintain DRG Patent Right(s). DRG Patent Right(s) will be held in the name of Penn and obtained with Patent Counsel. Penn shall control all actions and decisions with respect to the filing, prosecution and maintenance of DRG Patent Right(s). For the purposes of this Agreement, &#8220;maintenance&#8221; of the DRG Patent Right(s) includes </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">inter partes </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">patent review proceedings before the USPTO or a similar patent administration outside the US. For DRG Patent Rights, Penn will instruct Patent Counsel to provide Licensee copies of patent applications when filed, notices of allowance when received, office actions when issued and office action responses when filed.</font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="padding-left:82pt;padding-right:10.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:12.02pt;">In the event that DRG Technology is conceived and reduced to practice by the Wilson Lab and&#47;or Vector Operations during the Discovery Term without the use of any Licensee funding (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DRG Technology Improvement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;) and</font></div><div style="padding-left:82pt;padding-right:9.45pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">such DRG Technology Improvement is also incorporated into any clinical candidate of a Third Party with whom the Wilson Lab is collaborating, then Penn may file and prosecute a Patent Right that covers such clinical candidate of a Third Party with whom the Wilson Lab is collaborating incorporating such DRG Technology Improvement (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Third Party Candidate Patent Right</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;)&#59; provided, however, that if Penn files a Third Party Candidate Patent Right, Penn shall also separately file and prosecute a patent application specific for such DRG Technology Improvement distinct from such Third Party Candidate Patent Right.</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-45.71pt;padding-left:118pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">ii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:36.05pt;">Patent Costs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:67.4pt;padding-left:50.55pt;padding-right:8.8pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.05pt;">Subject to Section 8.7.2.3, within &#91;***&#93; after the Amendment  Date, Licensee will reimburse Penn for all documented out-of-pocket costs for the filing, prosecution and maintenance of DRG Patent Right(s) for the filing, prosecution and maintenance of DRG Patent Rights, including all accrued and documented attorney fees, expenses, official and filing fees (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DRG Patent Costs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;), incurred prior to the Amendment Date, which have not otherwise been reimbursed by Licensee or other licensees of such DRG Patent Rights (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Historic DRG Patent Costs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Notwithstanding the first sentence of this Section 8.7.2.1, for DRG Patent Right(s) licensed by Penn to more than one licensee, Licensee shall be responsible for payment to Penn of a pro rata </font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:50.55pt;padding-right:8.8pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">share of such documented Historic DRG Patent Costs based on the number of licensees for such Patent Rights.</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">15</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_31"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:67.4pt;padding-left:50.55pt;padding-right:8.7pt;text-align:justify;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.05pt;">Licensee will bear (a) all DRG Patent Costs incurred during the Term for DRG Patent Right(s) (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Ongoing DRG Patent Costs</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). Notwithstanding the foregoing, for DRG Patent Rights licensed by Penn to more than one licensee, Licensee shall be responsible for payment to Penn of a pro rata share of such documented Ongoing DRG Patent Costs based on the number of licensees for such DRG Patent Rights. No later than sixty (60) days prior to the end of each Calendar Year during the Term, Penn shall provide to Licensee, a good faith estimate and budget for the Ongoing DRG Patent Costs anticipated to be incurred for the next Calendar Year and, to the extent applicable, Licensee&#8217;s proportionate share of such Ongoing DRG Patent Costs. This Section 8.7.2 is subject to Section 8.7.1 above.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:67.4pt;padding-left:50.55pt;padding-right:8.7pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.05pt;">With respect to DRG Patent Right(s), Licensee shall be subject to Advance Payment. Notwithstanding whether Licensee makes an Advance Payment for any patent action, Licensee shall bear its pro rata share (based on the number of licensees for such DRG Patent Rights) of all DRG Patent Costs with respect to DRG Patent Right(s) as set forth in this Section 8.7.2, above, and shall pay such amounts within &#91;***&#93; of receipt of invoice for such patent actions.</font></div><div><font><br></font></div><div style="text-indent:67.4pt;padding-left:50.55pt;padding-right:8.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.05pt;">Licensee shall also have the right, on a DRG Patent Right-by-DRG Patent Right and country-by-country basis, to (i) elect not to fund at the time of disclosure, or (ii) elect not to continue to fund, in each case (i) and (ii), its pro rata share (as determined pursuant to this Section 8.7 above) of the DRG Patent Costs with respect to any DRG Patent Right(s) in a particular country, which election may be made by Licensee upon sixty (60) days prior written notice to Penn (&#8220;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">DRG Election Notice</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8221;). If Licensee delivers a DRG Election Notice to Penn, following the expiration of such sixty (60) day period, Licensee shall have no further obligation to pay Ongoing DRG Patent Costs with respect to any DRG Patent Right identified in such DRG Election Notice in any country identified in such DRG Election Notice and any such Patent Right in any such country shall thereafter be excluded from the DRG Patent Rights.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-49.04pt;padding-left:118pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">iii.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:29.39pt;">Infringement</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:67.4pt;padding-left:50.55pt;padding-right:8.9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.05pt;">If either Party believes that an infringement by a Third Party with respect to any DRG Patent Right is occurring or may potentially occur, the knowledgeable Party will provide the other Party with (a) written notice of such infringement or potential infringement and (b) evidence of such infringement or potential infringement. With respect to DRG Patent Rights, Penn shall have the exclusive right to enforce such Patent Rights and institute suit for Patent Infringement. If Penn institutes such suit, then Licensee may not join such suit without the prior written consent of Penn.</font></div><div><font><br></font></div><div style="text-indent:67.4pt;padding-left:50.55pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.05pt;">Any recovery or settlement received in connection with any suit will be the exclusive property of Penn.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:67.4pt;padding-left:50.55pt;padding-right:9.1pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.05pt;">Licensee will reasonably cooperate and assist Penn in litigation proceedings instituted hereunder at Penn&#8217;s request and expense.</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">17</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_34"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:67.4pt;padding-left:50.55pt;padding-right:9.15pt;text-align:justify;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.05pt;">Penn shall keep Licensee reasonably informed of the initiation and status of any action to enforce any DRG Patent Rights to which Licensee has rights hereunder.</font></div><div style="margin-top:0.05pt;"><font><br></font></div><div style="text-indent:67.4pt;padding-left:50.55pt;padding-right:8.55pt;text-align:justify;margin-top:4.5pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:17.05pt;">If, within &#91;***&#93; following the date of a notice delivered pursuant  to Section 8.7.3.1, infringing activity of potential commercial significance with respect to the DRG Patent Rights for a Licensee Option Indication has not been abated or Penn has not brought suit against the infringer, then payments due to Penn with respect to the DRG Patent Rights for a Licensee Product for a Licensee Product Option Indication pursuant to Section 6.15 and&#47;or Section 8.7.2 shall be suspended for so long as the infringing activity of potential commercial significance continues unabated by a Third Party competitor of a Licensee Product for the Licensee Product Option Indication and Penn does not bring suit against the infringer relating to such Licensee Product for the Licensee Product Option Indication that is the subject of the notice of infringement under Section 8.7.3.1. If such infringement is subsequently abated, whether as a result of acts of Penn or a Third Party, Licensee&#8217;s payment obligations with respect to the DRG Patent Rights for such infringed Licensee Product Option Indication shall be reinstated&#59; provided that Licensee shall have no obligation to pay any amounts that would have been due pursuant to Section 6.15 and&#47;or Section 8.7.2 during the period of any unabated infringement but for this Section 8.7.3.5.&#8221;</font></div><div style="margin-top:0.55pt;"><font><br></font></div><div style="text-indent:-18.05pt;padding-left:50.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">c.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.73pt;">Section 10.2.3 is hereby amended and restated in its entirety as follows&#58;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:82pt;padding-right:8.85pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#8220;Other than licenses granted under the Excluded Penn IP, rights granted to Patent Rights set forth in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Exhibit X</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or the arrangements with Third Parties described in </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 3.2.4</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"> or </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">Schedule 10.2.3</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">, to Penn&#8217;s knowledge, Penn has not entered into any arrangement with any Third Party for any Indication, Potential Indication or Exploratory Indication prior to the New Effective Date which is still in effect and pursuant to which a Third Party has license rights, or has an option to obtain rights, to any Patent Rights conceived or reduced to practice in the Wilson Lab.&#8221;</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18.05pt;padding-left:50.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">d.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.05pt;">Exhibit G is hereby amended and restated in its entirety with Exhibit G attached hereto.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18.05pt;padding-left:50.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">e.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9.73pt;">Exhibit H is hereby amended and restated in its entirety with Exhibit H attached hereto.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:50.55pt;padding-right:9.1pt;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">f.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:11.01pt;">Schedule 3.2.4 is hereby amended and restated in its entirety with Schedule 3.2.4 attached hereto.</font></div><div style="margin-top:0.45pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:28pt;padding-right:8.8pt;text-align:justify;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;">No Other Modification</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. Except as specifically set forth in this Amendment, the terms and conditions of the Collaboration Agreement shall continue in full force and effect and shall apply to this Amendment. This Amendment constitutes the complete and exclusive statement of agreement between the Parties with respect to the subject matter of this Amendment, and supersedes all prior agreements and understandings, and all prior and contemporaneous (oral or written) proposals, understanding, representations, conditions, warranties, covenants and all other communications between the Parties respecting the subject matter hereof. No wa</font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:28pt;padding-right:8.8pt;text-align:justify;margin-top:0.05pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">iver, modification or amendment of any provision of this Amendment shall be valid or effective</font></div><div style="text-align:justify;"><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">19</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_37"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:28pt;padding-right:1.45pt;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">unless made in a writing referencing this Amendment and signed by a duly authorized officer of each Party.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="text-indent:-18pt;padding-left:28pt;padding-right:9pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">6.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;">Miscellaneous</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">. This Amendment may be executed in counterparts, each of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A facsimile or a portable document format (PDF) copy of this Amendment, including the signature pages, will be deemed an original. This Amendment shall be governed by and interpreted in accordance with the laws of the Commonwealth of Pennsylvania, excluding application of any conflict of laws principles that would require application of the law of a jurisdiction outside of the Commonwealth of Pennsylvania.</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:68.1pt;padding-right:67.55pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%;">&#91;Remainder of the page intentionally left blank&#59; signature page follows.&#93;</font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">20</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_40"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:35.95pt;padding-left:10pt;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:128%;">IN WITNESS WHEREOF, </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:128%;">duly authorized representatives of the Parties have executed this Agreement as of the Amendment Date.</font></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:52.053%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA</font></td></tr><tr><td colspan="3" style="height:27pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:0.3pt;"><font><br></font></div><div style="padding-left:10pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%;">By&#58;      </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%;text-decoration: underline;">&#47;s&#47; John S. Swartley, PhD</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58; John S. Swartley, PhD</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-45.6pt;padding-left:55.55pt;padding-right:20.75pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;&#160;Associate Vice Provost for Research and Managing Director, Penn Center</font></div><div style="padding-left:55.55pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;">for Innovation</font></div></td></tr></table></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:40.349%;"><tr><td style="width:1.0%;"></td><td style="width:98.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:20.9pt;padding-right:9.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">AMICUS&#160;THERAPEUTICS, INC.</font></div></td></tr><tr><td colspan="3" style="height:27pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="margin-top:0.3pt;"><font><br></font></div><div style="padding-left:26.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%;">By&#58;    </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%;text-decoration: underline;">&#47;s&#47; John Crowley</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:109%;">&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name&#58; John Crowley</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><font style="font-size:12pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title&#58; Chairman and CEO</font></td></tr></table></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:13pt;font-weight:400;line-height:120%;"></font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:10pt;margin-top:10.35pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Read and Acknowledged&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:10pt;margin-top:11.65pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">By&#58;&#160;       </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration: underline;">&#47;s&#47; Dr. James M. Wilson</font></div><div style="padding-left:10pt;margin-top:1.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Name&#58;&#160;Dr. James M. Wilson</font></div><div style="padding-left:10pt;margin-top:1.8pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">Title&#58;&#160;Director, Gene Therapy Program</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">21</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_43"></div><hr style="page-break-after:always"><div style="height:75pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:68.1pt;padding-right:66.7pt;text-align:center;margin-top:11.25pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amended and Restated Exhibit G</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:68.1pt;padding-right:67.05pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;***&#93;</font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:14pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_46"></div><hr style="page-break-after:always"><div style="height:69pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:68.1pt;padding-right:59.1pt;text-align:center;margin-top:3pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amended and Restated Exhibit H</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:68.1pt;padding-right:59.1pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;">&#91;***&#93;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">2</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_49"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:68.1pt;padding-right:67.2pt;text-align:center;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Amended and Restated Schedule 3.2.4</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#91;***&#93;</font></div><div style="padding-left:68.1pt;padding-right:67.2pt;text-align:center;margin-top:3.95pt;"><font><br></font></div><div style="padding-left:68.1pt;padding-right:67.2pt;text-align:center;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Schedule 10.2.3</font></div><div style="padding-left:68.1pt;padding-right:67.2pt;text-align:center;margin-top:3.95pt;"><font><br></font></div><div style="padding-left:68.1pt;padding-right:67.2pt;text-align:center;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:68.1pt;padding-right:67.2pt;text-align:center;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit X</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:68.1pt;padding-right:67.2pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">6</font></div><div><font><br></font></div></div></div><div id="ie14a6327fdc2419494b8e4449751e33a_52"></div><hr style="page-break-after:always"><div style="height:68pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:68.1pt;padding-right:66.9pt;text-align:center;margin-top:3.95pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">Exhibit Y</font></div><div style="margin-top:0.5pt;"><font><br></font></div><div style="padding-left:67.4pt;padding-right:67.55pt;text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">&#91;***&#93;</font></div><div style="position:relative;width:100%;height:73pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:7%;">7</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>fold-03312020xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i88b1d59c9f254494b24741aa305273db_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;31.1</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATIONS PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION BY PRINCIPAL EXECUTIVE OFFICER</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, John F. Crowley, certify that&#58;</font></div><div style="text-indent:-9pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt;">I have reviewed this quarterly report on Form&#160;10-Q of Amicus Therapeutics,&#160;Inc.&#59;</font></div><div style="text-indent:-9pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-9pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-9pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:36pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:36pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:36pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:36pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-9pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:36pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:36pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 7, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; John F. Crowley</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">John F. Crowley</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chairman and Chief Executive Officer</font></td></tr></table></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font><br></font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>fold-03312020xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i42937d08fbaf4cb3a63807634ad0cb13_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;31.2</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATIONS PURSUANT TO SECTION&#160;302 OF</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">I, Daphne Quimi, certify that&#58;</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-indent:-9pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">1.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt;">I have reviewed this quarterly report on Form&#160;10-Q of Amicus Therapeutics,&#160;Inc.&#59;</font></div><div style="text-indent:-9pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">2.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="text-indent:-9pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">3.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="text-indent:-9pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">4.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div style="text-indent:36pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="text-indent:36pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:36pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(c)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:36pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(d)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:-9pt;padding-left:36pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">5.</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:1.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="text-indent:36pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(a)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="text-indent:36pt;padding-left:18pt;text-align:justify;margin-top:9pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">(b)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:48.000%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 7, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr></table></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>fold-03312020xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i709782d3b7794603a73aa0aaa5f8014d_1"></div><div style="height:42.75pt;width:100%;"><div><font><br></font></div></div><div style="text-align:right;-sec-extract:summary;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">Exhibit&#160;32.1</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">PRINCIPAL FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">18 U.S.C. SECTION&#160;1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each of the undersigned hereby certifies, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Amicus Therapeutics,&#160;Inc. (the &#8220;Company&#8221;), that, to his knowledge, the Quarterly Report of the Company on Form&#160;10-Q for the period ended March 31, 2020, fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of the Company. This written statement is being furnished to the Securities and Exchange Commission as an exhibit to such Form&#160;10-Q. A signed original of this statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:81.725%;"><tr><td style="width:1.0%;"></td><td style="width:45.763%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:3.903%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:44.334%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 7, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; John F. Crowley</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">John F. Crowley</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chairman and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date&#58; May 7, 2020</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">By&#58;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#47;s&#47; Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Daphne Quimi</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Chief Financial Officer</font></td></tr></table></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">&#160;</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:42.75pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>fold-20200331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d7d83936-4003-4695-9e73-95a98e869b39,g:49308d12-68e9-469e-b9d5-8a5a2cc3db36-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:fold="http://www.amicustherapeutics.com/20200331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.amicustherapeutics.com/20200331">
  <xs:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20200331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20200331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20200331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="fold-20200331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.amicustherapeutics.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossParenthetical" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical">
        <link:definition>1005006 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquity" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity">
        <link:definition>1006007 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessDetails" roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails">
        <link:definition>2402401 - Disclosure - Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2406402 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCash" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash">
        <link:definition>2107103 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables">
        <link:definition>2308302 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails">
        <link:definition>2409403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1">
        <link:definition>2409403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2">
        <link:definition>2409403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails">
        <link:definition>2410404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.amicustherapeutics.com/role/Inventories">
        <link:definition>2111104 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.amicustherapeutics.com/role/InventoriesTables">
        <link:definition>2312303 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails">
        <link:definition>2413405 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.amicustherapeutics.com/role/Debt">
        <link:definition>2114105 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.amicustherapeutics.com/role/DebtTables">
        <link:definition>2315304 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSummaryofLongTermDebtDetails" roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails">
        <link:definition>2416406 - Disclosure - Debt - Summary of Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails">
        <link:definition>2417407 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtInterestExpenseDetails" roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails">
        <link:definition>2418408 - Disclosure - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation">
        <link:definition>2119106 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables">
        <link:definition>2320305 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationWeightedaverageAssumptionsDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails">
        <link:definition>2421409 - Disclosure - Share-Based Compensation - Weighted-average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails">
        <link:definition>2422410 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>2423411 - Disclosure - Share-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRSUsandPBRSUsSummaryDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails">
        <link:definition>2424412 - Disclosure - Share-Based Compensation - RSUs and PBRSUs Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationExpenseSummaryDetails" roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails">
        <link:definition>2425413 - Disclosure - Share-Based Compensation - Expense Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValue" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue">
        <link:definition>2126107 - Disclosure - Assets and Liabilities Measured at Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueTables" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables">
        <link:definition>2327306 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails">
        <link:definition>2428414 - Disclosure - Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails" roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails">
        <link:definition>2429415 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShare" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare">
        <link:definition>2130108 - Disclosure - Basic and Diluted Net Loss per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShareTables" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables">
        <link:definition>2331307 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasicandDilutedNetLossperCommonShareDetails" roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails">
        <link:definition>2432416 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="fold_ATB200PompeProgramMember" abstract="true" name="ATB200PompeProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodValueContingentConsideration" abstract="false" name="StockIssuedDuringPeriodValueContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CallidusBiopharmaIncMember" abstract="true" name="CallidusBiopharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" abstract="false" name="GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" abstract="false" name="GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_IncreaseDecreaseInDeferredReimbursements" abstract="false" name="IncreaseDecreaseInDeferredReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ContingentConsiderationMeasurementInput" abstract="false" name="ContingentConsiderationMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="fold_ShortTermCorporateDebtSecuritiesMember" abstract="true" name="ShortTermCorporateDebtSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" abstract="false" name="ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_EmployeeAndDirectorsStockOptionsMember" abstract="true" name="EmployeeAndDirectorsStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" abstract="false" name="IncreaseDecreaseInNoncurrentOperatingLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_MeasurementInputProbabilityOfMilestoneAchievementMember" abstract="true" name="MeasurementInputProbabilityOfMilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_AmortizationDeferredFinancingCosts" abstract="false" name="AmortizationDeferredFinancingCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" abstract="false" name="DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" abstract="true" name="StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodSharesContingentConsideration" abstract="false" name="StockIssuedDuringPeriodSharesContingentConsideration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" abstract="false" name="DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" abstract="false" name="AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" abstract="false" name="DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ContingentConsiderationPaidInStockAdjustment" abstract="false" name="ContingentConsiderationPaidInStockAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ContingentConsiderationPaidInStock" abstract="false" name="ContingentConsiderationPaidInStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_SeniorSecuredTermLoanDue2023Member" abstract="true" name="SeniorSecuredTermLoanDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_PaymentsForRepurchaseOfRestrictedStockUnits" abstract="false" name="PaymentsForRepurchaseOfRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_DebtInstrumentsConvertibleThresholdTradingDays" abstract="false" name="DebtInstrumentsConvertibleThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ConvertibleSeniorNotes2016Due2023Member" abstract="true" name="ConvertibleSeniorNotes2016Due2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" abstract="true" name="ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="fold_ForeignCurrencyRemeasurementGainLossBeforeTax" abstract="false" name="ForeignCurrencyRemeasurementGainLossBeforeTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="fold_ProbabilityWeightedDiscountedCashFlowMember" abstract="true" name="ProbabilityWeightedDiscountedCashFlowMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>fold-20200331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d7d83936-4003-4695-9e73-95a98e869b39,g:49308d12-68e9-469e-b9d5-8a5a2cc3db36-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="fold-20200331.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_678cb5e1-a7d4-4bc4-a3ae-46457f72da21" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a4f364c8-3f32-402d-bca7-61ee4627b026" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_678cb5e1-a7d4-4bc4-a3ae-46457f72da21" xlink:to="loc_us-gaap_CommonStockValue_a4f364c8-3f32-402d-bca7-61ee4627b026" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_085b651b-54fc-4fbf-a279-00eae8602eb8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_678cb5e1-a7d4-4bc4-a3ae-46457f72da21" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_085b651b-54fc-4fbf-a279-00eae8602eb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_a90eda9e-dbe8-4d35-a3df-8d887018cb46" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_678cb5e1-a7d4-4bc4-a3ae-46457f72da21" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_a90eda9e-dbe8-4d35-a3df-8d887018cb46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9b152141-cc4d-4e39-9120-29b374721909" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_678cb5e1-a7d4-4bc4-a3ae-46457f72da21" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9b152141-cc4d-4e39-9120-29b374721909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_fc9ff9b9-57a2-4952-a375-a01256145f82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_678cb5e1-a7d4-4bc4-a3ae-46457f72da21" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_fc9ff9b9-57a2-4952-a375-a01256145f82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77fc3677-1bea-4091-8935-a2554f6f5d55" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_678cb5e1-a7d4-4bc4-a3ae-46457f72da21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_77fc3677-1bea-4091-8935-a2554f6f5d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_90ab4369-a6a2-44ac-acf2-592b952481ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8ac24e9c-8482-4f35-b6cf-d8ea15fb6347" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_90ab4369-a6a2-44ac-acf2-592b952481ec" xlink:to="loc_us-gaap_Liabilities_8ac24e9c-8482-4f35-b6cf-d8ea15fb6347" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_04475a22-eee4-4a0f-a526-8d71d9f4d5ad" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_90ab4369-a6a2-44ac-acf2-592b952481ec" xlink:to="loc_us-gaap_CommitmentsAndContingencies_04475a22-eee4-4a0f-a526-8d71d9f4d5ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_50597b41-125e-4603-9173-7de91118e02d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_90ab4369-a6a2-44ac-acf2-592b952481ec" xlink:to="loc_us-gaap_StockholdersEquity_50597b41-125e-4603-9173-7de91118e02d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6b4e6712-56c6-44bc-9656-630a32023dc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_afd17690-e80f-4c79-b30a-d812a762731b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b4e6712-56c6-44bc-9656-630a32023dc6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_afd17690-e80f-4c79-b30a-d812a762731b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5145a5ef-1a7b-43e5-92da-77bed45d2768" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b4e6712-56c6-44bc-9656-630a32023dc6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5145a5ef-1a7b-43e5-92da-77bed45d2768" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_719423d1-bf12-4f9d-878c-db1b7642547a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b4e6712-56c6-44bc-9656-630a32023dc6" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_719423d1-bf12-4f9d-878c-db1b7642547a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_de072828-579b-47d9-ae9e-f806f3fd1487" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b4e6712-56c6-44bc-9656-630a32023dc6" xlink:to="loc_us-gaap_InventoryNet_de072828-579b-47d9-ae9e-f806f3fd1487" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ec5ee93f-43c2-4a87-bc7f-348ee66f4ff9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_6b4e6712-56c6-44bc-9656-630a32023dc6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ec5ee93f-43c2-4a87-bc7f-348ee66f4ff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2c46745a-9ef0-4ad6-b38d-13fdd355b8db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_633707fd-2b53-4220-b3fd-c8a68ab1e2e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2c46745a-9ef0-4ad6-b38d-13fdd355b8db" xlink:to="loc_us-gaap_LiabilitiesCurrent_633707fd-2b53-4220-b3fd-c8a68ab1e2e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_cf97c233-a754-4989-9f9c-94c5529ce8cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2c46745a-9ef0-4ad6-b38d-13fdd355b8db" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_cf97c233-a754-4989-9f9c-94c5529ce8cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_6d4f45d9-330f-40f8-b616-505f95fd3fb6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2c46745a-9ef0-4ad6-b38d-13fdd355b8db" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_6d4f45d9-330f-40f8-b616-505f95fd3fb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_30712f6b-3d6b-4279-be42-ad89da96430d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2c46745a-9ef0-4ad6-b38d-13fdd355b8db" xlink:to="loc_us-gaap_SecuredLongTermDebt_30712f6b-3d6b-4279-be42-ad89da96430d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1a1e3d28-d662-4fb6-860c-3dd77ccf01b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2c46745a-9ef0-4ad6-b38d-13fdd355b8db" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_1a1e3d28-d662-4fb6-860c-3dd77ccf01b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_66cd8f9f-f71f-4acf-929e-a1b5f737b3b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2c46745a-9ef0-4ad6-b38d-13fdd355b8db" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_66cd8f9f-f71f-4acf-929e-a1b5f737b3b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aa9448c8-4359-4c43-ad88-9c37e9bbda90" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2c46745a-9ef0-4ad6-b38d-13fdd355b8db" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_aa9448c8-4359-4c43-ad88-9c37e9bbda90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e36018fb-b951-4f78-ba59-982507e9398b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_2c46745a-9ef0-4ad6-b38d-13fdd355b8db" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e36018fb-b951-4f78-ba59-982507e9398b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9de0ef20-1a9a-4a57-8573-edf6032602f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_0a3dd4a0-f774-40d2-9421-061797616814" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9de0ef20-1a9a-4a57-8573-edf6032602f8" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_0a3dd4a0-f774-40d2-9421-061797616814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_29e46645-e575-4c79-a8ea-6cb3ceb750c0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9de0ef20-1a9a-4a57-8573-edf6032602f8" xlink:to="loc_us-gaap_AccountsPayableCurrent_29e46645-e575-4c79-a8ea-6cb3ceb750c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c9ace28b-71e2-4e69-ba71-36625cd8aef4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9de0ef20-1a9a-4a57-8573-edf6032602f8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c9ace28b-71e2-4e69-ba71-36625cd8aef4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a6c82ebd-3f9e-42ff-b437-1607174c5e39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9de0ef20-1a9a-4a57-8573-edf6032602f8" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_a6c82ebd-3f9e-42ff-b437-1607174c5e39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c2a0871e-dd2f-48a9-9e70-46179c314b01" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_883eddac-e993-4896-a786-1d609b35e70d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c2a0871e-dd2f-48a9-9e70-46179c314b01" xlink:to="loc_us-gaap_AssetsCurrent_883eddac-e993-4896-a786-1d609b35e70d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9ce4027f-d20f-49e7-ae53-acc7ea365c73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c2a0871e-dd2f-48a9-9e70-46179c314b01" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9ce4027f-d20f-49e7-ae53-acc7ea365c73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3c49d226-15d8-4e46-8077-3cb5baf097ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c2a0871e-dd2f-48a9-9e70-46179c314b01" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3c49d226-15d8-4e46-8077-3cb5baf097ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_625eebdc-47c6-47d8-876a-1b12e1bf350e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c2a0871e-dd2f-48a9-9e70-46179c314b01" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_625eebdc-47c6-47d8-876a-1b12e1bf350e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6b4313f8-dc2d-429b-8861-e2dc8a6e7e88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c2a0871e-dd2f-48a9-9e70-46179c314b01" xlink:to="loc_us-gaap_Goodwill_6b4313f8-dc2d-429b-8861-e2dc8a6e7e88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b182f92e-9d91-41f1-92b7-cee59e5b66e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c2a0871e-dd2f-48a9-9e70-46179c314b01" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b182f92e-9d91-41f1-92b7-cee59e5b66e5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8b218526-117a-4b45-801a-5a574f5db14a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bc35a516-44b6-4fde-90cb-546ae1f8df6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8b218526-117a-4b45-801a-5a574f5db14a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bc35a516-44b6-4fde-90cb-546ae1f8df6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_15e830e8-9895-4381-bc13-e569cb181179" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8b218526-117a-4b45-801a-5a574f5db14a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_15e830e8-9895-4381-bc13-e569cb181179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_cc631360-c1b1-4c74-806d-fd69eaa58fa7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8b218526-117a-4b45-801a-5a574f5db14a" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_cc631360-c1b1-4c74-806d-fd69eaa58fa7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1cba906d-769c-4608-8e7d-f7aef3aedff9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8b218526-117a-4b45-801a-5a574f5db14a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1cba906d-769c-4608-8e7d-f7aef3aedff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ed19caf9-91d1-42f7-84f2-a572c9d55d39" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b9f1500-a0d7-43c4-b818-5ed84c449efd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ed19caf9-91d1-42f7-84f2-a572c9d55d39" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7b9f1500-a0d7-43c4-b818-5ed84c449efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a582535e-8b36-47af-a084-8a9f7b9a28f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_ed19caf9-91d1-42f7-84f2-a572c9d55d39" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a582535e-8b36-47af-a084-8a9f7b9a28f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_2a9dc49a-754f-4ab9-8fc9-e9281a7a07ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_4fe71457-44ef-410f-8a63-b4d3fc2e501a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2a9dc49a-754f-4ab9-8fc9-e9281a7a07ee" xlink:to="loc_us-gaap_GrossProfit_4fe71457-44ef-410f-8a63-b4d3fc2e501a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_461c1031-9c39-4443-85ac-b89558a496c3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_2a9dc49a-754f-4ab9-8fc9-e9281a7a07ee" xlink:to="loc_us-gaap_OperatingExpenses_461c1031-9c39-4443-85ac-b89558a496c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_1f4a36b0-3b37-4eab-9cf5-efab34f15f98" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e66de0de-ef14-452f-b1e2-2d31b0a6607e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1f4a36b0-3b37-4eab-9cf5-efab34f15f98" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e66de0de-ef14-452f-b1e2-2d31b0a6607e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6f459b84-eeb0-413a-9e60-338040cfb90a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_1f4a36b0-3b37-4eab-9cf5-efab34f15f98" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6f459b84-eeb0-413a-9e60-338040cfb90a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a958690a-4852-4bc9-87e3-2265aafb3250" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0bf779f6-e8cd-4305-9f2f-178edddc696b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a958690a-4852-4bc9-87e3-2265aafb3250" xlink:to="loc_us-gaap_OperatingIncomeLoss_0bf779f6-e8cd-4305-9f2f-178edddc696b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_510a6f88-c07a-4f8d-aa26-6a2adc4391dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a958690a-4852-4bc9-87e3-2265aafb3250" xlink:to="loc_us-gaap_InvestmentIncomeInterest_510a6f88-c07a-4f8d-aa26-6a2adc4391dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b503ce86-84dc-4d29-8093-f7be5afb15ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a958690a-4852-4bc9-87e3-2265aafb3250" xlink:to="loc_us-gaap_InterestExpense_b503ce86-84dc-4d29-8093-f7be5afb15ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_818aca2a-6a92-485d-a4a4-7c24fd526570" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a958690a-4852-4bc9-87e3-2265aafb3250" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_818aca2a-6a92-485d-a4a4-7c24fd526570" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d012cab8-0767-4ecf-a3c9-fd855fd76857" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_a958690a-4852-4bc9-87e3-2265aafb3250" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d012cab8-0767-4ecf-a3c9-fd855fd76857" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7cfdae4b-666b-4445-91a8-1694a14a3108" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b132c771-b35b-4d92-ab51-9f6fcae3c042" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7cfdae4b-666b-4445-91a8-1694a14a3108" xlink:to="loc_us-gaap_NetIncomeLoss_b132c771-b35b-4d92-ab51-9f6fcae3c042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6ecea35c-949a-4007-b08a-adddd2de6766" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7cfdae4b-666b-4445-91a8-1694a14a3108" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6ecea35c-949a-4007-b08a-adddd2de6766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e4fb79c0-acfc-4529-9ba5-8d3c673f3ae3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6e75c64f-7645-42d3-a592-330b0b810782" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e4fb79c0-acfc-4529-9ba5-8d3c673f3ae3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6e75c64f-7645-42d3-a592-330b0b810782" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_189c77eb-674d-49ce-a5d3-448c59665b04" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e4fb79c0-acfc-4529-9ba5-8d3c673f3ae3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_189c77eb-674d-49ce-a5d3-448c59665b04" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofComprehensiveLossParenthetical"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1a76fc18-2a15-448d-a1b7-e262b9bb4c87" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c707f98b-c9ed-48e7-b0a9-510f3558dc8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1a76fc18-2a15-448d-a1b7-e262b9bb4c87" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c707f98b-c9ed-48e7-b0a9-510f3558dc8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4fba15a8-9b57-42b7-986c-5ad7c6b0b33b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1a76fc18-2a15-448d-a1b7-e262b9bb4c87" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_4fba15a8-9b57-42b7-986c-5ad7c6b0b33b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3b76d1f4-97a1-4381-9a92-24257499f5de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1a76fc18-2a15-448d-a1b7-e262b9bb4c87" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3b76d1f4-97a1-4381-9a92-24257499f5de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74cc2ef8-dd1f-435f-b771-2f831f7dc6d5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_92a7d541-3ed9-4705-9b5b-54fc910e7f86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74cc2ef8-dd1f-435f-b771-2f831f7dc6d5" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_92a7d541-3ed9-4705-9b5b-54fc910e7f86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_9cc4d2fd-3758-40bb-9ae1-ed595d948005" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74cc2ef8-dd1f-435f-b771-2f831f7dc6d5" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_9cc4d2fd-3758-40bb-9ae1-ed595d948005" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_06dd48f2-4af5-45e3-81cc-aafaf25254da" xlink:href="fold-20200331.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74cc2ef8-dd1f-435f-b771-2f831f7dc6d5" xlink:to="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_06dd48f2-4af5-45e3-81cc-aafaf25254da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_3d003a45-e9a9-42cb-aa90-c73f644d19be" xlink:href="fold-20200331.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74cc2ef8-dd1f-435f-b771-2f831f7dc6d5" xlink:to="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_3d003a45-e9a9-42cb-aa90-c73f644d19be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_c47bc0be-6860-4398-bc92-eba609803390" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_74cc2ef8-dd1f-435f-b771-2f831f7dc6d5" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_c47bc0be-6860-4398-bc92-eba609803390" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0c309aa0-5dfe-4052-a026-9aa5984a704c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a17d15a-72b7-4bd6-aba6-249b378e1f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0c309aa0-5dfe-4052-a026-9aa5984a704c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8a17d15a-72b7-4bd6-aba6-249b378e1f3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8ccfac0d-4730-4577-9091-3a5bb8661c51" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0c309aa0-5dfe-4052-a026-9aa5984a704c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8ccfac0d-4730-4577-9091-3a5bb8661c51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_683cf444-440c-4712-8f47-017f0cc5fe05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0c309aa0-5dfe-4052-a026-9aa5984a704c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_683cf444-440c-4712-8f47-017f0cc5fe05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c7e165ca-665b-4968-9896-b24e4771cd42" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0c309aa0-5dfe-4052-a026-9aa5984a704c" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c7e165ca-665b-4968-9896-b24e4771cd42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_dbe8b2fa-5171-4fd6-b224-8ba0031bd14c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:to="loc_us-gaap_ProfitLoss_dbe8b2fa-5171-4fd6-b224-8ba0031bd14c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1c11cfc0-56b7-4d9d-a84d-04b2659678cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_1c11cfc0-56b7-4d9d-a84d-04b2659678cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_609c7416-4dc7-4e72-973a-101078c1b9f3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_609c7416-4dc7-4e72-973a-101078c1b9f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3d668add-4731-4061-96ce-de48300de37a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:to="loc_us-gaap_ShareBasedCompensation_3d668add-4731-4061-96ce-de48300de37a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dec234c1-8a17-4510-9d80-a886e47519bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_dec234c1-8a17-4510-9d80-a886e47519bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_996db04e-d858-4c04-80ba-26dda4c5964f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_996db04e-d858-4c04-80ba-26dda4c5964f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_5cca204b-da39-4b31-b26d-22bb5fb2789f" xlink:href="fold-20200331.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:to="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_5cca204b-da39-4b31-b26d-22bb5fb2789f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_300533ba-46db-4f9d-abf4-729db3aa9510" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_300533ba-46db-4f9d-abf4-729db3aa9510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_48d506a4-6893-4899-a2de-e90cbcb1abf3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_48d506a4-6893-4899-a2de-e90cbcb1abf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4c075614-2319-40d9-9962-df4f8055bd0a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4c075614-2319-40d9-9962-df4f8055bd0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2b6a9c54-888d-436c-a015-f6166799d60d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2b6a9c54-888d-436c-a015-f6166799d60d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_e096ba49-012f-4b1d-9f5a-553b0ea665d5" xlink:href="fold-20200331.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:to="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_e096ba49-012f-4b1d-9f5a-553b0ea665d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInDeferredReimbursements_a754cce7-be33-45da-80f0-0517f2af762d" xlink:href="fold-20200331.xsd#fold_IncreaseDecreaseInDeferredReimbursements"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_01d1e24e-b795-4413-9335-4ca57c835570" xlink:to="loc_fold_IncreaseDecreaseInDeferredReimbursements_a754cce7-be33-45da-80f0-0517f2af762d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="fold-20200331.xsd#DescriptionofBusiness"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#DescriptionofBusinessDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="fold-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="fold-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="fold-20200331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCash"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_3c23485c-6bd2-425f-9465-3ff0f94de2a1" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12189539-9fd4-4868-9beb-200330047050" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_3c23485c-6bd2-425f-9465-3ff0f94de2a1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12189539-9fd4-4868-9beb-200330047050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3f1b6bea-269d-4905-ac78-91ca53d66e62" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_3c23485c-6bd2-425f-9465-3ff0f94de2a1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3f1b6bea-269d-4905-ac78-91ca53d66e62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_fa1da3b1-1955-4aab-953f-5a58826abf70" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_03141254-3c3f-46b7-8a67-fd698ae822d0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_fa1da3b1-1955-4aab-953f-5a58826abf70" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_03141254-3c3f-46b7-8a67-fd698ae822d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_97833f21-365b-4fd7-b5c7-842b6db3ea67" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_fa1da3b1-1955-4aab-953f-5a58826abf70" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_97833f21-365b-4fd7-b5c7-842b6db3ea67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_35c1cc3b-badd-4cac-9d8c-e6fe4d72e118" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_3eed5d7f-6b33-41ca-92a5-67acee1eac2b" xlink:href="fold-20200331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_35c1cc3b-badd-4cac-9d8c-e6fe4d72e118" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_3eed5d7f-6b33-41ca-92a5-67acee1eac2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_8f5b7f76-95ca-4a85-9a37-b4c62103bcb7" xlink:href="fold-20200331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_35c1cc3b-badd-4cac-9d8c-e6fe4d72e118" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_8f5b7f76-95ca-4a85-9a37-b4c62103bcb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5445b181-44c5-45c1-aaf6-8e691a0c12e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_35c1cc3b-badd-4cac-9d8c-e6fe4d72e118" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5445b181-44c5-45c1-aaf6-8e691a0c12e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_56076238-c98a-4696-9441-363f4ac03bfa" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4cb93ab-4a1f-4e68-83e0-1ede30e0a0e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_56076238-c98a-4696-9441-363f4ac03bfa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4cb93ab-4a1f-4e68-83e0-1ede30e0a0e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1027c409-fb6c-4bad-8fda-ef42223025ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_56076238-c98a-4696-9441-363f4ac03bfa" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1027c409-fb6c-4bad-8fda-ef42223025ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ffa671bf-40f9-46fc-98e4-e8d9f2cdeb73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_56076238-c98a-4696-9441-363f4ac03bfa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ffa671bf-40f9-46fc-98e4-e8d9f2cdeb73" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_6c19b601-917d-4756-b431-be8f00a93cb4" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5750d5db-7e33-4b93-9bb8-5d5cf9f2e34a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_6c19b601-917d-4756-b431-be8f00a93cb4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5750d5db-7e33-4b93-9bb8-5d5cf9f2e34a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_5801345b-1c78-45d7-bb29-8a50fee70999" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_6c19b601-917d-4756-b431-be8f00a93cb4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_5801345b-1c78-45d7-bb29-8a50fee70999" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5336dad-1e71-47e2-af2c-44abb3540666" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_6c19b601-917d-4756-b431-be8f00a93cb4" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5336dad-1e71-47e2-af2c-44abb3540666" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_08f9501c-da56-4a79-b526-a33575085a72" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d145bc28-4faa-4b79-9234-8070a3790a7b" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_08f9501c-da56-4a79-b526-a33575085a72" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d145bc28-4faa-4b79-9234-8070a3790a7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_05691497-b367-444d-bef3-53873b0e5407" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_08f9501c-da56-4a79-b526-a33575085a72" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_05691497-b367-444d-bef3-53873b0e5407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_4df75ca4-0182-4fda-8186-462a6f390f81" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_08f9501c-da56-4a79-b526-a33575085a72" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_4df75ca4-0182-4fda-8186-462a6f390f81" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69d8566d-094a-4a1a-ad04-4d3508453be2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c1790c7-0c0a-48ec-877d-f4c7760772e9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69d8566d-094a-4a1a-ad04-4d3508453be2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8c1790c7-0c0a-48ec-877d-f4c7760772e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_e33d82e4-4105-486d-9d43-9958fc9911f7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69d8566d-094a-4a1a-ad04-4d3508453be2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_e33d82e4-4105-486d-9d43-9958fc9911f7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Inventories" xlink:type="simple" xlink:href="fold-20200331.xsd#Inventories"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/Inventories" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="simple" xlink:href="fold-20200331.xsd#InventoriesTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d68e7c01-0678-4ef1-aed0-3b9957c8725a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_48f65d2a-fbb4-4b41-a41b-f6da9f5784ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d68e7c01-0678-4ef1-aed0-3b9957c8725a" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_48f65d2a-fbb4-4b41-a41b-f6da9f5784ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_2f565ae6-0d56-40b8-9432-448a19cf79c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d68e7c01-0678-4ef1-aed0-3b9957c8725a" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_2f565ae6-0d56-40b8-9432-448a19cf79c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f21d26f2-9eb0-49e2-9cf3-076232587d41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_d68e7c01-0678-4ef1-aed0-3b9957c8725a" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_f21d26f2-9eb0-49e2-9cf3-076232587d41" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Debt" xlink:type="simple" xlink:href="fold-20200331.xsd#Debt"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/Debt" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="simple" xlink:href="fold-20200331.xsd#DebtTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_8a2a39b2-0565-4ba8-a9d4-566947607515" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_cedcf809-a014-498e-8846-6d5e3546163c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8a2a39b2-0565-4ba8-a9d4-566947607515" xlink:to="loc_us-gaap_DeferredOfferingCosts_cedcf809-a014-498e-8846-6d5e3546163c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_6458975f-9e53-4238-bffc-cf63a8513427" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8a2a39b2-0565-4ba8-a9d4-566947607515" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_6458975f-9e53-4238-bffc-cf63a8513427" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4d5e3376-4c86-4d99-b69e-7fb0ffab2e13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_8a2a39b2-0565-4ba8-a9d4-566947607515" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4d5e3376-4c86-4d99-b69e-7fb0ffab2e13" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#DebtNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#DebtInterestExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationRSUsandPBRSUsSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationExpenseSummaryDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="simple" xlink:href="fold-20200331.xsd#AssetsandLiabilitiesMeasuredatFairValue"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="simple" xlink:href="fold-20200331.xsd#AssetsandLiabilitiesMeasuredatFairValueTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_7e856e14-740b-4e78-b114-f8a35f516a07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_90b674c9-a2c1-4bd4-bea0-6ceaba7db9a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_7e856e14-740b-4e78-b114-f8a35f516a07" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_90b674c9-a2c1-4bd4-bea0-6ceaba7db9a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_124f6aa5-5999-460f-93fb-8dda04e1c474" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_7e856e14-740b-4e78-b114-f8a35f516a07" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_124f6aa5-5999-460f-93fb-8dda04e1c474" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="simple" xlink:href="fold-20200331.xsd#BasicandDilutedNetLossperCommonShare"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="simple" xlink:href="fold-20200331.xsd#BasicandDilutedNetLossperCommonShareTables"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#BasicandDilutedNetLossperCommonShareDetails"/>
  <link:calculationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>fold-20200331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d7d83936-4003-4695-9e73-95a98e869b39,g:49308d12-68e9-469e-b9d5-8a5a2cc3db36-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="fold-20200331.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="extended" id="i3eb5bb24154b46689ec9e46953aac658_CoverPage"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="ifdd1605cb8e84e5d9f2bde15030f6732_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i274151bceb924aae8ad490d6906e9e18_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i18031d5112914ece9c983fdf3c473cb0_ConsolidatedStatementsofOperations"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="i627d6c8dd0984717b012e52724df2fff_ConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofComprehensiveLossParenthetical"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical" xlink:type="extended" id="ic572d6049f534f1eb1202d4d80d8193f_ConsolidatedStatementsofComprehensiveLossParenthetical"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended" id="i05794b269f384f61b6d2765a7d7e8f09_ConsolidatedStatementsofChangesinStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_06533ba1-353f-4dcb-93ba-8f64e274b877" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06533ba1-353f-4dcb-93ba-8f64e274b877" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_33a6f1d9-ce4b-4d06-9a65-0b812ff140eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_33a6f1d9-ce4b-4d06-9a65-0b812ff140eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b4fb4372-8c59-48eb-844e-a594a14a9e32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_StockholdersEquity_b4fb4372-8c59-48eb-844e-a594a14a9e32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_65d9f851-0057-45b2-ac90-2093d7088296" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_65d9f851-0057-45b2-ac90-2093d7088296" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a20daf46-7477-4e54-bd32-c2319e8a1579" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a20daf46-7477-4e54-bd32-c2319e8a1579" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6b564d6c-0e0c-4b30-ab96-b66d37d319c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6b564d6c-0e0c-4b30-ab96-b66d37d319c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_c3b6ff0e-c384-4366-a3a1-68aeb5a39785" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_c3b6ff0e-c384-4366-a3a1-68aeb5a39785" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_74435a69-b141-4835-bcea-0946d7fb07b4" xlink:href="fold-20200331.xsd#fold_StockIssuedDuringPeriodSharesContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_74435a69-b141-4835-bcea-0946d7fb07b4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_ac0a63e0-1792-448c-bca6-4e490278808d" xlink:href="fold-20200331.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_ac0a63e0-1792-448c-bca6-4e490278808d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_346afa32-7652-4a30-b68f-dd5f0432dda6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_346afa32-7652-4a30-b68f-dd5f0432dda6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_2368cb85-47dc-4ab6-b5bb-81941e698a2a" xlink:href="fold-20200331.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_2368cb85-47dc-4ab6-b5bb-81941e698a2a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_f5384a78-eadf-45db-9504-c50c42f96534" xlink:href="fold-20200331.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_f5384a78-eadf-45db-9504-c50c42f96534" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_48a4e0cf-1f14-43f5-9be2-6f246a87a131" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_48a4e0cf-1f14-43f5-9be2-6f246a87a131" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_996bfaba-78cf-44be-8381-63e5196a9108" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_996bfaba-78cf-44be-8381-63e5196a9108" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_2c6856c8-1d49-467b-b31c-e612683c8c0f" xlink:href="fold-20200331.xsd#fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_2c6856c8-1d49-467b-b31c-e612683c8c0f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ada5867e-dc25-410f-90af-791ccc78769b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ada5867e-dc25-410f-90af-791ccc78769b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e1219b6c-b03d-4383-8ba6-97c0691f7747" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e1219b6c-b03d-4383-8ba6-97c0691f7747" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_40bb89c7-a114-40ce-aabf-54cc82b4535d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_NetIncomeLoss_40bb89c7-a114-40ce-aabf-54cc82b4535d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ad93a920-9457-40e6-b25f-3506eba96027" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bf902f99-cf27-45e5-89cc-fe0e36034d73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f6f01319-7544-4c61-9879-2b05e3a95952" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_06533ba1-353f-4dcb-93ba-8f64e274b877" xlink:to="loc_us-gaap_StatementTable_f6f01319-7544-4c61-9879-2b05e3a95952" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a3825e92-ef76-47ad-8d8e-a2dc5ff59c49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f6f01319-7544-4c61-9879-2b05e3a95952" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a3825e92-ef76-47ad-8d8e-a2dc5ff59c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a3825e92-ef76-47ad-8d8e-a2dc5ff59c49_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3825e92-ef76-47ad-8d8e-a2dc5ff59c49" xlink:to="loc_us-gaap_EquityComponentDomain_a3825e92-ef76-47ad-8d8e-a2dc5ff59c49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3825e92-ef76-47ad-8d8e-a2dc5ff59c49" xlink:to="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c3f926b3-2295-4047-ada2-d326c7f62978" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:to="loc_us-gaap_CommonStockMember_c3f926b3-2295-4047-ada2-d326c7f62978" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6f593f56-6fb2-44ed-bb17-a6588575e88d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6f593f56-6fb2-44ed-bb17-a6588575e88d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4e84631c-eb92-4649-ab2b-81f724e93e93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:to="loc_us-gaap_WarrantMember_4e84631c-eb92-4649-ab2b-81f724e93e93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_8af74266-6229-47a2-b7c3-d2fde1cb4839" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_8af74266-6229-47a2-b7c3-d2fde1cb4839" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8eaf0b2b-a176-4fe5-8aa2-c86cb9c312d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:to="loc_us-gaap_RetainedEarningsMember_8eaf0b2b-a176-4fe5-8aa2-c86cb9c312d7" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i88e77fe670454dac8ce4f797563eba27_ConsolidatedStatementsofCashFlows"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="fold-20200331.xsd#DescriptionofBusiness"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="extended" id="i422ca272733047ffb6d35472ba5838d2_DescriptionofBusiness"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#DescriptionofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="extended" id="iaa991388004f4ff2bf6680a79e320f4d_DescriptionofBusinessDetails"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="fold-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended" id="i29b3fc75c45141a38f3c380a629bdf02_SummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="fold-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="i3fd1032f3a234972a2716c8a0bfb69c5_SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="fold-20200331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i1cfb79f6ec1b45c59db906a1b47d5d1b_SummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i872266e209aa434891dfe74690202c9c_SummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_dc6c9451-9318-48cf-95eb-07219398fc88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e58c36cf-75cc-4cfe-9b03-5a823bfe63fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_dc6c9451-9318-48cf-95eb-07219398fc88" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e58c36cf-75cc-4cfe-9b03-5a823bfe63fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6ecad20b-c957-44f9-90c3-b6ce014123ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_dc6c9451-9318-48cf-95eb-07219398fc88" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6ecad20b-c957-44f9-90c3-b6ce014123ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d835adfb-bbcf-46b8-a93e-d48a9bd5ae25" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6ecad20b-c957-44f9-90c3-b6ce014123ba" xlink:to="loc_srt_StatementGeographicalAxis_d835adfb-bbcf-46b8-a93e-d48a9bd5ae25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d835adfb-bbcf-46b8-a93e-d48a9bd5ae25_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d835adfb-bbcf-46b8-a93e-d48a9bd5ae25" xlink:to="loc_srt_SegmentGeographicalDomain_d835adfb-bbcf-46b8-a93e-d48a9bd5ae25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8432d2fc-50a0-48a6-b9ed-e83e67def3de" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d835adfb-bbcf-46b8-a93e-d48a9bd5ae25" xlink:to="loc_srt_SegmentGeographicalDomain_8432d2fc-50a0-48a6-b9ed-e83e67def3de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fd057659-97f8-4bfe-ab5a-de42e78b510a" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8432d2fc-50a0-48a6-b9ed-e83e67def3de" xlink:to="loc_country_US_fd057659-97f8-4bfe-ab5a-de42e78b510a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_39fe1bd6-32d5-46dc-8f0a-75318db6e8e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8432d2fc-50a0-48a6-b9ed-e83e67def3de" xlink:to="loc_us-gaap_NonUsMember_39fe1bd6-32d5-46dc-8f0a-75318db6e8e4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCash"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="extended" id="i5f6505e99e5e4671bf2a633f9ef4154c_CashCashEquivalentsMarketableSecuritiesandRestrictedCash"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="extended" id="i70c59962d9864bb985f5914a01ffbab1_CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="extended" id="ifca3168bd84b4751bc5d97f2411eb35e_CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_533d07ba-c918-4d56-b8e6-7a576bf22c56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_533d07ba-c918-4d56-b8e6-7a576bf22c56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d1c2ec3-8503-4126-86b4-5487b5517f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d1c2ec3-8503-4126-86b4-5487b5517f5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_1c1a51c1-bbac-48b7-a6f7-aea86dc9bade" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_1c1a51c1-bbac-48b7-a6f7-aea86dc9bade" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_9abf9d6a-54a5-4ae8-b5a6-f92e2090d394" xlink:href="fold-20200331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_9abf9d6a-54a5-4ae8-b5a6-f92e2090d394" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_ca6bb7c5-260e-4eb2-8454-d4eac0e34aa1" xlink:href="fold-20200331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_ca6bb7c5-260e-4eb2-8454-d4eac0e34aa1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5762e2da-d793-4d07-860e-087645fd3372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5762e2da-d793-4d07-860e-087645fd3372" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b0c4e57d-9351-4891-a812-99f9db5623cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b0c4e57d-9351-4891-a812-99f9db5623cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_81172f4f-19dd-4134-846c-c3ebba9233db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_81172f4f-19dd-4134-846c-c3ebba9233db" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c22b64ce-f281-45ab-bf19-170f9d4b9e47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c22b64ce-f281-45ab-bf19-170f9d4b9e47" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4a1209b2-2d12-488a-975a-24a0a36ad11c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4a1209b2-2d12-488a-975a-24a0a36ad11c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_b633090e-611c-4c99-a407-8d5f6b82edc0" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_b633090e-611c-4c99-a407-8d5f6b82edc0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bcdd92b4-c4e4-4f60-94e7-96b9f89fc4b8" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bcdd92b4-c4e4-4f60-94e7-96b9f89fc4b8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b38ec1fb-f3a9-4469-9fc6-34dbba569a50" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b38ec1fb-f3a9-4469-9fc6-34dbba569a50" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_589c4051-9bec-48a9-aae8-248c28d766eb" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_589c4051-9bec-48a9-aae8-248c28d766eb" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b28c175a-ed0a-45eb-8b14-b8cfa62b7b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b28c175a-ed0a-45eb-8b14-b8cfa62b7b3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0f10a3b2-701e-4336-a461-492fbc5ed76c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b28c175a-ed0a-45eb-8b14-b8cfa62b7b3b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0f10a3b2-701e-4336-a461-492fbc5ed76c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f10a3b2-701e-4336-a461-492fbc5ed76c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0f10a3b2-701e-4336-a461-492fbc5ed76c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0f10a3b2-701e-4336-a461-492fbc5ed76c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0f10a3b2-701e-4336-a461-492fbc5ed76c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember_c42c3f65-1265-426f-9e22-8c4d7613ba63" xlink:href="fold-20200331.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:to="loc_fold_ShortTermCorporateDebtSecuritiesMember_c42c3f65-1265-426f-9e22-8c4d7613ba63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_079e1480-10a5-4a5e-8210-3cb9f55440cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_079e1480-10a5-4a5e-8210-3cb9f55440cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_1ac454bc-b54d-40a5-b735-983c20aecef1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_1ac454bc-b54d-40a5-b735-983c20aecef1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d0281e29-17fe-430f-b722-925b691cccf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d0281e29-17fe-430f-b722-925b691cccf6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_31d29a4d-3cf9-42b9-af97-5514291f791f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_31d29a4d-3cf9-42b9-af97-5514291f791f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0e499efd-82ed-4f4e-a745-7f987c1a2b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0e499efd-82ed-4f4e-a745-7f987c1a2b1d" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="extended" id="i40c636aed03e47a0b4ee3a56fff124fb_CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Inventories" xlink:type="simple" xlink:href="fold-20200331.xsd#Inventories"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/Inventories" xlink:type="extended" id="i930dbe204c1443a29ccfbe897cd6b13e_Inventories"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="simple" xlink:href="fold-20200331.xsd#InventoriesTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="extended" id="i09f5356c90b44a73af8433deb0902b99_InventoriesTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#InventoriesDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended" id="icf84e049df0c4362bd1d9d1c95270df6_InventoriesDetails"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Debt" xlink:type="simple" xlink:href="fold-20200331.xsd#Debt"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/Debt" xlink:type="extended" id="i670b95f8e4fb4fd4b43bb457d2931613_Debt"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="simple" xlink:href="fold-20200331.xsd#DebtTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="extended" id="i4f76f9b79f984bd88f738f1ebed5579f_DebtTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended" id="ib3021084eedf481ea613377a660e12ac_DebtSummaryofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_68fb56c4-fa04-40aa-ac9c-c1728752293d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_68fb56c4-fa04-40aa-ac9c-c1728752293d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6e58d9a3-b43a-4fe8-b356-79e4e7717d22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6e58d9a3-b43a-4fe8-b356-79e4e7717d22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_718b78ab-58ce-45a4-b300-4c13298cf696" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_us-gaap_DeferredOfferingCosts_718b78ab-58ce-45a4-b300-4c13298cf696" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5f902108-da59-4224-ad9c-77851b03b4a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_us-gaap_LongTermDebt_5f902108-da59-4224-ad9c-77851b03b4a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f9bbc157-0329-4518-a5cc-829d58cda1ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f9bbc157-0329-4518-a5cc-829d58cda1ce" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_9f421e76-4cf8-4406-bb55-09e0421caf14" xlink:href="fold-20200331.xsd#fold_DebtInstrumentsConvertibleThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_9f421e76-4cf8-4406-bb55-09e0421caf14" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c095ce0c-67ba-44ef-a98f-34fe989a308e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c095ce0c-67ba-44ef-a98f-34fe989a308e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_103e896c-407c-4f52-ad6a-2f63109a013e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_us-gaap_DebtInstrumentTable_103e896c-407c-4f52-ad6a-2f63109a013e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e5ae48dc-2cc4-4858-9c20-090644c98043" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_103e896c-407c-4f52-ad6a-2f63109a013e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e5ae48dc-2cc4-4858-9c20-090644c98043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e5ae48dc-2cc4-4858-9c20-090644c98043_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e5ae48dc-2cc4-4858-9c20-090644c98043" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e5ae48dc-2cc4-4858-9c20-090644c98043_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e5707564-bfde-45b9-80af-2149dbb46c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e5ae48dc-2cc4-4858-9c20-090644c98043" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e5707564-bfde-45b9-80af-2149dbb46c6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember_6e45e3b3-9d7e-42c3-a83f-663f26493270" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorLoansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e5707564-bfde-45b9-80af-2149dbb46c6c" xlink:to="loc_us-gaap_SeniorLoansMember_6e45e3b3-9d7e-42c3-a83f-663f26493270" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_8813d17e-99b0-4fe7-9c3c-039acd7df163" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e5707564-bfde-45b9-80af-2149dbb46c6c" xlink:to="loc_us-gaap_ConvertibleDebtMember_8813d17e-99b0-4fe7-9c3c-039acd7df163" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_03731ab8-1d62-494a-ab5c-69c284eeb23d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_103e896c-407c-4f52-ad6a-2f63109a013e" xlink:to="loc_us-gaap_DebtInstrumentAxis_03731ab8-1d62-494a-ab5c-69c284eeb23d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_03731ab8-1d62-494a-ab5c-69c284eeb23d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_03731ab8-1d62-494a-ab5c-69c284eeb23d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_03731ab8-1d62-494a-ab5c-69c284eeb23d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d2a836a0-d9b0-4d97-9b51-cb167008c0b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_03731ab8-1d62-494a-ab5c-69c284eeb23d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d2a836a0-d9b0-4d97-9b51-cb167008c0b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2023Member_deb4f41c-8a18-4fc2-a980-3a2933721bcd" xlink:href="fold-20200331.xsd#fold_SeniorSecuredTermLoanDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d2a836a0-d9b0-4d97-9b51-cb167008c0b5" xlink:to="loc_fold_SeniorSecuredTermLoanDue2023Member_deb4f41c-8a18-4fc2-a980-3a2933721bcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_3a45e0db-a439-449d-931e-996cbd8b98ef" xlink:href="fold-20200331.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d2a836a0-d9b0-4d97-9b51-cb167008c0b5" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_3a45e0db-a439-449d-931e-996cbd8b98ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e80b1137-2adf-45e2-94bf-b0c4ba932f5a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_103e896c-407c-4f52-ad6a-2f63109a013e" xlink:to="loc_srt_RangeAxis_e80b1137-2adf-45e2-94bf-b0c4ba932f5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e80b1137-2adf-45e2-94bf-b0c4ba932f5a_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e80b1137-2adf-45e2-94bf-b0c4ba932f5a" xlink:to="loc_srt_RangeMember_e80b1137-2adf-45e2-94bf-b0c4ba932f5a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_14f9aacd-6534-47d4-8b72-f45327e23ff1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e80b1137-2adf-45e2-94bf-b0c4ba932f5a" xlink:to="loc_srt_RangeMember_14f9aacd-6534-47d4-8b72-f45327e23ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3ec8ac41-9146-40f1-99de-ac4e82d577ea" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_14f9aacd-6534-47d4-8b72-f45327e23ff1" xlink:to="loc_srt_MinimumMember_3ec8ac41-9146-40f1-99de-ac4e82d577ea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="extended" id="ie3dfc5f04b514841a7f227eaa358d9a5_DebtNarrativeDetails"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#DebtInterestExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended" id="i8038abf42c9540debffd741586b9dd47_DebtInterestExpenseDetails"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="extended" id="i75ecc6b371d14aadb3ac16d961659ac3_ShareBasedCompensation"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended" id="i52f0fae7cb214aebbe615a394d313697_ShareBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended" id="ib810c8dc53344002a2cbd9fe90f44b93_ShareBasedCompensationWeightedaverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_193618c7-93f3-4507-bc76-5a0068cca04c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_fc06fbca-2c8d-419b-b045-d9fc98529a41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_193618c7-93f3-4507-bc76-5a0068cca04c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_fc06fbca-2c8d-419b-b045-d9fc98529a41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_128dbf71-6789-4f2e-98cd-9e4b47337192" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_193618c7-93f3-4507-bc76-5a0068cca04c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_128dbf71-6789-4f2e-98cd-9e4b47337192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_72a93c0b-8502-4b82-9f47-9f96c7a00712" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_193618c7-93f3-4507-bc76-5a0068cca04c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_72a93c0b-8502-4b82-9f47-9f96c7a00712" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_3f0fa9f8-426f-48f9-8311-1a0af7b967c0" xlink:href="fold-20200331.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_193618c7-93f3-4507-bc76-5a0068cca04c" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_3f0fa9f8-426f-48f9-8311-1a0af7b967c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2e55519-67a9-4757-9fac-a19fa10244b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_193618c7-93f3-4507-bc76-5a0068cca04c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2e55519-67a9-4757-9fac-a19fa10244b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4370a7ff-49d2-4c53-a558-ce74d6c74285" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2e55519-67a9-4757-9fac-a19fa10244b6" xlink:to="loc_us-gaap_AwardTypeAxis_4370a7ff-49d2-4c53-a558-ce74d6c74285" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4370a7ff-49d2-4c53-a558-ce74d6c74285_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4370a7ff-49d2-4c53-a558-ce74d6c74285" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4370a7ff-49d2-4c53-a558-ce74d6c74285_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5c2725c-e906-445e-b45d-8ee780801916" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4370a7ff-49d2-4c53-a558-ce74d6c74285" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5c2725c-e906-445e-b45d-8ee780801916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_9f813840-d949-4487-88ad-8b4ce8c2da53" xlink:href="fold-20200331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5c2725c-e906-445e-b45d-8ee780801916" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_9f813840-d949-4487-88ad-8b4ce8c2da53" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="i5aff2076d8144c639aa976f48e708d2f_ShareBasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1acbea45-c8c0-43a6-a005-149151f269fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1acbea45-c8c0-43a6-a005-149151f269fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bae029d1-5e6a-4a26-8111-52cde4b5c9ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bae029d1-5e6a-4a26-8111-52cde4b5c9ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_70e90033-ccda-4d6b-b97d-579e4ca2fd9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_70e90033-ccda-4d6b-b97d-579e4ca2fd9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c3e98ae4-8766-4065-9418-cfb1d04e9c86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c3e98ae4-8766-4065-9418-cfb1d04e9c86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d86322e0-ca4f-460a-a8a4-837cebc22878" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d86322e0-ca4f-460a-a8a4-837cebc22878" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c3675ffb-88a0-477c-b245-d42c4cd9d6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_dcf6cf85-94f1-4234-a288-d3f047db3e61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_dcf6cf85-94f1-4234-a288-d3f047db3e61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_649eab52-e015-4f14-b196-615aab5169b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_649eab52-e015-4f14-b196-615aab5169b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3a6611ff-8309-4b17-beeb-739529824303" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3a6611ff-8309-4b17-beeb-739529824303" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4c65ab72-b49f-4168-87c4-492e06b1f4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4c65ab72-b49f-4168-87c4-492e06b1f4f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4887d209-c1fa-4f1e-b60d-a2feacc8f88b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4887d209-c1fa-4f1e-b60d-a2feacc8f88b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_baa8899c-ed50-48f1-8dd1-9616f7b38710" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_baa8899c-ed50-48f1-8dd1-9616f7b38710" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a1b6c839-c0fe-4323-998b-336a3d645a63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a1b6c839-c0fe-4323-998b-336a3d645a63" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fd46b544-a662-4ed1-8f56-be7617aff449" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_024917d6-ab55-477d-87e4-573b0bd46422" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_024917d6-ab55-477d-87e4-573b0bd46422" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_37dc4fa0-0a16-4827-8674-2e213b089622" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_37dc4fa0-0a16-4827-8674-2e213b089622" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2049b149-8aa5-4403-a66c-7bf38d0cf91a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2049b149-8aa5-4403-a66c-7bf38d0cf91a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_56c47c97-294f-4d42-a8e7-adb86acb9e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_56c47c97-294f-4d42-a8e7-adb86acb9e8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_78fda2bc-7e1b-4b5b-8f38-71e1c81a59a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_78fda2bc-7e1b-4b5b-8f38-71e1c81a59a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_935cccd7-ed91-4d46-b638-ecb527a2a8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_935cccd7-ed91-4d46-b638-ecb527a2a8f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_388fb4d1-f252-404a-8efc-4b844ee51cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_388fb4d1-f252-404a-8efc-4b844ee51cdb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8b10fe28-a00f-41e5-8886-6ea1376f2a29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8b10fe28-a00f-41e5-8886-6ea1376f2a29" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97a1427b-77cb-4cea-8454-d1b23cfc595b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97a1427b-77cb-4cea-8454-d1b23cfc595b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_18c4c3ae-470b-4399-8c9e-7e95149fd31b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97a1427b-77cb-4cea-8454-d1b23cfc595b" xlink:to="loc_us-gaap_AwardTypeAxis_18c4c3ae-470b-4399-8c9e-7e95149fd31b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18c4c3ae-470b-4399-8c9e-7e95149fd31b_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_18c4c3ae-470b-4399-8c9e-7e95149fd31b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18c4c3ae-470b-4399-8c9e-7e95149fd31b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fa489b6-9fca-47db-a66b-4064d1d51ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_18c4c3ae-470b-4399-8c9e-7e95149fd31b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fa489b6-9fca-47db-a66b-4064d1d51ad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_2d817445-d76e-4d5b-8c07-4e41141eb2e4" xlink:href="fold-20200331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fa489b6-9fca-47db-a66b-4064d1d51ad3" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_2d817445-d76e-4d5b-8c07-4e41141eb2e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" id="i8e049883006f4a2ca9cd4e2d47387111_ShareBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64a8f98a-c0af-4a81-a3b0-391dda2ea325" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6de3cc23-db4f-461b-80f5-12ccdc50f3f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64a8f98a-c0af-4a81-a3b0-391dda2ea325" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6de3cc23-db4f-461b-80f5-12ccdc50f3f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00e22c2d-998f-4a41-961d-07f451b4a992" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64a8f98a-c0af-4a81-a3b0-391dda2ea325" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00e22c2d-998f-4a41-961d-07f451b4a992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f883c8-1a1b-4a5b-be5d-b0d961fd2286" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64a8f98a-c0af-4a81-a3b0-391dda2ea325" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f883c8-1a1b-4a5b-be5d-b0d961fd2286" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d2bfb4ce-55a8-4796-9b7e-938398a06a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f883c8-1a1b-4a5b-be5d-b0d961fd2286" xlink:to="loc_us-gaap_AwardTypeAxis_d2bfb4ce-55a8-4796-9b7e-938398a06a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2bfb4ce-55a8-4796-9b7e-938398a06a3a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d2bfb4ce-55a8-4796-9b7e-938398a06a3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d2bfb4ce-55a8-4796-9b7e-938398a06a3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a9e8836-2035-437f-b3ce-0865c4355653" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d2bfb4ce-55a8-4796-9b7e-938398a06a3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a9e8836-2035-437f-b3ce-0865c4355653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_ed58f2c0-d257-4773-ad86-7b8a58fe5f2a" xlink:href="fold-20200331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a9e8836-2035-437f-b3ce-0865c4355653" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_ed58f2c0-d257-4773-ad86-7b8a58fe5f2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d076a538-3845-413b-8ae4-1e8501f9dc82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a9e8836-2035-437f-b3ce-0865c4355653" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d076a538-3845-413b-8ae4-1e8501f9dc82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_25491d9b-dc09-4ebc-ac60-1fd62c9d5710" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f883c8-1a1b-4a5b-be5d-b0d961fd2286" xlink:to="loc_us-gaap_PlanNameAxis_25491d9b-dc09-4ebc-ac60-1fd62c9d5710" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_25491d9b-dc09-4ebc-ac60-1fd62c9d5710_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_25491d9b-dc09-4ebc-ac60-1fd62c9d5710" xlink:to="loc_us-gaap_PlanNameDomain_25491d9b-dc09-4ebc-ac60-1fd62c9d5710_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_83ecd52c-1543-4581-ae8d-34e4752c466b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_25491d9b-dc09-4ebc-ac60-1fd62c9d5710" xlink:to="loc_us-gaap_PlanNameDomain_83ecd52c-1543-4581-ae8d-34e4752c466b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_5e86c977-848a-4aaf-a1ec-452ecb997dd4" xlink:href="fold-20200331.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_83ecd52c-1543-4581-ae8d-34e4752c466b" xlink:to="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_5e86c977-848a-4aaf-a1ec-452ecb997dd4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationRSUsandPBRSUsSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="extended" id="i90a2ae114f91409aafd1a22226aaccf8_ShareBasedCompensationRSUsandPBRSUsSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37730493-9992-4146-ae68-31587d4d5713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a3520b9-2235-4f02-b5bd-2539100e16ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37730493-9992-4146-ae68-31587d4d5713" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a3520b9-2235-4f02-b5bd-2539100e16ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_690b6c28-b0eb-49ec-8162-6c255acafaf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a3520b9-2235-4f02-b5bd-2539100e16ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_690b6c28-b0eb-49ec-8162-6c255acafaf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2ac8fe8f-bcb4-46c6-9a5c-71f745aabbf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a3520b9-2235-4f02-b5bd-2539100e16ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2ac8fe8f-bcb4-46c6-9a5c-71f745aabbf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0d4f9c31-1cdf-435e-a2cf-9ab04e3bc4f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a3520b9-2235-4f02-b5bd-2539100e16ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0d4f9c31-1cdf-435e-a2cf-9ab04e3bc4f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_634db0bf-2c88-455f-8493-5462c40b5940" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a3520b9-2235-4f02-b5bd-2539100e16ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_634db0bf-2c88-455f-8493-5462c40b5940" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_157473c5-d667-4e2a-9bdb-220cee791a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e844f55-d7d3-4eb8-bd95-f94f0b619738" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37730493-9992-4146-ae68-31587d4d5713" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e844f55-d7d3-4eb8-bd95-f94f0b619738" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_258200f5-de58-472e-80f9-0a1751467127" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e844f55-d7d3-4eb8-bd95-f94f0b619738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_258200f5-de58-472e-80f9-0a1751467127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8185752-4600-452b-adb4-77861af6e914" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e844f55-d7d3-4eb8-bd95-f94f0b619738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8185752-4600-452b-adb4-77861af6e914" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a07d97f3-e27a-4955-9261-6a5718ea4c14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e844f55-d7d3-4eb8-bd95-f94f0b619738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a07d97f3-e27a-4955-9261-6a5718ea4c14" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_82088d31-9018-45f1-a841-25d1c2c7d8dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e844f55-d7d3-4eb8-bd95-f94f0b619738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_82088d31-9018-45f1-a841-25d1c2c7d8dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f28698c-cfa1-4731-a864-2f563096f4b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_58bb06a0-4023-4dec-98df-d16c72e20792" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37730493-9992-4146-ae68-31587d4d5713" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_58bb06a0-4023-4dec-98df-d16c72e20792" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_48ce2d24-f9d5-4435-be18-1055b0ce1ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_58bb06a0-4023-4dec-98df-d16c72e20792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_48ce2d24-f9d5-4435-be18-1055b0ce1ce7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_0de4ed95-6864-41cd-85cf-24de6958595f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_58bb06a0-4023-4dec-98df-d16c72e20792" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_0de4ed95-6864-41cd-85cf-24de6958595f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73d51584-0553-439c-97f1-496a5e3fa03f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37730493-9992-4146-ae68-31587d4d5713" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73d51584-0553-439c-97f1-496a5e3fa03f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_deadb844-b836-4166-825a-8fef4c368e06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73d51584-0553-439c-97f1-496a5e3fa03f" xlink:to="loc_us-gaap_AwardTypeAxis_deadb844-b836-4166-825a-8fef4c368e06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_deadb844-b836-4166-825a-8fef4c368e06_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_deadb844-b836-4166-825a-8fef4c368e06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_deadb844-b836-4166-825a-8fef4c368e06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70b3e99e-bf89-4021-b25f-9c21debbe63f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_deadb844-b836-4166-825a-8fef4c368e06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70b3e99e-bf89-4021-b25f-9c21debbe63f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4b35be75-7429-4372-bb06-0a71900a18cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70b3e99e-bf89-4021-b25f-9c21debbe63f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4b35be75-7429-4372-bb06-0a71900a18cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a46f96f7-4272-4b14-afbe-b99760bcca89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73d51584-0553-439c-97f1-496a5e3fa03f" xlink:to="loc_us-gaap_PlanNameAxis_a46f96f7-4272-4b14-afbe-b99760bcca89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a46f96f7-4272-4b14-afbe-b99760bcca89_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_a46f96f7-4272-4b14-afbe-b99760bcca89" xlink:to="loc_us-gaap_PlanNameDomain_a46f96f7-4272-4b14-afbe-b99760bcca89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_05eceb97-3490-4118-912b-882a533ce20d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_a46f96f7-4272-4b14-afbe-b99760bcca89" xlink:to="loc_us-gaap_PlanNameDomain_05eceb97-3490-4118-912b-882a533ce20d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_c08d3529-a5ff-443b-8e82-77cedd25ddf5" xlink:href="fold-20200331.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_05eceb97-3490-4118-912b-882a533ce20d" xlink:to="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_c08d3529-a5ff-443b-8e82-77cedd25ddf5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationExpenseSummaryDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="extended" id="i9d1a4d70e4ed4cb4958fd567ef21fc48_ShareBasedCompensationExpenseSummaryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_618de813-546a-4f3b-8e30-53ea7eee39db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8145e602-d9d1-4075-8096-fefdaf0271e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_618de813-546a-4f3b-8e30-53ea7eee39db" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8145e602-d9d1-4075-8096-fefdaf0271e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9489bda-0e67-418c-919e-a6689049337e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_618de813-546a-4f3b-8e30-53ea7eee39db" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9489bda-0e67-418c-919e-a6689049337e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2844ad22-f370-40a9-a5b3-2974f0e39f17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9489bda-0e67-418c-919e-a6689049337e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2844ad22-f370-40a9-a5b3-2974f0e39f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2844ad22-f370-40a9-a5b3-2974f0e39f17_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2844ad22-f370-40a9-a5b3-2974f0e39f17" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2844ad22-f370-40a9-a5b3-2974f0e39f17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d4f862cc-8b75-4942-b51c-92e354102202" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2844ad22-f370-40a9-a5b3-2974f0e39f17" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d4f862cc-8b75-4942-b51c-92e354102202" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c483d243-daad-4858-8dae-2147ff0d92e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4f862cc-8b75-4942-b51c-92e354102202" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c483d243-daad-4858-8dae-2147ff0d92e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_dff9f8a7-b03f-4b55-a102-2e0acb91f414" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4f862cc-8b75-4942-b51c-92e354102202" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_dff9f8a7-b03f-4b55-a102-2e0acb91f414" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="simple" xlink:href="fold-20200331.xsd#AssetsandLiabilitiesMeasuredatFairValue"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="extended" id="i43ac38ed93af4089aa2bbfa446ea5892_AssetsandLiabilitiesMeasuredatFairValue"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="simple" xlink:href="fold-20200331.xsd#AssetsandLiabilitiesMeasuredatFairValueTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="extended" id="ia7e7d8cd79ae46fbb499d23eb86f94a8_AssetsandLiabilitiesMeasuredatFairValueTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="extended" id="i7d3cc83d19674e0dae046473f8cc2080_AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a28f8b-05f9-4a9c-98d5-a0f90dd3dc72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_863d7730-8a99-4964-a51b-f0d009214837" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a28f8b-05f9-4a9c-98d5-a0f90dd3dc72" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_863d7730-8a99-4964-a51b-f0d009214837" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_33a28280-a358-43fe-b408-1023fd17675e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_863d7730-8a99-4964-a51b-f0d009214837" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_33a28280-a358-43fe-b408-1023fd17675e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5daff6b6-50da-4f76-a745-0438ee66d26d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a28f8b-05f9-4a9c-98d5-a0f90dd3dc72" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5daff6b6-50da-4f76-a745-0438ee66d26d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5c9d8e15-afd9-4b1a-b6e3-f583e58c4fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5daff6b6-50da-4f76-a745-0438ee66d26d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5c9d8e15-afd9-4b1a-b6e3-f583e58c4fe6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_b8755c19-3d1a-46a8-8c28-1a6c70d0d644" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5daff6b6-50da-4f76-a745-0438ee66d26d" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_b8755c19-3d1a-46a8-8c28-1a6c70d0d644" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e887e6f7-6740-4fb8-8615-3b02ef908473" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5daff6b6-50da-4f76-a745-0438ee66d26d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_e887e6f7-6740-4fb8-8615-3b02ef908473" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_b9d1ea81-4430-4059-b003-1188271e807e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a28f8b-05f9-4a9c-98d5-a0f90dd3dc72" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_b9d1ea81-4430-4059-b003-1188271e807e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput_48a28a1b-18e7-49a4-963d-d86ff19f3e32" xlink:href="fold-20200331.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a28f8b-05f9-4a9c-98d5-a0f90dd3dc72" xlink:to="loc_fold_ContingentConsiderationMeasurementInput_48a28a1b-18e7-49a4-963d-d86ff19f3e32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a28f8b-05f9-4a9c-98d5-a0f90dd3dc72" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942ebc33-bec4-4638-b38b-dba7936ab462" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942ebc33-bec4-4638-b38b-dba7936ab462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_942ebc33-bec4-4638-b38b-dba7936ab462_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942ebc33-bec4-4638-b38b-dba7936ab462" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_942ebc33-bec4-4638-b38b-dba7936ab462_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8da3-aebb-4bbd-8ba7-3a935b0fe8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942ebc33-bec4-4638-b38b-dba7936ab462" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8da3-aebb-4bbd-8ba7-3a935b0fe8ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_005edb1a-71ea-4396-b3b1-84c54a0f84b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8da3-aebb-4bbd-8ba7-3a935b0fe8ce" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_005edb1a-71ea-4396-b3b1-84c54a0f84b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d95e993a-bda9-4358-8c37-1f46a75dd3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8da3-aebb-4bbd-8ba7-3a935b0fe8ce" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d95e993a-bda9-4358-8c37-1f46a75dd3e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_42f10acf-0596-4aee-9a6b-8402cb414bed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_FinancialInstrumentAxis_42f10acf-0596-4aee-9a6b-8402cb414bed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_42f10acf-0596-4aee-9a6b-8402cb414bed_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_42f10acf-0596-4aee-9a6b-8402cb414bed" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_42f10acf-0596-4aee-9a6b-8402cb414bed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_42f10acf-0596-4aee-9a6b-8402cb414bed" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_c266ff60-cc99-4c59-a825-4385213a8860" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_c266ff60-cc99-4c59-a825-4385213a8860" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_49e9d300-a228-4c83-9299-422f3281c6df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_49e9d300-a228-4c83-9299-422f3281c6df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9ca03b5c-6486-4283-afde-cc3163909be4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9ca03b5c-6486-4283-afde-cc3163909be4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ef7bdab2-37ee-4e83-b7f8-d13351a7077c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ef7bdab2-37ee-4e83-b7f8-d13351a7077c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_58016165-0830-47df-934d-efaa607095e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_58016165-0830-47df-934d-efaa607095e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1118b79b-eb84-48dd-bf22-b3915a2be066" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1118b79b-eb84-48dd-bf22-b3915a2be066" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1118b79b-eb84-48dd-bf22-b3915a2be066_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1118b79b-eb84-48dd-bf22-b3915a2be066" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1118b79b-eb84-48dd-bf22-b3915a2be066_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8072b2f1-68c4-4377-aa9e-d0a8ea5f4263" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1118b79b-eb84-48dd-bf22-b3915a2be066" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8072b2f1-68c4-4377-aa9e-d0a8ea5f4263" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ATB200PompeProgramMember_300f90d1-c8d7-4a48-9a08-3ba472cd43ea" xlink:href="fold-20200331.xsd#fold_ATB200PompeProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8072b2f1-68c4-4377-aa9e-d0a8ea5f4263" xlink:to="loc_fold_ATB200PompeProgramMember_300f90d1-c8d7-4a48-9a08-3ba472cd43ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_66430058-b7a1-47ba-8854-2a53e13974e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_66430058-b7a1-47ba-8854-2a53e13974e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_66430058-b7a1-47ba-8854-2a53e13974e8_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_66430058-b7a1-47ba-8854-2a53e13974e8" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_66430058-b7a1-47ba-8854-2a53e13974e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_5a21f4ed-e619-41d8-b20a-542009e69a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_66430058-b7a1-47ba-8854-2a53e13974e8" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_5a21f4ed-e619-41d8-b20a-542009e69a6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_4a361e87-bae8-4098-b6a9-9ce77727a98a" xlink:href="fold-20200331.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_5a21f4ed-e619-41d8-b20a-542009e69a6f" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_4a361e87-bae8-4098-b6a9-9ce77727a98a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_c8a1acb1-a360-4c80-b9fb-2192d4749263" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_ValuationTechniqueAxis_c8a1acb1-a360-4c80-b9fb-2192d4749263" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_c8a1acb1-a360-4c80-b9fb-2192d4749263_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_c8a1acb1-a360-4c80-b9fb-2192d4749263" xlink:to="loc_us-gaap_ValuationTechniqueDomain_c8a1acb1-a360-4c80-b9fb-2192d4749263_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_069cb205-2a3b-4d8f-aacf-3d554929fb9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_c8a1acb1-a360-4c80-b9fb-2192d4749263" xlink:to="loc_us-gaap_ValuationTechniqueDomain_069cb205-2a3b-4d8f-aacf-3d554929fb9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_a240b10d-4c72-4042-8d44-d92b073f2d29" xlink:href="fold-20200331.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_069cb205-2a3b-4d8f-aacf-3d554929fb9a" xlink:to="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_a240b10d-4c72-4042-8d44-d92b073f2d29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0b79cf81-b033-41f9-a8f2-5dd19bd42e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0b79cf81-b033-41f9-a8f2-5dd19bd42e6d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0b79cf81-b033-41f9-a8f2-5dd19bd42e6d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0b79cf81-b033-41f9-a8f2-5dd19bd42e6d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0b79cf81-b033-41f9-a8f2-5dd19bd42e6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c801d627-0154-4f2e-9f14-05dc7ad31f57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0b79cf81-b033-41f9-a8f2-5dd19bd42e6d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c801d627-0154-4f2e-9f14-05dc7ad31f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_70af28c5-0f6d-4cde-84b7-25a982dbe8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c801d627-0154-4f2e-9f14-05dc7ad31f57" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_70af28c5-0f6d-4cde-84b7-25a982dbe8cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_9091ddef-3b36-4a85-a3d3-85e403453b7a" xlink:href="fold-20200331.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c801d627-0154-4f2e-9f14-05dc7ad31f57" xlink:to="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_9091ddef-3b36-4a85-a3d3-85e403453b7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fae785fc-7567-4fa9-b89b-5d8d9f1a5156" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_srt_RangeAxis_fae785fc-7567-4fa9-b89b-5d8d9f1a5156" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fae785fc-7567-4fa9-b89b-5d8d9f1a5156_default" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fae785fc-7567-4fa9-b89b-5d8d9f1a5156" xlink:to="loc_srt_RangeMember_fae785fc-7567-4fa9-b89b-5d8d9f1a5156_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3b47bf0-5e9d-4e06-865d-1b158e19fa1b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fae785fc-7567-4fa9-b89b-5d8d9f1a5156" xlink:to="loc_srt_RangeMember_d3b47bf0-5e9d-4e06-865d-1b158e19fa1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3bf4c3ac-1e57-479f-b4a3-e07b23db8bd6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d3b47bf0-5e9d-4e06-865d-1b158e19fa1b" xlink:to="loc_srt_MinimumMember_3bf4c3ac-1e57-479f-b4a3-e07b23db8bd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_afed7bad-a85a-4b73-967b-a4e87f4f4e62" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d3b47bf0-5e9d-4e06-865d-1b158e19fa1b" xlink:to="loc_srt_MaximumMember_afed7bad-a85a-4b73-967b-a4e87f4f4e62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5ca332c9-c440-462f-849e-dc4d0788299a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5ca332c9-c440-462f-849e-dc4d0788299a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5ca332c9-c440-462f-849e-dc4d0788299a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5ca332c9-c440-462f-849e-dc4d0788299a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5ca332c9-c440-462f-849e-dc4d0788299a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca8fcead-ea69-42cc-b316-0b3bf8b32a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5ca332c9-c440-462f-849e-dc4d0788299a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca8fcead-ea69-42cc-b316-0b3bf8b32a8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember_fa284b40-9d3f-42a6-99f9-9c0865a5b050" xlink:href="fold-20200331.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca8fcead-ea69-42cc-b316-0b3bf8b32a8f" xlink:to="loc_fold_CallidusBiopharmaIncMember_fa284b40-9d3f-42a6-99f9-9c0865a5b050" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails" xlink:type="extended" id="id47c9badd8724b3b91be8d88dc81a891_AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="simple" xlink:href="fold-20200331.xsd#BasicandDilutedNetLossperCommonShare"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="extended" id="i57bfe7fec00843508357bd4b9de51131_BasicandDilutedNetLossperCommonShare"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="simple" xlink:href="fold-20200331.xsd#BasicandDilutedNetLossperCommonShareTables"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="extended" id="i5443111045bc4ea08c9e622a2d13d452_BasicandDilutedNetLossperCommonShareTables"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#BasicandDilutedNetLossperCommonShareDetails"/>
  <link:definitionLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="extended" id="ie37f1545d1e14daa84d682391c6d5037_BasicandDilutedNetLossperCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a611b3fc-0ce9-4c7b-b556-85db5b6dca7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_82a13273-3bb8-4783-8e24-6689e22534f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a611b3fc-0ce9-4c7b-b556-85db5b6dca7b" xlink:to="loc_us-gaap_NetIncomeLossAbstract_82a13273-3bb8-4783-8e24-6689e22534f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f0e56e21-0f1d-48ac-9226-b28970ecb3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_82a13273-3bb8-4783-8e24-6689e22534f8" xlink:to="loc_us-gaap_NetIncomeLoss_f0e56e21-0f1d-48ac-9226-b28970ecb3e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ac02149-8964-4426-8249-c3b85aa317ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a611b3fc-0ce9-4c7b-b556-85db5b6dca7b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ac02149-8964-4426-8249-c3b85aa317ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_846cb825-4815-4637-946a-30dc98473090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ac02149-8964-4426-8249-c3b85aa317ee" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_846cb825-4815-4637-946a-30dc98473090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_63f4327b-6650-4221-86b0-5fde322309ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a611b3fc-0ce9-4c7b-b556-85db5b6dca7b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_63f4327b-6650-4221-86b0-5fde322309ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e2add7c2-4ad2-47e6-9fb9-0fc4c5e63f86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a611b3fc-0ce9-4c7b-b556-85db5b6dca7b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e2add7c2-4ad2-47e6-9fb9-0fc4c5e63f86" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2428ef5b-175b-4604-9228-fcbf63579c29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e2add7c2-4ad2-47e6-9fb9-0fc4c5e63f86" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2428ef5b-175b-4604-9228-fcbf63579c29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2428ef5b-175b-4604-9228-fcbf63579c29_default" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2428ef5b-175b-4604-9228-fcbf63579c29" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2428ef5b-175b-4604-9228-fcbf63579c29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c72ded20-0046-420a-a748-96dc23e7ce00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2428ef5b-175b-4604-9228-fcbf63579c29" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c72ded20-0046-420a-a748-96dc23e7ce00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_a6f77d53-4fe1-4f2e-9d99-faf1c98fa20e" xlink:href="fold-20200331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c72ded20-0046-420a-a748-96dc23e7ce00" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_a6f77d53-4fe1-4f2e-9d99-faf1c98fa20e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_11726868-4e3c-4bd2-9d22-b2e9bc37b2da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c72ded20-0046-420a-a748-96dc23e7ce00" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_11726868-4e3c-4bd2-9d22-b2e9bc37b2da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_bdbd7578-0e3f-4cf7-9aac-2fb6d8e068eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c72ded20-0046-420a-a748-96dc23e7ce00" xlink:to="loc_us-gaap_WarrantMember_bdbd7578-0e3f-4cf7-9aac-2fb6d8e068eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_34b50b99-8af2-4be2-9b69-0a64efdb828a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c72ded20-0046-420a-a748-96dc23e7ce00" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_34b50b99-8af2-4be2-9b69-0a64efdb828a" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>fold-20200331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d7d83936-4003-4695-9e73-95a98e869b39,g:49308d12-68e9-469e-b9d5-8a5a2cc3db36-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_38169d2d-89d2-46d8-8727-65de1ab25854_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment gain (loss), net of tax impact of $1,536 and $0, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e80c80cd-27cc-4356-8390-6a475bb12332_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_7a3ffaf8-40f0-4d07-b8b1-ab8743defe09_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_a8c17367-64ca-4c08-a3c0-d8a208e7f13f_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of the convertible notes</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3b9d0ac5-261d-429b-8ac5-833bf375cfcb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_e17a4b0e-0bf4-4c8f-8200-91af9f028194_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash changes in the fair value of contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_6b4c5e3b-7e1a-4b85-8156-1e3d2092cab5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale and redemption of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_349db39a-7f1f-405d-9102-8a8a1e15bf10_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_626b243e-22b8-4937-8981-19c889c10e91_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_4a2a3f83-363c-44ee-bbc6-bf74dac9afc1_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d9018b50-468d-4a44-8b83-88358c3d9e2c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ea155747-b601-415e-889c-c74272308acb_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_7f23b928-f854-4422-b8d9-42fb181614c4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research&#160;&amp; development</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f59fa0b4-1fa0-422b-a63a-e6519142ee2e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_269eff0c-97cd-4c17-bce3-58235180a289_terseLabel_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_fold_ShortTermCorporateDebtSecuritiesMember_documentation_en-US" xlink:label="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember" xlink:href="fold-20200331.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShortTermCorporateDebtSecuritiesMember" xlink:to="lab_fold_ShortTermCorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_3ae42932-0e16-4104-8efb-9b1a5c0643fc_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Warrants Exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents Stock issued from exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="fold-20200331.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_fold_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_52d3fc4e-e943-4ad6-a977-9e78fc524151_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8c95ee17-23cf-44a1-bbcd-febe4ec9d456_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d0f6630e-12ff-4b5c-aa8e-4c441e0aa0d0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b2d78e16-3d09-42d1-ad9b-4ad942c84068_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_c62c263e-9cec-4521-9b28-5cd4b682584f_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_label_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Measurement Input</link:label>
    <link:label id="lab_fold_ContingentConsiderationMeasurementInput_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput" xlink:href="fold-20200331.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationMeasurementInput" xlink:to="lab_fold_ContingentConsiderationMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_aae20a78-600b-4d1c-b12f-8e210b7505f2_terseLabel_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability Weighted Discounted Cash Flow</link:label>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_label_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability Weighted Discounted Cash Flow [Member]</link:label>
    <link:label id="lab_fold_ProbabilityWeightedDiscountedCashFlowMember_documentation_en-US" xlink:label="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to valuation technique of probability weighted discounted cash flow.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:href="fold-20200331.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:to="lab_fold_ProbabilityWeightedDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_5ad0aa44-8831-47de-8b0b-b847db85be62_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities with maturity date greater than 12 months</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_8b3c579e-5fbc-473f-bd0e-d97663858c20_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_8979bcdf-40ab-422d-9bdc-25d84741060a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ae5eb52f-053f-49b4-a8c0-6dc18001b5d1_negatedLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss, Cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_IncreaseDecreaseInDeferredReimbursements_074e906a-dbbe-4993-b5b1-ddad8d862af1_terseLabel_en-US" xlink:label="lab_fold_IncreaseDecreaseInDeferredReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred reimbursements</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInDeferredReimbursements_label_en-US" xlink:label="lab_fold_IncreaseDecreaseInDeferredReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Deferred Reimbursements</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInDeferredReimbursements_documentation_en-US" xlink:label="lab_fold_IncreaseDecreaseInDeferredReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the amount of deferred reimbursements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInDeferredReimbursements" xlink:href="fold-20200331.xsd#fold_IncreaseDecreaseInDeferredReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_IncreaseDecreaseInDeferredReimbursements" xlink:to="lab_fold_IncreaseDecreaseInDeferredReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8f37203a-7e60-4ce8-9b81-22a83cda7c17_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4e26449a-0cfc-4a11-9599-ee37ca623fbc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_6258fe7c-70cd-4ff0-8a19-408e15589e92_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationPaidInStockAdjustment_0d0c0cf1-1179-40bb-8923-6ad7f7b6b002_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStockAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment for contingent consideration paid in stock</link:label>
    <link:label id="lab_fold_ContingentConsiderationPaidInStockAdjustment_label_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStockAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Paid In Stock, Adjustment</link:label>
    <link:label id="lab_fold_ContingentConsiderationPaidInStockAdjustment_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStockAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Paid In Stock, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationPaidInStockAdjustment" xlink:href="fold-20200331.xsd#fold_ContingentConsiderationPaidInStockAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationPaidInStockAdjustment" xlink:to="lab_fold_ContingentConsiderationPaidInStockAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_f323f543-7a16-47c9-aa9c-5696bcbecce3_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange agreement, aggregate principal amount</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_label_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:href="fold-20200331.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:to="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_78938cd4-304f-4cd3-88a2-923068ba468f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive gain (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueContingentConsideration_18cb9f03-37d3-4aa4-bfec-12325eef0646_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued for contingent consideration</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueContingentConsideration_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Contingent Consideration</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodValueContingentConsideration_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:href="fold-20200331.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:to="lab_fold_StockIssuedDuringPeriodValueContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1c713bfe-f459-4664-9365-a12c2c06324d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_69ba93b8-7f27-4fb5-96bc-1bcfddf29dfb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9cf5c4fc-3f1f-4caf-a1b1-dd93422fcfd7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Developments</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8205294a-b8ca-41e3-995f-d2bfb14fc670_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3229a96d-6960-4fd1-a142-75a076e49fcf_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_06115840-2c52-4557-86f5-6c980d30bcf1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_5e0a6419-75a4-4b00-90b1-9290b9c10770_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_54667ed0-9b65-4cd1-9087-3cf0dac5cd06_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_b57969a2-b48e-4431-8aa0-4dbb93279c7c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a54e7e99-3d80-4ebe-bb73-ee82853a9941_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gain, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_3c272141-052f-4987-a047-28738ee7934c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_95842cd0-89b9-4bb0-94e6-138820e85ff5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_29f8c7a3-c60e-4d22-bebc-a247f01988f0_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock tax vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ATB200PompeProgramMember_4ad80432-4840-4f8d-a119-15a291252c35_terseLabel_en-US" xlink:label="lab_fold_ATB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATB200 Pompe Program</link:label>
    <link:label id="lab_fold_ATB200PompeProgramMember_label_en-US" xlink:label="lab_fold_ATB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATB200 Pompe Program [Member]</link:label>
    <link:label id="lab_fold_ATB200PompeProgramMember_documentation_en-US" xlink:label="lab_fold_ATB200PompeProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to ATB-200 Pompe program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ATB200PompeProgramMember" xlink:href="fold-20200331.xsd#fold_ATB200PompeProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ATB200PompeProgramMember" xlink:to="lab_fold_ATB200PompeProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_e57a2251-fca0-426e-826f-4957a70a479f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold consecutive trading days</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5d5c9adc-e4d2-41e2-a214-f97f3dd6fbf6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cfb77814-bb6a-40ae-af37-e44d1f823354_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b5038ad4-3a29-4fb2-a9a8-a8d09d884ac8_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_11f2019d-32d2-4548-b4e8-716ca97383da_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_bdb5be1c-d68d-40de-8e89-1d8d5b2ded07_terseLabel_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing</link:label>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_label_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Deferred Financing Costs</link:label>
    <link:label id="lab_fold_AmortizationDeferredFinancingCosts_documentation_en-US" xlink:label="lab_fold_AmortizationDeferredFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AmortizationDeferredFinancingCosts" xlink:href="fold-20200331.xsd#fold_AmortizationDeferredFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AmortizationDeferredFinancingCosts" xlink:to="lab_fold_AmortizationDeferredFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d13039f5-a76f-4252-8667-2b43bcd07714_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, less accumulated depreciation of $19,260 and $17,604 at March 31, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_160998ae-0c61-46cb-a5b8-3d92d22c22ca_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_71dc8277-535b-475a-b4b5-7125694a258b_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtFairValueDisclosures_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="lab_us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_692fb179-a272-49dd-b558-819809b74619_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_bb72fe45-8a9c-432d-b39b-0f259bda08c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Money Market Funds, and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_fba2692c-f4b9-4efc-a3d9-1eebd4d794ee_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8d631b63-8bae-46a4-9e4d-3de200a431a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_344dd571-b0f9-4379-b924-9da891bafec3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a6a5f085-4fcb-47ab-ab45-36425fbbcc39_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_50f3eb24-2539-4b3a-9a12-a30b2c96574e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ca4d42ae-83ac-4b18-8017-af7519fee661_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1012912a-098a-4ed0-aec7-6c278c42cc9b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized loss, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8c9fd661-c89a-4f86-aae9-6e4a1a9a6885_terseLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gain, Cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_d3a97054-e61b-4ebe-9f44-6b03dbfbd224_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_569ce549-0b0b-4928-9a3e-21ac37a75ae5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued from exercise of stock options, net</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_84d1193f-4def-4e47-bec0-bdcea7d2ca64_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_04f206c8-eedd-4ec1-b906-0c5e9c06b33f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_3bfae437-dd9b-4220-93ce-58e952e35ff2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvements paid through lease incentives</link:label>
    <link:label id="lab_us-gaap_PaymentsForTenantImprovements_label_en-US" xlink:label="lab_us-gaap_PaymentsForTenantImprovements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Tenant Improvements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForTenantImprovements" xlink:to="lab_us-gaap_PaymentsForTenantImprovements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8bf22547-c0ec-4c21-b443-1f50fcc1fa8a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_af179470-84c1-4683-a24e-bf7be1c99112_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_6bf13606-deb4-4ea3-ad54-c899a998ddf5_terseLabel_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of Milestone Achievement</link:label>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_label_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Milestone Achievement [Member]</link:label>
    <link:label id="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_documentation_en-US" xlink:label="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability Of Milestone Achievement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:href="fold-20200331.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:to="lab_fold_MeasurementInputProbabilityOfMilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6792914a-54e1-45c5-a6f9-46b504aa2dde_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_675e7727-f02f-4513-8a45-dde1040ff614_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventories for the period</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_cc135be8-c465-4c51-863e-a223af6ba304_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5bc8d698-d084-4fcc-97fa-1d947e22c167_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_72e8c473-ff37-4a38-bcbf-4ff93a1623e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_9ebb3993-800e-4a83-b4e3-5f01e4d48e46_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_8999dea0-db9a-4735-ab2c-9c0bd493c9e7_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_3cb0dde7-0915-4755-98a2-8df6a0f324bf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_590706a0-aa4b-4af3-b4c0-0e9d60064712_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_5925cd2e-2511-4feb-a8f4-8175fe857531_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, options outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_48244439-20bc-4fb4-b4af-2dc83485c7a1_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_e2873a61-1772-4d55-85dc-824aa202895d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8af9fe86-47fa-4c3d-b9ac-db6e6f593b56_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_219155cf-5d7d-457d-a220-62c6768cacd0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_b1183efd-e388-4a25-8ad1-012fc5606019_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_a14daff9-ead8-42ef-af71-58af7a0749c2_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_8c90a513-7d07-4b66-906a-040e94ee0355_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Liability Clinical and Regulatory Milestones</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Liability Clinical And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to clinical and regulatory contingent consideration milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:href="fold-20200331.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:to="lab_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_ae1ba59a-beeb-4c00-9d04-9000a429e37c_negatedTerseLabel_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, Gross Unrealized Loss</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_label_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_documentation_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="fold-20200331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ff6683a8-ee50-49e0-a34b-c6acc3c0803e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f290eb49-86a6-4a8b-ba5b-55051ed96ab4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_f6762778-3f65-4edf-b280-752bcb218ea7_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d495c25a-6c04-49fe-979d-a3ca7d4a7bf3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1aa86a3a-7341-4635-a63c-828c67c9f6c9_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b981d598-5eed-4491-b058-e95453bbf42b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at the end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_468df3f3-b1f0-4326-bfe4-102edc1ec403_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_c38e70bd-df10-49c5-81b6-b1b5a7851b64_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on exchange of convertible notes</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_7333009d-94d6-428a-800a-0bff97aa9f43_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on exchange of convertible debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1f1a9725-9f6d-46db-bf02-530d6fe60cbe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_ed718c1d-25ac-4ccf-bd9e-7683edfa31ea_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic and diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a855feab-1f61-40d3-b51a-4ea039315c75_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_799fcbdf-7850-4228-a535-4193aa4c87aa_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2525f8c6-a74e-4cb1-93bf-039b0b4e2bcd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_48c6ea05-8dd3-4fd8-957b-a9acaf552c6d_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_c52a07a3-0895-4f05-9e10-1cc64af034ca_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_a6878bc1-1ac2-4abf-a777-1126121c1e3b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of total interest expense</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_e205e89d-5185-4bf3-979f-ce01469dee45_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_aab3e7ff-6638-47fd-8be8-7e776aadad32_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: deferred financing</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_0ca589c7-c880-41c1-a0f3-f44899972a88_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_d9fe4275-e368-496b-a41d-3eef871441ab_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3e1c34a6-f112-457b-8a08-cacc3beeade5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_98877bfd-557f-4a24-8e98-510abce42034_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1ff17982-b1b0-40ef-96b9-1cccf3da7a08_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7f51ba54-58f2-4bbd-bf59-13b16a344a95_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_082adf81-218b-48a6-b186-8eb49282e528_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_79deed8f-05c6-47ee-8c1a-ee611d8f8712_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_510ff48b-e0c0-4b35-8798-4270605bc157_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_9d07bb09-fbf2-4e2c-8370-ba09f5bf7487_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange agreement, accrued and unpaid interest</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_label_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:href="fold-20200331.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:to="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_0ac25abd-752b-46a1-bb21-e89e29697d4d_terseLabel_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets and liabilities</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_label_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Noncurrent Operating Liabilities</link:label>
    <link:label id="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_documentation_en-US" xlink:label="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:href="fold-20200331.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:to="lab_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_adb05db4-883d-40cc-a2f8-5198c2ad1729_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d8b68409-e5a2-462e-98cf-7af82c2b6881_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b015e6ad-1240-4544-ac2d-7d347909347f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reconciliation of the numerator and denominator used in computing basic and diluted net loss per common share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_3fd3b4a7-7354-4f72-b1ee-f40de8856549_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_f8cc8e08-a79f-4ff8-81eb-6aa5507d6c8a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d5df7df9-f420-4dfb-9833-a3b6d7af2a7e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ff66074f-bb54-4925-9f6d-1dead6cdbd79_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_47350e69-1b56-4f02-b78d-c5d4b5dbc9fb_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_81b74e07-d1bd-43ac-b463-048945741519_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_3feb853f-9be4-495d-8a52-c264b3ad4abf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_69a74395-a8a9-4c90-a15a-d08f00e7f500_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f557732e-ffa9-47ae-835c-41ba9b827901_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_24e6b74c-0659-47cd-86dc-fe2e8aaecc3d_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents Stock issued from exercise of warrants (in shares).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="fold-20200331.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_fold_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_1bd335ce-d159-4d46-a6ef-7c1c29243b33_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_2671c2f4-77c7-4ac1-81b6-7f2ec4169929_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a30110aa-98d2-4f38-a305-369ac850711b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dc2e4a06-4210-448a-b973-7f1ede2d5bb2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_424d5f8e-d97b-4a60-b040-28499beeceed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4f9baa68-4e32-45fa-977e-79a9a32fa21c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_9fa5d90c-0ada-45e6-b467-b6d5d58c68eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_9d8fbd7e-29fb-424e-aa93-7874487c9ef6_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeMember" xlink:to="lab_us-gaap_ComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_8c4f253d-2fc5-4f1a-aa62-136567f28b23_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ff14bca7-2ed9-46b3-8d36-f3532403eed1_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_1141496c-dfc6-4943-b0d0-858888b3f5a1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred reimbursements</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_dc748417-7ea2-4a94-ad94-83072bd5d73d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_fd72e7cc-e082-4a3b-9507-2e61a5e49880_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_445d85ba-0482-41b7-8097-5651b8dcef9b_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_d360a173-2f41-45af-8b5d-3f5356f963f9_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding warrants, convertible to common stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_5e9a77be-7eef-4350-a218-b861e9d496be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ContingentConsiderationPaidInStock_dd86054d-1274-4d6b-a6b6-3ab021a505d3_terseLabel_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration paid in shares</link:label>
    <link:label id="lab_fold_ContingentConsiderationPaidInStock_label_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Paid in Stock</link:label>
    <link:label id="lab_fold_ContingentConsiderationPaidInStock_documentation_en-US" xlink:label="lab_fold_ContingentConsiderationPaidInStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Paid in Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationPaidInStock" xlink:href="fold-20200331.xsd#fold_ContingentConsiderationPaidInStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ContingentConsiderationPaidInStock" xlink:to="lab_fold_ContingentConsiderationPaidInStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_2e1b20a9-222a-4039-9da9-dc28640d4a1c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_e290188e-cadb-4a46-975f-4e26d692d355_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2270629d-a2c9-4f5a-8851-3ba1f8f6ec89_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_657e6a4e-e6b8-4977-8a07-c273527e2b96_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_e07e37d1-52b2-4b03-9adc-156fcc7a03a1_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on available-for-sale securities, net of tax impact of $(56) and $0, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d2770d2a-f228-48c3-9e35-aff0835b2df0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fc11377f-78ca-417f-b67c-1d66285df9a6_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5727ec5b-25b2-420f-9474-0754990782a1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0a088919-cf88-4bbf-8d2b-0c7c69f84f8d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_f5a41d9b-89ea-49a0-84d4-bb685bc536ab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_6d1007ae-26a5-49c3-b654-c6ef75de9ab1_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_4d5c0031-2b5e-4a7e-b412-020c76146d2a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ef644325-9bba-4362-90ba-497dabb5a96a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5d7ae90b-9bf1-492d-84b4-766ee5ba4442_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_61b84475-6874-48fc-82df-470746c65e67_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ba60d9dd-1149-456e-a3d4-5875022e2794_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_8009939f-bbe3-4b7b-9ce3-922da25b2d3c_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleLongTermNotesPayable_label_en-US" xlink:label="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleLongTermNotesPayable" xlink:to="lab_us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_acd54b92-c267-4b97-9692-4951704998b7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a92b4f09-793a-48d6-992d-97bcd260a442_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_fbf11cfc-7522-46fc-88d1-4ddca2200dc8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_8aa80eb1-c589-4912-bd45-57fdc967bddd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_97dcfeec-5878-4e4c-80dc-3d6bcaa91a57_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_48be33bc-5286-49f2-8a02-0d15646e2f27_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_62b4e5d0-92c4-4344-9460-ad915b460f11_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying value</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_e1a842b7-579b-4c07-afbd-78fd157219ca_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_196207cf-8ea1-4442-bbc8-b65d37e70542_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da3caa49-0e30-4901-b731-ce45462dc56d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_215b0591-0b44-44c6-b5f6-083518cffd5d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and unvested expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fb0d78fa-21df-46ab-9ffc-b63aef12e718_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_50a9e206-0e21-4727-a119-a6547716f9a6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise&#160; Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fd68ad8d-f619-4910-a827-d08f3d69d609_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9ece6aca-21b5-481b-8116-d4d97df773ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e7465c1e-4901-408e-ab11-8764157c3f80_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_7bae8e97-2b93-41de-9512-f3e6760899f3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_1f584d50-3202-4e6e-ab29-50c45540b8e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases_61365185-413f-4113-915d-1d218660b70a_terseLabel_en-US" xlink:label="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation and amortization on finance and operating lease right-of-use leases</link:label>
    <link:label id="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases_label_en-US" xlink:label="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation And Amortization, Finance And Operating Right-Of-Use Leases</link:label>
    <link:label id="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases_documentation_en-US" xlink:label="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation And Amortization, Finance And Operating Right-Of-Use Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" xlink:href="fold-20200331.xsd#fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" xlink:to="lab_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b017e8e8-80c5-494c-9b97-7c07c6238f03_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_8b553cab-c704-440a-b462-fe2adfb4dad2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_09b3ccf3-9e88-4770-9321-acc35c2d0040_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_f47b4aa5-dda4-474c-a280-ee67a9d11e69_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_c8e898e3-e1c0-4ce0-a153-9e6682de59d7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_9215f6cc-1862-4c7e-9ac2-86def2613bfd_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_c97e2d34-caa4-44a3-b3b2-ed9f6259a0fe_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_833f2ab4-6f3d-48cc-a40f-ac63d851dbaa_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration_d371c8a9-ef95-460b-9c8a-792b80dcf7d3_terseLabel_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued for contingent consideration (in shares)</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration_label_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Contingent Consideration</link:label>
    <link:label id="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration_documentation_en-US" xlink:label="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:href="fold-20200331.xsd#fold_StockIssuedDuringPeriodSharesContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:to="lab_fold_StockIssuedDuringPeriodSharesContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_1c9157e5-d274-4f31-8bdd-0bbee7b4f533_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_7c867ea7-60fa-4ff0-a79f-4fecc7fce488_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of available-for-sale debt securities in unrealized loss positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_87b27e67-aea2-447a-856a-fd9adc60d8c2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation costs, period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_a84bf8c1-d058-49be-832f-640cda80fc26_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2680c9e9-1f97-4bb5-bfdb-08a6958ccbd6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_fd58c2ae-2fbe-4ce6-ac82-d5ff2e64ca90_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_c745ca98-286d-4d3a-9d8d-93bba984b5a7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_82d7cc97-7e17-4960-9080-79b8124bc2dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_2b74cd82-05a7-4132-9e74-f3645a3e90db_terseLabel_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes 2016, Due 2023</link:label>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_label_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Senior Notes2016 Due2023 [Member]</link:label>
    <link:label id="lab_fold_ConvertibleSeniorNotes2016Due2023Member_documentation_en-US" xlink:label="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the 3.0% unsecured Convertible Senior Notes due 2023 (the "Convertible Notes).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:href="fold-20200331.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:to="lab_fold_ConvertibleSeniorNotes2016Due2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_2d79e989-81ec-4198-a7bc-dfa0b30f8a10_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_09722448-7991-411e-944c-3e0c211d92bd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_EmployeeAndDirectorsStockOptionsMember_61d18c54-f078-45ea-a420-682ba7665a0b_terseLabel_en-US" xlink:label="lab_fold_EmployeeAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_fold_EmployeeAndDirectorsStockOptionsMember_5fe464f3-573a-4366-93f5-fe71d6dd0f9d_verboseLabel_en-US" xlink:label="lab_fold_EmployeeAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_fold_EmployeeAndDirectorsStockOptionsMember_label_en-US" xlink:label="lab_fold_EmployeeAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee And Directors Stock Options [Member]</link:label>
    <link:label id="lab_fold_EmployeeAndDirectorsStockOptionsMember_documentation_en-US" xlink:label="lab_fold_EmployeeAndDirectorsStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember" xlink:href="fold-20200331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_EmployeeAndDirectorsStockOptionsMember" xlink:to="lab_fold_EmployeeAndDirectorsStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy_76eaa9a9-575f-4202-a0b9-cd2b833130f3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories and Cost of Goods Sold</link:label>
    <link:label id="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy_label_en-US" xlink:label="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Costs for Contracts or Programs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCostsForContractsOrProgramsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:to="lab_us-gaap_InventoryCostsForContractsOrProgramsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_a4dca0f9-72d5-45b7-b131-dcab50fca3b2_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_7947e552-b6e4-487a-950b-f35e3957360d_terseLabel_en-US" xlink:label="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from termination of capped call confirmations</link:label>
    <link:label id="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_label_en-US" xlink:label="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt</link:label>
    <link:label id="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_documentation_en-US" xlink:label="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:href="fold-20200331.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:to="lab_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_f298ccb5-6929-4f09-a942-560a9b1460b5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_245d57eb-9069-4e11-822a-b601155d3cd6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock tax vesting</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_53c2e7b2-5153-425a-a780-0fe13c49f701_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_a7ff09f9-4bd3-4626-9455-2a9dbb469b7c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_4157e77c-349d-450e-a56b-074ba1d6d699_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_18288ef2-f81b-4fe8-8724-e1547e3ff1e2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_cbdfb30e-4271-403f-8eea-6f866b184d61_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Compensation Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_9a5b243e-a4b8-427b-bfd2-b3b432da386a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_174d557f-5e8f-43fe-8a83-e4598681262d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_d7a90127-e67b-4095-ab7a-6d7b5c79cfb6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_28efaa9a-0cc6-423b-8ad9-e5964a681573_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5dbd7f04-1acd-4216-9da7-ea63ad92fdf5_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4a9e8bb4-d1ab-47d1-b151-6cb824a21bad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_309755a3-b8d7-48f2-a12e-5d8a082ec689_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_511b413b-2649-4b53-a169-398cb54f063f_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8c3f3118-1b77-4fd6-b004-4baca631fb91_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued from exercise of stock options, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_081fffcf-0632-4bbb-8b61-dbb1e645d53a_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6351fe65-b751-4f23-b20c-8862c2d85e08_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_1d224c7d-d8a1-4b55-9f44-df1240a5979d_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior secured term loan</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_42ddaf4c-5895-4d3e-a9ac-b952fe15009f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4e30b586-451b-443e-993b-e45ddeaa9565_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_0c67b896-24ed-4eaa-96d3-9ac918353cca_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_6bbdfbc7-f38e-4435-bfce-6780a83ba4f3_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f58cc2ad-9127-48cf-a414-0ed3acc94ace_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_b04587c6-e9f7-41ff-8a2d-77b433f0b46a_negatedTerseLabel_en-US" xlink:label="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of vested restricted stock units</link:label>
    <link:label id="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_label_en-US" xlink:label="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Repurchase Of Restricted Stock Units</link:label>
    <link:label id="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits_documentation_en-US" xlink:label="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash outflow to reacquire restricted stock units during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:href="fold-20200331.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:to="lab_fold_PaymentsForRepurchaseOfRestrictedStockUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_8ca74925-637f-45c3-935f-72e4e4be01d7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays_d5d4432c-aef4-4fb9-b19d-feb90fffa5be_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold trading days</link:label>
    <link:label id="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays_label_en-US" xlink:label="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instruments, Convertible, Threshold Trading Days</link:label>
    <link:label id="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays_documentation_en-US" xlink:label="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:href="fold-20200331.xsd#fold_DebtInstrumentsConvertibleThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:to="lab_fold_DebtInstrumentsConvertibleThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_20b4fc68-5dea-4ef4-8348-89ef1298a97d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_fbcaf188-6b6c-4409-b71c-a6272148946e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, and restricted cash at the end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b21228ad-00da-414e-a16f-bcbd01950321_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2023Member_905323c8-e737-44ad-a794-29b634f4d099_terseLabel_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan due 2023</link:label>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2023Member_label_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan due 2023 [Member]</link:label>
    <link:label id="lab_fold_SeniorSecuredTermLoanDue2023Member_documentation_en-US" xlink:label="lab_fold_SeniorSecuredTermLoanDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Secured Term Loan due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2023Member" xlink:href="fold-20200331.xsd#fold_SeniorSecuredTermLoanDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_SeniorSecuredTermLoanDue2023Member" xlink:to="lab_fold_SeniorSecuredTermLoanDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f04efc6d-8c5a-4944-9b44-4ce3f30472b4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_763b42d4-c5f6-4aff-b204-a075770dbb44_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f2795f07-7677-4ef1-92a4-14ef4a797479_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_39f7faee-d8a6-4b4f-913e-55f50abec0f1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_3193aac7-3078-46b4-9e00-e2ae4cc28dca_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_e901dc48-46a6-42e9-9b55-b5a7c937f40d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_beaccdf4-93c0-4e04-a439-01b580a6e57f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b9520166-b59d-49dd-a4d6-f88db239f13f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_5f76f9b3-94af-4e31-b042-38d869109152_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_10525548-bcd3-400f-855b-434effb0d2a0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6b5f5fc9-3a44-4bcd-8d6a-0d8b3ae5bbef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_1f577918-afe4-4457-b234-5da5c6cfd8b2_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_685dbe99-f121-4fcd-9515-dfb6367def11_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt discount and deferred financing</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2cfb38e3-14fb-49d5-8724-f6638f092bd8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, options vested and unvested expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_069670f6-1d93-434c-9449-019de27b4f31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Non-Vested RSU Activity under the Plan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_25a516a3-d238-4408-be0d-ee66782602cb_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_6e496e01-7cbd-430b-b897-6a77f7c96cd7_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e9001bdc-d2fb-4dce-b678-bfeda9da65ab_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_78d92984-38dd-4f12-8f25-8e8bbb8a190f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_262a1ea1-6301-4eea-9373-758802459c1b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_60d6e669-d037-4133-943d-a61b20722080_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_824038f0-e9ce-4d29-89e3-e6b279375280_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gain (loss) on debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_92066a37-e25f-4a6b-8cd0-6e7553393d21_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_8701c1b9-671b-467d-b2ea-81f7f6d24e5a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_c64f60fa-f5d7-4315-bb7f-30837732740c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_271bb1af-35f3-456f-868c-d06655103b4a_totalLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, Cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities Fair Value Disclosure</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8948bda3-839f-42c1-a11e-e6a534c2a183_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e6b23174-51e6-4d7a-9a9c-b9f8f1bcfe29_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8ba985f3-57a9-48c8-93a0-f578e100518f_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_834529a6-820a-422e-a1d5-97ab32a9c881_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_cf4caf6e-1167-4da3-9952-e298d32bc224_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f456bee2-bae9-49c0-83cd-fb3a8ec6d37e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_d2c80561-6eaa-45a6-9214-093980f7eeac_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d43e53d7-fe98-4fee-9ad2-6afe642be55a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity component of the convertible notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d0046bc1-1dc4-4b87-ad2d-8cca1430881b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2e5f4abc-427a-45cb-9c6b-6202763d1d04_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative expense</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_2c0cd647-5736-42e8-9907-30335236dc0f_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_4f515251-e51a-4b85-99b5-3ece31c7c393_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_f2ecfa52-c384-4125-9451-1e88ddb04154_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_d05430e0-d9b3-439b-a652-8d45f645210d_terseLabel_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, Gross Unrealized Gain</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_label_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:label id="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_documentation_en-US" xlink:label="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="fold-20200331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="lab_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7f5adf14-fecc-48a9-891d-6bf1a60ae9dd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation of property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e1369717-b0b0-4ab2-94eb-24b59dc15138_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_56f68b6a-6e32-4799-8b2d-cd7e3e45d776_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_72483741-f4d0-4668-b4fa-d5bedc7fd066_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_33034379-2333-4d26-a850-d8b26475ee6e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt Instruments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4e4b2c71-00cb-476e-bd38-7b3237d10e7a_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_20005776-a2f8-4ff6-b898-a5087d7a8816_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_159d7986-7656-42c4-871d-c8bcd16d12e2_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_72bddcbb-2f2d-409f-98ac-8c4b3c7a0e67_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8d929038-0f71-47a0-a159-6cfefbcbeccd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f7a36e95-e8f5-4683-a6ac-480e579045e4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_d53f1636-5690-454f-a4f3-132dc347b654_terseLabel_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt, fair value of common shares issued</link:label>
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_label_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued</link:label>
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_documentation_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:href="fold-20200331.xsd#fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:to="lab_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_f2b69678-2376-468a-a0ba-9a7db33da367_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_b4c3c902-f48b-4398-a2fe-dd9356166310_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_166b6d31-d9aa-41f4-b591-45599e893881_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_7d81207a-216a-4376-9f8f-664ef3e89a81_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_608d33ef-9c39-4ff8-a27c-067eb2d77f60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_80368297-f5ca-4ac1-8e48-6524f6eb9006_terseLabel_en-US" xlink:label="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of capped call confirmations</link:label>
    <link:label id="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_label_en-US" xlink:label="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital Premiums Paid From Termination Of Capped Call Confirmations</link:label>
    <link:label id="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_documentation_en-US" xlink:label="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of decrease in additional paid in capital (APIC) resulting from Termination of Capped Call Confirmations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:href="fold-20200331.xsd#fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:to="lab_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1d87d5d3-4eb2-4be7-ac07-bcbe35ae977d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options, Vested and unvested expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_124edaf9-6458-48ee-b93d-05bdc9dba8ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities subject to fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c2cd08e0-adae-4cec-81b8-6137ccf968f6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4a7cc394-08e1-401b-b921-7d6cd5e1b99c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_3ec2c852-e434-494c-ba78-b52ab5fd173d_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d8a51c12-8999-43fe-9323-da1fc70f91a8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 500,000,000 shares authorized, 257,449,955 and 255,417,869 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_a798a649-fd3e-43eb-8f26-be2df56db2ad_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_46e453b4-be5e-4539-b986-0722e7d9b152_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan liability</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_144fe110-9ea0-4b36-a8c4-b2b55a4b2354_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_6a6ad328-c850-4b66-9246-df3254b93640_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-vested units, weighted average remaining years</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_2fbb55bf-9ca4-42bf-8bbe-c9278e09ec15_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_e17a65b9-4dca-447a-b4cd-fc2697e6e95c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_1afb1695-d71a-4817-be83-48c8bb86c54f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Marketable Securities and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5f1aa903-9221-4f31-9462-72aaa7d2ff76_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_fc4be92c-6584-469d-80d7-179f33482779_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_8b2ef180-76cc-4199-b9cb-ab88e66bd939_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_7526b9f5-4a10-4327-b968-f90ddb81e35a_terseLabel_en-US" xlink:label="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan Amended Restated 2007 Equity Incentive Plan</link:label>
    <link:label id="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_label_en-US" xlink:label="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Plan Amended Restated2007 Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pertaining to the Company's Amended and Restated 2007 Equity Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:href="fold-20200331.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:to="lab_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_effd0e8b-4355-45e4-a93e-5b30106a03de_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_2392f9cb-a344-4935-80b0-d10e2d8780fb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_04e5e859-0baa-4f8c-a3a1-83c4cc8cbe99_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets, less accumulated amortization of $6,260 and $5,342 at March 31, 2020 and December 31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_12cd8370-3335-406d-928d-fcf87539d6e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_fc218924-6560-447b-8090-73e3c89ff765_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures unpaid at the end of period</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4c9d9157-b6bb-4c8b-aa80-c5be51648756_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2335916f-f2ab-4788-8990-5b74f448fbb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_8f9a1277-6800-48c1-80c3-8f7181cf6b0c_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_1a615247-475a-4e22-b6c7-2efa0c0b4417_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_0830f42b-2c78-4715-95d8-35eda9f5ad54_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_31e42930-72db-4171-9084-62ac17009fe7_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_c9f2be51-4932-4ea4-ae2a-11c3e5a40738_terseLabel_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual dividend per share (in dollars per share)</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_label_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share</link:label>
    <link:label id="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_documentation_en-US" xlink:label="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:href="fold-20200331.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:to="lab_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_79db47a5-bcff-4731-bc0a-f3e01af61be3_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of liability components of long term debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2782d19d-b52e-4564-a311-745dbdc8072b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e5fcc357-ae51-44de-ac62-dfb2b45924ea_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_fa63c662-0d74-4300-8d88-06627758ded5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorLoansMember_23d9cc2e-f692-453c-b75b-4cd3fd44c0ad_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorLoansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Loans</link:label>
    <link:label id="lab_us-gaap_SeniorLoansMember_label_en-US" xlink:label="lab_us-gaap_SeniorLoansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Loans [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorLoansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorLoansMember" xlink:to="lab_us-gaap_SeniorLoansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_d4d59783-570c-4196-80f8-69c1d2ca45a2_terseLabel_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Callidus Biopharma Inc</link:label>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_label_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Callidus Biopharma Inc [Member]</link:label>
    <link:label id="lab_fold_CallidusBiopharmaIncMember_documentation_en-US" xlink:label="lab_fold_CallidusBiopharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Callidus Biopharma, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember" xlink:href="fold-20200331.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CallidusBiopharmaIncMember" xlink:to="lab_fold_CallidusBiopharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_0b77809f-ebad-4bbd-9653-609420dab0f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash, cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_217128c4-70f6-4929-ae26-77e41a245609_terseLabel_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on extinguishment of debt, additional paid-in capital</link:label>
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_label_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Extinguishment Of Debt, Additional Paid-In Capital</link:label>
    <link:label id="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_documentation_en-US" xlink:label="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Extinguishment Of Debt, Additional Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" xlink:href="fold-20200331.xsd#fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" xlink:to="lab_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ebc01e70-f9b2-4ea1-85b7-f802ee5d3ef7_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_72417c6e-239e-40fb-b775-a5f79285b65d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_df7aeb88-0390-4cbf-8b58-7ac844663b1e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_c0b1b352-0e39-4712-8ab5-b922a5fcd4ad_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_91df28d2-5a91-414a-8b9d-18d518deb2eb_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_717512ac-417b-4637-a267-5a0be6be0d42_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value during the period, included in the Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_eac39a4e-a053-45b5-8f8d-3fd656c46280_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_64a12f4d-cc7d-44fd-8259-3455b2dd28ea_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4cfd4b45-8d0c-4682-a3b4-f4886398b8cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities subject to fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_7f762aca-0b6a-4bee-a0a1-2a4d5d0165b8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life, options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_f6ef48a1-1b6f-4255-89c0-eb3955b3b963_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_52fd086a-dab5-49a9-bfb6-a19018d2c94f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf50f682-531d-4a03-8f4b-ca2661efc83c_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_d2d0d404-a3b1-4615-acca-2a35a5241fd9_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_5acdf4ce-6f9d-4ba5-a449-8b3b232824e1_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_935777f6-aa50-4667-a095-2ed8a9416bca_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_ac814130-b4c6-4391-aad2-564560d00d48_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ex-U.S.</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_a54016f3-4fd6-4fb6-9202-f0826dbd19ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_882064d6-05f0-46e5-a158-d036238ce328_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_207f198e-7296-44ed-9b3e-172ffcda2db2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_fe2a338a-36eb-4d29-aa8d-1891840ebe2f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_9fa684fd-9d87-4925-8877-1405c99492cd_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_d7c582fe-5120-408c-9409-757bc3d74052_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Cash balances</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_de2fecc7-6e97-4c60-9ec2-2ce6fbc3ecbd_totalLabel_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Cash balances and available-for-sale securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_label_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents And Available-for-sale Debt Securities</link:label>
    <link:label id="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_documentation_en-US" xlink:label="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:to="lab_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_c94f31ea-46c6-4d7d-9832-6debeb4e3f38_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_aa4240ce-49c6-4e6c-8485-462b26398e8a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_4fb1d423-43b7-4346-a3c7-de5a4ce7290b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_5aee9203-1cec-4856-abf1-4a4b3a37a505_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_c378dc51-a604-4803-8689-e594ededc1da_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_44fe4055-69a7-414a-bb76-9ab9cdf66c81_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred reimbursements</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b04e2229-8446-4b96-ac97-57ab6caf52d6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_db93a7d2-b2f1-4268-b666-7188aa25e095_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ddcd5375-32ce-4018-950d-11809e5354e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of&#160;Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_274196e6-2c70-4e48-b5e1-832c5f78382a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e6ad8a1d-79dc-4980-936a-a3580acea943_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ce429338-d6f8-4be8-a104-9cdf96835410_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_16cf686a-1ff2-446c-b1b6-1ef3b39a3c94_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_dc077fb7-6e3d-4636-83d5-2ab25556e3a0_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_e690c41b-0fac-4fa8-ab52-085c4b85e455_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_aa2d986e-6f14-44eb-a0fd-1b2246a1494e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_bf1338b6-7266-44b8-b2b2-e641c5bb1b4c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_44ca16da-efda-4d49-851f-d68f83a4c4ed_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for inventory</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_d4415058-d2b7-4266-a1ce-68b4051528b0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_23da3d48-b0b9-49bb-9971-39048adffc2f_negatedLabel_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency remeasurement loss</link:label>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_label_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement Gain (Loss), Before Tax</link:label>
    <link:label id="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_documentation_en-US" xlink:label="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Remeasurement Gain (Loss), Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:href="fold-20200331.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:to="lab_fold_ForeignCurrencyRemeasurementGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_bb47c076-dbf0-441f-9acd-738526f3152b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_269660f3-9811-4a0f-bcc5-345b88595a0b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_faaffca2-da2a-4ee3-b3b0-38703c4f89ec_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3df34421-60bb-4cf2-851f-b3e53ac9d9fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_301061ea-32a5-4554-b94c-bf58893cfced_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f99619f7-29b9-42a4-856e-a561d05559c2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_e6432da8-5aca-4765-a891-1bb1776102b1_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agency bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_817841fb-e8c9-4326-9e62-3e85684fe7d8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c65f98e2-a56f-47b0-b63b-7d7bced6a394_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_307d0f2a-a982-4c15-bbaa-eb4805267b17_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_34b61c30-3569-47e6-80c0-eddbe3e620b5_terseLabel_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_label_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance</link:label>
    <link:label id="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_documentation_en-US" xlink:label="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:href="fold-20200331.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:to="lab_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_16a731f3-4f75-4aad-8f0a-b10e3fae015b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in contingent consideration payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_26a9d82c-9b2a-4f31-968c-5ab61c178a89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value, vested and unvested expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>fold-20200331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:d7d83936-4003-4695-9e73-95a98e869b39,g:49308d12-68e9-469e-b9d5-8a5a2cc3db36-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="simple" xlink:href="fold-20200331.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_393815cd-cab0-47b5-ba24-0baa685cebd9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_DocumentType_393815cd-cab0-47b5-ba24-0baa685cebd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_fbfa171f-b3ee-4478-888a-8ab1db4dc24f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_DocumentQuarterlyReport_fbfa171f-b3ee-4478-888a-8ab1db4dc24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_0febdd19-8d0e-409d-804f-10fd54b84407" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_DocumentPeriodEndDate_0febdd19-8d0e-409d-804f-10fd54b84407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_ae463d6c-135d-44fb-a2f0-8f23dfd871f3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_DocumentTransitionReport_ae463d6c-135d-44fb-a2f0-8f23dfd871f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_4c4bf407-78e8-4948-9cb1-cb7f3f01415a" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityFileNumber_4c4bf407-78e8-4948-9cb1-cb7f3f01415a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_035ae5af-52aa-4c92-8b1f-5b5f022d3b0f" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityRegistrantName_035ae5af-52aa-4c92-8b1f-5b5f022d3b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a42380cc-e0f0-4d75-8af0-63fba92b98f3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a42380cc-e0f0-4d75-8af0-63fba92b98f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_fc8d4dc8-7539-4b96-856b-477148894622" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityTaxIdentificationNumber_fc8d4dc8-7539-4b96-856b-477148894622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_6904950b-2d46-4f1d-a3db-9cf1cbcd7047" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityAddressAddressLine1_6904950b-2d46-4f1d-a3db-9cf1cbcd7047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_8f38ad5b-cee5-481b-84ac-44d82bf578bb" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityAddressCityOrTown_8f38ad5b-cee5-481b-84ac-44d82bf578bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3f7848a6-b14c-4d2b-8024-1e093cd7e0d4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityAddressStateOrProvince_3f7848a6-b14c-4d2b-8024-1e093cd7e0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_28ac2707-1d38-4437-a214-da1c848e1853" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityAddressPostalZipCode_28ac2707-1d38-4437-a214-da1c848e1853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_e375f7bb-f702-4bd7-9b0e-ddcf628ddeda" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_CityAreaCode_e375f7bb-f702-4bd7-9b0e-ddcf628ddeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1f857e60-0be7-49bb-acd8-e468388d15a1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_LocalPhoneNumber_1f857e60-0be7-49bb-acd8-e468388d15a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_61beb116-73d9-40db-a5b8-0577939c9817" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_Security12bTitle_61beb116-73d9-40db-a5b8-0577939c9817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4f301387-c39b-4e75-8d89-e0f0fa080ea8" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_TradingSymbol_4f301387-c39b-4e75-8d89-e0f0fa080ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_56b98219-1b6e-4839-a5dc-ce3a4d30bca2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_SecurityExchangeName_56b98219-1b6e-4839-a5dc-ce3a4d30bca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7a943916-5c56-44c8-a3bd-ffa56a4246df" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityCurrentReportingStatus_7a943916-5c56-44c8-a3bd-ffa56a4246df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a98b9073-7472-4bef-978b-d787a959fe1e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityInteractiveDataCurrent_a98b9073-7472-4bef-978b-d787a959fe1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_d8a53f2a-f2cb-42f6-a0da-79b82a246135" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityFilerCategory_d8a53f2a-f2cb-42f6-a0da-79b82a246135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_3d623522-7e05-44e3-a3dc-a2664dc4d5c2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntitySmallBusiness_3d623522-7e05-44e3-a3dc-a2664dc4d5c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_821154df-9bad-4f2d-a7c0-774856d6f4f2" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityEmergingGrowthCompany_821154df-9bad-4f2d-a7c0-774856d6f4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_9e45d4d7-60f8-4323-aff1-c434c613f302" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityShellCompany_9e45d4d7-60f8-4323-aff1-c434c613f302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0377c9b5-9b37-4190-a33d-db0078cfda58" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0377c9b5-9b37-4190-a33d-db0078cfda58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_30ef1a76-b877-46c0-b269-9eb708a061b3" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_EntityCentralIndexKey_30ef1a76-b877-46c0-b269-9eb708a061b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_95549d3c-79d1-4ad4-aac2-df3f856a6432" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_CurrentFiscalYearEndDate_95549d3c-79d1-4ad4-aac2-df3f856a6432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_66954c0a-5635-4825-aa2e-1462e1658aca" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_DocumentFiscalYearFocus_66954c0a-5635-4825-aa2e-1462e1658aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e39301a6-7d98-4662-9d3b-04bcacda72a9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e39301a6-7d98-4662-9d3b-04bcacda72a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_1417801d-2be3-45b4-a99f-60acb56618af" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ac4d80e3-b6d1-452a-a87e-6df2258ca002" xlink:to="loc_dei_AmendmentFlag_1417801d-2be3-45b4-a99f-60acb56618af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3efd054d-e0a1-4a99-9ac3-1d8a9d9d707f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_afe7e916-840c-4b72-b1b7-8699366c6777" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3efd054d-e0a1-4a99-9ac3-1d8a9d9d707f" xlink:to="loc_us-gaap_AssetsAbstract_afe7e916-840c-4b72-b1b7-8699366c6777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_3360d573-2b78-44f0-b74f-56ff5f0856d2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe7e916-840c-4b72-b1b7-8699366c6777" xlink:to="loc_us-gaap_AssetsCurrentAbstract_3360d573-2b78-44f0-b74f-56ff5f0856d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_270eb061-4f31-43c1-af42-57429ffff8df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3360d573-2b78-44f0-b74f-56ff5f0856d2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_270eb061-4f31-43c1-af42-57429ffff8df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2f60a52f-24a0-4677-9ac5-217b6de3675a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3360d573-2b78-44f0-b74f-56ff5f0856d2" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2f60a52f-24a0-4677-9ac5-217b6de3675a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_94a03208-b58e-4615-b2ad-5f38292af15c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3360d573-2b78-44f0-b74f-56ff5f0856d2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_94a03208-b58e-4615-b2ad-5f38292af15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b59a61a2-4e70-4e3f-b597-4bc764fbdab2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3360d573-2b78-44f0-b74f-56ff5f0856d2" xlink:to="loc_us-gaap_InventoryNet_b59a61a2-4e70-4e3f-b597-4bc764fbdab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_38863655-18be-419d-947b-b12132e860f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3360d573-2b78-44f0-b74f-56ff5f0856d2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_38863655-18be-419d-947b-b12132e860f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4e01f9fb-1d5b-425a-bed7-dd8ca786e450" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_3360d573-2b78-44f0-b74f-56ff5f0856d2" xlink:to="loc_us-gaap_AssetsCurrent_4e01f9fb-1d5b-425a-bed7-dd8ca786e450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_95cd62e6-9407-45ed-8423-d7a2ce25c3c4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe7e916-840c-4b72-b1b7-8699366c6777" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_95cd62e6-9407-45ed-8423-d7a2ce25c3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_02e639ab-eb56-49f1-ac01-dfe21680cf5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe7e916-840c-4b72-b1b7-8699366c6777" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_02e639ab-eb56-49f1-ac01-dfe21680cf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1953ff87-0a52-4a76-9658-d302114ff566" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe7e916-840c-4b72-b1b7-8699366c6777" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_1953ff87-0a52-4a76-9658-d302114ff566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_fedb3112-e178-4556-8a50-7bfcd23d2087" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe7e916-840c-4b72-b1b7-8699366c6777" xlink:to="loc_us-gaap_Goodwill_fedb3112-e178-4556-8a50-7bfcd23d2087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_e9275e6b-7f62-4c85-8a84-d445e1bfe7e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe7e916-840c-4b72-b1b7-8699366c6777" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_e9275e6b-7f62-4c85-8a84-d445e1bfe7e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_716780a2-c227-4555-af46-64ae0237c97c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_afe7e916-840c-4b72-b1b7-8699366c6777" xlink:to="loc_us-gaap_Assets_716780a2-c227-4555-af46-64ae0237c97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3efd054d-e0a1-4a99-9ac3-1d8a9d9d707f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_99f0c9ad-d2e7-4adf-8fea-562f4f2aa9bb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_99f0c9ad-d2e7-4adf-8fea-562f4f2aa9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d40e470e-fadd-482b-b335-12254b092c85" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_99f0c9ad-d2e7-4adf-8fea-562f4f2aa9bb" xlink:to="loc_us-gaap_AccountsPayableCurrent_d40e470e-fadd-482b-b335-12254b092c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_66981ca3-2462-4bf9-b2c0-31717089c709" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_99f0c9ad-d2e7-4adf-8fea-562f4f2aa9bb" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_66981ca3-2462-4bf9-b2c0-31717089c709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_853fd6bf-daf3-4dbf-a182-a8c6fec912f1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_99f0c9ad-d2e7-4adf-8fea-562f4f2aa9bb" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent_853fd6bf-daf3-4dbf-a182-a8c6fec912f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_96172d9d-4b94-425b-92c7-e1911ea96a92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_99f0c9ad-d2e7-4adf-8fea-562f4f2aa9bb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_96172d9d-4b94-425b-92c7-e1911ea96a92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f58af193-774e-414c-8db1-b1412d9a3b92" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_99f0c9ad-d2e7-4adf-8fea-562f4f2aa9bb" xlink:to="loc_us-gaap_LiabilitiesCurrent_f58af193-774e-414c-8db1-b1412d9a3b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_39041ed3-ec7c-41f4-b387-ff39b4387dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent_39041ed3-ec7c-41f4-b387-ff39b4387dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleLongTermNotesPayable_cb25699e-4d7e-47e5-a680-d8a430eda94e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:to="loc_us-gaap_ConvertibleLongTermNotesPayable_cb25699e-4d7e-47e5-a680-d8a430eda94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_57103b2d-8824-4534-8b75-4c17dd9ea375" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:to="loc_us-gaap_SecuredLongTermDebt_57103b2d-8824-4534-8b75-4c17dd9ea375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7d3e8b7b-5daf-40e3-a723-05667d1c42fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7d3e8b7b-5daf-40e3-a723-05667d1c42fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_38676087-54a3-482a-82a1-4cb3e75f1c10" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_38676087-54a3-482a-82a1-4cb3e75f1c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1ff3d447-09fb-43db-871f-39cc38866380" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1ff3d447-09fb-43db-871f-39cc38866380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_87e74a41-97a9-4067-b9c3-c69eda834170" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_87e74a41-97a9-4067-b9c3-c69eda834170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_180dc5fc-b6d1-4b16-bdfd-2669f866993c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:to="loc_us-gaap_Liabilities_180dc5fc-b6d1-4b16-bdfd-2669f866993c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e8aae9ea-2941-4549-b626-e45a04901bed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e8aae9ea-2941-4549-b626-e45a04901bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0cbaef35-b5ac-4dc0-936c-16e781638b07" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0cbaef35-b5ac-4dc0-936c-16e781638b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a531b88c-4278-4dd7-89de-1ff0c1cb2dde" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0cbaef35-b5ac-4dc0-936c-16e781638b07" xlink:to="loc_us-gaap_CommonStockValue_a531b88c-4278-4dd7-89de-1ff0c1cb2dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b912c5f1-4916-4139-aa4e-f3c2c983f18c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0cbaef35-b5ac-4dc0-936c-16e781638b07" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b912c5f1-4916-4139-aa4e-f3c2c983f18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_ed65bf7f-179b-4188-b02e-34ef1dfd2671" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0cbaef35-b5ac-4dc0-936c-16e781638b07" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_ed65bf7f-179b-4188-b02e-34ef1dfd2671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_f2aef636-e46f-4f9c-9210-20a1dfab91e6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_ed65bf7f-179b-4188-b02e-34ef1dfd2671" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_f2aef636-e46f-4f9c-9210-20a1dfab91e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d85fde82-69f1-4360-a117-35e23ff9ed43" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract_ed65bf7f-179b-4188-b02e-34ef1dfd2671" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d85fde82-69f1-4360-a117-35e23ff9ed43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_4da34c56-a9a8-4509-b6b6-ba81681154c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0cbaef35-b5ac-4dc0-936c-16e781638b07" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_4da34c56-a9a8-4509-b6b6-ba81681154c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d75c2689-b1e1-4b05-94ab-b5833c603ce4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0cbaef35-b5ac-4dc0-936c-16e781638b07" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d75c2689-b1e1-4b05-94ab-b5833c603ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c92cfe91-dc15-41cc-90ac-31b102d5b260" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0cbaef35-b5ac-4dc0-936c-16e781638b07" xlink:to="loc_us-gaap_StockholdersEquity_c92cfe91-dc15-41cc-90ac-31b102d5b260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2d07e46b-4219-4a21-98b9-7ce075ac7bcb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_26c75a5c-8f29-416e-a930-8ffd6645cacf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2d07e46b-4219-4a21-98b9-7ce075ac7bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d9f8380d-40db-4086-b61a-68689c7d27a1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases_65ebfde6-f907-4ec1-b010-e1a2c296ef68" xlink:href="fold-20200331.xsd#fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9f8380d-40db-4086-b61a-68689c7d27a1" xlink:to="loc_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases_65ebfde6-f907-4ec1-b010-e1a2c296ef68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d5e7f428-b349-4fc6-815c-0c0df5bf7ffd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9f8380d-40db-4086-b61a-68689c7d27a1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d5e7f428-b349-4fc6-815c-0c0df5bf7ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_93576987-28ee-4c0b-a81d-90900077b1a4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9f8380d-40db-4086-b61a-68689c7d27a1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_93576987-28ee-4c0b-a81d-90900077b1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1e714450-afda-4e57-9149-3c440083064c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9f8380d-40db-4086-b61a-68689c7d27a1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1e714450-afda-4e57-9149-3c440083064c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_54a8a350-3909-4cbf-8412-27f0354ac28f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9f8380d-40db-4086-b61a-68689c7d27a1" xlink:to="loc_us-gaap_CommonStockSharesIssued_54a8a350-3909-4cbf-8412-27f0354ac28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c5b38ff1-f2ba-44a0-9303-d93158022aa8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d9f8380d-40db-4086-b61a-68689c7d27a1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c5b38ff1-f2ba-44a0-9303-d93158022aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_45881092-750b-4b02-9952-818728c05e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_409909c3-413c-4179-8ac4-8dcc4c833b03" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45881092-750b-4b02-9952-818728c05e4e" xlink:to="loc_us-gaap_RevenuesAbstract_409909c3-413c-4179-8ac4-8dcc4c833b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_64620208-ca27-40fd-8509-f9af0786c3b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_409909c3-413c-4179-8ac4-8dcc4c833b03" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_64620208-ca27-40fd-8509-f9af0786c3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_52f43082-14db-4a2b-96dd-f1c915fb9f1c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_409909c3-413c-4179-8ac4-8dcc4c833b03" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_52f43082-14db-4a2b-96dd-f1c915fb9f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_6436c560-d4fe-47b6-b4b9-b71144aee106" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_409909c3-413c-4179-8ac4-8dcc4c833b03" xlink:to="loc_us-gaap_GrossProfit_6436c560-d4fe-47b6-b4b9-b71144aee106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8e87f308-41ac-4659-aa76-2ceaf7f43af9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45881092-750b-4b02-9952-818728c05e4e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8e87f308-41ac-4659-aa76-2ceaf7f43af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e08b8c1e-f61d-4d02-9ca4-b106e7f5ebc6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8e87f308-41ac-4659-aa76-2ceaf7f43af9" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_e08b8c1e-f61d-4d02-9ca4-b106e7f5ebc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f66de1da-3013-460d-aa62-da799a203183" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8e87f308-41ac-4659-aa76-2ceaf7f43af9" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f66de1da-3013-460d-aa62-da799a203183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_473d2dcd-26aa-4632-a36b-2f838c3625a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8e87f308-41ac-4659-aa76-2ceaf7f43af9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_473d2dcd-26aa-4632-a36b-2f838c3625a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_9da52bf3-54cd-49f5-a134-c179ec63235a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8e87f308-41ac-4659-aa76-2ceaf7f43af9" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_9da52bf3-54cd-49f5-a134-c179ec63235a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_bbcca838-391c-482f-94a7-92602a74479c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8e87f308-41ac-4659-aa76-2ceaf7f43af9" xlink:to="loc_us-gaap_OperatingExpenses_bbcca838-391c-482f-94a7-92602a74479c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d6b0592f-6454-43aa-ac70-ad7e14caa0a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45881092-750b-4b02-9952-818728c05e4e" xlink:to="loc_us-gaap_OperatingIncomeLoss_d6b0592f-6454-43aa-ac70-ad7e14caa0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dcec1cee-44d1-4127-b6fb-0cb8bd5c984c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45881092-750b-4b02-9952-818728c05e4e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dcec1cee-44d1-4127-b6fb-0cb8bd5c984c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_cb548a22-52b5-432e-abf2-b80d8cca6275" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dcec1cee-44d1-4127-b6fb-0cb8bd5c984c" xlink:to="loc_us-gaap_InvestmentIncomeInterest_cb548a22-52b5-432e-abf2-b80d8cca6275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8902efdc-35b6-4612-895f-4f636a73f372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dcec1cee-44d1-4127-b6fb-0cb8bd5c984c" xlink:to="loc_us-gaap_InterestExpense_8902efdc-35b6-4612-895f-4f636a73f372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2299936d-4865-45b5-9894-d3c948d09409" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dcec1cee-44d1-4127-b6fb-0cb8bd5c984c" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2299936d-4865-45b5-9894-d3c948d09409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8c0b716e-8649-4907-84e8-948d00c3d16a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_dcec1cee-44d1-4127-b6fb-0cb8bd5c984c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8c0b716e-8649-4907-84e8-948d00c3d16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c4df0827-a3bf-43da-8f4b-53f1f666057e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45881092-750b-4b02-9952-818728c05e4e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c4df0827-a3bf-43da-8f4b-53f1f666057e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_14cc1171-8297-4a31-96bb-6892451c325d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45881092-750b-4b02-9952-818728c05e4e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_14cc1171-8297-4a31-96bb-6892451c325d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74e5b970-57d0-4393-a140-8b62930500dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45881092-750b-4b02-9952-818728c05e4e" xlink:to="loc_us-gaap_NetIncomeLoss_74e5b970-57d0-4393-a140-8b62930500dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_82332e86-01ed-459f-bbe5-4e31d4bad509" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45881092-750b-4b02-9952-818728c05e4e" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_82332e86-01ed-459f-bbe5-4e31d4bad509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3ed6aee1-7580-4228-91de-8c1a2946232e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_45881092-750b-4b02-9952-818728c05e4e" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3ed6aee1-7580-4228-91de-8c1a2946232e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_313372bd-56a5-44a1-ad76-94f6e644e416" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_46691bab-26a8-4e56-8a47-b98b39606e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_313372bd-56a5-44a1-ad76-94f6e644e416" xlink:to="loc_us-gaap_NetIncomeLoss_46691bab-26a8-4e56-8a47-b98b39606e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a53f2e7a-1860-4f29-b765-fd775dc98566" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_313372bd-56a5-44a1-ad76-94f6e644e416" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a53f2e7a-1860-4f29-b765-fd775dc98566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2b4507ae-535e-467c-bc43-82fce2c21b7f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a53f2e7a-1860-4f29-b765-fd775dc98566" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_2b4507ae-535e-467c-bc43-82fce2c21b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4eca2f21-e5f7-4f3d-9da5-0b827101a76b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a53f2e7a-1860-4f29-b765-fd775dc98566" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_4eca2f21-e5f7-4f3d-9da5-0b827101a76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0f9f6076-fd1f-4fe2-b113-aac75ef3227e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a53f2e7a-1860-4f29-b765-fd775dc98566" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0f9f6076-fd1f-4fe2-b113-aac75ef3227e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_332a893e-dc99-4ee4-9e99-e01b878115b7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_313372bd-56a5-44a1-ad76-94f6e644e416" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_332a893e-dc99-4ee4-9e99-e01b878115b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofComprehensiveLossParenthetical"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6be5cf30-0c78-4410-8226-ac4af1d2cc5c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_90d4407f-c27d-4239-9aa1-52a15465707f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6be5cf30-0c78-4410-8226-ac4af1d2cc5c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_90d4407f-c27d-4239-9aa1-52a15465707f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_6c470dfe-4708-4db1-a307-ce3bbd04faba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6be5cf30-0c78-4410-8226-ac4af1d2cc5c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_6c470dfe-4708-4db1-a307-ce3bbd04faba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_413680e3-548f-4e1f-8a9d-78b6038fda64" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f6f01319-7544-4c61-9879-2b05e3a95952" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_413680e3-548f-4e1f-8a9d-78b6038fda64" xlink:to="loc_us-gaap_StatementTable_f6f01319-7544-4c61-9879-2b05e3a95952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a3825e92-ef76-47ad-8d8e-a2dc5ff59c49" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f6f01319-7544-4c61-9879-2b05e3a95952" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a3825e92-ef76-47ad-8d8e-a2dc5ff59c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3825e92-ef76-47ad-8d8e-a2dc5ff59c49" xlink:to="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c3f926b3-2295-4047-ada2-d326c7f62978" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:to="loc_us-gaap_CommonStockMember_c3f926b3-2295-4047-ada2-d326c7f62978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6f593f56-6fb2-44ed-bb17-a6588575e88d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6f593f56-6fb2-44ed-bb17-a6588575e88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4e84631c-eb92-4649-ab2b-81f724e93e93" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:to="loc_us-gaap_WarrantMember_4e84631c-eb92-4649-ab2b-81f724e93e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeMember_8af74266-6229-47a2-b7c3-d2fde1cb4839" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:to="loc_us-gaap_ComprehensiveIncomeMember_8af74266-6229-47a2-b7c3-d2fde1cb4839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8eaf0b2b-a176-4fe5-8aa2-c86cb9c312d7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b257e195-cdf9-4edf-ba0d-1ef88b0f0a58" xlink:to="loc_us-gaap_RetainedEarningsMember_8eaf0b2b-a176-4fe5-8aa2-c86cb9c312d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_06533ba1-353f-4dcb-93ba-8f64e274b877" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f6f01319-7544-4c61-9879-2b05e3a95952" xlink:to="loc_us-gaap_StatementLineItems_06533ba1-353f-4dcb-93ba-8f64e274b877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06533ba1-353f-4dcb-93ba-8f64e274b877" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_33a6f1d9-ce4b-4d06-9a65-0b812ff140eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_33a6f1d9-ce4b-4d06-9a65-0b812ff140eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b4fb4372-8c59-48eb-844e-a594a14a9e32" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_StockholdersEquity_b4fb4372-8c59-48eb-844e-a594a14a9e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_65d9f851-0057-45b2-ac90-2093d7088296" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_65d9f851-0057-45b2-ac90-2093d7088296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a20daf46-7477-4e54-bd32-c2319e8a1579" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a20daf46-7477-4e54-bd32-c2319e8a1579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6b564d6c-0e0c-4b30-ab96-b66d37d319c9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_6b564d6c-0e0c-4b30-ab96-b66d37d319c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_c3b6ff0e-c384-4366-a3a1-68aeb5a39785" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition_c3b6ff0e-c384-4366-a3a1-68aeb5a39785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_74435a69-b141-4835-bcea-0946d7fb07b4" xlink:href="fold-20200331.xsd#fold_StockIssuedDuringPeriodSharesContingentConsideration"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_fold_StockIssuedDuringPeriodSharesContingentConsideration_74435a69-b141-4835-bcea-0946d7fb07b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_ac0a63e0-1792-448c-bca6-4e490278808d" xlink:href="fold-20200331.xsd#fold_StockIssuedDuringPeriodValueContingentConsideration"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_fold_StockIssuedDuringPeriodValueContingentConsideration_ac0a63e0-1792-448c-bca6-4e490278808d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_346afa32-7652-4a30-b68f-dd5f0432dda6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_346afa32-7652-4a30-b68f-dd5f0432dda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_2368cb85-47dc-4ab6-b5bb-81941e698a2a" xlink:href="fold-20200331.xsd#fold_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_fold_StockIssuedDuringPeriodSharesWarrantsExercised_2368cb85-47dc-4ab6-b5bb-81941e698a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_f5384a78-eadf-45db-9504-c50c42f96534" xlink:href="fold-20200331.xsd#fold_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_fold_StockIssuedDuringPeriodValueWarrantsExercised_f5384a78-eadf-45db-9504-c50c42f96534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_48a4e0cf-1f14-43f5-9be2-6f246a87a131" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_48a4e0cf-1f14-43f5-9be2-6f246a87a131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_996bfaba-78cf-44be-8381-63e5196a9108" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_996bfaba-78cf-44be-8381-63e5196a9108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_2c6856c8-1d49-467b-b31c-e612683c8c0f" xlink:href="fold-20200331.xsd#fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations_2c6856c8-1d49-467b-b31c-e612683c8c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ada5867e-dc25-410f-90af-791ccc78769b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_ada5867e-dc25-410f-90af-791ccc78769b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e1219b6c-b03d-4383-8ba6-97c0691f7747" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e1219b6c-b03d-4383-8ba6-97c0691f7747" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_40bb89c7-a114-40ce-aabf-54cc82b4535d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_NetIncomeLoss_40bb89c7-a114-40ce-aabf-54cc82b4535d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_ad93a920-9457-40e6-b25f-3506eba96027" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_ad93a920-9457-40e6-b25f-3506eba96027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bf902f99-cf27-45e5-89cc-fe0e36034d73" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5183d349-1fed-4177-952e-2c3bea508336" xlink:to="loc_us-gaap_StockholdersEquity_bf902f99-cf27-45e5-89cc-fe0e36034d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="fold-20200331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_c7ea7a2d-2963-4583-9075-3f1b74c9f9f0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b95665b0-21e4-4092-bcd8-138ecb84dd41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ea7a2d-2963-4583-9075-3f1b74c9f9f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b95665b0-21e4-4092-bcd8-138ecb84dd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cf153a6f-cb04-4a38-a3cf-54a24e3fb27c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b95665b0-21e4-4092-bcd8-138ecb84dd41" xlink:to="loc_us-gaap_ProfitLoss_cf153a6f-cb04-4a38-a3cf-54a24e3fb27c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16e9fcd0-5661-4e71-8e9f-464bf670a1bd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b95665b0-21e4-4092-bcd8-138ecb84dd41" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16e9fcd0-5661-4e71-8e9f-464bf670a1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_144596d9-e940-4d91-8ea8-8d2d42b3c4fc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16e9fcd0-5661-4e71-8e9f-464bf670a1bd" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_144596d9-e940-4d91-8ea8-8d2d42b3c4fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e4ee20a9-93b8-453b-87b0-9dac6561c3f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16e9fcd0-5661-4e71-8e9f-464bf670a1bd" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e4ee20a9-93b8-453b-87b0-9dac6561c3f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_30b87325-190b-43ee-aad6-457b813b5512" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16e9fcd0-5661-4e71-8e9f-464bf670a1bd" xlink:to="loc_us-gaap_ShareBasedCompensation_30b87325-190b-43ee-aad6-457b813b5512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_14f7d86b-4ace-495f-bb84-7b23a9315c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16e9fcd0-5661-4e71-8e9f-464bf670a1bd" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_14f7d86b-4ace-495f-bb84-7b23a9315c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5de32b11-e23b-4aab-97dd-0de17cc285bc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16e9fcd0-5661-4e71-8e9f-464bf670a1bd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5de32b11-e23b-4aab-97dd-0de17cc285bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_65016d16-5cda-4dac-9aef-0e15aa71ccaf" xlink:href="fold-20200331.xsd#fold_ForeignCurrencyRemeasurementGainLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16e9fcd0-5661-4e71-8e9f-464bf670a1bd" xlink:to="loc_fold_ForeignCurrencyRemeasurementGainLossBeforeTax_65016d16-5cda-4dac-9aef-0e15aa71ccaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_39bcf752-e138-45a3-81ce-10f23b47b04c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_16e9fcd0-5661-4e71-8e9f-464bf670a1bd" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_39bcf752-e138-45a3-81ce-10f23b47b04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2f51e4ce-23d7-4e39-90bc-4ef40083957a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_39bcf752-e138-45a3-81ce-10f23b47b04c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2f51e4ce-23d7-4e39-90bc-4ef40083957a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6bf3b821-d869-45a3-aaf1-6419b4caa771" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_39bcf752-e138-45a3-81ce-10f23b47b04c" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6bf3b821-d869-45a3-aaf1-6419b4caa771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2a9837e3-4e5a-4ee6-872b-2f464d9fd7ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_39bcf752-e138-45a3-81ce-10f23b47b04c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2a9837e3-4e5a-4ee6-872b-2f464d9fd7ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_99dbcfb9-c83f-42fb-8b42-414b55a1611c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_39bcf752-e138-45a3-81ce-10f23b47b04c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_99dbcfb9-c83f-42fb-8b42-414b55a1611c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_d665b29a-4902-4b2a-aab6-9940fc8bce69" xlink:href="fold-20200331.xsd#fold_IncreaseDecreaseInNoncurrentOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_39bcf752-e138-45a3-81ce-10f23b47b04c" xlink:to="loc_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities_d665b29a-4902-4b2a-aab6-9940fc8bce69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_IncreaseDecreaseInDeferredReimbursements_061f87c2-7e4d-4def-9915-6a2e6bd50686" xlink:href="fold-20200331.xsd#fold_IncreaseDecreaseInDeferredReimbursements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_39bcf752-e138-45a3-81ce-10f23b47b04c" xlink:to="loc_fold_IncreaseDecreaseInDeferredReimbursements_061f87c2-7e4d-4def-9915-6a2e6bd50686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e71cb0ac-ddd1-43b7-8d90-1d519b114eca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b95665b0-21e4-4092-bcd8-138ecb84dd41" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e71cb0ac-ddd1-43b7-8d90-1d519b114eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_03d54ce6-7532-4e03-a621-3954446f7b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ea7a2d-2963-4583-9075-3f1b74c9f9f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_03d54ce6-7532-4e03-a621-3954446f7b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3346b888-da5e-4871-b6a2-159b1acea759" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_03d54ce6-7532-4e03-a621-3954446f7b4a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_3346b888-da5e-4871-b6a2-159b1acea759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bf929ef1-0b53-42d1-b878-50f8ddfc2171" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_03d54ce6-7532-4e03-a621-3954446f7b4a" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_bf929ef1-0b53-42d1-b878-50f8ddfc2171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_889b30ac-3da0-4fa7-81b5-9b23709c2a20" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_03d54ce6-7532-4e03-a621-3954446f7b4a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_889b30ac-3da0-4fa7-81b5-9b23709c2a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3da3a2fd-b73f-4d8a-8e5e-2d3809d8744a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_03d54ce6-7532-4e03-a621-3954446f7b4a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3da3a2fd-b73f-4d8a-8e5e-2d3809d8744a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5c13ff7-4155-41e4-a5df-461ffc5e976b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ea7a2d-2963-4583-9075-3f1b74c9f9f0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5c13ff7-4155-41e4-a5df-461ffc5e976b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_fc6818b9-917d-4615-9784-d87c8cf1f0e7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5c13ff7-4155-41e4-a5df-461ffc5e976b" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_fc6818b9-917d-4615-9784-d87c8cf1f0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_d86e9d75-eabf-44e1-a135-3d51f47ce5ed" xlink:href="fold-20200331.xsd#fold_PaymentsForRepurchaseOfRestrictedStockUnits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5c13ff7-4155-41e4-a5df-461ffc5e976b" xlink:to="loc_fold_PaymentsForRepurchaseOfRestrictedStockUnits_d86e9d75-eabf-44e1-a135-3d51f47ce5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_5b827a9d-62e0-48d6-b294-58ab780f815c" xlink:href="fold-20200331.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5c13ff7-4155-41e4-a5df-461ffc5e976b" xlink:to="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_5b827a9d-62e0-48d6-b294-58ab780f815c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e605fc7c-b84c-4da0-8cb6-2d5ccf32b777" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5c13ff7-4155-41e4-a5df-461ffc5e976b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e605fc7c-b84c-4da0-8cb6-2d5ccf32b777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_c5c177a5-4afe-444a-8ef8-a3110d4c5872" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5c13ff7-4155-41e4-a5df-461ffc5e976b" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_c5c177a5-4afe-444a-8ef8-a3110d4c5872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_39c7b461-f818-420d-87e9-d42598753402" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b5c13ff7-4155-41e4-a5df-461ffc5e976b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_39c7b461-f818-420d-87e9-d42598753402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecb67f41-663e-4f2b-954f-92949ef3ae71" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ea7a2d-2963-4583-9075-3f1b74c9f9f0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ecb67f41-663e-4f2b-954f-92949ef3ae71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_27a0dd6f-c869-42ee-87f7-37945f0b3b33" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ea7a2d-2963-4583-9075-3f1b74c9f9f0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_27a0dd6f-c869-42ee-87f7-37945f0b3b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c5855a4d-b4ca-4fd8-97d2-392eb5f67dd1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ea7a2d-2963-4583-9075-3f1b74c9f9f0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c5855a4d-b4ca-4fd8-97d2-392eb5f67dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d030a62e-8152-481c-9e9e-97a8b2652ee1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ea7a2d-2963-4583-9075-3f1b74c9f9f0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d030a62e-8152-481c-9e9e-97a8b2652ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_58dc58c1-1514-4bb2-97fb-c4a6d5bfe495" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_c7ea7a2d-2963-4583-9075-3f1b74c9f9f0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_58dc58c1-1514-4bb2-97fb-c4a6d5bfe495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForTenantImprovements_4845e2e8-3c06-4183-85e6-31fbab90662f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForTenantImprovements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_58dc58c1-1514-4bb2-97fb-c4a6d5bfe495" xlink:to="loc_us-gaap_PaymentsForTenantImprovements_4845e2e8-3c06-4183-85e6-31fbab90662f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_d7090e22-0f3e-4556-8edb-66ed9138d69c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_58dc58c1-1514-4bb2-97fb-c4a6d5bfe495" xlink:to="loc_us-gaap_InterestPaidNet_d7090e22-0f3e-4556-8edb-66ed9138d69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationPaidInStock_8051e641-42a1-41aa-8748-2962c2870734" xlink:href="fold-20200331.xsd#fold_ContingentConsiderationPaidInStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_58dc58c1-1514-4bb2-97fb-c4a6d5bfe495" xlink:to="loc_fold_ContingentConsiderationPaidInStock_8051e641-42a1-41aa-8748-2962c2870734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6f2c50e0-6d01-47c7-afce-5d0fa5716fe4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_58dc58c1-1514-4bb2-97fb-c4a6d5bfe495" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6f2c50e0-6d01-47c7-afce-5d0fa5716fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="simple" xlink:href="fold-20200331.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a8150c74-ad93-4896-a78e-712734b9a28f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a065dce2-48db-47ae-93dc-22a839e0db0f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a8150c74-ad93-4896-a78e-712734b9a28f" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a065dce2-48db-47ae-93dc-22a839e0db0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#DescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_068a286b-087d-4333-9b5e-fe203a1dd6ef" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74f680e5-accc-4cb6-84ab-dbc5e76ba9ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_068a286b-087d-4333-9b5e-fe203a1dd6ef" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74f680e5-accc-4cb6-84ab-dbc5e76ba9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="fold-20200331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e978f4f4-708a-4b35-a18e-818ee1e07e7a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f898d298-d60d-4a22-a29f-cd4e5b5233ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e978f4f4-708a-4b35-a18e-818ee1e07e7a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_f898d298-d60d-4a22-a29f-cd4e5b5233ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="fold-20200331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_98ff3b4b-8a31-4838-9bb5-5e19c4783d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f2e515ea-0096-467c-a4e7-3b7acd85cbd8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98ff3b4b-8a31-4838-9bb5-5e19c4783d9a" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f2e515ea-0096-467c-a4e7-3b7acd85cbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_ff2d51b8-a521-47d1-86ae-5df478f2dc1e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98ff3b4b-8a31-4838-9bb5-5e19c4783d9a" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_ff2d51b8-a521-47d1-86ae-5df478f2dc1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_62dc30f2-fd8b-4c7d-8949-3d8770a7ce6e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98ff3b4b-8a31-4838-9bb5-5e19c4783d9a" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_62dc30f2-fd8b-4c7d-8949-3d8770a7ce6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a517c829-db78-4437-afff-aee4ac855d99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98ff3b4b-8a31-4838-9bb5-5e19c4783d9a" xlink:to="loc_us-gaap_UseOfEstimates_a517c829-db78-4437-afff-aee4ac855d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_040d606e-3f0c-4398-a874-00199a4a1c8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98ff3b4b-8a31-4838-9bb5-5e19c4783d9a" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_040d606e-3f0c-4398-a874-00199a4a1c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_c2c16855-495d-436a-a996-fcdd848ed932" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98ff3b4b-8a31-4838-9bb5-5e19c4783d9a" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_c2c16855-495d-436a-a996-fcdd848ed932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8c13c9fa-4221-4911-befb-b95ef0fb2d61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98ff3b4b-8a31-4838-9bb5-5e19c4783d9a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8c13c9fa-4221-4911-befb-b95ef0fb2d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCostsForContractsOrProgramsPolicy_fc2a255f-f8b5-468e-a2d4-61b4fef56dff" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCostsForContractsOrProgramsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98ff3b4b-8a31-4838-9bb5-5e19c4783d9a" xlink:to="loc_us-gaap_InventoryCostsForContractsOrProgramsPolicy_fc2a255f-f8b5-468e-a2d4-61b4fef56dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_fe93a76a-4567-4875-ab03-ba7b58c87b05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98ff3b4b-8a31-4838-9bb5-5e19c4783d9a" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_fe93a76a-4567-4875-ab03-ba7b58c87b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d99fdb1a-7614-45b2-9e93-8ab74ae6c51f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_98ff3b4b-8a31-4838-9bb5-5e19c4783d9a" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_d99fdb1a-7614-45b2-9e93-8ab74ae6c51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="fold-20200331.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_66ae45aa-3ebf-4052-bae1-cff9d38da9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_ee9aee5a-b3a2-45d3-b2fd-2182a4395651" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_66ae45aa-3ebf-4052-bae1-cff9d38da9cc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_ee9aee5a-b3a2-45d3-b2fd-2182a4395651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a088ba0e-b8a2-417d-a3eb-e20d1a7ee9ab" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3330270a-096f-4d5e-a0d6-3f381be438a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a088ba0e-b8a2-417d-a3eb-e20d1a7ee9ab" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_3330270a-096f-4d5e-a0d6-3f381be438a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6ecad20b-c957-44f9-90c3-b6ce014123ba" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a088ba0e-b8a2-417d-a3eb-e20d1a7ee9ab" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6ecad20b-c957-44f9-90c3-b6ce014123ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d835adfb-bbcf-46b8-a93e-d48a9bd5ae25" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6ecad20b-c957-44f9-90c3-b6ce014123ba" xlink:to="loc_srt_StatementGeographicalAxis_d835adfb-bbcf-46b8-a93e-d48a9bd5ae25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8432d2fc-50a0-48a6-b9ed-e83e67def3de" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d835adfb-bbcf-46b8-a93e-d48a9bd5ae25" xlink:to="loc_srt_SegmentGeographicalDomain_8432d2fc-50a0-48a6-b9ed-e83e67def3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_fd057659-97f8-4bfe-ab5a-de42e78b510a" xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8432d2fc-50a0-48a6-b9ed-e83e67def3de" xlink:to="loc_country_US_fd057659-97f8-4bfe-ab5a-de42e78b510a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_39fe1bd6-32d5-46dc-8f0a-75318db6e8e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8432d2fc-50a0-48a6-b9ed-e83e67def3de" xlink:to="loc_us-gaap_NonUsMember_39fe1bd6-32d5-46dc-8f0a-75318db6e8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_dc6c9451-9318-48cf-95eb-07219398fc88" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_6ecad20b-c957-44f9-90c3-b6ce014123ba" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_dc6c9451-9318-48cf-95eb-07219398fc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e58c36cf-75cc-4cfe-9b03-5a823bfe63fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_dc6c9451-9318-48cf-95eb-07219398fc88" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_e58c36cf-75cc-4cfe-9b03-5a823bfe63fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCash"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_d0330d13-a35e-4338-8b2b-fe6f7bcbe8e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_141d282a-412d-4cc0-ba48-6f4b85e3a24f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_d0330d13-a35e-4338-8b2b-fe6f7bcbe8e2" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_141d282a-412d-4cc0-ba48-6f4b85e3a24f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4135489a-a994-4beb-9c15-abf3b7fb977c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_60f46ed3-f7e5-416d-9ada-379d915a20b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4135489a-a994-4beb-9c15-abf3b7fb977c" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_60f46ed3-f7e5-416d-9ada-379d915a20b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_c2c8880d-319e-4ab4-9ba1-94253252fb24" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_4135489a-a994-4beb-9c15-abf3b7fb977c" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_c2c8880d-319e-4ab4-9ba1-94253252fb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_968a5d2d-c7ea-49fe-a3d5-3c80d6dd8b16" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b28c175a-ed0a-45eb-8b14-b8cfa62b7b3b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_968a5d2d-c7ea-49fe-a3d5-3c80d6dd8b16" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b28c175a-ed0a-45eb-8b14-b8cfa62b7b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0f10a3b2-701e-4336-a461-492fbc5ed76c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b28c175a-ed0a-45eb-8b14-b8cfa62b7b3b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0f10a3b2-701e-4336-a461-492fbc5ed76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0f10a3b2-701e-4336-a461-492fbc5ed76c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShortTermCorporateDebtSecuritiesMember_c42c3f65-1265-426f-9e22-8c4d7613ba63" xlink:href="fold-20200331.xsd#fold_ShortTermCorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:to="loc_fold_ShortTermCorporateDebtSecuritiesMember_c42c3f65-1265-426f-9e22-8c4d7613ba63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_079e1480-10a5-4a5e-8210-3cb9f55440cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_079e1480-10a5-4a5e-8210-3cb9f55440cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_1ac454bc-b54d-40a5-b735-983c20aecef1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_1ac454bc-b54d-40a5-b735-983c20aecef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d0281e29-17fe-430f-b722-925b691cccf6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d0281e29-17fe-430f-b722-925b691cccf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_31d29a4d-3cf9-42b9-af97-5514291f791f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_31d29a4d-3cf9-42b9-af97-5514291f791f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0e499efd-82ed-4f4e-a745-7f987c1a2b1d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7871aeec-4aac-4345-80d7-b7af40486d6a" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0e499efd-82ed-4f4e-a745-7f987c1a2b1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_b28c175a-ed0a-45eb-8b14-b8cfa62b7b3b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_533d07ba-c918-4d56-b8e6-7a576bf22c56" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_533d07ba-c918-4d56-b8e6-7a576bf22c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d1c2ec3-8503-4126-86b4-5487b5517f5a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_0d1c2ec3-8503-4126-86b4-5487b5517f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_1c1a51c1-bbac-48b7-a6f7-aea86dc9bade" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_1c1a51c1-bbac-48b7-a6f7-aea86dc9bade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_9abf9d6a-54a5-4ae8-b5a6-f92e2090d394" xlink:href="fold-20200331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_9abf9d6a-54a5-4ae8-b5a6-f92e2090d394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_ca6bb7c5-260e-4eb2-8454-d4eac0e34aa1" xlink:href="fold-20200331.xsd#fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_ca6bb7c5-260e-4eb2-8454-d4eac0e34aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5762e2da-d793-4d07-860e-087645fd3372" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5762e2da-d793-4d07-860e-087645fd3372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b0c4e57d-9351-4891-a812-99f9db5623cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b0c4e57d-9351-4891-a812-99f9db5623cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_81172f4f-19dd-4134-846c-c3ebba9233db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_81172f4f-19dd-4134-846c-c3ebba9233db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c22b64ce-f281-45ab-bf19-170f9d4b9e47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c22b64ce-f281-45ab-bf19-170f9d4b9e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4a1209b2-2d12-488a-975a-24a0a36ad11c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4a1209b2-2d12-488a-975a-24a0a36ad11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_b633090e-611c-4c99-a407-8d5f6b82edc0" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities_b633090e-611c-4c99-a407-8d5f6b82edc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bcdd92b4-c4e4-4f60-94e7-96b9f89fc4b8" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bcdd92b4-c4e4-4f60-94e7-96b9f89fc4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b38ec1fb-f3a9-4469-9fc6-34dbba569a50" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b38ec1fb-f3a9-4469-9fc6-34dbba569a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_589c4051-9bec-48a9-aae8-248c28d766eb" xlink:href="fold-20200331.xsd#fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6503ddd7-7f33-4192-adce-4c2c1970e2fd" xlink:to="loc_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure_589c4051-9bec-48a9-aae8-248c28d766eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a3311592-79b7-4d45-b6db-a76f6a012364" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_968a5d2d-c7ea-49fe-a3d5-3c80d6dd8b16" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_a3311592-79b7-4d45-b6db-a76f6a012364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_a9d1af58-18a8-4047-8bef-40274d8b9915" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e1e7ebf-22a4-4c7f-a05a-3f86370d00bf" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_a9d1af58-18a8-4047-8bef-40274d8b9915" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e1e7ebf-22a4-4c7f-a05a-3f86370d00bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cca002b7-6c76-47dc-8b2f-1f43b5ba2352" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_a9d1af58-18a8-4047-8bef-40274d8b9915" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cca002b7-6c76-47dc-8b2f-1f43b5ba2352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_5f8d413e-1baa-4c47-aace-4e39f1468e05" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_a9d1af58-18a8-4047-8bef-40274d8b9915" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_5f8d413e-1baa-4c47-aace-4e39f1468e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6d3cee81-64c4-4d2b-a854-0a04376e9aa0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_a9d1af58-18a8-4047-8bef-40274d8b9915" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_6d3cee81-64c4-4d2b-a854-0a04376e9aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_27dbb242-c967-444d-9baf-56662352053b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_a9d1af58-18a8-4047-8bef-40274d8b9915" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_27dbb242-c967-444d-9baf-56662352053b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8facf466-aeb3-4957-a8f7-10c16463f1de" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_a9d1af58-18a8-4047-8bef-40274d8b9915" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8facf466-aeb3-4957-a8f7-10c16463f1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Inventories" xlink:type="simple" xlink:href="fold-20200331.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_80f16d88-e588-4111-9247-4bc8df41c5b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_d782f6f4-59b9-435f-b5c4-3a0386c4acc5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_80f16d88-e588-4111-9247-4bc8df41c5b9" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_d782f6f4-59b9-435f-b5c4-3a0386c4acc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="simple" xlink:href="fold-20200331.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_70e137a1-201c-4476-ae2f-e7bd293161b9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d1a54509-2a86-4e2a-90f8-df6880fbb396" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_70e137a1-201c-4476-ae2f-e7bd293161b9" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_d1a54509-2a86-4e2a-90f8-df6880fbb396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_df91401b-7952-49aa-addc-7b8810b40967" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a8875392-63a7-4bd3-9704-e30b97f43b00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_df91401b-7952-49aa-addc-7b8810b40967" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_a8875392-63a7-4bd3-9704-e30b97f43b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1fd4f18b-d056-4d9a-abe3-553038bfce38" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_df91401b-7952-49aa-addc-7b8810b40967" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1fd4f18b-d056-4d9a-abe3-553038bfce38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_06d8e39a-269a-4bef-90e7-a32ce5e82210" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_df91401b-7952-49aa-addc-7b8810b40967" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_06d8e39a-269a-4bef-90e7-a32ce5e82210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6544994f-ee0c-419a-9c32-1026601759dd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_df91401b-7952-49aa-addc-7b8810b40967" xlink:to="loc_us-gaap_InventoryNet_6544994f-ee0c-419a-9c32-1026601759dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_57c335b3-c11d-4fe6-ad77-8d49cd4f2bdc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_df91401b-7952-49aa-addc-7b8810b40967" xlink:to="loc_us-gaap_InventoryValuationReserves_57c335b3-c11d-4fe6-ad77-8d49cd4f2bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/Debt" xlink:type="simple" xlink:href="fold-20200331.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0c7861df-cea6-4cb3-a639-b84a56fbd8c1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_156226c5-d349-4f7d-9eb8-f8e15f18082a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0c7861df-cea6-4cb3-a639-b84a56fbd8c1" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_156226c5-d349-4f7d-9eb8-f8e15f18082a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="simple" xlink:href="fold-20200331.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b4219e2a-d6e9-47d5-814d-96bb2e472025" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_97d9a2b5-e8e9-4b93-b31f-4c2fa4aad528" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b4219e2a-d6e9-47d5-814d-96bb2e472025" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_97d9a2b5-e8e9-4b93-b31f-4c2fa4aad528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_3d60336d-e65c-4cef-9128-ab91c18fd187" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b4219e2a-d6e9-47d5-814d-96bb2e472025" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_3d60336d-e65c-4cef-9128-ab91c18fd187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#DebtSummaryofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_990bdb64-23c7-4eab-9862-5d897e5cc16e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_103e896c-407c-4f52-ad6a-2f63109a013e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_990bdb64-23c7-4eab-9862-5d897e5cc16e" xlink:to="loc_us-gaap_DebtInstrumentTable_103e896c-407c-4f52-ad6a-2f63109a013e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_e5ae48dc-2cc4-4858-9c20-090644c98043" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_103e896c-407c-4f52-ad6a-2f63109a013e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_e5ae48dc-2cc4-4858-9c20-090644c98043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e5707564-bfde-45b9-80af-2149dbb46c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_e5ae48dc-2cc4-4858-9c20-090644c98043" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e5707564-bfde-45b9-80af-2149dbb46c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorLoansMember_6e45e3b3-9d7e-42c3-a83f-663f26493270" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorLoansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e5707564-bfde-45b9-80af-2149dbb46c6c" xlink:to="loc_us-gaap_SeniorLoansMember_6e45e3b3-9d7e-42c3-a83f-663f26493270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_8813d17e-99b0-4fe7-9c3c-039acd7df163" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e5707564-bfde-45b9-80af-2149dbb46c6c" xlink:to="loc_us-gaap_ConvertibleDebtMember_8813d17e-99b0-4fe7-9c3c-039acd7df163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_03731ab8-1d62-494a-ab5c-69c284eeb23d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_103e896c-407c-4f52-ad6a-2f63109a013e" xlink:to="loc_us-gaap_DebtInstrumentAxis_03731ab8-1d62-494a-ab5c-69c284eeb23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d2a836a0-d9b0-4d97-9b51-cb167008c0b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_03731ab8-1d62-494a-ab5c-69c284eeb23d" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d2a836a0-d9b0-4d97-9b51-cb167008c0b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_SeniorSecuredTermLoanDue2023Member_deb4f41c-8a18-4fc2-a980-3a2933721bcd" xlink:href="fold-20200331.xsd#fold_SeniorSecuredTermLoanDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d2a836a0-d9b0-4d97-9b51-cb167008c0b5" xlink:to="loc_fold_SeniorSecuredTermLoanDue2023Member_deb4f41c-8a18-4fc2-a980-3a2933721bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ConvertibleSeniorNotes2016Due2023Member_3a45e0db-a439-449d-931e-996cbd8b98ef" xlink:href="fold-20200331.xsd#fold_ConvertibleSeniorNotes2016Due2023Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d2a836a0-d9b0-4d97-9b51-cb167008c0b5" xlink:to="loc_fold_ConvertibleSeniorNotes2016Due2023Member_3a45e0db-a439-449d-931e-996cbd8b98ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e80b1137-2adf-45e2-94bf-b0c4ba932f5a" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_103e896c-407c-4f52-ad6a-2f63109a013e" xlink:to="loc_srt_RangeAxis_e80b1137-2adf-45e2-94bf-b0c4ba932f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_14f9aacd-6534-47d4-8b72-f45327e23ff1" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e80b1137-2adf-45e2-94bf-b0c4ba932f5a" xlink:to="loc_srt_RangeMember_14f9aacd-6534-47d4-8b72-f45327e23ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3ec8ac41-9146-40f1-99de-ac4e82d577ea" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14f9aacd-6534-47d4-8b72-f45327e23ff1" xlink:to="loc_srt_MinimumMember_3ec8ac41-9146-40f1-99de-ac4e82d577ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_103e896c-407c-4f52-ad6a-2f63109a013e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_68fb56c4-fa04-40aa-ac9c-c1728752293d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_68fb56c4-fa04-40aa-ac9c-c1728752293d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6e58d9a3-b43a-4fe8-b356-79e4e7717d22" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_6e58d9a3-b43a-4fe8-b356-79e4e7717d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_718b78ab-58ce-45a4-b300-4c13298cf696" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_us-gaap_DeferredOfferingCosts_718b78ab-58ce-45a4-b300-4c13298cf696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5f902108-da59-4224-ad9c-77851b03b4a6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_us-gaap_LongTermDebt_5f902108-da59-4224-ad9c-77851b03b4a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f9bbc157-0329-4518-a5cc-829d58cda1ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger_f9bbc157-0329-4518-a5cc-829d58cda1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_9f421e76-4cf8-4406-bb55-09e0421caf14" xlink:href="fold-20200331.xsd#fold_DebtInstrumentsConvertibleThresholdTradingDays"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_fold_DebtInstrumentsConvertibleThresholdTradingDays_9f421e76-4cf8-4406-bb55-09e0421caf14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c095ce0c-67ba-44ef-a98f-34fe989a308e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_dea421c8-142c-488d-a136-dfb399bce716" xlink:to="loc_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_c095ce0c-67ba-44ef-a98f-34fe989a308e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6bb19134-8129-48a7-8fb5-788e90d9d257" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_bbba0226-2ed8-4f0c-b60d-b422fafbb87e" xlink:href="fold-20200331.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6bb19134-8129-48a7-8fb5-788e90d9d257" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount_bbba0226-2ed8-4f0c-b60d-b422fafbb87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_d4847c48-995d-40f3-9ec0-4df5717a4071" xlink:href="fold-20200331.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6bb19134-8129-48a7-8fb5-788e90d9d257" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance_d4847c48-995d-40f3-9ec0-4df5717a4071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_4de074d4-de43-49a0-aecb-45cabf7fd9c2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6bb19134-8129-48a7-8fb5-788e90d9d257" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_4de074d4-de43-49a0-aecb-45cabf7fd9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_8a2b4630-eadd-4d16-b930-d0dbc00fd6ae" xlink:href="fold-20200331.xsd#fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6bb19134-8129-48a7-8fb5-788e90d9d257" xlink:to="loc_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest_8a2b4630-eadd-4d16-b930-d0dbc00fd6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_e04e7953-62c3-4b3b-a837-cf0784cb355b" xlink:href="fold-20200331.xsd#fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6bb19134-8129-48a7-8fb5-788e90d9d257" xlink:to="loc_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital_e04e7953-62c3-4b3b-a837-cf0784cb355b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_285ff5fb-1e0a-4c76-9b2c-a17eccb82f27" xlink:href="fold-20200331.xsd#fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6bb19134-8129-48a7-8fb5-788e90d9d257" xlink:to="loc_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued_285ff5fb-1e0a-4c76-9b2c-a17eccb82f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0dd1488d-b9c6-4120-b4fd-c1b11a523a6c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6bb19134-8129-48a7-8fb5-788e90d9d257" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_0dd1488d-b9c6-4120-b4fd-c1b11a523a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_7a83495b-b69f-4866-b7ac-2b0761cedfae" xlink:href="fold-20200331.xsd#fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6bb19134-8129-48a7-8fb5-788e90d9d257" xlink:to="loc_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt_7a83495b-b69f-4866-b7ac-2b0761cedfae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#DebtInterestExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_16c8548f-3718-415a-8b59-4275ee4325ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_6b9c9fe1-deed-497b-a973-aac4f4c0e295" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_16c8548f-3718-415a-8b59-4275ee4325ce" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_6b9c9fe1-deed-497b-a973-aac4f4c0e295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_bd81880e-baf6-4ad6-8131-c7ab323a8621" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_16c8548f-3718-415a-8b59-4275ee4325ce" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_bd81880e-baf6-4ad6-8131-c7ab323a8621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_AmortizationDeferredFinancingCosts_b33be79e-0240-4f55-9c97-1e1db100f073" xlink:href="fold-20200331.xsd#fold_AmortizationDeferredFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_16c8548f-3718-415a-8b59-4275ee4325ce" xlink:to="loc_fold_AmortizationDeferredFinancingCosts_b33be79e-0240-4f55-9c97-1e1db100f073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43536d32-2ef7-4b5f-99da-d36b6a38883b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2c7f0403-0688-4e53-9a42-91ceda5d1469" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43536d32-2ef7-4b5f-99da-d36b6a38883b" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_2c7f0403-0688-4e53-9a42-91ceda5d1469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ea7c958-b9fd-4e55-97b9-5c35451049b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e026d3cb-d7ac-4c8c-870b-60e7c7247276" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ea7c958-b9fd-4e55-97b9-5c35451049b5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e026d3cb-d7ac-4c8c-870b-60e7c7247276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1b74c643-f8b7-4805-8d81-89679c48469c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ea7c958-b9fd-4e55-97b9-5c35451049b5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1b74c643-f8b7-4805-8d81-89679c48469c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_46f5a95a-3966-4fe5-a94d-0a7046dd8080" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ea7c958-b9fd-4e55-97b9-5c35451049b5" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_46f5a95a-3966-4fe5-a94d-0a7046dd8080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1c5ab7a2-6e10-4b0b-8961-dae2a2afdc4c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ea7c958-b9fd-4e55-97b9-5c35451049b5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1c5ab7a2-6e10-4b0b-8961-dae2a2afdc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationWeightedaverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d7325bb4-2d74-43e1-9bc0-a3e388689078" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2e55519-67a9-4757-9fac-a19fa10244b6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d7325bb4-2d74-43e1-9bc0-a3e388689078" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2e55519-67a9-4757-9fac-a19fa10244b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_4370a7ff-49d2-4c53-a558-ce74d6c74285" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2e55519-67a9-4757-9fac-a19fa10244b6" xlink:to="loc_us-gaap_AwardTypeAxis_4370a7ff-49d2-4c53-a558-ce74d6c74285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5c2725c-e906-445e-b45d-8ee780801916" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4370a7ff-49d2-4c53-a558-ce74d6c74285" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5c2725c-e906-445e-b45d-8ee780801916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_9f813840-d949-4487-88ad-8b4ce8c2da53" xlink:href="fold-20200331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e5c2725c-e906-445e-b45d-8ee780801916" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_9f813840-d949-4487-88ad-8b4ce8c2da53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_193618c7-93f3-4507-bc76-5a0068cca04c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c2e55519-67a9-4757-9fac-a19fa10244b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_193618c7-93f3-4507-bc76-5a0068cca04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_fc06fbca-2c8d-419b-b045-d9fc98529a41" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_193618c7-93f3-4507-bc76-5a0068cca04c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_fc06fbca-2c8d-419b-b045-d9fc98529a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_128dbf71-6789-4f2e-98cd-9e4b47337192" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_193618c7-93f3-4507-bc76-5a0068cca04c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_128dbf71-6789-4f2e-98cd-9e4b47337192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_72a93c0b-8502-4b82-9f47-9f96c7a00712" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_193618c7-93f3-4507-bc76-5a0068cca04c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_72a93c0b-8502-4b82-9f47-9f96c7a00712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_3f0fa9f8-426f-48f9-8311-1a0af7b967c0" xlink:href="fold-20200331.xsd#fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_193618c7-93f3-4507-bc76-5a0068cca04c" xlink:to="loc_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare_3f0fa9f8-426f-48f9-8311-1a0af7b967c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_34bd820e-29f5-4f99-afa3-a40e4ad8410c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97a1427b-77cb-4cea-8454-d1b23cfc595b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_34bd820e-29f5-4f99-afa3-a40e4ad8410c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97a1427b-77cb-4cea-8454-d1b23cfc595b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_18c4c3ae-470b-4399-8c9e-7e95149fd31b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97a1427b-77cb-4cea-8454-d1b23cfc595b" xlink:to="loc_us-gaap_AwardTypeAxis_18c4c3ae-470b-4399-8c9e-7e95149fd31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fa489b6-9fca-47db-a66b-4064d1d51ad3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_18c4c3ae-470b-4399-8c9e-7e95149fd31b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fa489b6-9fca-47db-a66b-4064d1d51ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_2d817445-d76e-4d5b-8c07-4e41141eb2e4" xlink:href="fold-20200331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fa489b6-9fca-47db-a66b-4064d1d51ad3" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_2d817445-d76e-4d5b-8c07-4e41141eb2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_97a1427b-77cb-4cea-8454-d1b23cfc595b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1acbea45-c8c0-43a6-a005-149151f269fd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1acbea45-c8c0-43a6-a005-149151f269fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bae029d1-5e6a-4a26-8111-52cde4b5c9ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_bae029d1-5e6a-4a26-8111-52cde4b5c9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_70e90033-ccda-4d6b-b97d-579e4ca2fd9c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_70e90033-ccda-4d6b-b97d-579e4ca2fd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c3e98ae4-8766-4065-9418-cfb1d04e9c86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c3e98ae4-8766-4065-9418-cfb1d04e9c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d86322e0-ca4f-460a-a8a4-837cebc22878" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_d86322e0-ca4f-460a-a8a4-837cebc22878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c3675ffb-88a0-477c-b245-d42c4cd9d6a5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1e93ecd3-af76-4fea-a23c-e8f3ca971ed5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c3675ffb-88a0-477c-b245-d42c4cd9d6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_dcf6cf85-94f1-4234-a288-d3f047db3e61" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_dcf6cf85-94f1-4234-a288-d3f047db3e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_649eab52-e015-4f14-b196-615aab5169b2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_649eab52-e015-4f14-b196-615aab5169b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3a6611ff-8309-4b17-beeb-739529824303" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3a6611ff-8309-4b17-beeb-739529824303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4c65ab72-b49f-4168-87c4-492e06b1f4f9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4c65ab72-b49f-4168-87c4-492e06b1f4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4887d209-c1fa-4f1e-b60d-a2feacc8f88b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4887d209-c1fa-4f1e-b60d-a2feacc8f88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_baa8899c-ed50-48f1-8dd1-9616f7b38710" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_baa8899c-ed50-48f1-8dd1-9616f7b38710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a1b6c839-c0fe-4323-998b-336a3d645a63" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a1b6c839-c0fe-4323-998b-336a3d645a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fd46b544-a662-4ed1-8f56-be7617aff449" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_69d3bd17-ab4c-40f1-82b4-dad55abb73ec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fd46b544-a662-4ed1-8f56-be7617aff449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_024917d6-ab55-477d-87e4-573b0bd46422" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_024917d6-ab55-477d-87e4-573b0bd46422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_37dc4fa0-0a16-4827-8674-2e213b089622" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_37dc4fa0-0a16-4827-8674-2e213b089622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d92a5afe-318c-4b2d-bf95-b5194af611c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2049b149-8aa5-4403-a66c-7bf38d0cf91a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2049b149-8aa5-4403-a66c-7bf38d0cf91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_56c47c97-294f-4d42-a8e7-adb86acb9e8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_56c47c97-294f-4d42-a8e7-adb86acb9e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_78fda2bc-7e1b-4b5b-8f38-71e1c81a59a8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_78fda2bc-7e1b-4b5b-8f38-71e1c81a59a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_935cccd7-ed91-4d46-b638-ecb527a2a8f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_935cccd7-ed91-4d46-b638-ecb527a2a8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_388fb4d1-f252-404a-8efc-4b844ee51cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_388fb4d1-f252-404a-8efc-4b844ee51cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8b10fe28-a00f-41e5-8886-6ea1376f2a29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_17ab8736-fa95-4c97-a191-4f2dccdaab5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_8b10fe28-a00f-41e5-8886-6ea1376f2a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a218a112-4f88-4768-9384-cf70a85c6a47" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f883c8-1a1b-4a5b-be5d-b0d961fd2286" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a218a112-4f88-4768-9384-cf70a85c6a47" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f883c8-1a1b-4a5b-be5d-b0d961fd2286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d2bfb4ce-55a8-4796-9b7e-938398a06a3a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f883c8-1a1b-4a5b-be5d-b0d961fd2286" xlink:to="loc_us-gaap_AwardTypeAxis_d2bfb4ce-55a8-4796-9b7e-938398a06a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a9e8836-2035-437f-b3ce-0865c4355653" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d2bfb4ce-55a8-4796-9b7e-938398a06a3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a9e8836-2035-437f-b3ce-0865c4355653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_ed58f2c0-d257-4773-ad86-7b8a58fe5f2a" xlink:href="fold-20200331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a9e8836-2035-437f-b3ce-0865c4355653" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_ed58f2c0-d257-4773-ad86-7b8a58fe5f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d076a538-3845-413b-8ae4-1e8501f9dc82" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a9e8836-2035-437f-b3ce-0865c4355653" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d076a538-3845-413b-8ae4-1e8501f9dc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_25491d9b-dc09-4ebc-ac60-1fd62c9d5710" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f883c8-1a1b-4a5b-be5d-b0d961fd2286" xlink:to="loc_us-gaap_PlanNameAxis_25491d9b-dc09-4ebc-ac60-1fd62c9d5710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_83ecd52c-1543-4581-ae8d-34e4752c466b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_25491d9b-dc09-4ebc-ac60-1fd62c9d5710" xlink:to="loc_us-gaap_PlanNameDomain_83ecd52c-1543-4581-ae8d-34e4752c466b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_5e86c977-848a-4aaf-a1ec-452ecb997dd4" xlink:href="fold-20200331.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_83ecd52c-1543-4581-ae8d-34e4752c466b" xlink:to="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_5e86c977-848a-4aaf-a1ec-452ecb997dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64a8f98a-c0af-4a81-a3b0-391dda2ea325" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a4f883c8-1a1b-4a5b-be5d-b0d961fd2286" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64a8f98a-c0af-4a81-a3b0-391dda2ea325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6de3cc23-db4f-461b-80f5-12ccdc50f3f5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64a8f98a-c0af-4a81-a3b0-391dda2ea325" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_6de3cc23-db4f-461b-80f5-12ccdc50f3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00e22c2d-998f-4a41-961d-07f451b4a992" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_64a8f98a-c0af-4a81-a3b0-391dda2ea325" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_00e22c2d-998f-4a41-961d-07f451b4a992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationRSUsandPBRSUsSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cfeb9b70-7ff5-4cc7-8560-58cf262d10ea" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73d51584-0553-439c-97f1-496a5e3fa03f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cfeb9b70-7ff5-4cc7-8560-58cf262d10ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73d51584-0553-439c-97f1-496a5e3fa03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_deadb844-b836-4166-825a-8fef4c368e06" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73d51584-0553-439c-97f1-496a5e3fa03f" xlink:to="loc_us-gaap_AwardTypeAxis_deadb844-b836-4166-825a-8fef4c368e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70b3e99e-bf89-4021-b25f-9c21debbe63f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_deadb844-b836-4166-825a-8fef4c368e06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70b3e99e-bf89-4021-b25f-9c21debbe63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4b35be75-7429-4372-bb06-0a71900a18cd" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70b3e99e-bf89-4021-b25f-9c21debbe63f" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4b35be75-7429-4372-bb06-0a71900a18cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_a46f96f7-4272-4b14-afbe-b99760bcca89" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73d51584-0553-439c-97f1-496a5e3fa03f" xlink:to="loc_us-gaap_PlanNameAxis_a46f96f7-4272-4b14-afbe-b99760bcca89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_05eceb97-3490-4118-912b-882a533ce20d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_a46f96f7-4272-4b14-afbe-b99760bcca89" xlink:to="loc_us-gaap_PlanNameDomain_05eceb97-3490-4118-912b-882a533ce20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_c08d3529-a5ff-443b-8e82-77cedd25ddf5" xlink:href="fold-20200331.xsd#fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_05eceb97-3490-4118-912b-882a533ce20d" xlink:to="loc_fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember_c08d3529-a5ff-443b-8e82-77cedd25ddf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37730493-9992-4146-ae68-31587d4d5713" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_73d51584-0553-439c-97f1-496a5e3fa03f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37730493-9992-4146-ae68-31587d4d5713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a3520b9-2235-4f02-b5bd-2539100e16ed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37730493-9992-4146-ae68-31587d4d5713" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a3520b9-2235-4f02-b5bd-2539100e16ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_690b6c28-b0eb-49ec-8162-6c255acafaf9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a3520b9-2235-4f02-b5bd-2539100e16ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_690b6c28-b0eb-49ec-8162-6c255acafaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2ac8fe8f-bcb4-46c6-9a5c-71f745aabbf1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a3520b9-2235-4f02-b5bd-2539100e16ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2ac8fe8f-bcb4-46c6-9a5c-71f745aabbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0d4f9c31-1cdf-435e-a2cf-9ab04e3bc4f4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a3520b9-2235-4f02-b5bd-2539100e16ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0d4f9c31-1cdf-435e-a2cf-9ab04e3bc4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_634db0bf-2c88-455f-8493-5462c40b5940" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a3520b9-2235-4f02-b5bd-2539100e16ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_634db0bf-2c88-455f-8493-5462c40b5940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_157473c5-d667-4e2a-9bdb-220cee791a3e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4a3520b9-2235-4f02-b5bd-2539100e16ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_157473c5-d667-4e2a-9bdb-220cee791a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e844f55-d7d3-4eb8-bd95-f94f0b619738" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37730493-9992-4146-ae68-31587d4d5713" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e844f55-d7d3-4eb8-bd95-f94f0b619738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_258200f5-de58-472e-80f9-0a1751467127" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e844f55-d7d3-4eb8-bd95-f94f0b619738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_258200f5-de58-472e-80f9-0a1751467127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8185752-4600-452b-adb4-77861af6e914" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e844f55-d7d3-4eb8-bd95-f94f0b619738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d8185752-4600-452b-adb4-77861af6e914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a07d97f3-e27a-4955-9261-6a5718ea4c14" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e844f55-d7d3-4eb8-bd95-f94f0b619738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a07d97f3-e27a-4955-9261-6a5718ea4c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_82088d31-9018-45f1-a841-25d1c2c7d8dc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e844f55-d7d3-4eb8-bd95-f94f0b619738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_82088d31-9018-45f1-a841-25d1c2c7d8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f28698c-cfa1-4731-a864-2f563096f4b1" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1e844f55-d7d3-4eb8-bd95-f94f0b619738" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5f28698c-cfa1-4731-a864-2f563096f4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_58bb06a0-4023-4dec-98df-d16c72e20792" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37730493-9992-4146-ae68-31587d4d5713" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_58bb06a0-4023-4dec-98df-d16c72e20792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_48ce2d24-f9d5-4435-be18-1055b0ce1ce7" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_58bb06a0-4023-4dec-98df-d16c72e20792" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_48ce2d24-f9d5-4435-be18-1055b0ce1ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_0de4ed95-6864-41cd-85cf-24de6958595f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_58bb06a0-4023-4dec-98df-d16c72e20792" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested_0de4ed95-6864-41cd-85cf-24de6958595f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#ShareBasedCompensationExpenseSummaryDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_982d3537-50f1-44dc-8b30-db354d7bf31e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9489bda-0e67-418c-919e-a6689049337e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_982d3537-50f1-44dc-8b30-db354d7bf31e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9489bda-0e67-418c-919e-a6689049337e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2844ad22-f370-40a9-a5b3-2974f0e39f17" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9489bda-0e67-418c-919e-a6689049337e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2844ad22-f370-40a9-a5b3-2974f0e39f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d4f862cc-8b75-4942-b51c-92e354102202" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2844ad22-f370-40a9-a5b3-2974f0e39f17" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d4f862cc-8b75-4942-b51c-92e354102202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c483d243-daad-4858-8dae-2147ff0d92e4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4f862cc-8b75-4942-b51c-92e354102202" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c483d243-daad-4858-8dae-2147ff0d92e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_dff9f8a7-b03f-4b55-a102-2e0acb91f414" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d4f862cc-8b75-4942-b51c-92e354102202" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_dff9f8a7-b03f-4b55-a102-2e0acb91f414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_618de813-546a-4f3b-8e30-53ea7eee39db" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e9489bda-0e67-418c-919e-a6689049337e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_618de813-546a-4f3b-8e30-53ea7eee39db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8145e602-d9d1-4075-8096-fefdaf0271e5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_618de813-546a-4f3b-8e30-53ea7eee39db" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8145e602-d9d1-4075-8096-fefdaf0271e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="simple" xlink:href="fold-20200331.xsd#AssetsandLiabilitiesMeasuredatFairValue"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dbdc67b0-0184-4195-a7a3-3543bfda78fe" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e9640c85-3617-473d-a153-fad1f9f0b306" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dbdc67b0-0184-4195-a7a3-3543bfda78fe" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e9640c85-3617-473d-a153-fad1f9f0b306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="simple" xlink:href="fold-20200331.xsd#AssetsandLiabilitiesMeasuredatFairValueTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_35ff9bb9-d4f8-4d2b-aa75-b7f8c30bd000" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4c2d1946-9b90-4281-b651-bca09b49fcac" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_35ff9bb9-d4f8-4d2b-aa75-b7f8c30bd000" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4c2d1946-9b90-4281-b651-bca09b49fcac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40625401-c976-4521-9b51-aefe352bbbe3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_35ff9bb9-d4f8-4d2b-aa75-b7f8c30bd000" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_40625401-c976-4521-9b51-aefe352bbbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_32365e0e-0643-4007-b807-5dfa91aa7ff6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_35ff9bb9-d4f8-4d2b-aa75-b7f8c30bd000" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_32365e0e-0643-4007-b807-5dfa91aa7ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0166db86-a255-4cdd-87d6-19964b2c6f6b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0166db86-a255-4cdd-87d6-19964b2c6f6b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942ebc33-bec4-4638-b38b-dba7936ab462" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942ebc33-bec4-4638-b38b-dba7936ab462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8da3-aebb-4bbd-8ba7-3a935b0fe8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_942ebc33-bec4-4638-b38b-dba7936ab462" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8da3-aebb-4bbd-8ba7-3a935b0fe8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_005edb1a-71ea-4396-b3b1-84c54a0f84b5" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8da3-aebb-4bbd-8ba7-3a935b0fe8ce" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_005edb1a-71ea-4396-b3b1-84c54a0f84b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d95e993a-bda9-4358-8c37-1f46a75dd3e0" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_53bb8da3-aebb-4bbd-8ba7-3a935b0fe8ce" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d95e993a-bda9-4358-8c37-1f46a75dd3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_42f10acf-0596-4aee-9a6b-8402cb414bed" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_FinancialInstrumentAxis_42f10acf-0596-4aee-9a6b-8402cb414bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_42f10acf-0596-4aee-9a6b-8402cb414bed" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_c266ff60-cc99-4c59-a825-4385213a8860" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_c266ff60-cc99-4c59-a825-4385213a8860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_49e9d300-a228-4c83-9299-422f3281c6df" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_49e9d300-a228-4c83-9299-422f3281c6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9ca03b5c-6486-4283-afde-cc3163909be4" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9ca03b5c-6486-4283-afde-cc3163909be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ef7bdab2-37ee-4e83-b7f8-d13351a7077c" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_ef7bdab2-37ee-4e83-b7f8-d13351a7077c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_58016165-0830-47df-934d-efaa607095e2" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5d0ea03-db80-433a-841d-8709c33b8a9d" xlink:to="loc_us-gaap_MoneyMarketFundsMember_58016165-0830-47df-934d-efaa607095e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1118b79b-eb84-48dd-bf22-b3915a2be066" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1118b79b-eb84-48dd-bf22-b3915a2be066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8072b2f1-68c4-4377-aa9e-d0a8ea5f4263" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1118b79b-eb84-48dd-bf22-b3915a2be066" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8072b2f1-68c4-4377-aa9e-d0a8ea5f4263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ATB200PompeProgramMember_300f90d1-c8d7-4a48-9a08-3ba472cd43ea" xlink:href="fold-20200331.xsd#fold_ATB200PompeProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8072b2f1-68c4-4377-aa9e-d0a8ea5f4263" xlink:to="loc_fold_ATB200PompeProgramMember_300f90d1-c8d7-4a48-9a08-3ba472cd43ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_66430058-b7a1-47ba-8854-2a53e13974e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_66430058-b7a1-47ba-8854-2a53e13974e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_5a21f4ed-e619-41d8-b20a-542009e69a6f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_66430058-b7a1-47ba-8854-2a53e13974e8" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_5a21f4ed-e619-41d8-b20a-542009e69a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_4a361e87-bae8-4098-b6a9-9ce77727a98a" xlink:href="fold-20200331.xsd#fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_5a21f4ed-e619-41d8-b20a-542009e69a6f" xlink:to="loc_fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember_4a361e87-bae8-4098-b6a9-9ce77727a98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_c8a1acb1-a360-4c80-b9fb-2192d4749263" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_ValuationTechniqueAxis_c8a1acb1-a360-4c80-b9fb-2192d4749263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_069cb205-2a3b-4d8f-aacf-3d554929fb9a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_c8a1acb1-a360-4c80-b9fb-2192d4749263" xlink:to="loc_us-gaap_ValuationTechniqueDomain_069cb205-2a3b-4d8f-aacf-3d554929fb9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_a240b10d-4c72-4042-8d44-d92b073f2d29" xlink:href="fold-20200331.xsd#fold_ProbabilityWeightedDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_069cb205-2a3b-4d8f-aacf-3d554929fb9a" xlink:to="loc_fold_ProbabilityWeightedDiscountedCashFlowMember_a240b10d-4c72-4042-8d44-d92b073f2d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_0b79cf81-b033-41f9-a8f2-5dd19bd42e6d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_0b79cf81-b033-41f9-a8f2-5dd19bd42e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c801d627-0154-4f2e-9f14-05dc7ad31f57" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_0b79cf81-b033-41f9-a8f2-5dd19bd42e6d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c801d627-0154-4f2e-9f14-05dc7ad31f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_70af28c5-0f6d-4cde-84b7-25a982dbe8cc" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c801d627-0154-4f2e-9f14-05dc7ad31f57" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_70af28c5-0f6d-4cde-84b7-25a982dbe8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_9091ddef-3b36-4a85-a3d3-85e403453b7a" xlink:href="fold-20200331.xsd#fold_MeasurementInputProbabilityOfMilestoneAchievementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_c801d627-0154-4f2e-9f14-05dc7ad31f57" xlink:to="loc_fold_MeasurementInputProbabilityOfMilestoneAchievementMember_9091ddef-3b36-4a85-a3d3-85e403453b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fae785fc-7567-4fa9-b89b-5d8d9f1a5156" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_srt_RangeAxis_fae785fc-7567-4fa9-b89b-5d8d9f1a5156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3b47bf0-5e9d-4e06-865d-1b158e19fa1b" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fae785fc-7567-4fa9-b89b-5d8d9f1a5156" xlink:to="loc_srt_RangeMember_d3b47bf0-5e9d-4e06-865d-1b158e19fa1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3bf4c3ac-1e57-479f-b4a3-e07b23db8bd6" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d3b47bf0-5e9d-4e06-865d-1b158e19fa1b" xlink:to="loc_srt_MinimumMember_3bf4c3ac-1e57-479f-b4a3-e07b23db8bd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_afed7bad-a85a-4b73-967b-a4e87f4f4e62" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d3b47bf0-5e9d-4e06-865d-1b158e19fa1b" xlink:to="loc_srt_MaximumMember_afed7bad-a85a-4b73-967b-a4e87f4f4e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5ca332c9-c440-462f-849e-dc4d0788299a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5ca332c9-c440-462f-849e-dc4d0788299a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca8fcead-ea69-42cc-b316-0b3bf8b32a8f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5ca332c9-c440-462f-849e-dc4d0788299a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca8fcead-ea69-42cc-b316-0b3bf8b32a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_CallidusBiopharmaIncMember_fa284b40-9d3f-42a6-99f9-9c0865a5b050" xlink:href="fold-20200331.xsd#fold_CallidusBiopharmaIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ca8fcead-ea69-42cc-b316-0b3bf8b32a8f" xlink:to="loc_fold_CallidusBiopharmaIncMember_fa284b40-9d3f-42a6-99f9-9c0865a5b050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a28f8b-05f9-4a9c-98d5-a0f90dd3dc72" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5472032d-1d23-4510-a4da-7f70d4e12e28" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a28f8b-05f9-4a9c-98d5-a0f90dd3dc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_863d7730-8a99-4964-a51b-f0d009214837" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a28f8b-05f9-4a9c-98d5-a0f90dd3dc72" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_863d7730-8a99-4964-a51b-f0d009214837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_33a28280-a358-43fe-b408-1023fd17675e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_863d7730-8a99-4964-a51b-f0d009214837" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_33a28280-a358-43fe-b408-1023fd17675e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5daff6b6-50da-4f76-a745-0438ee66d26d" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a28f8b-05f9-4a9c-98d5-a0f90dd3dc72" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5daff6b6-50da-4f76-a745-0438ee66d26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5c9d8e15-afd9-4b1a-b6e3-f583e58c4fe6" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5daff6b6-50da-4f76-a745-0438ee66d26d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5c9d8e15-afd9-4b1a-b6e3-f583e58c4fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_b8755c19-3d1a-46a8-8c28-1a6c70d0d644" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5daff6b6-50da-4f76-a745-0438ee66d26d" xlink:to="loc_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent_b8755c19-3d1a-46a8-8c28-1a6c70d0d644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e887e6f7-6740-4fb8-8615-3b02ef908473" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_5daff6b6-50da-4f76-a745-0438ee66d26d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_e887e6f7-6740-4fb8-8615-3b02ef908473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtFairValueDisclosures_b9d1ea81-4430-4059-b003-1188271e807e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a28f8b-05f9-4a9c-98d5-a0f90dd3dc72" xlink:to="loc_us-gaap_ConvertibleDebtFairValueDisclosures_b9d1ea81-4430-4059-b003-1188271e807e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationMeasurementInput_48a28a1b-18e7-49a4-963d-d86ff19f3e32" xlink:href="fold-20200331.xsd#fold_ContingentConsiderationMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a1a28f8b-05f9-4a9c-98d5-a0f90dd3dc72" xlink:to="loc_fold_ContingentConsiderationMeasurementInput_48a28a1b-18e7-49a4-963d-d86ff19f3e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7258cd00-f381-49f5-ad4d-4e43f0fa7fa9" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d9ea4a59-420c-410d-bfd5-b47b816e93e8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7258cd00-f381-49f5-ad4d-4e43f0fa7fa9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d9ea4a59-420c-410d-bfd5-b47b816e93e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_866421fd-dafd-4921-bc9a-2c7b50e9d0be" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d9ea4a59-420c-410d-bfd5-b47b816e93e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_866421fd-dafd-4921-bc9a-2c7b50e9d0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8c8ed3ae-8d72-4964-b0b0-ff80992211cb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d9ea4a59-420c-410d-bfd5-b47b816e93e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8c8ed3ae-8d72-4964-b0b0-ff80992211cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_ContingentConsiderationPaidInStockAdjustment_d90c17fe-22f5-42e7-9e61-bc21ddb9900b" xlink:href="fold-20200331.xsd#fold_ContingentConsiderationPaidInStockAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d9ea4a59-420c-410d-bfd5-b47b816e93e8" xlink:to="loc_fold_ContingentConsiderationPaidInStockAdjustment_d90c17fe-22f5-42e7-9e61-bc21ddb9900b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a45e23b4-8cb9-49cb-ad1c-7c1499cdff13" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_d9ea4a59-420c-410d-bfd5-b47b816e93e8" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a45e23b4-8cb9-49cb-ad1c-7c1499cdff13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="simple" xlink:href="fold-20200331.xsd#BasicandDilutedNetLossperCommonShare"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dda29b3f-aa0a-46a7-9a15-25f670d53577" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7c33de95-a558-4a7c-a1e2-52b500a8963f" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dda29b3f-aa0a-46a7-9a15-25f670d53577" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7c33de95-a558-4a7c-a1e2-52b500a8963f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="simple" xlink:href="fold-20200331.xsd#BasicandDilutedNetLossperCommonShareTables"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_d8f849d1-b3b9-417f-8540-ba9783ce0078" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9e4437e1-4a54-4d31-8e4b-a34967d3505e" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d8f849d1-b3b9-417f-8540-ba9783ce0078" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9e4437e1-4a54-4d31-8e4b-a34967d3505e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22c693ea-79ee-430e-8b9a-8d725d69cb99" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_d8f849d1-b3b9-417f-8540-ba9783ce0078" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_22c693ea-79ee-430e-8b9a-8d725d69cb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="simple" xlink:href="fold-20200331.xsd#BasicandDilutedNetLossperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_00fb239c-bba6-470e-9e57-c904f25e3598" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e2add7c2-4ad2-47e6-9fb9-0fc4c5e63f86" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_00fb239c-bba6-470e-9e57-c904f25e3598" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e2add7c2-4ad2-47e6-9fb9-0fc4c5e63f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2428ef5b-175b-4604-9228-fcbf63579c29" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e2add7c2-4ad2-47e6-9fb9-0fc4c5e63f86" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2428ef5b-175b-4604-9228-fcbf63579c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c72ded20-0046-420a-a748-96dc23e7ce00" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2428ef5b-175b-4604-9228-fcbf63579c29" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c72ded20-0046-420a-a748-96dc23e7ce00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_fold_EmployeeAndDirectorsStockOptionsMember_a6f77d53-4fe1-4f2e-9d99-faf1c98fa20e" xlink:href="fold-20200331.xsd#fold_EmployeeAndDirectorsStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c72ded20-0046-420a-a748-96dc23e7ce00" xlink:to="loc_fold_EmployeeAndDirectorsStockOptionsMember_a6f77d53-4fe1-4f2e-9d99-faf1c98fa20e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_11726868-4e3c-4bd2-9d22-b2e9bc37b2da" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c72ded20-0046-420a-a748-96dc23e7ce00" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_11726868-4e3c-4bd2-9d22-b2e9bc37b2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_bdbd7578-0e3f-4cf7-9aac-2fb6d8e068eb" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c72ded20-0046-420a-a748-96dc23e7ce00" xlink:to="loc_us-gaap_WarrantMember_bdbd7578-0e3f-4cf7-9aac-2fb6d8e068eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_34b50b99-8af2-4be2-9b69-0a64efdb828a" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c72ded20-0046-420a-a748-96dc23e7ce00" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_34b50b99-8af2-4be2-9b69-0a64efdb828a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a611b3fc-0ce9-4c7b-b556-85db5b6dca7b" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e2add7c2-4ad2-47e6-9fb9-0fc4c5e63f86" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a611b3fc-0ce9-4c7b-b556-85db5b6dca7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_82a13273-3bb8-4783-8e24-6689e22534f8" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a611b3fc-0ce9-4c7b-b556-85db5b6dca7b" xlink:to="loc_us-gaap_NetIncomeLossAbstract_82a13273-3bb8-4783-8e24-6689e22534f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f0e56e21-0f1d-48ac-9226-b28970ecb3e3" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_82a13273-3bb8-4783-8e24-6689e22534f8" xlink:to="loc_us-gaap_NetIncomeLoss_f0e56e21-0f1d-48ac-9226-b28970ecb3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ac02149-8964-4426-8249-c3b85aa317ee" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a611b3fc-0ce9-4c7b-b556-85db5b6dca7b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ac02149-8964-4426-8249-c3b85aa317ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_846cb825-4815-4637-946a-30dc98473090" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ac02149-8964-4426-8249-c3b85aa317ee" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_846cb825-4815-4637-946a-30dc98473090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_63f4327b-6650-4221-86b0-5fde322309ca" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_a611b3fc-0ce9-4c7b-b556-85db5b6dca7b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_63f4327b-6650-4221-86b0-5fde322309ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6725652976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">60,525<span></span>
</td>
<td class="nump">$ 34,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">17,772<span></span>
</td>
<td class="nump">9,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Ex-U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 42,753<span></span>
</td>
<td class="nump">$ 24,978<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636562416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Options</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected stock price volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Expected life of options (years)</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.67</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.68</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected annual dividend per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;______________________________</span></div>(1) The average expected life is determined using actual historical data.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the Company's stock options for the three months ended March 31, 2020 were as follows:</span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise&#160;<br/>Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining <br/>Years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,724&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,944&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(968)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(355)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(259)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.08&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and unvested expected to vest, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,808&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Non-Vested RSU Activity under the Plan</a></td>
<td class="text">A summary of non-vested RSU activity under the Plan for the three months ended March 31, 2020 is as follows:<table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.029%;"><tr><td style="width:1.0%;"/><td style="width:39.076%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.384%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.569%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.384%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.569%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.384%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.569%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.465%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of&#160;Shares<br/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted <br/>Average Grant  <br/>Date Fair  <br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted&#160;<br/>Average<br/>Remaining&#160;<br/>Years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,792&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,600)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(230)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.67&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested units as of March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Equity Compensation Expenses</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity compensation expense recognized in:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,253&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,032&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,343&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,712&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity compensation expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,596&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,744&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634334784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Weighted-average Assumptions (Details) - Options to purchase common stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">75.20%<span></span>
</td>
<td class="nump">74.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (years)</a></td>
<td class="text">5 years 8 months 1 day<span></span>
</td>
<td class="text">5 years 8 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare', window );">Expected annual dividend per share (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6776445168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Expense Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 12,596<span></span>
</td>
<td class="nump">$ 12,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">5,253<span></span>
</td>
<td class="nump">5,032<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total equity compensation expense</a></td>
<td class="nump">$ 7,343<span></span>
</td>
<td class="nump">$ 7,712<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6637228624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company's net product sales from Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> disaggregated by geographic area:</span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:71.900%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.316%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.318%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,772&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,068&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ex-U.S.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,753&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,978&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6787337744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Net product sales</a></td>
<td class="nump">$ 60,525<span></span>
</td>
<td class="nump">$ 34,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">6,552<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">53,973<span></span>
</td>
<td class="nump">29,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">89,120<span></span>
</td>
<td class="nump">64,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">40,215<span></span>
</td>
<td class="nump">44,303<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value of contingent consideration payable</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">132,030<span></span>
</td>
<td class="nump">111,270<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(78,057)<span></span>
</td>
<td class="num">(81,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,515<span></span>
</td>
<td class="nump">2,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3,729)<span></span>
</td>
<td class="num">(6,454)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on exchange of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(36,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income</a></td>
<td class="num">(8,316)<span></span>
</td>
<td class="nump">1,086<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(88,587)<span></span>
</td>
<td class="num">(120,131)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(361)<span></span>
</td>
<td class="num">(168)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (88,948)<span></span>
</td>
<td class="num">$ (120,299)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.35)<span></span>
</td>
<td class="num">$ (0.56)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">256,968,248<span></span>
</td>
<td class="nump">213,519,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6636209424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's Equity Incentive Plans consist of the Amended and Restated 2007 Equity Incentive Plan (the "Plan") and the 2007 Director Option Plan (the "2007 Director Plan"). The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. </span></div><div style="text-indent:18pt;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Stock Option Grants</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:</span></div><div style="text-align:justify;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.792%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected stock price volatility</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">74.2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Risk free interest rate</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.7&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Expected life of options (years)</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.67</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.68</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expected annual dividend per share</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;______________________________</span></div><div style="text-align:justify;margin-bottom:15pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> The average expected life is determined using actual historical data. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the Company's stock options for the three months ended March 31, 2020 were as follows:</span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.852%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of<br/>Shares</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Exercise&#160;<br/>Price</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted Average Remaining <br/>Years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,724&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.15&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,944&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.57&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercised</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(968)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.28&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(355)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.40&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Expired</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(259)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13.08&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options outstanding, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.30&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7.0</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.5&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested and unvested expected to vest, March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,629&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.23&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6.8</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Exercisable at March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,808&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.59&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5.4</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21.4&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As of March 31, 2020, the total unrecognized compensation cost related to non-vested stock options granted was $42.8 million and is expected to be recognized over a weighted average period of three years.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Restricted Stock Units</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">and Performance-Based Restricted Stock Units (collectively "RSUs")</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the three months ended March 31, 2020 is as follows:</span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.029%;"><tr><td style="width:1.0%;"/><td style="width:39.076%;"/><td style="width:1.0%;"/><td style="width:1.0%;"/><td style="width:13.384%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.569%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.384%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.569%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.384%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.569%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:8.465%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Number&#160;of&#160;Shares<br/></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted <br/>Average Grant  <br/>Date Fair  <br/>Value</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted&#160;<br/>Average<br/>Remaining&#160;<br/>Years</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in millions)</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested units as of December 31, 2019</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,792&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Granted</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,600&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Vested</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,600)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8.94&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Forfeited</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(230)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10.67&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Non-vested units as of March 31, 2020</span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11.18&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2.7</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">69.9&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">All non-vested units are expected to vest over their normal term. As of March 31, 2020, there was $73.4 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of three years.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Compensation Expense Related to Equity Awards</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Equity compensation expense recognized in:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,253&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,032&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Selling, general, and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,343&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,712&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total equity compensation expense</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,596&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,744&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6774981280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2019.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2019. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Consolidation</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Transactions</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of March 31, 2020 and through the issuance of this report. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company's Consolidated Balance Sheets. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">. The Company's accounts receivable at March 31, 2020 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers and the geographic economic environments and conditions to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of March 31, 2020, the Company recorded an allowance for doubtful accounts of $0.1 million.</span></div><div style="text-indent:18pt;text-align:justify;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's net product sales consist of sales of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> are generally received from distributors and pharmacies with the ultimate payor often a government authority. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the sale of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table summarizes the Company's net product sales from Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> disaggregated by geographic area:</span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:71.900%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.316%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.318%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S.</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,772&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,068&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Ex-U.S.</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">42,753&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,978&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total net product sales</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">60,525&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">34,046&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Inventories and Cost of Goods Sold</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lease term for all of the Company's leases include the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories. </span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Developments - Guidance Adopted in 2020</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2018-15 - In August 2018, the Financial Accounting Standards Board ("FASB") issued&#160;Accounting Standards Update ("ASU") 2018-15,&#160;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): ("ASU 2018-15"), relating to a customer&#8217;s accounting for implementation, set-up, and other upfront costs incurred in a&#160;cloud computing&#160;arrangement that is hosted by a vendor. Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance does not affect the accounting for the service element of a hosting arrangement that is a service contract. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized software costs and related amortization expense and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for public companies. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2018-13 - In August 2018, the FASB issued ASU 2018-03, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on (i) changes in unrealized gains and losses, (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and (iii) the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2017-04 - In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2016-13 - In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected and amends guidance on the impairment of financial instruments. ASU 2016-13 is effective for public companies who are SEC filers for fiscal years beginning after December 15, 2019, including interim periods within those years. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Developments - Guidance Not Yet Adopted</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2019-12 - In December 2019, the FASB issued ASU 2019-15, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following apply in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#8217; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted for public business entities for periods for which financial statements have not yet been issued. The Company is currently assessing the impact that this standard will have on the Company's Consolidated Financial Statements upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790718064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (88,948)<span></span>
</td>
<td class="num">$ (120,299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and deferred financing</a></td>
<td class="nump">231<span></span>
</td>
<td class="nump">1,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,764<span></span>
</td>
<td class="nump">991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">12,596<span></span>
</td>
<td class="nump">12,744<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on exchange of convertible debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Non-cash changes in the fair value of contingent consideration payable</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ForeignCurrencyRemeasurementGainLossBeforeTax', window );">Foreign currency remeasurement loss</a></td>
<td class="nump">10,662<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(8,358)<span></span>
</td>
<td class="num">(1,001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(251)<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,016<span></span>
</td>
<td class="nump">3,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(35,251)<span></span>
</td>
<td class="num">(8,858)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities', window );">Other non-current assets and liabilities</a></td>
<td class="num">(5,334)<span></span>
</td>
<td class="num">(3,507)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_IncreaseDecreaseInDeferredReimbursements', window );">Deferred reimbursements</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(107,942)<span></span>
</td>
<td class="num">(78,546)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Sale and redemption of marketable securities</a></td>
<td class="nump">106,140<span></span>
</td>
<td class="nump">135,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(12,088)<span></span>
</td>
<td class="num">(52,178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="num">(806)<span></span>
</td>
<td class="num">(2,944)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">93,246<span></span>
</td>
<td class="nump">80,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance leases</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_PaymentsForRepurchaseOfRestrictedStockUnits', window );">Purchase of vested restricted stock units</a></td>
<td class="num">(7,543)<span></span>
</td>
<td class="num">(1,938)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt', window );">Proceeds from termination of capped call confirmations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">6,077<span></span>
</td>
<td class="nump">3,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds of exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">812<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(1,487)<span></span>
</td>
<td class="nump">17,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="num">(4,265)<span></span>
</td>
<td class="num">(2,350)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash at the end of the period</a></td>
<td class="num">(20,448)<span></span>
</td>
<td class="nump">16,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">146,341<span></span>
</td>
<td class="nump">82,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at the end of period</a></td>
<td class="nump">125,893<span></span>
</td>
<td class="nump">98,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForTenantImprovements', window );">Tenant improvements paid through lease incentives</a></td>
<td class="nump">254<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">3,693<span></span>
</td>
<td class="nump">4,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationPaidInStock', window );">Contingent consideration paid in shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures unpaid at the end of period</a></td>
<td class="nump">$ 589<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationPaidInStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Paid in Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationPaidInStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ForeignCurrencyRemeasurementGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Remeasurement Gain (Loss), Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ForeignCurrencyRemeasurementGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncreaseDecreaseInDeferredReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of deferred reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncreaseDecreaseInDeferredReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_IncreaseDecreaseInNoncurrentOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_IncreaseDecreaseInNoncurrentOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_PaymentsForRepurchaseOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire restricted stock units during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_PaymentsForRepurchaseOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForTenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForTenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6631937600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Interest Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="nump">$ 3,585<span></span>
</td>
<td class="nump">$ 4,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">1,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AmortizationDeferredFinancingCosts', window );">Amortization of deferred financing</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AmortizationDeferredFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AmortizationDeferredFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6767934320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - RSUs and PBRSUs Summary (Details) - Unvested restricted stock units - Stock Option Plan Amended Restated 2007 Equity Incentive Plan<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of&#160;Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units (in shares) | shares</a></td>
<td class="nump">5,792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1,600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(230)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Non-vested units (in shares) | shares</a></td>
<td class="nump">7,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">10.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">8.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">10.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Non-vested units (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Non-vested units, weighted average remaining years</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested', window );">Non-vested units, aggregate intrinsic value | $</a></td>
<td class="nump">$ 69.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6635323744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Assets and Liabilities Measured at Fair Value</a></td>
<td class="text">Assets and Liabilities Measured at Fair Value<div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows:</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 1</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 2</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Level 3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> &#8212; Inputs that are unobservable for the asset or liability.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of March 31, 2020 are identified in the following table:</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands) </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,378&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,378&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">218,619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">218,619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:58.058%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.481%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.775%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.484%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands) </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,612&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,612&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,612&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,667&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2019 are identified in the following table:</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,710&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,710&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">314,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">314,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:61.876%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.306%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.306%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.310%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,681&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,681&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,681&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's Convertible Notes fall into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. The fair value of the Convertible Notes at March 31, 2020 was $4.7 million.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's Senior Secured Term Loan fall into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan approximates the fair value.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company did not have any Level 3 assets as of March 31, 2020 or December 31, 2019.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Money Market Funds, and Marketable Securities</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Contingent Consideration Payable</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. ("Callidus") in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The contingent consideration payable for Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market.&#160;If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program: </span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.567%;"><tr><td style="width:1.0%;"/><td style="width:18.625%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.581%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.468%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.581%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.625%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.581%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.625%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.581%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.533%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent&#160;Consideration<br/>Liability</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value as of March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation&#160;Technique</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable&#160;Input</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.4%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,985&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability weighted discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability of achievement of milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75% - 78%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021 - 2022</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows the change in the balance of contingent consideration payable for the three months ended March 31, 2020 and March 31, 2019, respectively:</span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,681&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in fair value during the period, included in the Consolidated Statements of Operations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">931&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,383&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment for contingent consideration paid in stock </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(316)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, end of the period</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,612&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,767&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Deferred Compensation Plan - Investment and Liability</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Deferred Compensation Plan (the "Deferral Plan") provides certain key employees and members of the Board of Directors with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. Deferral Plan assets are classified as trading securities and recorded at fair value with changes in the investment's fair value recognized in the period they occur. The asset investments consist of market exchanged mutual funds. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and related liability within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these securities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6632594288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash<div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">As of March 31, 2020, the Company held $123.2 million in cash and cash equivalents and $215.6 million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within accumulated other comprehensive loss in the Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#8217;s fair value is determined to less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss the Company would recognize an allowance and the corresponding credit loss would be included in earnings.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: </span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.198%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.725%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,231&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,231&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(119)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,812&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(161)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338,873&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,231&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,231&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Included in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215,613&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(161)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215,642&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(161)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338,873&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.120%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">121&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,710&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,731&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">452,502&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">452,740&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Included in marketable securities</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309,903</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">452,502&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">452,740&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________________________</span></div><div style="text-align:justify;margin-bottom:12pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">As of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">December 31, 2019</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">, $9.5 million of marketable securities have maturity dates greater than 12 months and are available to convert into cash, if needed.&#160;</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">For the three months ended March 31, 2020 there were nominal realized gains. For the fiscal year ended December 31, 2019, there were no realized gains or losses. The cost of securities sold is based on the specific identification method.</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Unrealized loss positions in the marketable securities as of March 31, 2020 and December 31, 2019 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized in other comprehensive gain (loss). The fair value of these marketable securities in unrealized loss positions was $99.5 million and $42.6 million as of March 31, 2020 and December 31, 2019, respectively.&#160; </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.181%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.184%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,231&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,662&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634810320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities led by the first, oral monotherapy for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease in the clinic, and an industry leading rare disease gene therapy portfolio. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The cornerstone of the Company's portfolio is Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several other geographies around the world. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. In February 2019, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In the first quarter of 2020, the British Medicines and Healthcare Products Regulatory Agency issued a Promising Innovative Medicine designation for AT-GAA for the treatment of late-onset Pompe disease. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has established an industry leading gene therapy portfolio of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital ("Nationwide Children's") and an expanded collaboration with the University of Pennsylvania ("Penn"). The Company's pipeline includes gene therapy programs in rare, neurologic lysosomal disorders ("LDs"), specifically: CLN6, CLN3, and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), Niemann-Pick Type C (&#8220;NPC&#8221;), Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). This expanded collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies In the first quarter of 2020, the FDA granted Fast Track designation to the CLN3 Batten disease gene therapy, AT-GTX-502, for the treatment of pediatric patients less than 18 years of age. </span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company's operations have not yet been significantly impacted from the novel coronavirus (&#8220;COVID-19&#8221;) pandemic. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, and maintained its clinical trials, with minimal disruption. The Company believes its ability to continue to operate without any significant disruptions will depend on the continued health of its employees, the ongoing demand for Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"> and the continued operation of its global supply chain. The Company has continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of its global workforce. However, the Company's results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.</span></div><div style="text-indent:18pt;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company had an accumulated deficit of $1.9 billion as of March 31, 2020 and anticipates incurring losses through the fiscal year ending December 31, 2020 and beyond. The Company has historically funded its operations through stock offerings, debt issuances, Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> revenues, collaborations, and other financing arrangements. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The current cash position, including expected Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> revenues, is sufficient to fund ongoing Fabry, Pompe, and gene therapy program operations well into the second half of 2022. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6633176400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of cash, cash equivalents and marketable securities</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: </span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:44.198%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.719%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.725%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31, 2020</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,231&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,231&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107,152&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">65&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(119)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,812&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(42)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(161)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338,873&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,231&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,231&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Included in marketable securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215,613&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(161)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">215,642&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338,844&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">190&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(161)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">338,873&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:44.120%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.741%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of December 31, 2019</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Gain</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gross<br/>Unrealized<br/>Loss</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145,875&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">121&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(5)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,659&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">53&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,710&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,731&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">79&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,999&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(10)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">350&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Certificates of deposit</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">51&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">452,502&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">452,740&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Included in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">142,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Included in marketable securities</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309,665&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">309,903</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total cash, cash equivalents, and marketable securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">452,502&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">255&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">452,740&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________________________</span></div><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1) </sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;">As of </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">December 31, 2019</span>, $9.5 million of marketable securities have maturity dates greater than 12 months and are available to convert into cash, if needed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of cash, cash equivalents, and restricted cash</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"/><td style="width:68.175%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.181%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.530%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.184%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">123,231&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">96,349&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Restricted cash</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,662&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,579&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">125,893&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">98,928&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789411616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Apr. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Amicus Therapeutics,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">71-0869350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1 Cedar Brook Drive,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cranbury,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(609)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">662-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">FOLD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,664,403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001178879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6730918368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (88,948)<span></span>
</td>
<td class="num">$ (120,299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive gain (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment gain (loss), net of tax impact of $1,536 and $0, respectively</a></td>
<td class="nump">4,196<span></span>
</td>
<td class="num">(1,804)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (loss) gain on available-for-sale securities, net of tax impact of $(56) and $0, respectively</a></td>
<td class="num">(209)<span></span>
</td>
<td class="nump">584<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income</a></td>
<td class="nump">3,987<span></span>
</td>
<td class="num">(1,220)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (84,961)<span></span>
</td>
<td class="num">$ (121,519)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791188592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 123,231<span></span>
</td>
<td class="nump">$ 142,837<span></span>
</td>
<td class="nump">$ 96,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair Value, Cash balances</a></td>
<td class="nump">123,231<span></span>
</td>
<td class="nump">142,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">215,613<span></span>
</td>
<td class="nump">309,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="num">(161)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, Available-for-sale debt securities</a></td>
<td class="nump">215,642<span></span>
</td>
<td class="nump">309,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities', window );">Cost, Cash balances and available-for-sale securities</a></td>
<td class="nump">338,844<span></span>
</td>
<td class="nump">452,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, Cash balances and available-for-sale securities</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, Cash balances and available-for-sale securities</a></td>
<td class="num">(161)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure', window );">Fair value, Cash balances and available-for-sale securities</a></td>
<td class="nump">338,873<span></span>
</td>
<td class="nump">452,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities with maturity date greater than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, Cost</a></td>
<td class="nump">107,152<span></span>
</td>
<td class="nump">145,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, Gross Unrealized Gain</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, Gross Unrealized Loss</a></td>
<td class="num">(119)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, Fair Value</a></td>
<td class="nump">107,098<span></span>
</td>
<td class="nump">145,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">35,248<span></span>
</td>
<td class="nump">73,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, Available-for-sale debt securities</a></td>
<td class="nump">35,348<span></span>
</td>
<td class="nump">73,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, Cost</a></td>
<td class="nump">68,812<span></span>
</td>
<td class="nump">77,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, Gross Unrealized Gain</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, Gross Unrealized Loss</a></td>
<td class="num">(42)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, Fair Value</a></td>
<td class="nump">68,795<span></span>
</td>
<td class="nump">77,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Corporate debt securities, Cost</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">11,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Corporate debt securities, Gross Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Corporate debt securities, Gross Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Corporate debt securities, Fair Value</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">11,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, Available-for-sale debt securities</a></td>
<td class="nump">350<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Cash, Money Market Funds, and Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost, available-for-sale securities</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gain, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized loss, available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, Available-for-sale debt securities</a></td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=fold_ShortTermCorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6641096064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of assets and liabilities subject to fair value measurements</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of March 31, 2020 are identified in the following table:</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands) </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">35,348&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">68,795&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">107,098&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,378&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,378&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">218,619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">218,619&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:58.058%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.481%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.775%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.484%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands) </span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,612&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,612&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,055&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,612&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,667&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2019 are identified in the following table:</span></div><div style="text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">&#160;</span></div><div style="text-align:justify;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Assets:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Commercial paper</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,710&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">73,710&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Asset-backed securities</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">77,810&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">145,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">U.S. government agency bonds</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,991&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,768&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">314,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">314,270&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-align:justify;margin-bottom:6pt;"><span><br/></span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:61.876%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.306%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.306%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:9.310%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;2</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Level&#160;3</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent consideration payable</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,681&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,681&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred compensation plan liability</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,419&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,681&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">27,100&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program: </span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.567%;"><tr><td style="width:1.0%;"/><td style="width:18.625%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.581%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:13.468%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.581%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.625%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.581%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:18.625%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.581%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:17.533%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contingent&#160;Consideration<br/>Liability</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Fair Value as of March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Valuation&#160;Technique</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unobservable&#160;Input</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Range</span></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9.4%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Clinical and regulatory milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,985&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability weighted discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Probability of achievement of milestones</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">75% - 78%</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Projected year of payments</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2021 - 2022</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of changes in contingent consideration payable</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table shows the change in the balance of contingent consideration payable for the three months ended March 31, 2020 and March 31, 2019, respectively:</span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, beginning of the period</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">22,681&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,700&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Changes in fair value during the period, included in the Consolidated Statements of Operations</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">931&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,383&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment for contingent consideration paid in stock </span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(316)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Balance, end of the period</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">23,612&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,767&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>33
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "fold-20200331.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 98,
   "dts": {
    "calculationLink": {
     "local": [
      "fold-20200331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "fold-20200331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "fold-20200331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "fold-20200331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "fold-20200331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "fold-20200331.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 371,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 14,
    "http://www.amicustherapeutics.com/20200331": 4,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 23
   },
   "keyCustom": 28,
   "keyStandard": 287,
   "memberCustom": 10,
   "memberStandard": 24,
   "nsprefix": "fold",
   "nsuri": "http://www.amicustherapeutics.com/20200331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.amicustherapeutics.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107103 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111104 - Disclosure - Inventories",
     "role": "http://www.amicustherapeutics.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114105 - Disclosure - Debt",
     "role": "http://www.amicustherapeutics.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119106 - Disclosure - Share-Based Compensation",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126107 - Disclosure - Assets and Liabilities Measured at Fair Value",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue",
     "shortName": "Assets and Liabilities Measured at Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130108 - Disclosure - Basic and Diluted Net Loss per Common Share",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare",
     "shortName": "Basic and Diluted Net Loss per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3f47f80cc42645f4afb99b7ca72c39f8_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3f47f80cc42645f4afb99b7ca72c39f8_I20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312303 - Disclosure - Inventories (Tables)",
     "role": "http://www.amicustherapeutics.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315304 - Disclosure - Debt (Tables)",
     "role": "http://www.amicustherapeutics.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320305 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2327306 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables",
     "shortName": "Assets and Liabilities Measured at Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331307 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables",
     "shortName": "Basic and Diluted Net Loss per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3f47f80cc42645f4afb99b7ca72c39f8_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business (Details)",
     "role": "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails",
     "shortName": "Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3f47f80cc42645f4afb99b7ca72c39f8_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3f47f80cc42645f4afb99b7ca72c39f8_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3f47f80cc42645f4afb99b7ca72c39f8_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3f47f80cc42645f4afb99b7ca72c39f8_I20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3f47f80cc42645f4afb99b7ca72c39f8_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)",
     "role": "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails",
     "shortName": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtSecuritiesRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3f47f80cc42645f4afb99b7ca72c39f8_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Inventories (Details)",
     "role": "http://www.amicustherapeutics.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3f47f80cc42645f4afb99b7ca72c39f8_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i140e72212c4a4bfb81bf6148fb2aa0a6_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416406 - Disclosure - Debt - Summary of Long Term Debt (Details)",
     "role": "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails",
     "shortName": "Debt - Summary of Long Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i140e72212c4a4bfb81bf6148fb2aa0a6_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "ia85c7d4cee774ba29ddedfa2ec518587_I20190331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417407 - Disclosure - Debt - Narrative (Details)",
     "role": "http://www.amicustherapeutics.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "ia85c7d4cee774ba29ddedfa2ec518587_I20190331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Debt - Interest Expense (Details)",
     "role": "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails",
     "shortName": "Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421409 - Disclosure - Share-Based Compensation - Weighted-average Assumptions (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails",
     "shortName": "Share-Based Compensation - Weighted-average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3357c282064f406dac5037a4c2b21d13_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422410 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
     "shortName": "Share-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3357c282064f406dac5037a4c2b21d13_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3b6358ff594f435b8c28ece99c733032_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423411 - Disclosure - Share-Based Compensation - Narrative (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
     "shortName": "Share-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3b6358ff594f435b8c28ece99c733032_I20200331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "id011b45be10140f38519fd2adf3253d2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424412 - Disclosure - Share-Based Compensation - RSUs and PBRSUs Summary (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
     "shortName": "Share-Based Compensation - RSUs and PBRSUs Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "id011b45be10140f38519fd2adf3253d2_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425413 - Disclosure - Share-Based Compensation - Expense Summary (Details)",
     "role": "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails",
     "shortName": "Share-Based Compensation - Expense Summary (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3f47f80cc42645f4afb99b7ca72c39f8_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428414 - Disclosure - Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i3f47f80cc42645f4afb99b7ca72c39f8_I20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i196c9221c6d643fdaa0ea733f27450c9_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429415 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Rollforward (Details)",
     "role": "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails",
     "shortName": "Assets and Liabilities Measured at Fair Value - Level 3 Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i196c9221c6d643fdaa0ea733f27450c9_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432416 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)",
     "role": "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
     "shortName": "Basic and Diluted Net Loss per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Loss (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i05bc9b3b7144464c88b636e60eedf49a_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i05bc9b3b7144464c88b636e60eedf49a_I20181231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.amicustherapeutics.com/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "fold-20200331.htm",
      "contextRef": "i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 37,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "fold_ATB200PompeProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the information pertaining to ATB-200 Pompe program.",
        "label": "ATB200 Pompe Program [Member]",
        "terseLabel": "ATB200 Pompe Program"
       }
      }
     },
     "localname": "ATB200PompeProgramMember",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated Depreciation And Amortization, Finance And Operating Right-Of-Use Leases",
        "label": "Accumulated Depreciation And Amortization, Finance And Operating Right-Of-Use Leases",
        "terseLabel": "Less accumulated depreciation and amortization on finance and operating lease right-of-use leases"
       }
      }
     },
     "localname": "AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from Termination of Capped Call Confirmations.",
        "label": "Adjustments To Additional Paid In Capital Premiums Paid From Termination Of Capped Call Confirmations",
        "terseLabel": "Termination of capped call confirmations"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_AmortizationDeferredFinancingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortization of specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Amortization Deferred Financing Costs",
        "terseLabel": "Amortization of deferred financing"
       }
      }
     },
     "localname": "AmortizationDeferredFinancingCosts",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CallidusBiopharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to Callidus Biopharma, Inc.",
        "label": "Callidus Biopharma Inc [Member]",
        "terseLabel": "Callidus Biopharma Inc"
       }
      }
     },
     "localname": "CallidusBiopharmaIncMember",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Also includes amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities",
        "totalLabel": "Cost, Cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecurities",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "terseLabel": "Gross unrealized gain, Cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedLabel": "Gross unrealized loss, Cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_2": {
       "order": 3.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents cash and cash equivalents and marketable securities.",
        "label": "Cash, Cash Equivalents And Available-for-sale Debt Securities Fair Value Disclosure",
        "totalLabel": "Fair value, Cash balances and available-for-sale securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to clinical and regulatory contingent consideration milestones.",
        "label": "Contingent Consideration Liability Clinical And Regulatory Milestones [Member]",
        "terseLabel": "Contingent Consideration Liability Clinical and Regulatory Milestones"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ContingentConsiderationMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Consideration, Measurement Input",
        "label": "Contingent Consideration, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "ContingentConsiderationMeasurementInput",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "fold_ContingentConsiderationPaidInStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Consideration Paid in Stock",
        "label": "Contingent Consideration Paid in Stock",
        "terseLabel": "Contingent consideration paid in shares"
       }
      }
     },
     "localname": "ContingentConsiderationPaidInStock",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ContingentConsiderationPaidInStockAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contingent Consideration Paid In Stock, Adjustment",
        "label": "Contingent Consideration Paid In Stock, Adjustment",
        "terseLabel": "Adjustment for contingent consideration paid in stock"
       }
      }
     },
     "localname": "ContingentConsiderationPaidInStockAdjustment",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ConvertibleSeniorNotes2016Due2023Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertaining to the 3.0% unsecured Convertible Senior Notes due 2023 (the \"Convertible Notes).",
        "label": "Convertible Senior Notes2016 Due2023 [Member]",
        "terseLabel": "Convertible Senior Notes 2016, Due 2023"
       }
      }
     },
     "localname": "ConvertibleSeniorNotes2016Due2023Member",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest",
        "label": "Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest",
        "terseLabel": "Exchange agreement, accrued and unpaid interest"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount",
        "label": "Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount",
        "terseLabel": "Exchange agreement, aggregate principal amount"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance",
        "label": "Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance",
        "terseLabel": "Shares authorized for issuance (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_DebtInstrumentsConvertibleThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instruments, Convertible, Threshold Trading Days",
        "terseLabel": "Threshold trading days"
       }
      }
     },
     "localname": "DebtInstrumentsConvertibleThresholdTradingDays",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "terseLabel": "Corporate debt securities, Gross Unrealized Gain"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Loss, Before Tax, Current",
        "negatedTerseLabel": "Corporate debt securities, Gross Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_EmployeeAndDirectorsStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An arrangement whereby an employee or member of the Board of Directors is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.",
        "label": "Employee And Directors Stock Options [Member]",
        "terseLabel": "Options to purchase common stock",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeAndDirectorsStockOptionsMember",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ForeignCurrencyRemeasurementGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Currency Remeasurement Gain (Loss), Before Tax",
        "label": "Foreign Currency Remeasurement Gain (Loss), Before Tax",
        "negatedLabel": "Foreign currency remeasurement loss"
       }
      }
     },
     "localname": "ForeignCurrencyRemeasurementGainLossBeforeTax",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (Loss) On Extinguishment Of Debt, Additional Paid-In Capital",
        "label": "Gain (Loss) On Extinguishment Of Debt, Additional Paid-In Capital",
        "terseLabel": "Gain (loss) on extinguishment of debt, additional paid-in capital"
       }
      }
     },
     "localname": "GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued",
        "label": "Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued",
        "terseLabel": "Gain (loss) on extinguishment of debt, fair value of common shares issued"
       }
      }
     },
     "localname": "GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_IncreaseDecreaseInDeferredReimbursements": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of deferred reimbursements.",
        "label": "Increase (Decrease) In Deferred Reimbursements",
        "terseLabel": "Deferred reimbursements"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredReimbursements",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_IncreaseDecreaseInNoncurrentOperatingLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of noncurrent liabilities that result from activities that generate operating income.",
        "label": "Increase (Decrease) In Noncurrent Operating Liabilities",
        "terseLabel": "Other non-current assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInNoncurrentOperatingLiabilities",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_MeasurementInputProbabilityOfMilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement Input, Probability Of Milestone Achievement [Member]",
        "label": "Measurement Input, Probability Of Milestone Achievement [Member]",
        "terseLabel": "Probability of Milestone Achievement"
       }
      }
     },
     "localname": "MeasurementInputProbabilityOfMilestoneAchievementMember",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_PaymentsForRepurchaseOfRestrictedStockUnits": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire restricted stock units during the period.",
        "label": "Payments For Repurchase Of Restricted Stock Units",
        "negatedTerseLabel": "Purchase of vested restricted stock units"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfRestrictedStockUnits",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_ProbabilityWeightedDiscountedCashFlowMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents information pertaining to valuation technique of probability weighted discounted cash flow.",
        "label": "Probability Weighted Discounted Cash Flow [Member]",
        "terseLabel": "Probability Weighted Discounted Cash Flow"
       }
      }
     },
     "localname": "ProbabilityWeightedDiscountedCashFlowMember",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt",
        "label": "Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt",
        "terseLabel": "Proceeds from termination of capped call confirmations"
       }
      }
     },
     "localname": "ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_SeniorSecuredTermLoanDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Secured Term Loan due 2023",
        "label": "Senior Secured Term Loan due 2023 [Member]",
        "terseLabel": "Senior Secured Term Loan due 2023"
       }
      }
     },
     "localname": "SeniorSecuredTermLoanDue2023Member",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the estimated dividend per share to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Fair Value Assumptions Expected Dividend Per Share",
        "terseLabel": "Expected annual dividend per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "fold_ShortTermCorporateDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Short Term Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "ShortTermCorporateDebtSecuritiesMember",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "fold_StockIssuedDuringPeriodSharesContingentConsideration": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period Shares Contingent Consideration",
        "label": "Stock Issued During Period Shares Contingent Consideration",
        "terseLabel": "Stock issued for contingent consideration (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesContingentConsideration",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents Stock issued from exercise of warrants (in shares).",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "fold_StockIssuedDuringPeriodValueContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period Value Contingent Consideration",
        "label": "Stock Issued During Period Value Contingent Consideration",
        "terseLabel": "Stock issued for contingent consideration"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueContingentConsideration",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents Stock issued from exercise of warrants.",
        "label": "Stock Issued During Period, Value, Warrants Exercised",
        "terseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pertaining to the Company's Amended and Restated 2007 Equity Incentive Plan.",
        "label": "Stock Option Plan Amended Restated2007 Equity Incentive Plan [Member]",
        "terseLabel": "Stock Option Plan Amended Restated 2007 Equity Incentive Plan"
       }
      }
     },
     "localname": "StockOptionPlanAmendedRestated2007EquityIncentivePlanMember",
     "nsuri": "http://www.amicustherapeutics.com/20200331",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r117",
      "r175",
      "r177",
      "r290",
      "r292",
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r16",
      "r118",
      "r119",
      "r176"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r32",
      "r156"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation of property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax",
        "verboseLabel": "Unrealized (loss) gain on available-for-sale securities"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r46",
      "r49",
      "r51",
      "r52",
      "r247",
      "r250",
      "r251"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.",
        "label": "Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Accumulated other comprehensive loss:"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt": {
     "auth_ref": [
      "r162"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.",
        "label": "Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt",
        "terseLabel": "Equity component of the convertible notes"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition",
        "terseLabel": "Restricted stock tax vesting"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r183",
      "r208",
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total equity compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r120",
      "r132",
      "r134",
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r66",
      "r80",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of debt discount"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r80",
      "r255"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt discount and deferred financing"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r129",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r115",
      "r268",
      "r281"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r45"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Fair value of assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r127"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gain, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross unrealized loss, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r125",
      "r140"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Cost, available-for-sale securities"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r122",
      "r126",
      "r140"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair value, Available-for-sale debt securities",
        "verboseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r124",
      "r140"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Corporate debt securities, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r124",
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities with maturity date greater than 12 months"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r185",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r219",
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r79",
      "r225"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "verboseLabel": "Non-cash changes in the fair value of contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r221",
      "r222",
      "r224"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r221",
      "r223"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration payable"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures unpaid at the end of period"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r31",
      "r82"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": 3.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": 1.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value, Cash balances"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r8",
      "r83",
      "r89",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Marketable Securities and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, and Short-term Investments [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r8",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]",
        "terseLabel": "Cash, Cash Equivalents, Marketable Securities, and Restricted Cash"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r76",
      "r82",
      "r88"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at the end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r76",
      "r249"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash at the end of the period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r179",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r40",
      "r159",
      "r272",
      "r287"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.01 par value, 500,000,000 shares authorized, 257,449,955 and 255,417,869 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income [Member]",
        "terseLabel": "Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r55",
      "r57",
      "r58"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r105",
      "r279"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r229",
      "r235",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtFairValueDisclosures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt, Fair Value Disclosures",
        "terseLabel": "Fair value of the Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtFairValueDisclosures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Convertible Debt Securities [Member]",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.",
        "label": "Convertible Debt [Table Text Block]",
        "terseLabel": "Schedule of liability components of long term debt"
       }
      }
     },
     "localname": "ConvertibleDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r179",
      "r181",
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r269",
      "r270",
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r13",
      "r163",
      "r270",
      "r280"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "terseLabel": "Threshold consecutive trading days"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.",
        "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger",
        "terseLabel": "Threshold percentage"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r38",
      "r92",
      "r169",
      "r170",
      "r171",
      "r172",
      "r253",
      "r254",
      "r256",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Debt Instruments"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r253",
      "r256"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Less: debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails_1": {
       "order": 2.0,
       "parentTag": "fold_CashCashEquivalentsAndAvailableforsaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Amortized Cost, Current",
        "totalLabel": "Corporate debt securities, Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r130",
      "r141",
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair value of available-for-sale debt securities in unrealized loss positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Realized Gain (Loss)",
        "terseLabel": "Realized gain (loss) on debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.",
        "label": "Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent",
        "terseLabel": "Deferred compensation plan liability"
       }
      }
     },
     "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).",
        "label": "Deferred Credits and Other Liabilities, Current",
        "terseLabel": "Deferred reimbursements"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).",
        "label": "Deferred Credits and Other Liabilities, Noncurrent",
        "terseLabel": "Deferred reimbursements"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r216",
      "r217"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r44",
      "r151"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "negatedLabel": "Less: deferred financing"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r80",
      "r113"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss attributable to common stockholders per common share - basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r249"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation costs, period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Financial assets and liabilities subject to fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r245",
      "r246"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of assets and liabilities subject to fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of significant unobservable inputs used in the valuation of the contingent consideration payable"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r239",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Assets and Liabilities Measured at Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r239",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r179",
      "r180",
      "r181",
      "r239",
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r243"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "Changes in fair value of contingent consideration payable",
        "negatedTerseLabel": "Changes in fair value during the period, included in the Consolidated Statements of Operations"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of the period",
        "periodStartLabel": "Balance, beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r259",
      "r261"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r133",
      "r136",
      "r137",
      "r138",
      "r139",
      "r142",
      "r143",
      "r144",
      "r145"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r248",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Transactions"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r80",
      "r165",
      "r166"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Loss on exchange of convertible debt",
        "terseLabel": "Loss on exchange of convertible notes"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.amicustherapeutics.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r60",
      "r97",
      "r266",
      "r274",
      "r289"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r114",
      "r218"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r154",
      "r155"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "In-process research\u00a0&amp; development"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r59",
      "r112",
      "r252",
      "r255",
      "r276"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "terseLabel": "Contractual interest expense"
       }
      }
     },
     "localname": "InterestExpenseDebtExcludingAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Components of total interest expense"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r74",
      "r77",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryCostsForContractsOrProgramsPolicy": {
     "auth_ref": [
      "r26",
      "r28",
      "r89"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for costs relating to long-term contracts or programs. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average). Elements of costs in inventory may include retained costs representing the excess of manufacturing or production costs over the amounts charged to cost of sales or delivered or in-process units, initial tooling or other deferred startup costs.",
        "label": "Inventory Costs for Contracts or Programs, Policy [Policy Text Block]",
        "terseLabel": "Inventories and Cost of Goods Sold"
       }
      }
     },
     "localname": "InventoryCostsForContractsOrProgramsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r22",
      "r149"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r43",
      "r147"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r24",
      "r149"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r43",
      "r94",
      "r147",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "terseLabel": "Reserve for inventory"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r23",
      "r149"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r65",
      "r111"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r271",
      "r285"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r238"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Fair value of liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r13",
      "r164",
      "r270",
      "r282"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Net carrying value"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r38",
      "r160"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r4",
      "r36"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Investments in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r76",
      "r78",
      "r81"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r53",
      "r56",
      "r61",
      "r81",
      "r101",
      "r275",
      "r288"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss attributable to common stockholders",
        "verboseLabel": "Net loss attributable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r96",
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Developments"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Ex-U.S."
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r257"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use assets, less accumulated amortization of $6,260 and $5,342 at March 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r237"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r227",
      "r228",
      "r232"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized holding gain (loss) on available-for-sale securities",
        "verboseLabel": "Unrealized (loss) gain on available-for-sale securities, net of tax impact of $(56) and $0, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r227",
      "r228",
      "r232"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment gain (loss), net of tax impact of $1,536 and $0, respectively",
        "verboseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": {
     "auth_ref": [
      "r227",
      "r228",
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustment, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r47",
      "r48",
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax",
        "terseLabel": "Available-for-sale securities, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r54",
      "r57",
      "r227",
      "r228",
      "r232"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive gain (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForTenantImprovements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for the allowance granted to lessee and/or direct costs incurred by lessor used to prepare the leased premises for tenant's occupancy.",
        "label": "Payments for Tenant Improvements",
        "terseLabel": "Tenant improvements paid through lease incentives"
       }
      }
     },
     "localname": "PaymentsForTenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r185",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r29",
      "r30"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r70",
      "r71",
      "r123"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Sale and redemption of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r73",
      "r211"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds of exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r53",
      "r56",
      "r75",
      "r115",
      "r116",
      "r227",
      "r230",
      "r231",
      "r233",
      "r234"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r9",
      "r10",
      "r157",
      "r286"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property and equipment, less accumulated depreciation of $19,260 and $17,604 at March 31, 2020 and December 31, 2019, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r8",
      "r82",
      "r88",
      "r267",
      "r283"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r18",
      "r173",
      "r284"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r174",
      "r175"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "Net product sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations",
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Cash, Money Market Funds, and Marketable Securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of changes in contingent consideration payable"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of reconciliation of the numerator and denominator used in computing basic and diluted net loss per common share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r183",
      "r207",
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Equity Compensation Expenses"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r7",
      "r25",
      "r26",
      "r27"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventories for the period"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r8",
      "r88",
      "r267",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r185",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r187",
      "r198",
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Options Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Non-Vested RSU Activity under the Plan"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Secured Long-term Debt, Noncurrent",
        "terseLabel": "Senior secured term loan"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64",
      "r146"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general, and administrative expense"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorLoansMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A senior loan takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for [must receive] repayment [prior] relative to junior and unsecured (general) creditors.",
        "label": "Senior Loans [Member]",
        "terseLabel": "Senior Loans"
       }
      }
     },
     "localname": "SeniorLoansMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Non-vested units (in shares)",
        "periodStartLabel": "Non-vested units (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of\u00a0Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Non-vested units (in dollars per share)",
        "periodStartLabel": "Non-vested units (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Non-vested units, weighted average remaining years"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options, Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options, Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedTerseLabel": "Options, Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options, Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options, Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r189",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding (in shares)",
        "periodStartLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding (in dollars per share)",
        "periodStartLabel": "Options outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise\u00a0 Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, vested and unvested expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options, Vested and unvested expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options, Vested and unvested expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r182",
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options, Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Nonvested",
        "terseLabel": "Non-vested units, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r204",
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life, options vested and unvested expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r42",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r41",
      "r168",
      "r169",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Equity component of the convertible notes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r14",
      "r15",
      "r168",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Restricted stock tax vesting (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r168",
      "r173",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options, Exercised (in shares)",
        "terseLabel": "Stock issued from exercise of stock options, net (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r14",
      "r15",
      "r173",
      "r184",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r168",
      "r173"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Stock issued from exercise of stock options, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r121"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government agency bonds"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails",
      "http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r103",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Outstanding warrants, convertible to common stock",
        "verboseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average common shares outstanding - basic and diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails",
      "http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=27011391&loc=d3e105025-122735"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4852-112606"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=SL116692626-108610"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.6(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r294": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r295": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r296": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r297": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r298": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r299": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "8",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>34
<FILENAME>0001178879-20-000023-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001178879-20-000023-xbrl.zip
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MT5T6X[)9$DGE)\?+B$K\ -09N4?IK(FFMN>QJ7U'THO-N.TC.=Z"G4/Z4Y0
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MA?_!"M1'LG>;"-Q2\S8$  %:0L1BG["=H?[BU']+:<XB?\D@S>KJXO2<G1,
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M>\!NKHQZKK$Y7(6/&=OYUJ^RP$=KVX;5Y5$0<B=]WG;65B")IT$(8".9J>?
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M"_*A>Z!#??IF &?=R>ON:'!FC3^<##Y"MS?5-177K6SLQ/1W*A6;/YV5XEY
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M_JSKRL6Q/FB57Y7-^0U/:M5U55'6&+.!ZO7@#%_<TH?"_C-*?2!LF 7:34Z
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M8899[G$]@%GF3RW[!.S/C HX8P1&>93G<'K@SD^=&996N^S5:9X=PP^E$:^
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M=$O=*4:Z</\9>2VY3??-V/\:6G?J2A4(@#""OH3>90PB4,3UC?]Y'X$>6I>
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MZ1H8YJ>K]V?1LZ1GLE8.>,HDR\%3J?ZIJCC.N.(\Y6*[2Z8SR+ZZGE_+EPT
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M*Y?!OG%U>3FGK\7^S+3/IJ2A%2A.2?)@!6Z\&KQ+_5TJ_+V!NM58E++,+['
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M#==5@<6RRFQ[I[.Y%_RVWV[N;\#E&[\_>@SE;6,XOP!PQQ V^ZD!HE:5GG%
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M[I]J=+(['N;UCH-LJ7?&955WAL.8_Q\:U+3E[/#"==U]WGG[?H<?[NV(-_2
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MJFRTD3EL"'(Z"L2#Y\@X3Y#W*FKN.96<;VVSMJ(/[(C;]'*F5;M% /,:&8H
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MFA8, 0BX?PCX0=40(*!Y$##3(:W)F^L=19X8C3B6!NG2U$![[Y-@&>LER1!
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MQV9^**?QO.RD0!%[@;A1#FE"*9(B,.HU%42;K6V*KW=6@,180,N-0TM0!T#
M-UK 5U56 ^I @]6!^0!.2%P2E3C2(5C$N1"E@SQ%(3")E=2,4 $*02,#-QM=
M*?.\/\@'Z[4R(.1;W)^U1H/\FYTZ8-NRE^@ A3--TGHV/?P*J2D@X"#@(. -
MV#H0<!!P$' 0<!#P]13PY89I;IT]^S5/S=0<VYU:8\?%&)N<^4XO',],,_#;
M/)C?YFPNC..]2,DHC201 O&8!'*:>805U4EX+9P66]N\32#K%C#UT6 J* T@
MX!LMX TMN0&EH<%*PWRPQQD5+6,8&68#XB(%Y$)2R%"LJ30X6F% ;6ARS&>C
MBW7RW5]7YT#Q39.4GTT/S4(J"P@X"#@(> .V#@0<!!P$' 0<!!P$' 0<!+QQ
M KY0.CGS@GG.(E:>*RZ<+^5&1C..E?'8/LB4AL,XFO@>_]L?#L%5N("K\*C,
M4'@U&]:>> PL120H9XC+*)'#-" 6$M/!"I$$V=K6NFVXAM1PP#[ OH<JI0'L
M6P[VS<(DUMD48E#(>J,0IUP@$V7>JF@D52+FG32 ?4T-D6QT6<SOMF-[/K;L
MJ'5@!_ZDQ4B[52"D&84PKC\(<5 ?(2]=:]CO5*%U>9&3-Z>'8_G]T!^[3KS\
MP)H1PE?Y8%C:3 Z_H(3$J29!<IMHX%0Y+7Q,AG,B';9:BW_W;V*"_</G"S#
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M&2FD-ZG8(2Q3" ,* 0H!"@$*>? V,<X:;B1+*3I. ]9!!XEQXB;Z8+#X.H4
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M#8BB 2QO:+0(P+C98#PS'I1E.L54REIX-AY\<LA@'I'7ADLL)8LN@S&1;='
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MFJ644(,D(PK13&(D<.:0HXE+J(;%S_3U&A*R^R&H (+V1R<A\+]RA85:3>%
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MMAP;2[B5B6^7>HYAK_OX</DF*-XLT9M37&_'?K/]T7$E&J#>JRF<9G^*GQM
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M%CJ7-,D1RVB&J"(826,%,@XG0J7:I$D2E.4T*LL=-<,^W%#8Y[[[+:I+8,=
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M(:4H22VE2:XRX$]T,Z&1/]TU?UJL +)2Z^.:6EO?O^( /\GN/;=LPGXHE3F
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M&JGI]*2!HQ-3VAOIW$HHQ"M&16F%%'ZBRO\QG!P;)WNWTNL;1?7H7STCG/=
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M0.B\]BYJ#6&HE$***)RTQ,XRZ)DR69/419/,8R($SQB1.@!J9-0D3'L@G?3
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MELP2:RNDN%48(\L=IR0XK:'7@I 074X&;=Z4KI&VFDMRTH00AS6@4BA M3)
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M=J==M9CX= $I_SPWN;S7BB0H[Z%F]RW<__;Q9W/W .WL?OS9>/\VWN,@CO>
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MI*X(VS0>S?UKN( $;):C%W9!<H3E41@L%<T@-T :!')R_03-,DWK1# +&2U
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M*?T W51^E"4!2D>2WVA :A<-' >U.]AQ31[?ASQRQQV&6^@&5S%-E!3XG%8
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MT#@,,_C/211RURF5$?@'AEBL=QG8--*ZC%Q?HI SNE6I0)%'Q6!HDF>ARXC
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MM_YA;]#LC>[X_,Z'6TWGK@][G?8CG[WSK4ZK.>@,ZBU_^RUW=T6,GPGO&/<
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M9U@4('5:&V :^*%LS/AWD)Q_7@/#C]TIO?BEGP),W5WVCHZ$#W'D96YJ78I
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MVUA5([2\HQ? /;QO;UC=MB86^0R+3\"P8K20"40?BVX*Q26]9C!]4$;RCEI
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M]C_]A7R3W:9U\O[BZN/[MY?DE_SP\?W)V2FZ(I\968]S35HIYP7KM"CO68L
M4";_SC72(!ZVQ!K_;E-%":<@%)D=2O,#JB9=5D\$+M(L5+.-1+=K!-N"2.;8
MS)G]F 52O:DC&D[O6+[@7_$AI^>9?RHR""X+S]>9EAACUD*=4:=+21F4Z@KG
MY#14\VN8U(O!5Q''Z/U"+E0LG60 IQL_40?%,WT (>3Z"R#NLR_4<A+XR7LL
M&E9SHHK/"Y&B/K<+NX25:_A::BP-5RVX9Y/*I?E5I^B0!"Z SFKW?3LI?V=M
M-W@EF"(BV3"RE75LX GI[XPH]J[W21X8C0L\3 TSA<C33%]+$AZ!1&$Z_S\L
MT;TB_\7F2H$42"!8ZJR7LCQ2::Z4>FR$^;E=FK+]>;TB&V"*'0VH,<P$%!_C
MBDLH0ZE&JR< E44G(Z#]^)VVXF,IGYO-,ZY#UNGA&0ZO4(7)99Q9'9#Y58B*
M)(-)SZ WP]ML,G2Q*D7?BR==HHK$4 ]R:!1H\MPTJ%.SZ(0T -5T8HW1,E+H
M'';TN6BEI-"##54ZR+L546^+0D$I\L:.1<+F/]L>R$N3$C.=KC/3Z1HS-7'P
MA>I;X9+.[YDY.9A*OGI$^C*>1*M5A@^#S&LZMDH!6UJ!_QDQ*8W6OV\_[.AU
M4/Z1Z-II/450WFEU]B(JO\<*[8?QQRNFU/-SI1M8[Z]^._MHG5^\?O_QW?CJ
M_/W%X^V)_B9[XB 3X\DR<)K6V[,WX[=L$IR=GE^\>1*;8 M<*MW"K10Z*_O@
M!&FIW"(R!'X-@CY@'4ZBO'\:]PC"K',7R+89J[OB]NAAN+UWN#Q6_  S:JS7
MXY.K]Q_7D;DB!]G6L8#_#_VW1>TSN58X!063#52C28JB>U)7(:A"N'PF<_$,
M.05O,#$]6!J*^=/ZE+; >0O*_NA+V#WQ=.U:UMMVEKIVZDZ8G$(]G;*Y@T$Y
M+W,E%92J!IL<]&-_=]XMM-Q4E,H*\KC, V%\!X%7A9KO) ($M@9L 594JL%:
MQ."?<MY/LABX*R E-R9U*?=FF5 "?%'^R>E%%-%D0%-9NTQ,?T8^#S%%%3QI
M E$H,\X/*4LB'Z#!$\^I :O9@^9:!7CP-;  6\*@;B_)8L@3AJ:1FY&# =[/
MY11(=_E9S<*96""V%4-R,90:^[R39BFKE]Z3&]I@FY+QN_%@NF3:V+H^$+=#
M6PV\6BMMDLO%V4DTE[JN1#$5':'1[=E RP <P^V$Z#$(: !00O!#OP\%;A1P
MUFX1+'"LS66'$3IJP!(R2UQT)%T/N(27S*7NU)#8=!E%EH3AWIYD2S4D!8VK
M1#<WU NKY> !O]26T-BSSEI33>0V97< UB*T=4J)[@&!=T?MR8.EG5>5P6$Q
M_8YB<S.  B%> ^@_B50*H='XER(0\T40+:5.LC- IUI"Q/D6J3[GWDWE.*CP
M '&88\QA/I^Y'#DRH;0VQ5O3X0J<"DYGX%3^G"SM*7??Z:^27\YL7XSU_CIW
M,%9F]#0+IM@9 Q[TX8R3 ,-[7#$74<MDU5BC=&L<TE%1N5)MN<(S5:&$"8=F
ML##G39POD<(*P&0UP6(D"/XZX[(G11\;AB?86+.')*L[-(-:::O'XZ(#GQ=G
MUY3,JKV%3$GVYFD]^$/*C,LVPJ93J3JZ2'1R"7>IZ:H8!))7ART-[A-PG#3O
MLD@9,>HVISF"J+X.5&(64:$<K!XA@(PJKWM2C3;*J\,4=.6L&VHW6RZJ+ @N
M2TC^\8@,&19!.T0,<DY>8]B!%4"Q\-E7*F^B@%K1<W:J]FR3\F*ODKRAD1B\
M?TN>R,:<DL 'H>EIQ"GR2"B<S>DV*EAMXP\SL3#=9)R[X$ELAU#T#BEDH^JA
MGJEI(9Y<2*Z]-.?%%^6,F!,-1\ET0TO:TT0N(S5>]W,8W0:</QAKYUJ)*#'Y
MAI*$5?IQ&C$[\#+=9 G[8& &<<Z<"HY@J[9%BO6(SS)<T04I8V3N)TF)ID#9
MP  ^\G0ZOZUJ94O]YT&R12@D.4D\IS%#9Z1YESG7PCN<@R2^9 LBW:A><3WU
M$L5YY/J"ZW5=K2:A7%MHI2EOB(QB1"#?H!8:7BE,\BC$L5<Q)V^N;[A'S>[Z
M\"72C8S"8MC.%/1[@X4)]35RMOJS**+ 3A[>" R.Z*M\9D8IS6D# 6@T(T("
M^B<= YGX=MO_X6'G'2UYI_U(+U55^.%=9GR[:7VZ^'CVYOSRZNSCV:EU.7Y[
M=FF]?VV=_?W3^=7_LR[/3CY]/+\Z/^-8]J?+,_Q0^:_N<5[M-714]>.E;BSV
M*00%'O/HT4(I(K^[]>EJ-=MW-^JJ'%2V^.LNHO"^V-K!>6Z3) -&]@%,QQGU
M@ =D..,RIV^'!A4&T\,P8U<>VWM>D8!.TSH]>SW^]/;JTOKTX?T%\-F+\_<?
M#7;[S +87XD^P^>%/MVF]>[\X@RD]>LS$-)&M6N--@] F[9SV#&:7G.78.US
M1) Z36.G- WG2=(TVA7O\K<!JP%D;@/61!_P2TX9K(Y_ZRZ2[S>MLW_^=O[K
M^=5.QIG"PXU!<%4/7X(1#1$161KI1PC:_)<)U<0UJ"OV(I$O]0\F(\'G7YF<
M!L_F^<DB$,N7?DBGHO>JJQZ-FH/6@&X[C>%_GMZ/PH0F8\+/J;?^X;#I.(/M
M']_Y;*OIW/5AK]-YY+-W[WC0='IW?%YZ^&<"" ,%0(UW_=>CSE%!7SSV!56=
M]N)+/@9&W3'^:4<$7KV^E;%+O.#*?+-%,7>&,<19%Q4%A@\W(/C.A%*FKQW/
M=/3+V9>9/_%3X@\7&8;7<WI1H/]>0%4T^/1@=7X 6%?:9!X**'\$AIY2(SCJ
MVE>"YSV$KX0"BLLG)7#%WLET6J065;!9^E"[P?8.=/A6NZ[LQIX*G%41 SA]
M[ZN8U2:=]%N3V%_^XH"TWH%;50LG*WBI3Y!F-IU^&UL&K04ZIX<50104>\G%
M+_@UW+S8NTV7[!/)JLRK(VL6R^E?C]3O3LMISM(YCAJ,D]0:8R6:'D&"\<BQ
M*DW#:-M'22U!Z0<:1&*O=,S_+S%?O++>JCE,Q2@'+F+.,Q2Q90UF*&*<D(._
M/*)A//<Q"^N*!A_(#' LL:WST&WF4=BK.$M2*?-2L$^ACPD.*LZ+<W2297 C
M0E^ .2]63;K=Y6*_JA*FWE@MW;Z!=&O7TNU)I-NWS'NJ)=]32[XV2[Y+'GU<
M$GU/+?M(&ATX'+ES6;O/G<N>PXEK!6:O](3*;JQ68+Y"@>DX.QGG^^3J_B%P
M_+%.V5KU>@ZJUS0*O$:KTW%00_@BOW0<Y7TXP9N?J@HA$H5W] =9;<IC-I+H
M6GD#B2YF',^S@-O(F0\]L"_/XR1Q!<FDYC8UWZX1<F<PU@3^=6K9+EZEFKP/
MF+QKM:PRFWZ@6M:^5RU;[]A7JV7[S[6KQVUJOETC9*V6/9U:UJZ]9<^=O&NU
MK#*;?IA:UGZ,MVQ;-]U##-!]6XAM4G0ON94+LX-1JY^/!1+Q1(0R:;S_$LBE
M5F';K5;[6<']*6!5J_@'+KEJ':!&R%K%?S)X8DKO^<5EG=+WK37E<D'D<!T1
MJE.JR\6PYU0[:?WSUX]OK?,0&W:ZTCJ-7!XAU%#C%-7?/?UW+Y+<X$PL%MAO
M5O6S/-?=#W%6DD@%*$H!#B]R!4Y>Q$Y:])Y47*NY&_.)]#S51"M?H]A0_KY:
MX#\]/[@\^<VJ&<)!7:M).U?B"_::6X(Q0[TN<?JO.Y-SD5-W+5Z?DIQ.QF]K
M<CJL:[V'G$Y$@--FR7WPU@\_3[ _;:6):U^M*J2OM^-?:_IZ5O3U5DQD4%/6
M-Z>L#Q_/:LHZN)N]A[@^\ 3B6GI]'QH[/7M=T]C!W>P]-':*PPW]FL*^ X5U
M:^(ZM$L]H>F9'\3U-K_B,<^UY0$L);\A3\Y1LX+A,]6SRP)._&*=\'ZFQG&/
MZ'?W@!'E3[!45?W(/"3C+W^QRO]WF4W^A8,I:!!1./6Q:Q\-P<"Q+.34Q?&[
M,M&CHRO;:[/2+1VW->!LKWC,']F <U#M!IP/H:H??E5;NF]>GK^Y&%\]PQ;,
M'U;2O-4T;AX-H]- BM1OY.F;T[_Y89RQ$.-R.'O'RW#:%4:=/'-ZM1I[G@#@
M>$P]AJ0F<B:"J1X31=DMZ@LTZCH+<6P/KB>R=!;%<$1OITD&A]PBM=/LMGN/
M;%9ZYX?=?G/8[G^+E3O-]F#X318>-KN#73NWWJ/I/U,5]:N]E]5(43&AV-]#
M*/X(+7_\[OSDTZ6%W>;''\X^79V?7-IJ</C%27,'JTYSN##BA-^:S X+06HZ
M^[Z)B8^AIQKT=X'^5*3R99T2^I50?">6UD#W$:MA^56P_'7YP_!Q<Z?UO83B
MS\G/UM^B66B];EHG,4XH73[$JU\K(8>BZ]=0W ,H;F<\3]!1OT)<J>9(-2W5
M4-P'*!Z0*G0R$WX,:Y&7_F3FR^EZ#6W-B6H:JJ%822@>$"<ZOJ.*?T/N1\V"
M#N'2:Q]Q[2/>;]#7/N+:1UPM6-8^XJ?R$9^*Q2R4UM\S?^[7&DBMOM=0K"04
MGXN#N&9'-2'54*P\%+_==/<?XR!&G_!:W\2:_]244T.QDE \+/YS?$?SUA]4
M$OBCZ]HJ7A[4Z6PO8?MY$GE+^,\LG0>__']02P,$%     @ T8.G4%XTV[O-
M#   %8$  !$   !F;VQD+3(P,C P,S,Q+GAS9.U=_W/:N!+_O7^%'[^\>S,E
MV$"^D&EZ0Y+F+C-IDTG2U_NM(VP9]&I;/LDFX?[ZMRO;8&(0MB$7>M!IIP2T
MGY7VL]I=R4+Y\.NS[QEC*B3CP5G#.C ;!@UL[K!@>-;X^GC5/&G\^O'=NP__
M:C;_.+^_,2ZY'?LTB(P+04E$'>.)12/CFT/E#\,5W#>^<?&#C4FS^5$)7?!P
M(MAP%!EMLVV^_%2<.L?.2:?7.6IV3;/3[![U#IL]>MQI]@Y)[X2>'/4&G=[[
MX6FWUS%/'*O=/#JA/6Q&FX.><]@\(8>D;=L=9P 0"/HL3Z4]HCXQ8&"!/'V6
M9XU1%(6GK=;3T]/!4^> BV&K;9I6ZX_/-P^J:2-MZ['@QUSKYX'PLO:=%GX\
M())FS5WN.7/-B<_L6$8C*DA(XXC9\L#F?@L';G8Z5B:'J$RCAP4R(H$]U1/P
M((C]Q0).)%K1)*0M:-2$5E0P>RJW6B@3(%$DV"".Z!47_B5U2>Q%9XTX^#,F
M'G,9=< K/(J\SS7(?1P1,:31%^)3&1*;5K++QW>&@<0Q/^0B,H("B$OD0/5<
MB@C$K%[3M)IHT(3J&VZ32/EOVEZ-M"#4HEXD\:?F#.+@63J-5OD.Q+(Y)"2L
MWHF\8-*1])WJG<GYL=7K]5K/Z)A+NU'T+]6^B2^;,*$JJ5WFJ.5UPT_-3&X3
M?9A-RFI]R.36[,/B^5>F*WG)+XD@]J6'?;&.UNM+O7[4[82"DM0^&/)QR^9Q
M$(D)^OFQ;H)(G6#V0W.&4J<O#F4K)VJA'YD0OE@Z-TD0\$BAX#OI>V'( I<G
M;\!;Z&&GF9O=4S>+_H4LLV NJ_].B; %]U9,_%8H>$A%Q*C,9R@%,!+4/6M@
MGFIFP?:[3;P#Z$G6I*!@?J[@QRT0L6-/#?=F-IX, 9WGK"&!$H\F%MKFX3O4
MK3I\$&$!^T>,WB.#JJ,'$>K]] ,/!:TZ<!"14/#4<7N4?X3/#08%X@6'\OJ.
M#*%_^/[7^^LRQ9'JPDPTP\\TS'SRHPFU+/PUFK/:O&DH20-%/[1>"KR BB5U
M;H./ZO7+,:?":1.-X(L045IN?FXM%$O?S&RJM70@N<<<7)><$P]+C(<1I9&L
M8_EE4!HF+,5$&\S_ ":D4RIF4$:*921@>VXB>4<$C&I$P?[$VR!1\[AZUG#2
MEV?-^&4.^S\[RN+46I*[MQ"+5=?6G&I+,/7L=4RSJV-O!FIPUYC![GES+[@/
M QO10+(QO>%R@_05H?4L=DWSL#R+<^@&PN_9+)I\@[&U@AX]SX>F>;0.S_OH
M6^1C1((AE2QXB+C]8P2%+Q7RTY\QBR8;)%VC1,_XD6D>5V \T6.PP,AK^K>1
MZ-K3[5X0.;KR^-,F@_444D_EL6F>5* 24 T%NT.L75)I"Q8B&G?/8Y@PM$Y:
M70RC8:=MF9:5+ .9M#TN8T'QAQD.4I(A[3HAES0BS-L4+QF:CIZN"7_+TF/\
MDD+N4GI[B'V?B EW']@P8"YD]R#JVVHKF 7#.P@R-J,U*"N)JY];'4LM[.?(
M2X&1N!RT,<,V,O ]BR^L_=ILEF*U;7;;Q2E9GE4H1=-7^VGZDH!',O!>C]X4
M74=NQSSLK$=NHF1/[4OCU\Z=U>#UR?2HNTX\WLG\BN4X_L.%U)AX6*5_)N('
M& +\_(':L6#X/(4$SCV5D6 V5/38OL8RHZXF?0X^MM0V[1SG*/8^66GDM+TW
M9OJ,F<+W!J@T9CJ5W-X#5O)2-YBOJ4\?WD\ZQ0BPOC?L8MBO2Q-NSO$ F]=.
M"9M3K4\7O>YKA ZU_9%U9)]3UN'ON_6&SO/=VKO/3^X^[;=TG_;>?7XJ]^D[
MCNH"\:X#EPM?#>-OSV':7F@=RC*[ZI'WYAUJUB<CUZF==*[K8 R=YZ+6+E5>
M6+NH@3]%*G/2NVGPN@N.(H1V#6'!,J(0F',8N[@8R V_=D1<@*&/9YVN.ORQ
MG(<=C#^7=!#5>3X%4OJ( ^FC8&P4VS';UHTQ.5E]<#GL%",["N]B5,%Q3[=_
M;W@P?*3X/;)!M,:#V!6(^HASU%7'D(KDS&TC(ZZ!P"EQ.QJ&OA"!9R;'="VV
M"BAZAHZ[ZMC0(H:F2#O+R'4041A$].DYI(%<CY<E6'IV3KKJ)- B=C(\(P7<
M29(>1D30<P+2N$8',ZC^U'AFMAA'G^%[5C&X*:"F0C+R4#O/2>TGU3HT;670
M-CO%"FP9/[M8+2PV[3>*]PA0AXR!CB'M2QG[ZN34&D^D:RK2QL:VU35[I>EM
M&IFZ9JK/R"G<Q\ZII=1IX%MEEKX-R9]%DPWSKM&@)QQWY"H0KO08B2(CT[1G
M>FJB]<O-DKAZ5CM=JWA^:#FKNUV4+K;X_<-7W/>^.\<7Z;IJPZ3J5.CY[7:M
MXA&BY?PBOMHU3U1-EXE[MC,CI?7^Z_"\&%S/\&'7*FSO:AC.UBN[S"S4'C3"
M"77#R(!YZF'19TK0> Z)K@@3_R5>7..[[&6!M2N;]I%5W!1(D-74S&$;&;A!
M(@/A#86_I_*EQ>NN?ZK!ZQ=$QYWB@K42K;NX2BI)P.R,P&#R.P,FA3V:W- Q
M]6I'Z(UIUH?ODZY5V$"OYA5S)R0&$V/:"T-U8Q_AEY.G#-2YYY[G<O%$A//:
MWK)4H=Y)>EVKL)=2U4D29^@8.>4[Z1I0%>&1>>>2>7%$G2\TPF]<AU3 +/)A
M?8RE4W7^2Z%JTW['M(J[S0I6<9P"&X"<?$4<L(T$/"GW]A3.&;MNQJ^ K4WW
M'2"T4,55H',7DWT9V]>.T%7 M=&X@T]6UV+VGQUU/[3F+PI,?IZ[3!"O$DSO
M6E7$XSUFW_N/YVW3O,/EZIW@0T'\S]0?4-$PR$!&@MC162,2N"S#*Q$AQR]M
M'S#/P\F3M5>7T9X"#XP[C^I*,R<6Z;,J&0,XBV+\Z3?!X_"LD31G$?4;1G(#
M6G([[:G#?<*":_@ 468W)1:&HC8_KZ6,J7,9"_S>E]*=%HSJ:UK0'F\58 [-
M>C(;I4L\.1UF+:PJ%D@^&R37/YTU;"@>6%32,,D[X-K@T6)2PC(7Q/.8$\MS
MQD.8##ZY#FP]S3J)-R?Z-VB&D_PV^/2,3,1,CK#%K8O/B6<'3>\(<ZZ#"Q*R
M""^I64)U3;2M)5L_GFE1?.OF0K!,7+VFC59@;JVEP*<%%.Z0@)+_KX-+ZE(!
M.N\I\P>QD,F-(TO-4AY@#1LX=/"*D6%Q+$O7,]CV.@CC:*D%2LNO-D!R=W.U
MD3K49C[QRB2'$1<1GK>ZX"+DT$NJCGE-CZWKPV%9Z3</C9"3;4H=>26X#Z$J
MQ.\#>!YPX[+TQ+W\]&RKBY!PL@9CO.D4.IP<"5U"\GJ@V^KZG_S0XQ-*^UB=
M"FI'7,C<<]H5'E%6^LT]HABCOO  _!9O.DMO+ R&N;V,"L%N%="V,C\_=_MC
M6!9@-Z^X>" >[=MV[&/I3AU0*>77 (;KL;^H@QGPG+H<UZ+/%\G(EYIKLTHJ
MA,^?P9)83[RZ)1<KJ6_)URU&7J9,"+J#9"Y-;MW/S*,R K"^/6)TK%KIXU-M
MN#</6'T?<BW[*_W.6E).7;$ .(#X<L&EIAXK([K-0>D:/$^HB[9?9-$LO?:'
M@BHY\'KHO0/9YVL0JH5)<C)6.XDV ;^MYLOEWCO0UX=/':J^%HF1H6V:Q\DM
MCY#%0(Z-*;9:4?2M _GFTVC)#D:R-/N&)XI@8?+IF0J;2<W*KRK,QL>=O".3
M%>6:P][0+M *L+<V0;6IG@RF'T>PQ,&L"6D51YS\]IV-!!.MAM=9%Y:V5:YZ
MN*0AU/%,$0.!+Y]+DAR"M?ZTT+W'D[6W[E=);[ 8UN2DS6G8UM)E\;&J/L:&
MH6IZ/IDUN2,3E6'P4>ATXRAW+AF/2N'WQB_9&.94X,"42Y\.+IND?X_VS0=T
MB.9A"E]J#[=P%P#Z4%8-0YDKB?=B6V+YMDTML"U>A%0H;8;P:@C3\0X"NLU"
MXL$\C%<L/S8!OZVSMXXOE%QT;=3_2NO<6D,O+AB2YPJJU.@[_XMEY.L6P]5
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M6G(EC6_!BSLPC6G]K$>+6D:HQHK7LZ\X]KP_17I.$E##+;=$&8>\- D= G!
MLJ4Z"YS-I&T29ET&,:8,9SV[;ZWF:H9^U\.Q[]*OWX]A-@ N7LLDZU4)(2H
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M)ZN=J.6IOD7W==68BGF#\2ZSA'NFRAR72E=A0X!K'EP(,K:YM&ESB!7:R$2
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MH^?HKAPX1+I,6Q&SE))(24MC=,:)S=(@JTRF,:H,;4+];=-EAPW:'C]'=^5
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M%RM5R<H'[HCUBF8 0YUS8\QV/[)=EYW(U]BL59N\WU^ $I40.J&[RJ"TM#/
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MPPXSQ4,>OW_EWCL#G,W9Y4M9*/[UC_\/4$L#!!0    ( -&#IU"Q_>U;*#<
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M >E5^N.3LUS"GDS6&YL\$UG7ZRHNLJA$8FB%M%XEGWA9:2EN)>'C9.;A@+J
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M5*(+Q6(249MD0HZ!6Z ?7#99Q!51NZUC6\RV6)#6>\$>4%MER?).4GB$D@<
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M*UT7>OW2'\(P]6'P9CBA]]5'SJXF\"(H_*&PR'%!%E+*DFMK*=H.LL1DD(9
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M27\(P]2'P54MQ-EDJF41'%*A.(9XJP&1!;"1R,MEBEKHB$U.(Y?(\\3]Z@Y
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MI=+J7)Y]=]@J)D=Z(V$]^H+N<-X=T(+K+<-:]"NP$7XLC"]/<[P8ZV?.=1R
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M25UO..U,YQ_%75,.1_>F*IN0V<^BO/,7D2=#0=7T&T2A+AP:$I@2/X D]&C
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MT\1#H)J>)0X%:JJ3Q!:;3D!02^CR$/$$ &Z/$ \--/$!X@E=]X\/3WW863$
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MN>3*.,1$@%@J+P,RD0'"4 QX*F4L,L@(MJ+;/=?XU,R$D2\P M;\./9UVT^
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MM+ RB5R>SQDF-?[>SRNFH=WXYQ[3T+OK_&1:$O;T-MB#X-N%^"C/JW1$I7W
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M+4T*\''Y]KN.K-@6Y8/N0A/CT,VNXI>F#=6$ 16=:$4S.N=I(J,LR4":X1#
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M#9^FHZ.W4>W&=:V/C8;%&S=Z(]7:>[?DK96W67@_[ITD]<"'U7)]X#,=I01
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MMNQ ; 1FRW.]3X'9L@,52V;+KA;ZAM)H;U>?0YF%=W]:@7$689F#&.O;[)A
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MWIN5^7,4Y/4U9MYJ\WH3Z-+*W9XH[]5/_^=_-;]1_Z>GZ?_Y7_\?4$L#!!0
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M&6FT!NY"KLFO!%[90%:DX%)D9UAA+3"S!6WC]!-I!Z6AU=$!PFX2KS+CQ9=
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M^436LV>,61LX-G%_MZ!M[+1/8U0.K9V^ '<^=/;D;/UIL9S^1TX3GBU72C/
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M  X              ( !J0P  &5X:&EB:70Q,#(N:'1M4$L! A0#%     @
MT8.G4,>_2>F:"   %#,  !<              ( !F4   &9O;&0M,#,S,3(P
M,C!X97@S,3$N:'1M4$L! A0#%     @ T8.G4)Q)O*23"   B#,  !<
M         ( !:$D  &9O;&0M,#,S,3(P,C!X97@S,3(N:'1M4$L! A0#%
M  @ T8.G4+C'X[\!!@  JRP  !<              ( !,%(  &9O;&0M,#,S
M,3(P,C!X97@S,C$N:'1M4$L! A0#%     @ T8.G4(T0L$+JF@$ [;85 !$
M             ( !9E@  &9O;&0M,C R,# S,S$N:'1M4$L! A0#%     @
MT8.G4%XTV[O-#   %8$  !$              ( !?_,! &9O;&0M,C R,# S
M,S$N>'-D4$L! A0#%     @ T8.G4(-0\9A('P  ,T,! !4
M ( !>P " &9O;&0M,C R,# S,S%?8V%L+GAM;%!+ 0(4 Q0    ( -&#IU"Q
M_>U;*#<  /EY @ 5              "  ?8? @!F;VQD+3(P,C P,S,Q7V1E
M9BYX;6Q02P$"% ,4    " #1@Z=0X[G+2E.Y   MIP< %0
M@ %15P( 9F]L9"TR,#(P,#,S,5]L86(N>&UL4$L! A0#%     @ T8.G4&[?
MRXZ!8P  DJH$ !4              ( !UQ # &9O;&0M,C R,# S,S%?<')E
:+GAM;%!+!08     "P + -$"  "+= ,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6776468016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.</span></div>The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2019.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2019.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Consolidation</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Foreign Currency Transactions</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="text-indent:18pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of March 31, 2020 and through the issuance of this report. The Company&#8217;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents, Marketable Securities and Restricted Cash</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.</span></div>Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company's Consolidated Balance Sheets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Concentration of Credit Risk</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup>. The Company's accounts receivable at March 31, 2020 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers and the geographic economic environments and conditions to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Revenue Recognition</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's net product sales consist of sales of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> are generally received from distributors and pharmacies with the ultimate payor often a government authority. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the sale of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryCostsForContractsOrProgramsPolicy', window );">Inventories and Cost of Goods Sold</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Inventories and Cost of Goods Sold</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.</span></div>Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Leases</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. </span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The lease term for all of the Company's leases include the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. </span></div>Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Developments</a></td>
<td class="text"><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Developments - Guidance Adopted in 2020</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2018-15 - In August 2018, the Financial Accounting Standards Board ("FASB") issued&#160;Accounting Standards Update ("ASU") 2018-15,&#160;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): ("ASU 2018-15"), relating to a customer&#8217;s accounting for implementation, set-up, and other upfront costs incurred in a&#160;cloud computing&#160;arrangement that is hosted by a vendor. Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance does not affect the accounting for the service element of a hosting arrangement that is a service contract. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized software costs and related amortization expense and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for public companies. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2018-13 - In August 2018, the FASB issued ASU 2018-03, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on (i) changes in unrealized gains and losses, (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and (iii) the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2017-04 - In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2016-13 - In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected and amends guidance on the impairment of financial instruments. ASU 2016-13 is effective for public companies who are SEC filers for fiscal years beginning after December 15, 2019, including interim periods within those years. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Recent Accounting Developments - Guidance Not Yet Adopted</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">ASU 2019-12 - In December 2019, the FASB issued ASU 2019-15, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following apply in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#8217; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted for public business entities for periods for which financial statements have not yet been issued. The Company is currently assessing the impact that this standard will have on the Company's Consolidated Financial Statements upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryCostsForContractsOrProgramsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the basis and manner that goods are added and removed from inventory for costs relating to long-term contracts or programs. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory and how cost is determined (such as FIFO, LIFO, average). Elements of costs in inventory may include retained costs representing the excess of manufacturing or production costs over the amounts charged to cost of sales or delivered or in-process units, initial tooling or other deferred startup costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryCostsForContractsOrProgramsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6641601936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's debt consists of the following: </span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.208%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.662%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.664%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Senior Secured Term Loan due 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Less: debt discount </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,142)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,315)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Less: deferred financing </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(289)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(311)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net carrying value of the Senior Secured Term Loan</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">147,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">147,374&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Convertible Notes due 2023 </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,825&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,825&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Less: debt discount </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(625)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(659)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Less: deferred financing </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net carrying value of the Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,131&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________________________</span></div><div style="text-align:justify;margin-top:3pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> Included in the Consolidated Balance Sheets within Convertible Notes and Senior Secured Term Loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</span></div><div style="text-align:justify;margin-top:3pt;margin-bottom:15pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> The Convertible Notes are currently convertible as the last reported sale price of the Company's common stock was equal to or more than 130% of the conversion price for at least 20 trading days of the 30 consecutive trading days ending on the last day of the quarter. </span></div><div style="text-indent:22.5pt;text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">During the first quarter of 2019, the Company entered into separate, privately negotiated Exchange Agreements with a limited number of holders ("the Holders") of the unsecured Convertible Senior Notes due in 2023 ("the Convertible Notes"). Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of $219.3&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately 39.0&#160;million shares of Company common stock, par value $0.01 per share. In addition, pursuant to the Exchange Agreements, the Company made aggregate cash payments of $1.0&#160;million to the Holders to satisfy accrued and unpaid interest to the closing date of the transactions, along with cash in lieu of fractional shares. These transactions resulted in $190.4&#160;million in additional paid-in-capital and common stock of $0.4&#160;million on the Consolidated Balance Sheets as of March 31, 2019. Additionally, the Company recognized a net loss on the exchange of debt of $36.1&#160;million on the Consolidated Statements of Operations for the three months ended March 31, 2019. </span></div><div style="text-indent:22.5pt;text-align:justify;"><span><br/></span></div><div style="text-indent:22.5pt;text-align:justify;margin-top:1pt;margin-bottom:1pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;">During the first quarter of 2019, the Company terminated the Capped Call Confirmations related to the exchange of the Convertible Notes for proceeds of approximately $14.6&#160;million.  </span></div><div style="text-indent:22.5pt;"><span><br/></span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth interest expense recognized related to the Company's debt for the three months ended March 31, 2020 and 2019, respectively:</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:70.140%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.049%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.052%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>39
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M7'_X781=,'9K_['Q65"V\.LNY!=02P,$%     @ T8.G4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MZ4]G]KP=VKGAPNC3V*HF4[^\_@-02P,$%     @ T8.G4$]!-7BB!   $Q<
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MMM5A.'U\KJHV=@[-IVZDMK'<7&[V\;GM+_/NNCZ?RIYOVNHTGCC/+L?>B_\
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MW&R:?XWH(4C9W(05:L,#FQT%M8_F;;#MN&:CX[&;7A";GW'Q&U!+ P04
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M#. +X"[F85.BJ/R3\*+(K!F)G7K?B_#$NP/'WI3!&5L1[U"\0^^EX,D^8Y=
M-,<<IQB^BMDM$0S9EQ1\*\61_P/GV_#]IL)]A.__4)AN$Z2;!&DD2/];XE;,
M]5])V*JG"FP3I\F1T@PZ3O+*NPSL/8]O\CM\FO9'89M..W(V'E\V]K\VQ@-*
M2:YPA%K\8(LAH?;A>(MG.XW99'C3SS^(+=^X> =02P,$%     @ T8.G4,YC
MHQZU 0  T ,  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL?5/;;MP@
M$/T5Q <$+]YLHI5M*9LJ:J566J5J^\S:8QL%/"[@=?KW!>PX5F/U!9CAG#,7
MAFQ$\V); $=>M>IL3EOG^B-CMFQ!"WN#/73^ID:CA?.F:9CM#8@JDK1B/$D.
M3 O9T2*+OK,I,AR<DAV<#;&#UL+\.8'",:<[^N9XEDWK@H,562\:^ [N1W\V
MWF*+2B4U=%9B1PS4.7W8'4_[@(^ GQ)&NSJ34,D%\2487ZJ<)B$A4%"ZH"#\
M=H5'4"H(^31^SYIT"1F(Z_.;^E.LW==R$18>4?V2E6MS>D])!;48E'O&\3/,
M]=Q2,A?_%:Z@/#QDXF.4J&Q<23E8AWI6\:EH\3KMLHO[.-VD?*9M$_A,X OA
M/L9A4Z"8^2?A1)$9'(F9>M^+\,2[(_>]*8,SMB+>^>2M]UZ+0YJQ:]"9(:<)
MPE>0W8)@7GR)P+<BG/@'.M^FIYL)II&>KNG)85M@ORFPCP+[_U7X$<*3NW]B
ML%5'-9@FSI(E)0Y=G..5=QG7A_B$[!T^S?HW81K967)!Y]\U=K]&=.!326[\
M +7^>RV&@MJ%XYT_FVG()L-A/_\?MGSBXB]02P,$%     @ T8.G4*,:2<BU
M 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL?5-A;]P@#/TK
MB!]0$NZVWDY)I%ZG:9,VZ=1IW6<N<1)4B#,@E^[?#TB:96O4+X"-W_.S,=F(
MYLFV (X\:]79G+;.]4?&;-F"%O8&>^C\38U&"^=-TS#;&Q!5!&G%>)*\9UK(
MCA99])U-D>'@E.S@;(@=M!;F]PD4CCE-Z8OC03:M"PY69+UHX#NX'_W9>(LM
M+)74T%F)'3%0Y_0N/9[V(3X&/$H8[>I,0B47Q*=@?*ERF@1!H*!T@4'X[0KW
MH%0@\C)^S9QT21F Z_,+^Z=8NZ_E(BS<H_HI*]?F]$!)!;48E'O \3/,];RC
M9"[^*UQ!^?"@Q.<H4=FXDG*P#O7,XJ5H\3SMLHO[.-WPVQFV#> S@"^ 0\S#
MID11^4?A1)$9'(F9>M^+\,3ID?O>E,$96Q'OO'CKO=>")X>,70/1''.:8O@J
M)ETBF&=?4O"M%"?^"LZWX;M-A;L(W_VC\,,VP7Z38!\)]F^6N!&3)O\E8:N>
M:C!-G"9+2ARZ.,DK[S*P=SR^R=_P:=J_"=/(SI(+.O^RL?\UH@,O);GQ(]3Z
M#[88"FH7CK?^;*8QFPR'_?R#V/*-BS]02P,$%     @ T8.G4 B:"+ZS 0
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MV4QC-AD.^_D'L>4;%[\!4$L#!!0    ( -&#IU"A@(D\M0$  -(#   9
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M]3>IDM* +25ZL TW]JE8 @Z5<=NCW:MI8*; R'Y^"\CR(.5_ %!+ P04
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M9ZF7B5KS?HSW&\G:X8KRQGLR_PM02P,$%     @ T8.G4/I30"#*!   $AH
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MHGHE/\@%,-#$G@N),5\8]4YN\;)LBQY$9PE$GF)AS"F6G9.D+\N>*$IBT3\
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MO]'NK+2H>Q5CI69OW;-LW//:Z[^'A0-@'P"' #/WK0#4!Z"/ '(S(.L#LH^
M[&8 [@/P+"#I<G?%W#+-5@LIKI'LMD/+[*Y+[[%9KIT==*OCWIEZ*C-Z62%
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MT?U<!E6SU3/1'B:BM\SSPM2YR40]9JLQ[@@#!X0CL@\2KDEBZ\[H[J/ ;HZ
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M#   &0   'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6R-EUUOFS 4AO\*XGZ
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M4IGM1N_%,&R&@^+=.$C1-,VSOU!+ P04    " #1@Z=0/4(^,8P"  #B"
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MQ4Z $^<*M,CH0=]7K3\*HT'AI,PVUWOA)J,S%.^&J8_&3T_Y#U!+ P04
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MAI+2D)@B2;VHN_DG(8]Y8"Y+Y%9=XRRI$07.&:#\UEGBN2#17'#-LZ2,1^F
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M$?0?*5SC-M+<Z?0'G6&_E23K,9[!AP'<MA)T>5O80^/[?POF/H=7Y_SZ(@G
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MA ^:_K[$B&J5S>-=;5:K!1$TN$9(JH&L;4J^@C3(#3 @  _'4349;M(<HVE
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M6B@^ H@!F[J5'FQ4!@*WU8VMT8/DXP:0&F,'<]B=Z")*8/IQ3<0,:2 S2[@
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MDEDR[S:P)^),$:XBY 52MY%U=)0KTE:Y=H &"Y,LK< ?+JQ,U][21- (O,?
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MG,$+6S&SWX>II]$ H-<[X;_ZOPQ*GHX&\:B' >F#T8B.:W(B'T].>_MCY%[
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M<RHO'U 7N=DT@U*+9,TM,AAY[AEJ7(%0*49@*Y392.%Z=T+_!FJ'J+2'J!4
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M\_EDN'\'^;W.87<'^0$PA#&H";@:7@M]<CKXC/;QN_;8UAS^\Y'S=$#-=%N
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M];4AV]>&;/^6B/FU(=O_9PW9MK'\O2*Z/[7_2J.R^;7_RW^G_B];/3(N+N=
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MHED!UQ@88G=%[ 8F\E\T7#=4\3\A9K=UBT'0;OCD 1&Z!Q^VBPT-.:H+\PQ
M %NV08;*:>X'*NH@1?0OR/)!P,$CK6K6XA:/T<'1@@>J>^[Q;ZIJ_=W_!5!+
M P04    " #1@Z=0J[I:ZE<"   \#   #0   'AL+W-T>6QE<RYX;6S55UMK
MVS 4_BM"':.%45^RI.UJ&[9"8;".0O.PMZ+8LBW0Q9/E+.FOGRZ^)27=EG4C
M>8G.^8[.=SY9LG42U6I-\4.)L0(K1GD=PU*IZH/GU6F)&:K/186YCN1",J2T
M*PNOKB1&66V2&/5"WY]Y#!$.DX@W[):I&J2BX2J&TQX"+O]&9#B&CZ=OOS="
M7;\!;CQY=W+B/YY=;^.G-G &@>/XG,4PF+V'WN^3GON[>75LBWKZ9]0O,&\1
MSW80#T0[$B]>3O3'J<^6<VF2O79+DB@7?-B9"72 9D<,@R6B,;Q!E"PD,5DY
M8H2N'1P:(!542*#TD=#5 X/43RX<.,^<EI:'$2ZDK>TJN-]%.WTKT'E&(*&T
M%QA"!R11A93"DM]JQTZVX+,0:.WYNM(*"XG603B%0X(==)&%D!F6?9D =E 2
M49P;.9(4I1F5J#P35$HP;60$%8(CJZ'+: U-FV)*'\RK]"W?X%[EP,TQ6^)#
M8%1TIEYU:PZ[YEO)8S;'/:8-]^(%%5D*]:G1R^'6-P<6WTN<DY7U5WDO0+.C
MJJ+KCY04G&&WF%\6#/8LF$2HJP-*(<F3YC-')=4 EA LL50D'2,_)*KF>*6Z
MX[3*]]4<'J'FUW[.!>98(CH6K<_^(3_E_ZQX<O'WDNU795OP*VHT%^,1B)P>
MOLC)U>%K-"W%$8@\BO?F\A^+]-K[>]0D;+0(/0H6#:&*\%9N2;(,.SVF1XOA
M5], THV+>N@4-+U""]W*;_#KW SGJ*'JWBS1!F,XV%^,\&#6SYKW%#$<[#N<
MD89=V8+#_X7D)U!+ P04    " #1@Z=06)4/':0#   :&P  #P   'AL+W=O
M<FMB;V]K+GAM;,696T_;,!2 _XJ5)R;!VL3E*HH$E&U(W$09>YS<Y+2U<.S.
M=LKEU\].89Q*]&@OID]I;"?^<NR>STX.'XU]&!GSP)YJI5T_FWH_.^AT7#F%
M6KBO9@8ZU(R-K84/IW;2<3,+HG)3 %^K3M'M[G1J(75V=/AVKQO;P2?&0^FE
MT:$P%MQ+>'3O]?&4B=!@#G=BU,^Z&1.--]^D\F 'PL-W:YJ9U)-^EF=L+*WS
MP]AWV[*66M;R!:KVS$W-XP]CY8O17JAA:8U2[56QHKTH].#^E=R#];)<:NC%
MZ%8$UGZVTPTWG$LG1U))_]S/VM\*LO 4'?08;1S>CHL@'MC_":,9CV4) U,V
M-6B_B*,%%7O7;BIG+F-:U-#/3LT<++L1$XC8H9?S:O$(/@3GG8O9 QDJ['F5
M1\:4/-H9):O0>\5.A!*Z!-9&UR' @@ LU@;(-FX$@N0$)/]$R&&$B!<X9L;L
M>@860?8(R-[:($]-/4.0VP3D]AHA?Q<(<H> W%D?Y%1H!+E+0.ZN#U*X*8+<
M(R#WTD(.P)56SF)Y!#MIG-3@<.K9)^#VT\(-F[H6]CF"#>5$RW"9T)X=EZ5I
MM)<X@7>I#-Y-/-!A-#?;,65G?QHY%RJ.\R:[%/8!/,Z0.2F:Q*8YU_/0( @=
M\/#FE%KRQ&X9P,AC%LH@>6*%#*?"PM:)<.'?&M,Q:-<VPGR4//+$]CAV+BI7
MZ(I=2-&NH\)(LDL0KK%084Q*'WEB?X0 RK*E'$C5Q-1W%7JZ,,ZQ(&*&,2F!
MY(D-0J:6)<WEE$+RQ ZA,3G&I"22)[8(F0&7HTGI)$_L$Y0!V4;8O"AP7_ B
MFY)(D5@B,15^"$4IHTBLC%4Y\1448Y([E,0:(5/CTO0K*,,4B0U#IL9E3$HT
M16+1K%@2LHU!6,Q(A3$IT12)14.GQA[&I$13I-ZJD*D19_""$DV1>K-"8BY%
MDQ)-D5@T2QE\,1^7LR6EER*Q7MH4OL70Q+PP>L+NP-8LU.$W)91I^&>89HM=
M"6M%?$_X82 YI1V>6#NOA.?:@P7GV=E3- ]\D($XI1V>6#LK[;C%?H&<8$SR
MU=B:-C9QJGI38DQ*.SRQ=@C,.%4Q)J4=GEH[JS%OAS_QSII3VN&I]S>K,>._
M"6-2VN&)M4.OW+ =.:4=GE@[-":V(Z<$Q!,+B%Y@XFCV* 'U6@%UWK[%5# .
M"\#J*G3A0GDI5'EC63PLWA_UMN.F;MPH=1K*KO6%$>TGE7B/M\]21W\!4$L#
M!!0    ( -&#IU#^]TY#I $  -T8   :    >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'/%V<]N@D 0Q_%7,3Q EYG!?XUZZL5KVQ<@N *1?]G=IOKVI5R*
MB3(]F)\7#,',?$\?-[AYMU4:RK;Q1=GYV;FN&K^-BA"Z5V-\5M@Z]2]M9YO^
MR;%U=1KZ6Y>;+LU.:6X-Q_'"N/&,:+<9SYSM#]O([0\4S3Y3E]NPC<RY,M^M
M._G"VN#-\$$O_8+^*Y?._F=]>SR6F7UKLZ_:-N%&Q=^"R-P.XND@A@?)=)#
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M=_](Z=!OL6:X/OP7;)CZ&V&N_LW8_0!02P,$%     @ T8.G4''*SM&H 0
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M&U!+ 0(4 Q0    ( -&#IU ?(\\#P    !,"   +              "  0
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( -&#IU GZ(<.@@   +$    0
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M965T,RYX;6Q02P$"% ,4    " #1@Z=0SUC#EXL#  "-#@  &
M    @ &5$P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
MT8.G4(BK_51/ @  W08  !@              ( !5A<  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( -&#IU"3=LD$[@$  .D$   8
M          "  =L9  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " #1@Z=0_E8^!0$%  !@&   &               @ '_&P  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ T8.G4+:L>@>Y!    A<
M !@              ( !-B$  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( -&#IU 11]\!L0$  -(#   8              "  24F  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #1@Z=0T[3*J+,!
M  #2 P  &0              @ $,*   >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( -&#IU Q?L"MM0$  -(#   9              "
M ?8I  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ T8.G
M4,YCHQZU 0  T ,  !D              ( !XBL  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " #1@Z=0HQI)R+4!  #2 P  &0
M        @ '.+0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( -&#IU (F@B^LP$  -(#   9              "  ;HO  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ T8.G4#E0:M>U 0  T@,
M !D              ( !I#$  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " #1@Z=0H8")/+4!  #2 P  &0              @ &0,P
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( -&#IU!*U-&-
M, (  &P'   9              "  7PU  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ T8.G4/-,/#&V 0  T@,  !D
M ( !XS<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #1
M@Z=0VCC;(<0!   W!   &0              @ '0.0  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( -&#IU"4L)==MP$  -(#   9
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M970R-"YX;6Q02P$"% ,4    " #1@Z=0:Z)\KKD!  #9 P  &0
M    @ '+10  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M -&#IU '=5M24 (  #,'   9              "  ;M'  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ T8.G4/I30"#*!   $AH  !D
M             ( !0DH  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " #1@Z=0GQ808)("  !Q"   &0              @ %#3P  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( -&#IU#@8*M0$ (
M /X%   9              "  0Q2  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ T8.G4-.W=8'! @  MPH  !D              ( !
M4U0  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #1@Z=0
M<2=W*G$"  #X!P  &0              @ %+5P  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( -&#IU"A%76?"P(  '8%   9
M      "  ?-9  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ T8.G4-QTT%0/ @  ^@4  !D              ( !-5P  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #1@Z=0IZ(\X2D#  #Z#
M&0              @ %[7@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( -&#IU#+!,1K!@(  -D%   9              "  =MA  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ T8.G4#U"/C&,
M @  X@@  !D              ( !&&0  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " #1@Z=0_D'8\3$"  "&!@  &0
M@ ';9@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( -&#
MIU!<>?0XFP0  /@9   9              "  4-I  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ T8.G4/2R^$LE @  !@8  !D
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M='EL97,N>&UL4$L! A0#%     @ T8.G4%B5#QVD P  &AL   \
M     ( !O<0  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( -&#IU#^]TY#
MI $  -T8   :              "  8[(  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( -&#IU!QRL[1J $  "X9   3
M  "  6K*  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     Q #$ 20T  $/,
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6616686944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases', window );">Less accumulated depreciation and amortization on finance and operating lease right-of-use leases</a></td>
<td class="nump">$ 6,260<span></span>
</td>
<td class="nump">$ 5,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation of property and equipment</a></td>
<td class="nump">$ 19,260<span></span>
</td>
<td class="nump">$ 17,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">257,449,955<span></span>
</td>
<td class="nump">255,417,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">257,449,955<span></span>
</td>
<td class="nump">255,417,869<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated Depreciation And Amortization, Finance And Operating Right-Of-Use Leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6791584080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Warrants</div></th>
<th class="th"><div>Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,383,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 342,912<span></span>
</td>
<td class="nump">$ 1,942<span></span>
</td>
<td class="nump">$ 1,740,061<span></span>
</td>
<td class="nump">$ 13,063<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="num">$ (1,412,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued from exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">578,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issued from exercise of stock options, net</a></td>
<td class="nump">3,953<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">3,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock tax vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Restricted stock tax vesting</a></td>
<td class="num">(1,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,940)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesContingentConsideration', window );">Stock issued for contingent consideration (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueContingentConsideration', window );">Stock issued for contingent consideration</a></td>
<td class="nump">9,316<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">9,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">12,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="nump">812<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
<td class="num">(676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Equity component of the convertible notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,043,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Equity component of the convertible notes</a></td>
<td class="nump">190,758<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
<td class="nump">190,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations', window );">Termination of capped call confirmations</a></td>
<td class="nump">14,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding gain (loss) on available-for-sale securities</a></td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,804)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,804)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(120,299)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,299)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,180,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 451,668<span></span>
</td>
<td class="nump">$ 2,347<span></span>
</td>
<td class="nump">1,970,607<span></span>
</td>
<td class="nump">12,387<span></span>
</td>
<td class="num">(1,152)<span></span>
</td>
<td class="num">(1,532,521)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">255,417,869<span></span>
</td>
<td class="nump">255,417,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 476,425<span></span>
</td>
<td class="nump">$ 2,598<span></span>
</td>
<td class="nump">2,227,225<span></span>
</td>
<td class="nump">12,387<span></span>
</td>
<td class="nump">2,825<span></span>
</td>
<td class="num">(1,768,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued from exercise of stock options, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock issued from exercise of stock options, net</a></td>
<td class="nump">6,077<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">6,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock tax vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,073,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition', window );">Restricted stock tax vesting</a></td>
<td class="num">(7,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">12,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized holding gain (loss) on available-for-sale securities</a></td>
<td class="num">(209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment</a></td>
<td class="nump">4,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (88,948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(88,948)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">257,449,955<span></span>
</td>
<td class="nump">257,449,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 402,594<span></span>
</td>
<td class="nump">$ 2,607<span></span>
</td>
<td class="nump">$ 2,238,346<span></span>
</td>
<td class="nump">$ 12,387<span></span>
</td>
<td class="nump">$ 6,812<span></span>
</td>
<td class="num">$ (1,857,558)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from Termination of Capped Call Confirmations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants (in shares).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents Stock issued from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6716744144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Summary of Long Term Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>day</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember', window );">Senior Loans | Senior Secured Term Loan due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount</a></td>
<td class="num">(2,142)<span></span>
</td>
<td class="num">(2,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Less: deferred financing</a></td>
<td class="num">(289)<span></span>
</td>
<td class="num">(311)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="nump">147,569<span></span>
</td>
<td class="nump">147,374<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | Convertible Senior Notes 2016, Due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt</a></td>
<td class="nump">2,825<span></span>
</td>
<td class="nump">2,825<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: debt discount</a></td>
<td class="num">(625)<span></span>
</td>
<td class="num">(659)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Less: deferred financing</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(35)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Net carrying value</a></td>
<td class="nump">$ 2,167<span></span>
</td>
<td class="nump">$ 2,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger', window );">Threshold percentage</a></td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Threshold consecutive trading days | day</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Notes | Convertible Senior Notes 2016, Due 2023 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentsConvertibleThresholdTradingDays', window );">Threshold trading days</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentsConvertibleThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentsConvertibleThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_SeniorSecuredTermLoanDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=fold_ConvertibleSeniorNotes2016Due2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6606240576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Option Activity (Details) - Options to purchase common stock<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">16,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options, Granted (in shares) | shares</a></td>
<td class="nump">3,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options, Exercised (in shares) | shares</a></td>
<td class="num">(968)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options, Forfeited (in shares) | shares</a></td>
<td class="num">(355)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options, Expired (in shares) | shares</a></td>
<td class="num">(259)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">19,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options, Vested and unvested expected to vest (in shares) | shares</a></td>
<td class="nump">17,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options, Exercisable (in shares) | shares</a></td>
<td class="nump">10,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise&#160; Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 9.15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options, Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">9.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options, Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">6.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options, Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">10.40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Options, Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">13.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">9.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options, Vested and unvested expected to vest (in dollars per share) | $ / shares</a></td>
<td class="nump">9.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options, Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life, options outstanding</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, options vested and unvested expected to vest</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life, options exercisable</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, options outstanding | $</a></td>
<td class="nump">$ 23.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and unvested expected to vest | $</a></td>
<td class="nump">23.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, exercisable | $</a></td>
<td class="nump">$ 21.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6790105536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">$ 218,619<span></span>
</td>
<td class="nump">$ 314,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">23,612<span></span>
</td>
<td class="nump">22,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">3,055<span></span>
</td>
<td class="nump">4,419<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">26,667<span></span>
</td>
<td class="nump">27,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fold_ATB200PompeProgramMember', window );">ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Callidus Biopharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">$ 22,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fold_ATB200PompeProgramMember', window );">ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability of Milestone Achievement | Minimum | Callidus Biopharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=fold_ATB200PompeProgramMember', window );">ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability of Milestone Achievement | Maximum | Callidus Biopharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">$ 35,348<span></span>
</td>
<td class="nump">73,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">68,795<span></span>
</td>
<td class="nump">77,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">107,098<span></span>
</td>
<td class="nump">145,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">11,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">3,378<span></span>
</td>
<td class="nump">4,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">218,619<span></span>
</td>
<td class="nump">314,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">3,055<span></span>
</td>
<td class="nump">4,419<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">3,055<span></span>
</td>
<td class="nump">4,419<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Fair value of the Convertible Notes</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">35,348<span></span>
</td>
<td class="nump">73,710<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">68,795<span></span>
</td>
<td class="nump">77,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">107,098<span></span>
</td>
<td class="nump">145,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | U.S. government agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">11,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value of assets</a></td>
<td class="nump">3,378<span></span>
</td>
<td class="nump">4,768<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">23,612<span></span>
</td>
<td class="nump">22,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent', window );">Deferred compensation plan liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value of liabilities</a></td>
<td class="nump">$ 23,612<span></span>
</td>
<td class="nump">$ 22,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3 | ATB200 Pompe Program | Contingent Consideration Liability Clinical and Regulatory Milestones | Probability Weighted Discounted Cash Flow | Discount Rate | Callidus Biopharma Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=fold_ATB200PompeProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=fold_ATB200PompeProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=fold_ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=fold_CallidusBiopharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=fold_MeasurementInputProbabilityOfMilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=fold_ProbabilityWeightedDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>fold-20200331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:fold="http://www.amicustherapeutics.com/20200331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="fold-20200331.xsd" xlink:type="simple"/>
    <context id="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i99ffeda6d436452d9771eb87cc47254e_I20200427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2020-04-27</instant>
        </period>
    </context>
    <context id="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i196c9221c6d643fdaa0ea733f27450c9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iec6b6ea5594b4731a877338c089938f3_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9ab7b2af443045e981707c6d83e68f71_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic617e48d8a10423db3184a6dfab2b3bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7607f8134f5b416d9727cf6788be5ff0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9d497ab4f2c34411849a9c0b7f6ad148_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibac1144c427c4ab28f9978dedda26866_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7f01de7d9dd44ea8b91087aef6dc8069_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ia98f9eda9405487aa88f7722bcf90c06_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i03c53c43e07c4745bc497b9834079c0a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if4281d64af2d427b85cef94416b0a885_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if69166eb2b574a688fba8c17a396ddc1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3c8339ddd7df40d5a162d23e286d54ae_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ibf2972e46bfc4f359a17c8f36be0ac34_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i26248ac6987b40c48626b19b6e0c9195_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i05bc9b3b7144464c88b636e60eedf49a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ifcbb93cbfad34e7d97f71f16ddd6c611_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i96c0a7cbb6b3472bb1e2424eaa5e6177_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ibba94963ffeb42d08d8d600f49ecd905_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="idadd57a0cda848479ab4cb0f85af2845_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="icab07bfc15ea4b0a9b2e3d5dfe987d2a_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i4a73b1ec2ad049afa1945e4ac428aa91_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i727363bd8bbd43adae093805b3e3a8eb_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="iab7bd98c579140b5b443d931338863c7_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i9528373dcfb944969e8d059bcea89906_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i5491ffc350124a71b70a57e9a6ea8c72_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="id9251812ad7e4ed885bebff24390dfb9_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i5462b45a2d554a69b26d20db9f69d769_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i9d09871cf6ad4200a92e067dd3180699_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ia85c7d4cee774ba29ddedfa2ec518587_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i31b61ba1de064ab9a35f6ea596b4cac0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6665e4e8d56945d6a3eb5b178eed1e42_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i4e9b6c86da6148bc9f33450341bbd731_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i713aa7461f474212a79f6fbf3e5b8ce4_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ie299466a221248989d0654e27aa2fa15_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i76dd233dc95c43edb284968ccf887232_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i79d9f3582ceb4f39b144041e9d62cd8f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6e582d44c1854742ab6c8ed5ee290d43_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i14951a04eb4e4b7b9d35f47bed16e634_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3ef63e91418e4383b7ebde0b9c4cffe0_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i555c0f48291d4b38b8d561d915768eff_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">fold:ShortTermCorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i69bfb02d155d46d7a1e1ec0c33f195ca_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i780f97fa745c46f2a97bd268ba15bc18_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia1cd03431da34173829810953c60ca83_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i87a274e586cf4c16a08587c4031550b4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if972968827f048e9b40900a185eca935_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaae514757a6c44d4a4b8a4a9a318e979_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i140e72212c4a4bfb81bf6148fb2aa0a6_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i3674ca7debaf4f0aafd63c83f885edf1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:SeniorSecuredTermLoanDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorLoansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icb44be7fb6564606a0f40b69c09e76c5_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i0b34927c8eaa48f08e87f87c3ed7a95c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic6b8135fdb4c48c0a197d684b3bef8b9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i44debd31ac6748d0a90567edb19522f6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">fold:ConvertibleSeniorNotes2016Due2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibe7c67f71a114f90ae76db8af5fe4c45_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3357c282064f406dac5037a4c2b21d13_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3b6358ff594f435b8c28ece99c733032_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="id011b45be10140f38519fd2adf3253d2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i16020fa576b847e0be1314bfb846de53_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i086ab493f15f4e6680cd436cde171e07_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">fold:StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie57efb8719074ac89dbe8b6a28e6d637_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1bddcfce942349258e4cb92f5ce02164_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ib0c9afa9ca0b4b35bab63830db5c839b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i1dc1a4e6d9264abd9af1dd18a8a59526_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i69ecdce58c8e44a7b7446b787e6b5571_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ib14953c89ea842048d571e925165ae39_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ifd85987fc9fb44248ab3d5d19af0664e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ic98cbd8bf78c4e479a4b68211ebe7595_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9850e46e79c9490ca6d79c93c720720b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if74e828956b7436da5162de1eb41377f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i975aba94542c4c2988e78b6ee343ef08_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i4a2116def0d444d1b2c560065e4d05c1_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i41235f69acc344c2ab91f52c5639a874_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i00deaed1957b488787cdaa82dc50e59b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i65b648c925e740579dcae60193ae3051_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7fa313342b3241bba30e7d90a90214b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib5ecdd9caab3473cb281d4bc13e0eca9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2e7a3776ad894ab5b362c7b3cf1a371c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia1230a6c7511406892e2964d9334d607_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i55f9cd444bfc49af80a93225821ade9c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib43a922550c542ecb66e87e81bc9113b_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">fold:ProbabilityWeightedDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i44733de43da34221b7d954e41f00c039_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ie0ba4a524aed416486913ea7a9dba98f_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i9feff19608a147b4a577c14d3cd15368_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">fold:CallidusBiopharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">fold:ContingentConsiderationLiabilityClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">fold:MeasurementInputProbabilityOfMilestoneAchievementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">fold:ATB200PompeProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="ia053dc80670e4de08f203297971a38ee_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ibd00e196fb5248c38c3a76f7e124b8ff_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">fold:EmployeeAndDirectorsStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic483241cafdd4ff19dea8e3ded6ae7c9_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="ie9fe2af9630e470c8859c9adef1e1816_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i208a59305dc0405a95804c555ac42287_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i2456a772e9a5467790859303b3e7e057_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="id8d7af76424f479fa3108e53610e4c9a_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i41dc54a86052461baed38b6ea6e9142a_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001178879</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="day">
        <measure>fold:day</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180L2ZyYWc6ZTk0NGM4MTVlMThkNDJjOGJhODdlMzAxNmQ5MGJmNDMvdGFibGU6MDEzMzI1MTVmZTg5NGI5NmFhMTk1YzdlZTdiZmVmNjgvdGFibGVyYW5nZTowMTMzMjUxNWZlODk0Yjk2YWExOTVjN2VlN2JmZWY2OF8zLTEtMS0xLTA_54a13a3b-132c-4082-b6d6-6b83663e1231">0001178879</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180L2ZyYWc6ZTk0NGM4MTVlMThkNDJjOGJhODdlMzAxNmQ5MGJmNDMvdGFibGU6MDEzMzI1MTVmZTg5NGI5NmFhMTk1YzdlZTdiZmVmNjgvdGFibGVyYW5nZTowMTMzMjUxNWZlODk0Yjk2YWExOTVjN2VlN2JmZWY2OF80LTEtMS0xLTA_f4df3328-e9b0-4bf0-bfbf-4936c6ec5142">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180L2ZyYWc6ZTk0NGM4MTVlMThkNDJjOGJhODdlMzAxNmQ5MGJmNDMvdGFibGU6MDEzMzI1MTVmZTg5NGI5NmFhMTk1YzdlZTdiZmVmNjgvdGFibGVyYW5nZTowMTMzMjUxNWZlODk0Yjk2YWExOTVjN2VlN2JmZWY2OF81LTEtMS0xLTA_dd2fec19-23ae-4b78-81cd-211640c2e13d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180L2ZyYWc6ZTk0NGM4MTVlMThkNDJjOGJhODdlMzAxNmQ5MGJmNDMvdGFibGU6MDEzMzI1MTVmZTg5NGI5NmFhMTk1YzdlZTdiZmVmNjgvdGFibGVyYW5nZTowMTMzMjUxNWZlODk0Yjk2YWExOTVjN2VlN2JmZWY2OF83LTEtMS0xLTA_e21418f0-bcd4-438e-9025-8b382c02a0c5">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180L2ZyYWc6ZTk0NGM4MTVlMThkNDJjOGJhODdlMzAxNmQ5MGJmNDMvdGFibGU6MDEzMzI1MTVmZTg5NGI5NmFhMTk1YzdlZTdiZmVmNjgvdGFibGVyYW5nZTowMTMzMjUxNWZlODk0Yjk2YWExOTVjN2VlN2JmZWY2OF84LTEtMS0xLTA_ef39271a-681e-4523-a76a-a3daf9880331">Q1</dei:DocumentFiscalPeriodFocus>
    <fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMy0xLTEtMS0w_266a35b8-1c26-4c76-b874-18ce15c059a6"
      unitRef="usd">6260000</fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases>
    <fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMy0yLTEtMS0w_2562b098-113a-4dbf-a353-469d5ff5bbe4"
      unitRef="usd">5342000</fold:AccumulatedDepreciationAndAmortizationFinanceAndOperatingRightOfUseLeases>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfNi0xLTEtMS0w_467b7ade-6ba8-40e1-99b8-de2dce227898"
      unitRef="usd">19260000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfNi0yLTEtMS0w_71e7e7e7-ef34-482e-aad0-ce6bc4b813e5"
      unitRef="usd">17604000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfOS0xLTEtMS0w_5b06617e-3037-4e4c-858e-45007eb54b2c"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfOS0yLTEtMS0w_3dcd4003-c980-4ced-8ddb-85e2f0d8da07"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMTAtMS0xLTEtMA_d20a9205-e17d-48dc-b38a-6cb31098a4a6"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMTAtMi0xLTEtMA_0956017f-f4ab-4ef3-8048-c327ac4d42b2"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMTEtMS0xLTEtMA_214578af-d8a2-4017-91e7-e5f9b6de87fe"
      unitRef="shares">257449955</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMTEtMi0xLTEtMA_9821553b-4eea-4f8b-ac83-f768ae0b1ecf"
      unitRef="shares">255417869</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMTItMS0xLTEtMA_f072800a-e9d5-4108-aa86-7b70d4631749"
      unitRef="shares">257449955</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yMi9mcmFnOmIwMmFmNDE5MTJhYzRhNWY5YTUxNmRmZmYxZDJhNzhlL3RhYmxlOmIxMmYyYTRiZjM1NDQ1NDhiY2MyZjcxNTQ3ZTU0YmEzL3RhYmxlcmFuZ2U6YjEyZjJhNGJmMzU0NDU0OGJjYzJmNzE1NDdlNTRiYTNfMTItMi0xLTEtMA_7d79e806-098f-4642-8ed4-2c0e5c316841"
      unitRef="shares">255417869</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zMS9mcmFnOmNiMGM4OTI4Njg1ZDQ4YTg5MmY3ZmY4MDIzMTVjMDU1L3RhYmxlOjBjMmFiNWYyNjMzYjQzYzFhMjAzOWMzN2RiNWFiYjRkL3RhYmxlcmFuZ2U6MGMyYWI1ZjI2MzNiNDNjMWEyMDM5YzM3ZGI1YWJiNGRfMi0xLTEtMS0w_bdf5b18d-e2f7-4c47-9df4-0a6f75296461"
      unitRef="usd">1536000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zMS9mcmFnOmNiMGM4OTI4Njg1ZDQ4YTg5MmY3ZmY4MDIzMTVjMDU1L3RhYmxlOjBjMmFiNWYyNjMzYjQzYzFhMjAzOWMzN2RiNWFiYjRkL3RhYmxlcmFuZ2U6MGMyYWI1ZjI2MzNiNDNjMWEyMDM5YzM3ZGI1YWJiNGRfMi0zLTEtMS0w_673d9174-550f-4834-97ab-bcadb9e23a5c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zMS9mcmFnOmNiMGM4OTI4Njg1ZDQ4YTg5MmY3ZmY4MDIzMTVjMDU1L3RhYmxlOjBjMmFiNWYyNjMzYjQzYzFhMjAzOWMzN2RiNWFiYjRkL3RhYmxlcmFuZ2U6MGMyYWI1ZjI2MzNiNDNjMWEyMDM5YzM3ZGI1YWJiNGRfMy0xLTEtMS0w_35091da9-3eca-49ab-845b-fe49b3307327"
      unitRef="usd">-56000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zMS9mcmFnOmNiMGM4OTI4Njg1ZDQ4YTg5MmY3ZmY4MDIzMTVjMDU1L3RhYmxlOjBjMmFiNWYyNjMzYjQzYzFhMjAzOWMzN2RiNWFiYjRkL3RhYmxlcmFuZ2U6MGMyYWI1ZjI2MzNiNDNjMWEyMDM5YzM3ZGI1YWJiNGRfMy0zLTEtMS0w_95f3be2e-190f-43a8-ab2e-171d76e929e4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="ie0ba4a524aed416486913ea7a9dba98f_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183Ni9mcmFnOmM1ZGNjNTZlMmMzYjQ3NTg4Y2JhN2Q4MzU0NzQ1OTI2L3RleHRyZWdpb246YzVkY2M1NmUyYzNiNDc1ODhjYmE3ZDgzNTQ3NDU5MjZfMTg_e46e8f55-bb7d-4f1c-afca-a18978b6f096"
      unitRef="number">0.75</fold:ContingentConsiderationMeasurementInput>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="i9feff19608a147b4a577c14d3cd15368_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183Ni9mcmFnOmM1ZGNjNTZlMmMzYjQ3NTg4Y2JhN2Q4MzU0NzQ1OTI2L3RleHRyZWdpb246YzVkY2M1NmUyYzNiNDc1ODhjYmE3ZDgzNTQ3NDU5MjZfMjQ_3871914a-e2a2-4a19-9ee4-061f41bb8817"
      unitRef="number">0.78</fold:ContingentConsiderationMeasurementInput>
    <dei:DocumentType
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMDk4_798761d4-1399-4814-99ad-e48d022834d1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMDk5_30cc9af9-d6a4-4905-a0d1-69a905f0c2e9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMzU_f25d6a6c-6a6a-4e62-9566-fc58b51834eb">2020-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMTAw_0946edb2-c16f-409c-bac2-03c82b8f022c">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMTAx_fb1d3f03-17ae-47b3-9355-26f7666b93a4">001-33497</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMTAy_2f4f2ed0-3f8c-486b-bab3-d5f8f0496e22">Amicus Therapeutics,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN18wLTAtMS0xLTA_fdfe448d-1460-4809-9bd2-96569a9f9bd0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN18wLTQtMS0xLTA_be1cc0b5-0d28-495e-8bd9-9b4a4b4d7d5a">71-0869350</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN180LTAtMS0xLTA_3c0b2937-5cd2-4be0-b569-041ffc20781a">1 Cedar Brook Drive,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN180LTEtMS0xLTA_58c34d63-b821-4867-aa99-be0e783c437a">Cranbury,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN180LTItMS0xLTA_f2d64f29-45c9-4292-bb76-43116dc73887">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN180LTQtMS0xLTA_bff9e0b9-9fc9-4147-a890-debb54e9f1d2">08512</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN183LTAtMS0xLTA_8c3204f7-d9ac-43cd-a81a-f902a13838ea">(609)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YzM5MDlmN2FiNmIwNDQ4N2FjYTA1YjY5ZGJiY2UwMDcvdGFibGVyYW5nZTpjMzkwOWY3YWI2YjA0NDg3YWNhMDViNjlkYmJjZTAwN183LTMtMS0xLTA_a2f94321-c0fa-4674-b509-32c14995316f">662-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YjYxZTEyZTQ4YzdjNGI3OTg3MGI4N2VkZjhkZjIzZDcvdGFibGVyYW5nZTpiNjFlMTJlNDhjN2M0Yjc5ODcwYjg3ZWRmOGRmMjNkN18xLTAtMS0xLTA_6fac4170-1d5f-440f-90c4-60283b12e7ce">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YjYxZTEyZTQ4YzdjNGI3OTg3MGI4N2VkZjhkZjIzZDcvdGFibGVyYW5nZTpiNjFlMTJlNDhjN2M0Yjc5ODcwYjg3ZWRmOGRmMjNkN18xLTEtMS0xLTA_1eadf553-8b96-4c7b-b124-63cc207f8859">FOLD</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6YjYxZTEyZTQ4YzdjNGI3OTg3MGI4N2VkZjhkZjIzZDcvdGFibGVyYW5nZTpiNjFlMTJlNDhjN2M0Yjc5ODcwYjg3ZWRmOGRmMjNkN18xLTItMS0xLTA_0c1d6c73-3d8a-4a92-b969-f4ebf20d8f49">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMTAz_90577830-3b59-45af-a84b-e324ea0c75b8">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMTA0_e31530a7-2a89-41e8-a2d3-ce87d59df547">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6MGI1Yzk4ODk1ZjI5NGUwOGJjN2ZlODliYmNiZWE4OTkvdGFibGVyYW5nZTowYjVjOTg4OTVmMjk0ZTA4YmM3ZmU4OWJiY2JlYTg5OV8wLTAtMS0xLTA_88481743-66d6-4a9f-afbd-31a8c7371bd0">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6MGI1Yzk4ODk1ZjI5NGUwOGJjN2ZlODliYmNiZWE4OTkvdGFibGVyYW5nZTowYjVjOTg4OTVmMjk0ZTA4YmM3ZmU4OWJiY2JlYTg5OV8xLTctMS0xLTA_017c6bc3-9af4-4e38-b879-17a1ce11245b">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGFibGU6MGI1Yzk4ODk1ZjI5NGUwOGJjN2ZlODliYmNiZWE4OTkvdGFibGVyYW5nZTowYjVjOTg4OTVmMjk0ZTA4YmM3ZmU4OWJiY2JlYTg5OV8yLTctMS0xLTA_af9126ec-9155-4b90-b07b-b9305a6cb625">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8yMDk3_bcb1ae70-cd72-47f1-b9e8-b0196e5f3ad0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i99ffeda6d436452d9771eb87cc47254e_I20200427"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xL2ZyYWc6YjFhNzlmNzkxMWEyNGQwMGI1ZjhmMWE3ZmViZDc2YTEvdGV4dHJlZ2lvbjpiMWE3OWY3OTExYTI0ZDAwYjVmOGYxYTdmZWJkNzZhMV8xNjQ5MjY3NDQzODUz_3afefa32-2be1-4850-b7c6-8ff53f03bf5b"
      unitRef="shares">257664403</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMy0xLTEtMS0w_d8ca31d5-3f3b-446a-9957-4d0d7593675a"
      unitRef="usd">123231000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMy0zLTEtMS0w_568bb4b8-2271-4129-a92b-0fcfc09c4f7e"
      unitRef="usd">142837000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNC0xLTEtMS0w_39df2fc1-91ad-405f-a956-21f10145945c"
      unitRef="usd">215642000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNC0zLTEtMS0w_ecceb39a-c9b8-408f-90e7-d0ee3275613b"
      unitRef="usd">309903000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNS0xLTEtMS0w_9100607f-08d9-4273-8cc6-43b7d4770c67"
      unitRef="usd">40555000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNS0zLTEtMS0w_e3500550-32ae-4af1-b1ff-fc48b5f6b3f1"
      unitRef="usd">33284000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNi0xLTEtMS0w_25a4e6b8-5fc0-460c-be8d-25c054fb793a"
      unitRef="usd">12831000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNi0zLTEtMS0w_8eeeee6a-5173-44c3-8a7c-5b324101565e"
      unitRef="usd">14041000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNy0xLTEtMS0w_882d1c3c-b59f-44c0-a56d-5b2763136596"
      unitRef="usd">15690000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfNy0zLTEtMS0w_648d95bc-eeea-41d2-a50b-f51c6e97b801"
      unitRef="usd">20008000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfOC0xLTEtMS0w_e2169321-7e41-45c3-bf4a-45ffe5a8f82e"
      unitRef="usd">407949000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfOC0zLTEtMS0w_11a991a2-bf9b-4409-a653-0acc04f24825"
      unitRef="usd">520073000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfOS0xLTEtMS0w_dcc03a0a-9b95-4712-aab2-1a29504444b0"
      unitRef="usd">32501000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfOS0zLTEtMS0w_8d92e676-6239-49e3-b88d-524e61066d8c"
      unitRef="usd">33315000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTAtMS0xLTEtMA_46724608-9493-4c20-9257-90fdcce95d1f"
      unitRef="usd">47688000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTAtMy0xLTEtMA_148c56f5-0042-41a4-b1e5-bbee84571f02"
      unitRef="usd">47705000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTEtMS0xLTEtMA_d021d95a-74c1-4700-b7fd-3b0c45c1444e"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTEtMy0xLTEtMA_cdba57d9-2d65-4633-b610-345580ebc6df"
      unitRef="usd">23000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTItMS0xLTEtMA_8fe125a0-058d-45b0-81d8-705b2d375b80"
      unitRef="usd">197797000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTItMy0xLTEtMA_86d890cf-e521-4f5e-a1e8-9e6efa76338a"
      unitRef="usd">197797000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTMtMS0xLTEtMA_6ee1814d-c520-4dcf-a183-758900c5f1cc"
      unitRef="usd">29414000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTMtMy0xLTEtMA_270fcbc7-a82e-4039-8cfc-a0827eeabe3a"
      unitRef="usd">28317000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTQtMS0xLTEtMA_99e85bd6-eeb5-46e4-a3a3-5573f0c6534d"
      unitRef="usd">738349000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTQtMy0xLTEtMA_6dacf2a1-1380-4739-991f-2e40c4bebc9c"
      unitRef="usd">850207000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTctMS0xLTEtMA_91f8b1a1-d3ae-47df-b81c-9cdd821054a9"
      unitRef="usd">16239000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTctMy0xLTEtMA_3ef41925-2985-4aed-b014-711afcdee549"
      unitRef="usd">21722000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTgtMS0xLTEtODY0_d8e4233b-0d58-427e-9035-e504dd0fb641"
      unitRef="usd">66722000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTgtMy0xLTEtODY0_04592105-65b0-4ed5-9113-c2b49d3a713d"
      unitRef="usd">98651000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTgtMS0xLTEtMA_11a807f5-33f8-4473-be94-42c002a08ab9"
      unitRef="usd">1250000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTgtMy0xLTEtMA_c6308a7c-08ef-4fdc-8905-e5465cb4a057"
      unitRef="usd">1250000</us-gaap:DeferredCreditsAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTktMS0xLTEtMA_a6b100af-ff26-4035-8cdc-e904be49ec44"
      unitRef="usd">7503000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMTktMy0xLTEtMA_7ff3108e-089b-4940-a0b4-ca71344f61e6"
      unitRef="usd">7189000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjAtMS0xLTEtMA_f24f6411-5605-4e21-97f2-d03345beb789"
      unitRef="usd">91714000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjAtMy0xLTEtMA_3d54b11f-29c2-4dd0-8eb5-09605af9334c"
      unitRef="usd">128812000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjEtMS0xLTEtMA_ae113134-5385-410d-87ab-63df5006e1a4"
      unitRef="usd">8906000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjEtMy0xLTEtMA_08206f49-c6a4-45ac-9a91-692f767b57bf"
      unitRef="usd">8906000</us-gaap:DeferredCreditsAndOtherLiabilitiesNoncurrent>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjItMS0xLTEtMA_2d95a5b9-bf15-4b70-a07f-e85a3784fe5f"
      unitRef="usd">2167000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjItMy0xLTEtMA_a45f0370-cfc7-40c1-a088-05aa2376f3c8"
      unitRef="usd">2131000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:SecuredLongTermDebt
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjMtMS0xLTEtMA_30d09906-66eb-4647-a010-896805858077"
      unitRef="usd">147569000</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjMtMy0xLTEtMA_097067a3-5bae-4ade-a9b6-277fcbc834c8"
      unitRef="usd">147374000</us-gaap:SecuredLongTermDebt>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjQtMS0xLTEtMA_a9e945f1-285a-444b-8416-18acc71acf7b"
      unitRef="usd">23612000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjQtMy0xLTEtMA_f6d62cb5-888a-4701-a434-da3747260fa2"
      unitRef="usd">22681000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjUtMS0xLTEtMA_02b6ed96-3905-4bd7-b0c8-4954554ea0d3"
      unitRef="usd">5051000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjUtMy0xLTEtMA_35328afb-e6f0-48f8-b651-4e9c164a8c13"
      unitRef="usd">5051000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjYtMS0xLTEtMA_a3e7a986-23ea-4f02-aa17-3241d1666ab5"
      unitRef="usd">52522000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjYtMy0xLTEtMA_c637f8e5-f0aa-4991-a9a8-7f089630e0ad"
      unitRef="usd">53531000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjctMS0xLTEtMA_f7554b0b-cfbf-4482-8606-345e1bebfe02"
      unitRef="usd">4214000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjctMy0xLTEtMA_9eaa902a-76c6-471e-b966-7613b04e1a10"
      unitRef="usd">5296000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjgtMS0xLTEtMA_6b7efecb-a75a-4477-bc3a-e236944d616f"
      unitRef="usd">335755000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjgtMy0xLTEtMA_567f1c47-cec2-4ceb-9067-0bf2493ce793"
      unitRef="usd">373782000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjktMS0xLTEtMA_e6f9ff73-2a0d-4703-bf86-819b4de13859"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMjktMy0xLTEtMA_5c39323e-6b1b-45fc-b48b-7dd0e980e79b"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzEtMS0xLTEtMA_dcc5de39-118b-4ba9-98f8-d572a198c346"
      unitRef="usd">2607000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzEtMy0xLTEtMA_9a829223-5feb-44f0-9e5b-00f7cb04dea7"
      unitRef="usd">2598000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzItMS0xLTEtMA_91ecc778-1e0e-4fbf-bb5e-cdf35b8e96bb"
      unitRef="usd">2238346000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzItMy0xLTEtMA_35b9dc24-4045-479d-96f2-988000fab1a5"
      unitRef="usd">2227225000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzQtMS0xLTEtMA_3858cf78-fc20-40c4-b3aa-ddafaa777a8a"
      unitRef="usd">6981000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzQtMy0xLTEtMA_49f6edbb-3528-40bd-9c46-2887442fbeac"
      unitRef="usd">2785000</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzUtMS0xLTEtMA_a65ebe06-0cd5-4992-a52f-d37e04339aeb"
      unitRef="usd">-169000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzUtMy0xLTEtMA_6d44e2af-b543-443e-881e-fb6ec957402f"
      unitRef="usd">40000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzYtMS0xLTEtMA_11c093f6-1502-4012-8f62-7adb4abece1f"
      unitRef="usd">12387000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzYtMy0xLTEtMA_2557b782-34c9-4d8e-9a0a-ff180a3e8f3d"
      unitRef="usd">12387000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzctMS0xLTEtMA_768e0604-6441-4341-885a-60bc09da59ee"
      unitRef="usd">-1857558000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzctMy0xLTEtMA_82483467-ae3e-4c6c-8e5c-d32ef568adda"
      unitRef="usd">-1768610000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzgtMS0xLTEtMA_36673c06-86d6-4a34-8daa-6231b17df492"
      unitRef="usd">402594000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzgtMy0xLTEtMA_063db597-dc5f-4e5e-94c7-de98b9f91dd3"
      unitRef="usd">476425000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzktMS0xLTEtMA_69f30971-afbc-4d9e-ac1f-edbc0486e778"
      unitRef="usd">738349000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18xOS9mcmFnOjgyODMxODVmMjI5YTRhYTJhYjRmMDY0ODhhMTQzM2U2L3RhYmxlOmFmNmEzNDMyYWJiYTQ4NGY5MzZiYTZiYWJkNmNkYjFhL3RhYmxlcmFuZ2U6YWY2YTM0MzJhYmJhNDg0ZjkzNmJhNmJhYmQ2Y2RiMWFfMzktMy0xLTEtMA_9270e85a-774e-42c2-99a9-8a27dafef9d8"
      unitRef="usd">850207000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMi0xLTEtMS0w_992918da-861e-41a2-84cc-8b9342c00b5c"
      unitRef="usd">60525000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMi0zLTEtMS0w_1fe533f2-2cc5-48df-bd88-9eb34cbbb6d8"
      unitRef="usd">34046000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMy0xLTEtMS0w_e6af2db3-c364-4518-af86-2a04859fa374"
      unitRef="usd">6552000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMy0zLTEtMS0w_31be2956-8225-4aad-80cc-e73ca5fe6c7e"
      unitRef="usd">4055000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfNC0xLTEtMS0w_885d82e6-7948-41e5-bc8f-b4540f3901d0"
      unitRef="usd">53973000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfNC0zLTEtMS0w_f3876c14-4678-46ee-a9f7-a3cc5196450a"
      unitRef="usd">29991000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfNi0xLTEtMS0w_5ccc2742-e2db-4ae0-9edc-bc226c337cc9"
      unitRef="usd">89120000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfNi0zLTEtMS0w_b677c440-8167-46fc-bca4-3779d14e03cf"
      unitRef="usd">64593000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfNy0xLTEtMS0w_5e050faf-ca75-44fb-915a-5666c6680f82"
      unitRef="usd">40215000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfNy0zLTEtMS0w_3cdbd0e3-57c0-4b30-92ed-73652c94c8f8"
      unitRef="usd">44303000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfOC0xLTEtMS0w_713d3f8c-10ff-4ffb-9fd1-73295650e17e"
      unitRef="usd">-931000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfOC0zLTEtMS0w_fdb61de1-7aef-4926-80d8-4c8775d5e1e0"
      unitRef="usd">-1383000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfOS0xLTEtMS0w_f4ff83aa-0974-43cb-a258-0def82137c24"
      unitRef="usd">1764000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfOS0zLTEtMS0w_11397961-5956-4168-aebc-829472503516"
      unitRef="usd">991000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTAtMS0xLTEtMA_87d1609e-9c35-4942-a875-c03c34ac1222"
      unitRef="usd">132030000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTAtMy0xLTEtMA_eaf573c7-3f6a-4f09-a41a-8528b6c8e4da"
      unitRef="usd">111270000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTEtMS0xLTEtMA_7b91b131-8d46-41ab-8ede-345605cd00fe"
      unitRef="usd">-78057000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTEtMy0xLTEtMA_ce4b4438-68e3-4e80-83da-dff12078f7ca"
      unitRef="usd">-81279000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTMtMS0xLTEtMA_7b6d5cae-4b32-4faf-9906-a716450a0b2a"
      unitRef="usd">1515000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTMtMy0xLTEtMA_3c3bbc0e-03b7-445a-99fd-1134549ddd13"
      unitRef="usd">2639000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTQtMS0xLTEtMA_eae3b091-b8e5-4dc4-9bc1-cc7e84c42644"
      unitRef="usd">3729000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTQtMy0xLTEtMA_97a1fd5a-9fad-450c-9f7f-fadea0cd2260"
      unitRef="usd">6454000</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTUtMS0xLTEtMA_c82ea145-5f90-49ed-a1fd-79683bfe4a88"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTUtMy0xLTEtMA_1625c83f-791b-47bc-98a9-9dee2d10d503"
      unitRef="usd">-36123000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTctMS0xLTEtMA_f3375a79-2853-4797-9441-d384447e698b"
      unitRef="usd">-8316000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTctMy0xLTEtMA_671aa4c9-36b6-44fb-915b-c3e24989b3a5"
      unitRef="usd">1086000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTgtMS0xLTEtMA_f4587935-24f3-4c7c-904b-ca9a21c70f44"
      unitRef="usd">-88587000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTgtMy0xLTEtMA_011c4b57-5501-47b7-841d-8ed0cec2ece2"
      unitRef="usd">-120131000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTktMS0xLTEtMA_13f77cfc-79be-4677-a65b-5627bd768f07"
      unitRef="usd">361000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMTktMy0xLTEtMA_f59cb45a-6765-4d7d-9bf8-c20f93dd45c7"
      unitRef="usd">168000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMjAtMS0xLTEtMA_f974a23b-36b5-45b2-80dd-2d4f651a5d2e"
      unitRef="usd">-88948000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMjAtMy0xLTEtMA_bdc8ae54-83f8-4bd4-af50-d7a599cebfa6"
      unitRef="usd">-120299000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMjEtMS0xLTEtMA_ca29e06d-432d-43b5-8b61-1c66f19f8036"
      unitRef="usdPerShare">-0.35</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMjEtMy0xLTEtMA_ddfe25f1-d4b0-4d1d-9256-e82fa2c35b9f"
      unitRef="usdPerShare">-0.56</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMjItMS0xLTEtMA_068caca2-9a3f-48ea-94f1-9924af0a46e4"
      unitRef="shares">256968248</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yNS9mcmFnOmFlZjA4NDA5Y2M2ZTRhMmI5YzNlMTZhNjk5OTJjOTJiL3RhYmxlOjllMWFlZDJmNjI5MDRmYmNiN2MzMmM0ZjdhZTc2NGU0L3RhYmxlcmFuZ2U6OWUxYWVkMmY2MjkwNGZiY2I3YzMyYzRmN2FlNzY0ZTRfMjItMy0xLTEtMA_a9c85cb2-c198-4069-8441-8cccf533ab61"
      unitRef="shares">213519287</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfMi0xLTEtMS0w_b6367402-c938-4b0e-a672-ef58984a3d30"
      unitRef="usd">-88948000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfMi0zLTEtMS0w_ab9cdcbb-6c4c-4456-9663-c7cb60e75cd7"
      unitRef="usd">-120299000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNC0xLTEtMS0w_c822256a-d199-4f7e-8fde-11dcd63c167d"
      unitRef="usd">4196000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNC0zLTEtMS0w_cf02fa09-8133-4152-9909-41f7be721193"
      unitRef="usd">-1804000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNS0xLTEtMS0w_e6870bc4-eef2-4c48-88b0-31fa31b83b0e"
      unitRef="usd">-209000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNS0zLTEtMS0w_aec299f3-bc81-4a56-9b78-fc51a80f7ca6"
      unitRef="usd">584000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNi0xLTEtMS0w_d1f90a98-e146-4197-bf05-7058f6ac353f"
      unitRef="usd">3987000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNi0zLTEtMS0w_bb5e24c1-5824-4f49-b9aa-5b84efe8b680"
      unitRef="usd">-1220000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNy0xLTEtMS0w_5e8a524b-fae1-48eb-b51f-c2c8eaabc9e0"
      unitRef="usd">-84961000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18yOC9mcmFnOjlkMzQ1ZGE4N2NkYjQyYTU5NDY2M2U1MDdkZTBkMzdhL3RhYmxlOjkzZDQ4ZTBmNmQ1ZTQ5M2FhMzFjMzA1ZDMzYzU5YjUwL3RhYmxlcmFuZ2U6OTNkNDhlMGY2ZDVlNDkzYWEzMWMzMDVkMzNjNTliNTBfNy0zLTEtMS0w_7525ab83-fbf2-4219-a952-ca018f5557f9"
      unitRef="usd">-121519000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iec6b6ea5594b4731a877338c089938f3_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi0xLTEtMS0w_06f1b3bd-5329-4c0a-9dbe-a00d709291bb"
      unitRef="shares">255417869</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="iec6b6ea5594b4731a877338c089938f3_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi0zLTEtMS0w_590cd324-fe4f-4e1f-a53f-ed5c100ce68b"
      unitRef="usd">2598000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9ab7b2af443045e981707c6d83e68f71_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi01LTEtMS0w_cd94a986-2bf5-48bb-8be1-840ee09196e2"
      unitRef="usd">2227225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic617e48d8a10423db3184a6dfab2b3bf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi03LTEtMS0w_687279d9-a0ca-4794-a2c5-23f1807f6ec2"
      unitRef="usd">12387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7607f8134f5b416d9727cf6788be5ff0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi05LTEtMS0w_e380e8b3-88cf-4f5a-904e-8b33266fec2b"
      unitRef="usd">2825000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9d497ab4f2c34411849a9c0b7f6ad148_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi0xMS0xLTEtMA_62ff0e0c-b033-4f7e-bf32-ff30c6d844c2"
      unitRef="usd">-1768610000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMi0xMy0xLTEtMA_3f49de86-d271-4b1d-ac16-1590bbc3b2fa"
      unitRef="usd">476425000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibac1144c427c4ab28f9978dedda26866_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMy0xLTEtMS0w_816c3561-f580-47f1-bce0-ad32a650e909"
      unitRef="shares">958947</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibac1144c427c4ab28f9978dedda26866_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMy0zLTEtMS0w_f223533d-8bcf-4ee2-892d-1e5fae49c699"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7f01de7d9dd44ea8b91087aef6dc8069_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMy01LTEtMS0w_b6c69fae-0f64-4142-ad9d-0e60a660ad4b"
      unitRef="usd">6068000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfMy0xMy0xLTEtMA_c60b2229-7c03-4dfb-bece-6c968c3b95a5"
      unitRef="usd">6077000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ibac1144c427c4ab28f9978dedda26866_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNC0xLTEtMS0w_4f1c60c6-4825-4cc4-85f5-700f8ebb575f"
      unitRef="shares">1073139</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="i7f01de7d9dd44ea8b91087aef6dc8069_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNC01LTEtMS0w_d21e5e6e-bd9d-47aa-802b-e5235f565668"
      unitRef="usd">-7543000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNC0xMy0xLTEtMA_93d20842-0326-4803-bf33-52992e341eee"
      unitRef="usd">-7543000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7f01de7d9dd44ea8b91087aef6dc8069_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNS01LTEtMS0w_56288ae7-ecb9-4f13-b35b-d62431e958c3"
      unitRef="usd">12596000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNS0xMy0xLTEtMA_347a6206-62d4-4b30-b2d3-837b9a855178"
      unitRef="usd">12596000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia98f9eda9405487aa88f7722bcf90c06_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNi05LTEtMS0w_9c402005-e0c5-497b-8122-65d32c825189"
      unitRef="usd">-209000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNi0xMy0xLTEtMA_df4617f4-8dda-4455-ad92-dd3607683125"
      unitRef="usd">-209000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="ia98f9eda9405487aa88f7722bcf90c06_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNy05LTEtMS0w_cc5ff978-6155-4ef5-b83c-0728f5c85b85"
      unitRef="usd">4196000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfNy0xMy0xLTEtMA_b97ea330-93ad-45fd-bdf7-92082690ea59"
      unitRef="usd">4196000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i03c53c43e07c4745bc497b9834079c0a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOC0xMS0xLTEtMA_cf4ed3fe-5243-46e6-b02d-3df38da55f51"
      unitRef="usd">-88948000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOC0xMy0xLTEtMA_abafded7-ac97-4245-9e61-2e96275eab29"
      unitRef="usd">-88948000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if4281d64af2d427b85cef94416b0a885_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS0xLTEtMS0w_f507029d-8da4-4211-8798-6e77bff9fb6e"
      unitRef="shares">257449955</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if4281d64af2d427b85cef94416b0a885_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS0zLTEtMS0w_942f6ec9-e68f-47ca-8977-4969891d3ae7"
      unitRef="usd">2607000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if69166eb2b574a688fba8c17a396ddc1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS01LTEtMS0w_10d4f46d-d4e1-4833-b22d-5a17665cc818"
      unitRef="usd">2238346000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3c8339ddd7df40d5a162d23e286d54ae_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS03LTEtMS0w_d4aa656a-0bae-4db3-9474-8b400d2cf238"
      unitRef="usd">12387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibf2972e46bfc4f359a17c8f36be0ac34_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS05LTEtMS0w_71eb14d5-ee76-4a9f-86fd-66deeaebb5a2"
      unitRef="usd">6812000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i26248ac6987b40c48626b19b6e0c9195_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS0xMS0xLTEtMA_68d4d71b-d3f9-4354-93ba-1a604b649be8"
      unitRef="usd">-1857558000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOmVjMjZmZjdlMGU0MDRkMjk4Y2NjNGY2YWYyYjgyM2JjL3RhYmxlcmFuZ2U6ZWMyNmZmN2UwZTQwNGQyOThjY2M0ZjZhZjJiODIzYmNfOS0xMy0xLTEtMA_c9038627-5706-4029-893b-0378c163d356"
      unitRef="usd">402594000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i05bc9b3b7144464c88b636e60eedf49a_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi0xLTEtMS0w_95bc5ec2-df88-49ea-b6e6-f559d42d3a32"
      unitRef="shares">189383924</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i05bc9b3b7144464c88b636e60eedf49a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi0zLTEtMS0w_2de5a27d-1ee4-415c-9943-993872bcc665"
      unitRef="usd">1942000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifcbb93cbfad34e7d97f71f16ddd6c611_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi01LTEtMS0w_4fe46d83-bd3b-4d92-a450-648f94ecabc2"
      unitRef="usd">1740061000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i96c0a7cbb6b3472bb1e2424eaa5e6177_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi03LTEtMS0w_571e1f90-6a6e-4da2-baf9-aa344656c9f5"
      unitRef="usd">13063000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibba94963ffeb42d08d8d600f49ecd905_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi05LTEtMS0w_8cdc92c1-aacb-474a-a2c2-b858f76db81b"
      unitRef="usd">68000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idadd57a0cda848479ab4cb0f85af2845_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi0xMS0xLTEtMA_3e33e286-7f18-4ca5-833f-b04716a99b7e"
      unitRef="usd">-1412222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icab07bfc15ea4b0a9b2e3d5dfe987d2a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMi0xMy0xLTEtMA_12086ebd-959d-4aab-a447-870b3da17cf2"
      unitRef="usd">342912000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMy0xLTEtMS0w_ab4028c9-eec7-4132-8e4b-281ac7c14e2e"
      unitRef="shares">578451</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMy0zLTEtMS0w_a9bad4f6-c063-4b17-a6a9-cc6c58f8767d"
      unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMy01LTEtMS0w_05a875c7-ca35-471c-82bb-a319739dcecc"
      unitRef="usd">3947000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMy0xMy0xLTEtMA_6ef8924e-9ba3-44fb-ae04-13aea26e5799"
      unitRef="usd">3953000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNC0xLTEtMS0w_cf42c359-1305-419e-b862-8840de9c9bb7"
      unitRef="shares">301058</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNC01LTEtMS0w_1f3dc95f-ac97-491a-bf2f-5c835f99f40b"
      unitRef="usd">-1940000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNC0xMy0xLTEtMA_37813d3f-7faa-4560-aa4b-5bb009325cf1"
      unitRef="usd">-1940000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition>
    <fold:StockIssuedDuringPeriodSharesContingentConsideration
      contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNS0xLTEtMS0w_52830030-f071-4e22-b190-907ab1d64a93"
      unitRef="shares">771804</fold:StockIssuedDuringPeriodSharesContingentConsideration>
    <fold:StockIssuedDuringPeriodValueContingentConsideration
      contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNS0zLTEtMS0w_42d7cc04-e695-4cab-98b9-0fa547e5b11e"
      unitRef="usd">8000</fold:StockIssuedDuringPeriodValueContingentConsideration>
    <fold:StockIssuedDuringPeriodValueContingentConsideration
      contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNS01LTEtMS0w_41b29e10-4120-4241-94c7-73e1522fe98a"
      unitRef="usd">9308000</fold:StockIssuedDuringPeriodValueContingentConsideration>
    <fold:StockIssuedDuringPeriodValueContingentConsideration
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNS0xMy0xLTEtMTI5MA_b5f27325-aac6-45c5-9f91-1890e44fbea2"
      unitRef="usd">9316000</fold:StockIssuedDuringPeriodValueContingentConsideration>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNi01LTEtMS0w_498f689b-3408-4b41-a91e-22dab309ff60"
      unitRef="usd">12744000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNi0xMy0xLTEtMA_a4faf784-2e2e-4d84-8873-473ae6984320"
      unitRef="usd">12744000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <fold:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNy0xLTEtMS0w_a7941284-4a0c-445e-b003-e9ab6e434b0b"
      unitRef="shares">101787</fold:StockIssuedDuringPeriodSharesWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNy0zLTEtMS0w_37eb9500-0723-48c5-ac67-2d7d29d38280"
      unitRef="usd">1000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNy01LTEtMS0w_c2397472-4ff8-4690-b6fe-9435e40dace8"
      unitRef="usd">1487000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i4a73b1ec2ad049afa1945e4ac428aa91_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNy03LTEtMS0w_873f4a6d-5fe6-4fff-ba9d-8e848f03e216"
      unitRef="usd">-676000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <fold:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfNy0xMy0xLTEtMA_12983161-076e-48f3-99fa-70f9287c5959"
      unitRef="usd">812000</fold:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfOC0xLTEtMS0w_389eed30-e4ab-4760-b917-adca6957e099"
      unitRef="shares">39043690</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i2d1dead8d19c4c67811e738a08cab9d1_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfOC0zLTEtMS0w_e77707d4-06f3-4ca7-bb84-287e55c9f8c9"
      unitRef="usd">390000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfOC01LTEtMS0w_c1579afa-ea70-41e9-a322-79dceef0aa78"
      unitRef="usd">190368000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfOC0xMy0xLTEtMTI5Mg_a4de2464-707f-475e-826a-4817a3ae9812"
      unitRef="usd">190758000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
    <fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations
      contextRef="i8b36f2661b2843b5b72c492b54472a17_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfOS01LTEtMS0w_f6971f85-8285-4390-bb19-acb1ae39254c"
      unitRef="usd">14632000</fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations>
    <fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfOS0xMy0xLTEtMTI5NA_a3366de2-c29f-4797-88fb-8536f6125e00"
      unitRef="usd">14632000</fold:AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i727363bd8bbd43adae093805b3e3a8eb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTAtOS0xLTEtMA_11825845-7a00-4766-b5d7-a07080af5287"
      unitRef="usd">584000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTAtMTMtMS0xLTA_c0bec97c-583a-4b92-8256-56888e2a06b2"
      unitRef="usd">584000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i727363bd8bbd43adae093805b3e3a8eb_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTEtOS0xLTEtMA_15fc0f18-85b3-4f9c-82b4-20460e419e79"
      unitRef="usd">-1804000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTEtMTMtMS0xLTA_beb09a88-1117-440b-8440-6d55d059dc3a"
      unitRef="usd">-1804000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="iab7bd98c579140b5b443d931338863c7_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTItMTEtMS0xLTA_51292a7f-748d-4a93-a49f-a56c956fa502"
      unitRef="usd">-120299000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTItMTMtMS0xLTA_40e7e32a-4293-41ec-ac16-94e036ffccc5"
      unitRef="usd">-120299000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9528373dcfb944969e8d059bcea89906_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtMS0xLTEtMA_73cee19d-2c51-4867-a1f4-f82540ab849f"
      unitRef="shares">230180714</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9528373dcfb944969e8d059bcea89906_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtMy0xLTEtMA_c5ae57f6-1d53-47ea-b1e7-d0fc05fa27d4"
      unitRef="usd">2347000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5491ffc350124a71b70a57e9a6ea8c72_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtNS0xLTEtMA_30dbe9ae-ae4e-4b95-b6e3-6ae7320acb86"
      unitRef="usd">1970607000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id9251812ad7e4ed885bebff24390dfb9_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtNy0xLTEtMA_b49137be-2be5-4731-bd72-8785abc4e4c1"
      unitRef="usd">12387000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5462b45a2d554a69b26d20db9f69d769_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtOS0xLTEtMA_69214e82-9bf5-4a21-bf4d-6ad0294054f3"
      unitRef="usd">-1152000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9d09871cf6ad4200a92e067dd3180699_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtMTEtMS0xLTA_5986fce3-2456-4fa5-9de0-bf89c9d7198d"
      unitRef="usd">-1532521000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNC9mcmFnOjVhYjBjNmZjZjVmNzRlOTViNzFiMzJhNjE4Y2FjNjNjL3RhYmxlOjAwMzQ1NWIwNTMxOTQ1NGU5MDgyZjU2NmRkMTEwNmUzL3RhYmxlcmFuZ2U6MDAzNDU1YjA1MzE5NDU0ZTkwODJmNTY2ZGQxMTA2ZTNfMTMtMTMtMS0xLTA_1b1c9918-33ad-4c33-8282-e86c63946742"
      unitRef="usd">451668000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMy0xLTEtMS0w_68d77885-0308-4342-8af9-12cc4d20390b"
      unitRef="usd">-88948000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMy0zLTEtMS0w_4c2b06c6-5f90-4b62-b56b-3de3b1efebc2"
      unitRef="usd">-120299000</us-gaap:ProfitLoss>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfNS0xLTEtMS0w_e1375b84-fa97-4ce9-b8c4-1a3286939027"
      unitRef="usd">231000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfNS0zLTEtMS0w_cbfc51e9-eb2c-40cb-8c1b-2112e999c2ea"
      unitRef="usd">1649000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfNi0xLTEtMS0w_3262ae03-eee7-460b-9829-8523da184f41"
      unitRef="usd">1764000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfNi0zLTEtMS0w_9fe8655a-a31d-46db-b098-d47ff84604c6"
      unitRef="usd">991000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfNy0xLTEtMS0w_5f59e031-efe0-423a-bd39-5245b6fa6ec3"
      unitRef="usd">12596000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfNy0zLTEtMS0w_d8def44a-df4d-4ffb-a323-764c2d93da2d"
      unitRef="usd">12744000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfOC0xLTEtMS0w_ee627fec-3cff-41cf-b5f0-7d5891847d1c"
      unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfOC0zLTEtMS0w_c00f1468-16ea-42c8-91bb-3f11840df404"
      unitRef="usd">-36123000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfOS0xLTEtMS0w_056917c4-ca0a-4b8a-b66c-761b09a18ecd"
      unitRef="usd">931000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfOS0zLTEtMS0w_1d8a3e4e-3073-4e19-8464-f1a1ce22acaa"
      unitRef="usd">1383000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTAtMS0xLTEtMA_5656bcb2-c5c6-4421-ad4c-8ef684d2beec"
      unitRef="usd">-10662000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <fold:ForeignCurrencyRemeasurementGainLossBeforeTax
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTAtMy0xLTEtMA_0a9de204-11cf-40fb-baca-04474f5e9442"
      unitRef="usd">-325000</fold:ForeignCurrencyRemeasurementGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTMtMS0xLTEtMA_1e40781c-d4ca-47a0-8ef0-5395b25384f8"
      unitRef="usd">8358000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTMtMy0xLTEtMA_ad6c1053-305f-4dca-b0f0-f81f9cdc0792"
      unitRef="usd">1001000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTQtMS0xLTEtMA_fbbcedfc-6ba9-4b6e-a321-84218219599f"
      unitRef="usd">251000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTQtMy0xLTEtMA_abc65449-9fb6-4edc-b7bd-5ee9cfc8b47e"
      unitRef="usd">-345000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTUtMS0xLTEtMA_f79255ad-c379-4d2d-8b1f-19f0da8e2785"
      unitRef="usd">-4016000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTUtMy0xLTEtMA_020682f9-36eb-4b4f-9e5b-fe977a0accfd"
      unitRef="usd">-3059000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTYtMS0xLTEtMA_4a33217f-0a7e-4ed9-be3f-570de96864f4"
      unitRef="usd">-35251000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTYtMy0xLTEtMA_efaee182-07ea-4cb4-8e3f-4cde773c9528"
      unitRef="usd">-8858000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTctMS0xLTEtMA_d8784d87-73f4-4b22-9a97-8efcc453a0f8"
      unitRef="usd">-5334000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <fold:IncreaseDecreaseInNoncurrentOperatingLiabilities
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTctMy0xLTEtMA_13a62bb0-474e-4ce6-8eb6-f6042d61be60"
      unitRef="usd">-3507000</fold:IncreaseDecreaseInNoncurrentOperatingLiabilities>
    <fold:IncreaseDecreaseInDeferredReimbursements
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTgtMS0xLTEtMA_e6087293-3488-46bd-8501-c59c0dc49e16"
      unitRef="usd">0</fold:IncreaseDecreaseInDeferredReimbursements>
    <fold:IncreaseDecreaseInDeferredReimbursements
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTgtMy0xLTEtMA_6bafb3a8-62f6-438c-acb1-2b109e04be2a"
      unitRef="usd">-1500000</fold:IncreaseDecreaseInDeferredReimbursements>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTktMS0xLTEtMA_e369d2f0-3c70-4a97-8683-78b36a13e303"
      unitRef="usd">-107942000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMTktMy0xLTEtMA_9451b23c-8669-461b-a28e-eb3129550ba7"
      unitRef="usd">-78546000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjEtMS0xLTEtMA_f7003280-94d1-4935-8ce0-815af7758ef2"
      unitRef="usd">106140000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjEtMy0xLTEtMA_1652e8a7-b90d-4548-978c-a65fc38b69aa"
      unitRef="usd">135187000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjItMS0xLTEtMA_757afa68-0a96-4e05-b3c9-6913f36ec2fc"
      unitRef="usd">12088000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjItMy0xLTEtMA_291bad1a-ba05-48ad-adb1-90c958f5a0fa"
      unitRef="usd">52178000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjMtMS0xLTEtMA_bf1c1386-4d9d-42f7-9002-b72098a4184b"
      unitRef="usd">806000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjMtMy0xLTEtMA_5ad9fb4a-a708-4684-9ac3-9f04e26cf392"
      unitRef="usd">2944000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjQtMS0xLTEtMA_4d5b4844-e8d3-4815-ad94-3abff1ffad61"
      unitRef="usd">93246000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjQtMy0xLTEtMA_3464ea43-e893-46bf-93e4-55b8fdcee288"
      unitRef="usd">80065000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjYtMS0xLTEtMA_493d928a-69f1-475d-af47-2f1545a4cba5"
      unitRef="usd">21000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjYtMy0xLTEtMA_d7bb520c-f0b2-448f-9dd7-da6825949d0a"
      unitRef="usd">75000</us-gaap:FinanceLeasePrincipalPayments>
    <fold:PaymentsForRepurchaseOfRestrictedStockUnits
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjctMS0xLTEtMA_f223c8a3-e087-474b-9ea2-0ca38180ba85"
      unitRef="usd">7543000</fold:PaymentsForRepurchaseOfRestrictedStockUnits>
    <fold:PaymentsForRepurchaseOfRestrictedStockUnits
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjctMy0xLTEtMA_22196f43-5171-4292-a9f5-930c124a758f"
      unitRef="usd">1938000</fold:PaymentsForRepurchaseOfRestrictedStockUnits>
    <fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjgtMS0xLTEtMA_e6f6dc51-fa51-4c51-a978-416c5f794eb2"
      unitRef="usd">0</fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt>
    <fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjgtMy0xLTEtMA_33096a50-69d8-4323-b12f-5f7c1db889bb"
      unitRef="usd">14632000</fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjktMS0xLTEtMA_943f7c98-3307-4cd1-9b00-3975bdb6677c"
      unitRef="usd">6077000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMjktMy0xLTEtMA_1d36bb28-aa62-45e5-9194-b5bbd589b54d"
      unitRef="usd">3953000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzAtMS0xLTEtMA_8c79c40c-15c4-4f86-a3e6-e85dc85dad73"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzAtMy0xLTEtMA_24be7b6c-d40b-447c-bbe3-dfe1bffbd951"
      unitRef="usd">812000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzEtMS0xLTEtMA_16335d61-3bda-473a-a6cb-08e4fd1e2664"
      unitRef="usd">-1487000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzEtMy0xLTEtMA_f6f8e74d-d4fe-4d31-a2f0-272f51d921e0"
      unitRef="usd">17384000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzItMS0xLTEtMA_391fb534-eaf8-4852-a55a-98e534d5256c"
      unitRef="usd">-4265000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzItMy0xLTEtMA_c1756038-87bf-4183-94fc-95490bfce3cc"
      unitRef="usd">-2350000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzMtMS0xLTEtMA_90ff90dc-d4b4-4d17-9fb1-b4f0a3e204a8"
      unitRef="usd">-20448000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzMtMy0xLTEtMA_7a38fef8-aa4f-4cfb-904e-c89460663eb8"
      unitRef="usd">16553000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzQtMS0xLTEtMA_589ed14a-e59c-4c61-8ba5-795e94c0d27c"
      unitRef="usd">146341000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="icab07bfc15ea4b0a9b2e3d5dfe987d2a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzQtMy0xLTEtMA_a7487938-d12b-4062-9f36-18d0c521c0d3"
      unitRef="usd">82375000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzUtMS0xLTEtMA_f6b5b814-0091-4cbe-baeb-ba0486d84660"
      unitRef="usd">125893000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzUtMy0xLTEtMA_7b01fc10-ef79-4068-8274-50ed4d4884ea"
      unitRef="usd">98928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzctMS0xLTEtMTEw_09afcbee-e485-403e-a2cc-218456188aaa"
      unitRef="usd">254000</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:PaymentsForTenantImprovements
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzctMy0xLTEtMTEw_813e0e8d-5099-46fe-a251-3f9a60f209fd"
      unitRef="usd">0</us-gaap:PaymentsForTenantImprovements>
    <us-gaap:InterestPaidNet
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzctMS0xLTEtMA_2212d51e-425e-40b7-859b-411597cdfa38"
      unitRef="usd">3693000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzctMy0xLTEtMA_f2c2bd2f-ab75-4737-ad06-33174652f0b8"
      unitRef="usd">4846000</us-gaap:InterestPaidNet>
    <fold:ContingentConsiderationPaidInStock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzktMS0xLTEtMTMwNA_beff6829-18e8-4242-b91e-6f55cc2d836b"
      unitRef="usd">0</fold:ContingentConsiderationPaidInStock>
    <fold:ContingentConsiderationPaidInStock
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzktMy0xLTEtMTMwNg_7152cb4b-d99e-4c76-9c10-c7fbcb729e39"
      unitRef="usd">9316000</fold:ContingentConsiderationPaidInStock>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzgtMS0xLTEtMA_b5cd8d53-d7aa-4d43-ae5d-69f209903c56"
      unitRef="usd">589000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY18zNy9mcmFnOjMyYmIwM2QwNWJmMzQ5MDQ4ZDEwMjQyMTQ0MDYxNTNlL3RhYmxlOmIzMDJjZWNiN2NmNjQ4ZTJiYWE4YTM1OTBmYzI4YjRlL3RhYmxlcmFuZ2U6YjMwMmNlY2I3Y2Y2NDhlMmJhYThhMzU5MGZjMjhiNGVfMzgtMy0xLTEtMA_7f10c3c5-a757-4c0b-9de4-f53a55e5e911"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180My9mcmFnOmRhZDZiZTAwMWM3OTRkNmY4YjUzNzY2YWE0OWJiM2M5L3RleHRyZWdpb246ZGFkNmJlMDAxYzc5NGQ2ZjhiNTM3NjZhYTQ5YmIzYzlfMTA0NDUzNjA0NjkxNjg_bcf4a323-960d-4499-9353-6cc4dad43fd7">Description of Business&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Amicus Therapeutics, Inc. (the "Company") is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering novel medicines for rare diseases. The Company has a portfolio of product opportunities led by the first, oral monotherapy for Fabry disease that has achieved widespread global approval, a differentiated biologic for Pompe disease in the clinic, and an industry leading rare disease gene therapy portfolio. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The cornerstone of the Company's portfolio is Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; (also referred to as "migalastat"), the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants. Migalastat is currently approved under the trade name Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; in the United States ("U.S."), European Union ("E.U."), United Kingdom ("U.K."), and Japan, with multiple additional approvals granted and applications pending in several other geographies around the world. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The lead biologics program of the Company's pipeline is Amicus Therapeutics GAA ("AT-GAA", also known as ATB200/AT2221), a novel, clinical-stage, potential best-in-class treatment paradigm for Pompe disease. In February 2019, the U.S. Food and Drug Administration ("FDA") granted Breakthrough Therapy designation ("BTD") to AT-GAA for the treatment of late onset Pompe disease. In the first quarter of 2020, the British Medicines and Healthcare Products Regulatory Agency issued a Promising Innovative Medicine designation for AT-GAA for the treatment of late-onset Pompe disease. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has established an industry leading gene therapy portfolio of potential therapies for people living with rare metabolic diseases, through a license with Nationwide Children's Hospital ("Nationwide Children's") and an expanded collaboration with the University of Pennsylvania ("Penn"). The Company's pipeline includes gene therapy programs in rare, neurologic lysosomal disorders ("LDs"), specifically: CLN6, CLN3, and CLN1 Batten disease, Pompe disease, Fabry disease, CDKL5 deficiency disorder ("CDD"), Niemann-Pick Type C (&#x201c;NPC&#x201d;), Mucopolysaccharidosis Type IIIB ("MPSIIIB"), as well as a next generation program in Mucopolysaccharidosis Type IIIA ("MPSIIIA"). This expanded collaboration with Penn also provides the Company with exclusive disease-specific access and option rights to develop potentially disruptive new gene therapy platform technologies and programs for most LDs and a broader portfolio of more prevalent rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy, and select other muscular dystrophies In the first quarter of 2020, the FDA granted Fast Track designation to the CLN3 Batten disease gene therapy, AT-GTX-502, for the treatment of pediatric patients less than 18 years of age. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company's operations have not yet been significantly impacted from the novel coronavirus (&#x201c;COVID-19&#x201d;) pandemic. The Company has maintained operations in all geographies, secured its global supply chain for its commercial and clinical products, and maintained its clinical trials, with minimal disruption. The Company believes its ability to continue to operate without any significant disruptions will depend on the continued health of its employees, the ongoing demand for Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt; and the continued operation of its global supply chain. The Company has continued to provide uninterrupted access to medicines for those in need of treatment, while prioritizing the health and safety of its global workforce. However, the Company's results of operations in future periods may be negatively impacted by unknown future impacts from the COVID-19 pandemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company had an accumulated deficit of $1.9 billion as of March 31, 2020 and anticipates incurring losses through the fiscal year ending December 31, 2020 and beyond. The Company has historically funded its operations through stock offerings, debt issuances, Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; revenues, collaborations, and other financing arrangements. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The current cash position, including expected Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; revenues, is sufficient to fund ongoing Fabry, Pompe, and gene therapy program operations well into the second half of 2022. Potential future business development collaborations, pipeline expansion, and investment in manufacturing capabilities could impact the Company's future capital requirements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180My9mcmFnOmRhZDZiZTAwMWM3OTRkNmY4YjUzNzY2YWE0OWJiM2M5L3RleHRyZWdpb246ZGFkNmJlMDAxYzc5NGQ2ZjhiNTM3NjZhYTQ5YmIzYzlfMzU4Nw_b75c25dc-fd47-4805-86f8-e059b963dfbd"
      unitRef="usd">-1900000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNzE_12be4865-a151-4271-9f79-6add5f4bd99b">Summary of Significant Accounting Policies&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2019.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of March 31, 2020 and through the issuance of this report. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company's Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;. The Company's accounts receivable at March 31, 2020 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers and the geographic economic environments and conditions to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis. As of March 31, 2020, the Company recorded an allowance for doubtful accounts of $0.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's net product sales consist of sales of Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; are generally received from distributors and pharmacies with the ultimate payor often a government authority. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the sale of Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the Company's net product sales from Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; disaggregated by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.900%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.318%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ex-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Inventories and Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The lease term for all of the Company's leases include the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Developments - Guidance Adopted in 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2018-15 - In August 2018, the Financial Accounting Standards Board ("FASB") issued&#160;Accounting Standards Update ("ASU") 2018-15,&#160;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): ("ASU 2018-15"), relating to a customer&#x2019;s accounting for implementation, set-up, and other upfront costs incurred in a&#160;cloud computing&#160;arrangement that is hosted by a vendor. Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance does not affect the accounting for the service element of a hosting arrangement that is a service contract. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized software costs and related amortization expense and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for public companies. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2018-13 - In August 2018, the FASB issued ASU 2018-03, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on (i) changes in unrealized gains and losses, (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and (iii) the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2017-04 - In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2016-13 - In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected and amends guidance on the impairment of financial instruments. ASU 2016-13 is effective for public companies who are SEC filers for fiscal years beginning after December 15, 2019, including interim periods within those years. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Developments - Guidance Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2019-12 - In December 2019, the FASB issued ASU 2019-15, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following apply in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#x2019; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted for public business entities for periods for which financial statements have not yet been issued. The Company is currently assessing the impact that this standard will have on the Company's Consolidated Financial Statements upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyMzc_68ecc617-a80e-4ea2-a800-b98288aa97c8">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company has prepared the accompanying unaudited Consolidated Financial Statements in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10-01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of management, the accompanying unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's interim financial information.&lt;/span&gt;&lt;/div&gt;The accompanying unaudited Consolidated Financial Statements and related notes should be read in conjunction with the Company's financial statements and related notes as contained in the Company's Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2019.&#160;For a complete description of the Company's accounting policies, please refer to the Annual Report on Form&#160;10-K for the fiscal year ended December 31, 2019.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNjk_489d504f-a47f-4c09-8690-12c46b736687">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Consolidated Financial Statements include the accounts of the Company and its subsidiaries. Intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyMTQ_dcd07184-f2a6-41a1-b8bb-62303a5c26bd">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Foreign Currency Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The functional currency for most of the Company's foreign subsidiaries is their local currency. For non-U.S. subsidiaries that transact in a functional currency other than the U.S. dollar, assets and liabilities are translated at current rates of exchange at the balance sheet date. Income and expense items are translated at the average foreign exchange rates for the period. Adjustments resulting from the translation of the financial statements of the Company's foreign operations into U.S. dollars are excluded from the determination of net income and are recorded in accumulated other comprehensive income, a separate component of stockholders' equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNDk_ca70bc75-005a-4479-bc22-c3330582cb2e">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of March 31, 2020 and through the issuance of this report. The Company&#x2019;s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyMjQ_7926f5dd-ad0f-4b76-8a73-a744228f43dd">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Cash Equivalents, Marketable Securities, and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Marketable securities consist of fixed income investments with a maturity of greater than three months and other highly liquid investments that can be readily purchased or sold using established markets. These investments are classified as available-for-sale and are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are reported within comprehensive income (loss) in the Statements of Comprehensive Loss. Fair value is based on available market information including quoted market prices, broker or dealer quotations, or other observable inputs.&lt;/span&gt;&lt;/div&gt;Restricted cash consists primarily of funds held to satisfy the requirements of certain agreements that are restricted in their use and is included in non-current assets on the Company's Consolidated Balance Sheets.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNjA_b671912f-2e9c-46bd-a0fe-bf447cd2c540">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;. The Company's accounts receivable at March 31, 2020 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers and the geographic economic environments and conditions to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfNDg2NA_b7dcf3ec-de49-4c23-bb43-be94af94a029"
      unitRef="usd">100000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNjY_6f89e176-55bf-47cf-bad5-9b6a5408a0cf">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's net product sales consist of sales of Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; for the treatment of Fabry disease. The Company has recorded revenue on sales where Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; is available either on a commercial basis or through a reimbursed early access program ("EAP"). Orders for Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; are generally received from distributors and pharmacies with the ultimate payor often a government authority. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company recognizes revenue when its performance obligations to its customers have been satisfied, which occurs at a point in time when the pharmacies or distributors obtain control of Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. The transaction price is determined based on fixed consideration in the Company's customer contracts and is recorded net of estimates for variable consideration, which are third party discounts and rebates. The identified variable consideration is recorded as a reduction of revenue at the time revenues from the sale of Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; are recognized. The Company recognizes revenue to the extent that it is probable that a significant revenue reversal will not occur in a future period. These estimates may differ from actual consideration received. The Company evaluates these estimates each reporting period to reflect known changes.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNjE_b463424d-a52b-46a1-916f-f40f04c1fb6c">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes the Company's net product sales from Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; disaggregated by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.900%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.316%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.318%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Ex-U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;42,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;24,978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total net product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;60,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;34,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i31b61ba1de064ab9a35f6ea596b4cac0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RhYmxlOjFkZmU2MTlhM2ExZDRkMGViNmVjZjUxYzEzMWNlZjVjL3RhYmxlcmFuZ2U6MWRmZTYxOWEzYTFkNGQwZWI2ZWNmNTFjMTMxY2VmNWNfMi0yLTEtMS0w_90f6ab7f-4021-4b6a-bbfb-a4f38a83095c"
      unitRef="usd">17772000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i6665e4e8d56945d6a3eb5b178eed1e42_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RhYmxlOjFkZmU2MTlhM2ExZDRkMGViNmVjZjUxYzEzMWNlZjVjL3RhYmxlcmFuZ2U6MWRmZTYxOWEzYTFkNGQwZWI2ZWNmNTFjMTMxY2VmNWNfMi00LTEtMS0w_fd7d8fb1-8f2d-4d43-b034-447ee679ac5e"
      unitRef="usd">9068000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i4e9b6c86da6148bc9f33450341bbd731_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RhYmxlOjFkZmU2MTlhM2ExZDRkMGViNmVjZjUxYzEzMWNlZjVjL3RhYmxlcmFuZ2U6MWRmZTYxOWEzYTFkNGQwZWI2ZWNmNTFjMTMxY2VmNWNfMy0yLTEtMS0w_6467ee1b-c67f-4dcc-a06c-f6f5721062d1"
      unitRef="usd">42753000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i713aa7461f474212a79f6fbf3e5b8ce4_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RhYmxlOjFkZmU2MTlhM2ExZDRkMGViNmVjZjUxYzEzMWNlZjVjL3RhYmxlcmFuZ2U6MWRmZTYxOWEzYTFkNGQwZWI2ZWNmNTFjMTMxY2VmNWNfMy00LTEtMS0w_a30d795a-508a-40bc-9ddc-f31f3403596c"
      unitRef="usd">24978000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RhYmxlOjFkZmU2MTlhM2ExZDRkMGViNmVjZjUxYzEzMWNlZjVjL3RhYmxlcmFuZ2U6MWRmZTYxOWEzYTFkNGQwZWI2ZWNmNTFjMTMxY2VmNWNfNC0yLTEtMS0w_6885a132-58ba-4ede-ab37-080db877f2a2"
      unitRef="usd">60525000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RhYmxlOjFkZmU2MTlhM2ExZDRkMGViNmVjZjUxYzEzMWNlZjVjL3RhYmxlcmFuZ2U6MWRmZTYxOWEzYTFkNGQwZWI2ZWNmNTFjMTMxY2VmNWNfNC00LTEtMS0w_9cebf099-9765-4d1a-83b1-ca12ebbfebc9"
      unitRef="usd">34046000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:InventoryCostsForContractsOrProgramsPolicy
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyMzM_e1b729b7-3267-427f-b8a7-47e444452d9e">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Inventories and Cost of Goods Sold&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Inventories are stated at the lower of cost and net realizable value, determined by the first-in, first-out method. Inventories are reviewed periodically to identify slow-moving or obsolete inventory based on projected sales activity as well as product shelf-life. In evaluating the recoverability of inventories produced, the probability that revenue will be obtained from the future sale of the related inventory is considered and inventory value is written down for inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of goods sold in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;Cost of goods sold includes the cost of inventory sold, manufacturing and supply chain costs, product shipping and handling costs, provisions for excess and obsolete inventory, as well as royalties payable.</us-gaap:InventoryCostsForContractsOrProgramsPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyNDg_ac8e4271-d185-46b9-97e4-faf4a14c2cff">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company primarily enters into lease agreements for office space, equipment, and vehicles. The leases have varying terms, some of which could include options to renew, extend, and early terminate. The Company determines if an arrangement is a lease at contract inception. Operating leases are included in right-of-use ("ROU") assets and lease liabilities on the Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ROU assets represent the Company's right to control the use of an explicitly or implicitly identified fixed asset for a period of time and lease liabilities represent the Company's obligation to make lease payments arising from the lease. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Lease payments included in the measurement of the lease liability are comprised of fixed payments. Variable lease payments are excluded from the ROU asset and lease liability and are recognized in the period in which the obligation for those payments is incurred. Variable lease payments are presented in the Consolidated Statements of Operations in the same line item as expenses arising from fixed lease payments for operating leases. The Company has lease agreements that include lease and non-lease components, which the Company accounts for as a single lease component for all underlying asset categories. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The lease term for all of the Company's leases include the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. &lt;/span&gt;&lt;/div&gt;Leases with an initial term of 12 months or less are not recorded on the Consolidated Balance Sheets. The Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY180Ni9mcmFnOjJjNDU1Y2E0ZjliMjQxOTdhMDc5ZDBjZDk0MDgyM2U3L3RleHRyZWdpb246MmM0NTVjYTRmOWIyNDE5N2EwNzlkMGNkOTQwODIzZTdfMTUyMzQ_2361916e-1c4e-4b41-bb4d-03ac610181e6">&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Developments - Guidance Adopted in 2020&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2018-15 - In August 2018, the Financial Accounting Standards Board ("FASB") issued&#160;Accounting Standards Update ("ASU") 2018-15,&#160;Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): ("ASU 2018-15"), relating to a customer&#x2019;s accounting for implementation, set-up, and other upfront costs incurred in a&#160;cloud computing&#160;arrangement that is hosted by a vendor. Under the new guidance, a customer will apply the same criteria for capitalizing implementation costs as it would for an arrangement that has a software license. The new guidance does not affect the accounting for the service element of a hosting arrangement that is a service contract. The new guidance also prescribes the balance sheet, income statement and cash flow classification of the capitalized software costs and related amortization expense and requires additional quantitative and qualitative disclosures. ASU 2018-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 for public companies. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2018-13 - In August 2018, the FASB issued ASU 2018-03, Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement ("ASU 2018-13"). The amendments modify the disclosure requirements in Topic 820. ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on (i) changes in unrealized gains and losses, (ii) the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and (iii) the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2017-04 - In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment ("ASU 2017-04"). ASU 2017-04 simplifies the recognition and measurement of a goodwill impairment loss by eliminating Step 2 of the quantitative goodwill impairment test. The guidance requires a one-step impairment test in which an entity compares the fair value of a reporting unit with its carrying amount and recognizes an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value, if any. ASU 2017-04 is effective for fiscal years beginning after December&#160;15, 2019 and should be applied on a prospective basis. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2016-13 - In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ("ASU 2016-13"). ASU 2016-13 requires financial assets measured at amortized cost basis to be presented at the net amount expected to be collected and amends guidance on the impairment of financial instruments. ASU 2016-13 is effective for public companies who are SEC filers for fiscal years beginning after December 15, 2019, including interim periods within those years. The Company adopted this guidance on January 1, 2020. The adoption did not have a material impact on the Company's Consolidated Financial Statements or related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Recent Accounting Developments - Guidance Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;ASU 2019-12 - In December 2019, the FASB issued ASU 2019-15, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes ("ASU 2019-12"). This new guidance removes specific exceptions to the general principles in Topic 740. It eliminates the need for an organization to analyze whether the following apply in a given period: (i) exception to the incremental approach for intraperiod tax allocation; (ii) exceptions to accounting for basis differences when there are ownership changes in foreign investments; and (iii) exception in interim period income tax accounting for year-to-date losses that exceed anticipated losses. ASU 2019-12 also improves financial statement preparers&#x2019; application of income tax-related guidance and simplifies the following: (i) franchise taxes that are partially based on income; (ii) transactions with a government that result in a step up in the tax basis of goodwill; (iii) separate financial statements of legal entities that are not subject to tax; and (iv) enacted changes in tax laws in interim periods. ASU 2019 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted for public business entities for periods for which financial statements have not yet been issued. The Company is currently assessing the impact that this standard will have on the Company's Consolidated Financial Statements upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMjY0NA_ece4b62d-7e7d-4228-9fde-7169f6d24abe">Cash, Cash Equivalents, Marketable Securities, and Restricted Cash&lt;div style="text-indent:18pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;As of March 31, 2020, the Company held $123.2 million in cash and cash equivalents and $215.6 million of marketable securities which are reported at fair value on the Company's Consolidated Balance Sheets. Unrealized holding gains and losses are generally reported within accumulated other comprehensive loss in the Statements of Comprehensive Loss. If a decline in the fair value of a marketable security below the Company's cost basis is determined to be other-than-temporary or if an available-for-sale debt security&#x2019;s fair value is determined to less than the amortized cost and the Company intends or is more than likely to sell the security before recovery and it is not considered a credit loss, such security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. If the unrealized loss of an available-for-sale debt security is determined to be a result of credit loss the Company would recognize an allowance and the corresponding credit loss would be included in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company regularly invests excess operating cash in deposits with major financial institutions, money market funds, notes issued by the U.S. government, as well as fixed income investments and U.S. bond funds, both of which can be readily purchased and sold using established markets. The Company believes that the market risk arising from its holdings of these financial instruments is mitigated as many of these securities are either government backed or of the highest credit rating. Investments that have original maturities greater than three months but less than one year are classified as current.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.198%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.725%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;107,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;107,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Included in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.120%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;142,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;142,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;452,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;452,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;142,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;142,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;Included in marketable securities&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;309,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;309,903&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;452,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;452,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1) &lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;As of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;December 31, 2019&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;, $9.5 million of marketable securities have maturity dates greater than 12 months and are available to convert into cash, if needed.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;For the three months ended March 31, 2020 there were nominal realized gains. For the fiscal year ended December 31, 2019, there were no realized gains or losses. The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;Unrealized loss positions in the marketable securities as of March 31, 2020 and December 31, 2019 reflect temporary impairments and are not a result of credit loss. Additionally, as these positions have been in a loss position for less than twelve months and the Company does not intend to sell these securities before recovery, the losses are recognized in other comprehensive gain (loss). The fair value of these marketable securities in unrealized loss positions was $99.5 million and $42.6 million as of March 31, 2020 and December 31, 2019, respectively.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.181%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.184%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;98,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMTA4_9c29018c-aa9e-42de-b621-575acd2d67c7"
      unitRef="usd">123200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMTQ2_1ecae38d-d3b8-4c83-9dea-f354c4b48a7a"
      unitRef="usd">215600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfODI0NjMzNzIxMTIxNQ_891cf6ba-d209-44cb-a57b-d8e115ef34b3">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Cash, cash equivalents and marketable securities are classified as current unless mentioned otherwise below and consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.198%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.719%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.725%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;107,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;107,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Included in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;215,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;338,873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.120%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="21" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;142,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;142,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;452,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;452,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;142,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;142,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;Included in marketable securities&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;309,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;309,903&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total cash, cash equivalents, and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;452,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;452,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1) &lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt;As of &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;December 31, 2019&lt;/span&gt;, $9.5 million of marketable securities have maturity dates greater than 12 months and are available to convert into cash, if needed.</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMi0yLTEtMS0w_85bfa4f7-10d1-4d51-84e3-31d711cdd9e2"
      unitRef="usd">123231000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMi04LTEtMS0w_35603d1b-d313-4061-a500-4f9cb075c150"
      unitRef="usd">123231000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ie299466a221248989d0654e27aa2fa15_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMy0yLTEtMS0w_2ea2c522-d9db-4ff5-82ed-871af3ae3ee8"
      unitRef="usd">107152000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ie299466a221248989d0654e27aa2fa15_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMy00LTEtMS0w_77b73d06-a681-4815-8f35-c7364a2607f8"
      unitRef="usd">65000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ie299466a221248989d0654e27aa2fa15_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMy02LTEtMS0w_012b35a7-0b7c-4d3c-9757-328c978fd360"
      unitRef="usd">119000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie299466a221248989d0654e27aa2fa15_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMy04LTEtMS0w_c1005547-4e80-40a7-bd92-c1eb6b5ec314"
      unitRef="usd">107098000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i76dd233dc95c43edb284968ccf887232_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNC0yLTEtMS0w_6355260f-de4d-4943-83ed-413d1d6eecb3"
      unitRef="usd">35248000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i76dd233dc95c43edb284968ccf887232_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNC00LTEtMS0w_7338bb3a-d313-4701-99b2-f42ed972b4bd"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i76dd233dc95c43edb284968ccf887232_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNC02LTEtMS0w_2da51c30-d4e8-4738-a800-cdb3ef1d5617"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i76dd233dc95c43edb284968ccf887232_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNC04LTEtMS0w_19c7a407-5646-4b21-ade9-df109b3cd300"
      unitRef="usd">35348000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i79d9f3582ceb4f39b144041e9d62cd8f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNS0yLTEtMS0w_fcbb2cf0-3563-4744-bcfb-c25ba66264d0"
      unitRef="usd">68812000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i79d9f3582ceb4f39b144041e9d62cd8f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNS00LTEtMS0w_34887a56-6d5b-450e-96ef-ea23c4885988"
      unitRef="usd">25000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i79d9f3582ceb4f39b144041e9d62cd8f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNS02LTEtMS0w_34c22f33-9a5e-4d8a-a4dd-baf17fbd223e"
      unitRef="usd">42000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i79d9f3582ceb4f39b144041e9d62cd8f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNS04LTEtMS0w_74feb5d3-4ebf-4da8-a4f8-7b69a0c7c77f"
      unitRef="usd">68795000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i6e582d44c1854742ab6c8ed5ee290d43_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNi0yLTEtMS0w_3c0531d6-f277-4b1a-8a28-57b923bdfd79"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i6e582d44c1854742ab6c8ed5ee290d43_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNi00LTEtMS0w_ec9acbcf-c823-4e30-addb-ab586adb0329"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i6e582d44c1854742ab6c8ed5ee290d43_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNi02LTEtMS0w_30d06b2f-d673-47e6-a5da-75ed5eb0b1ad"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6e582d44c1854742ab6c8ed5ee290d43_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNi04LTEtMS0w_bcf6bc94-684e-4c30-812c-ac8fce8efa77"
      unitRef="usd">4000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i14951a04eb4e4b7b9d35f47bed16e634_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNy0yLTEtMS0w_22769555-ec42-4b9e-8aff-ee28ba18a0fc"
      unitRef="usd">350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i14951a04eb4e4b7b9d35f47bed16e634_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNy00LTEtMS0w_798a7505-da94-4c3f-9c52-e9d004f19b30"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i14951a04eb4e4b7b9d35f47bed16e634_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNy02LTEtMS0w_724fc1a2-56e7-4fa7-b185-bf0922fa25d1"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i14951a04eb4e4b7b9d35f47bed16e634_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfNy04LTEtMS0w_dd8016d7-1c5a-49b0-9e28-8c3f0aa7339f"
      unitRef="usd">350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3ef63e91418e4383b7ebde0b9c4cffe0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOC0yLTEtMS0w_653c5999-4c6c-4095-ad0f-6e44530f5390"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3ef63e91418e4383b7ebde0b9c4cffe0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOC00LTEtMS0w_aca4ccc7-0977-4377-98e8-219939f6a345"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3ef63e91418e4383b7ebde0b9c4cffe0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOC02LTEtMS0w_1e4b43f1-8347-4c81-bfe6-6a0eaae80100"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ef63e91418e4383b7ebde0b9c4cffe0_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOC04LTEtMS0w_99a18386-05be-4c61-a538-2cb7abe1f18f"
      unitRef="usd">51000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOS0yLTEtMS0w_3265eef3-d5f3-4f9f-82a4-e08975cd1ef3"
      unitRef="usd">338844000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOS00LTEtMS0w_75d5046c-d256-4513-b2cd-fec4a321bcb4"
      unitRef="usd">190000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOS02LTEtMS0w_34927268-9d13-4a73-9394-243085884225"
      unitRef="usd">161000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfOS04LTEtMS0w_5ebe1d79-48c1-4ed9-97bb-375b78876c6f"
      unitRef="usd">338873000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTAtMi0xLTEtMA_ade16c0d-02d7-4c23-95f1-cb08a8627c1c"
      unitRef="usd">123231000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTAtOC0xLTEtMA_be5fd57d-2c53-4737-9564-f64089ff4ad8"
      unitRef="usd">123231000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTEtMi0xLTEtMA_236e9615-fdb2-4a37-8919-16679d2416a7"
      unitRef="usd">215613000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTEtNC0xLTEtMA_83881467-1274-4ea3-a901-b969e67a379b"
      unitRef="usd">190000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTEtNi0xLTEtMA_100620b7-6d15-4a1a-bc0b-bcde85862f6d"
      unitRef="usd">161000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTEtOC0xLTEtMA_ab799070-c49d-405a-bc9e-0f5f2f360149"
      unitRef="usd">215642000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTItMi0xLTEtMA_c8518b48-839f-48ce-b981-597a13992221"
      unitRef="usd">338844000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTItNC0xLTEtMA_e1f3b87b-aa1a-4946-b50a-a16ccf5bbfec"
      unitRef="usd">190000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTItNi0xLTEtMA_348c14b9-a25d-4b64-a031-ec0c95c60d78"
      unitRef="usd">161000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOmY2MDZhZjI4ZGY1NDQ5MTE4YzZjN2JlOTkyNmFkNGQxL3RhYmxlcmFuZ2U6ZjYwNmFmMjhkZjU0NDkxMThjNmM3YmU5OTI2YWQ0ZDFfMTItOC0xLTEtMA_4ba24fb6-4761-437c-9d6f-91570c12a900"
      unitRef="usd">338873000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMi0yLTEtMS0w_8317968b-dc57-4f11-9b16-9cd6b9e2f0ac"
      unitRef="usd">142837000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMi04LTEtMS0w_1099c751-00b7-40c5-9556-01260e1ab351"
      unitRef="usd">142837000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i555c0f48291d4b38b8d561d915768eff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMy0yLTEtMS0w_2627fb3e-9a2d-4178-9459-43fcd38cd2ed"
      unitRef="usd">145875000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i555c0f48291d4b38b8d561d915768eff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMy00LTEtMS0w_53e4b64a-7477-4c43-8b83-77e7bee2846d"
      unitRef="usd">121000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i555c0f48291d4b38b8d561d915768eff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMy02LTEtMS0w_eac929ee-082e-437d-a5ab-42abff31babf"
      unitRef="usd">5000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i555c0f48291d4b38b8d561d915768eff_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMy04LTEtMS0w_bbea5b33-41fc-489f-8dc8-b76017289606"
      unitRef="usd">145991000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i69bfb02d155d46d7a1e1ec0c33f195ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNC0yLTEtMS0w_2f1a8b58-4ba4-48d9-b765-64167e2d8db5"
      unitRef="usd">73659000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i69bfb02d155d46d7a1e1ec0c33f195ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNC00LTEtMS0w_ebc5433b-9dc0-4f18-bd18-0fdbabf84ac4"
      unitRef="usd">53000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i69bfb02d155d46d7a1e1ec0c33f195ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNC02LTEtMS0w_d232e621-f8eb-4c46-a953-cb3bbd4a0b76"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i69bfb02d155d46d7a1e1ec0c33f195ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNC04LTEtMS0w_bad0aad4-6b07-402e-b08d-52be6f9318d1"
      unitRef="usd">73710000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i780f97fa745c46f2a97bd268ba15bc18_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNS0yLTEtMS0w_9ec543d8-0dde-4d95-9432-ab0a8838b61c"
      unitRef="usd">77731000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i780f97fa745c46f2a97bd268ba15bc18_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNS00LTEtMS0w_80c3a5e0-997f-45b1-ab0c-a24428200220"
      unitRef="usd">79000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i780f97fa745c46f2a97bd268ba15bc18_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNS02LTEtMS0w_52e76dc8-7ed1-46ee-9593-8c3d5df772ef"
      unitRef="usd">0</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i780f97fa745c46f2a97bd268ba15bc18_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNS04LTEtMS0w_09a37801-d4da-402a-a116-22d90534bf7c"
      unitRef="usd">77810000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ia1cd03431da34173829810953c60ca83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNi0yLTEtMS0w_2ebbc635-bf2e-41fc-b531-a045259bb793"
      unitRef="usd">11999000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ia1cd03431da34173829810953c60ca83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNi00LTEtMS0w_e5310d11-f15b-46e3-9bbf-de0d08eab492"
      unitRef="usd">2000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ia1cd03431da34173829810953c60ca83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNi02LTEtMS0w_50fd97d1-5925-4417-8ad0-7b814f038a7e"
      unitRef="usd">10000</fold:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ia1cd03431da34173829810953c60ca83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNi04LTEtMS0w_88f5ac96-f368-41f3-baa9-b4114862778e"
      unitRef="usd">11991000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i87a274e586cf4c16a08587c4031550b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNy0yLTEtMS0w_55219b0d-57fb-42d6-8922-e0406321eeae"
      unitRef="usd">350000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i87a274e586cf4c16a08587c4031550b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNy00LTEtMS0w_43d9b376-82cb-4ddb-bc71-eb41e79ef4a3"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i87a274e586cf4c16a08587c4031550b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNy02LTEtMS0w_1c6c62a1-f273-4ac4-8443-60fbde736e3d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i87a274e586cf4c16a08587c4031550b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfNy04LTEtMS0w_64cad344-2fa2-490d-93e5-84b2b71a2152"
      unitRef="usd">350000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if972968827f048e9b40900a185eca935_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOC0yLTEtMS0w_032be3d9-a5c6-4e14-9e32-f6aa9ffb2b03"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if972968827f048e9b40900a185eca935_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOC00LTEtMS0w_15b32a2c-e183-4d45-b874-6820c6664eed"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if972968827f048e9b40900a185eca935_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOC02LTEtMS0w_5f84e12a-1e3f-4aae-88bb-ac05e31c365b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if972968827f048e9b40900a185eca935_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOC04LTEtMS0w_2750830b-8efa-43d4-9b5b-836d9d644989"
      unitRef="usd">51000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOS0yLTEtMS0w_4923a47d-dd53-4cec-bf78-f1ddede26f66"
      unitRef="usd">452502000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOS00LTEtMS0w_b39fc1b4-4252-4152-91e2-412e6cd47125"
      unitRef="usd">255000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOS02LTEtMS0w_0cf2080d-5242-40e5-b36b-1937b5b2f076"
      unitRef="usd">17000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfOS04LTEtMS0w_1b48e9c9-cf5b-4182-ac51-0c151b9da98d"
      unitRef="usd">452740000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTAtMi0xLTEtMA_3ec4aefc-249a-4c90-a0b3-c3593c882771"
      unitRef="usd">142837000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTAtOC0xLTEtMA_5fe347ad-e7a8-461a-b786-635af9d5751f"
      unitRef="usd">142837000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTEtMi0xLTEtMA_b30af807-da81-46ee-bd00-05c9138d75e8"
      unitRef="usd">309665000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTEtNC0xLTEtMA_6e3a6755-cf95-44f1-96db-50408a312e93"
      unitRef="usd">255000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTEtNi0xLTEtMA_7381f057-f2ec-4f66-b8e3-98aa27208996"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTEtOC0xLTEtMA_fc0f61d9-6261-4159-a728-6568c96386dd"
      unitRef="usd">309903000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTItMi0xLTEtMA_1dbbb68d-8509-4abb-a80f-d9e7f2b0e97d"
      unitRef="usd">452502000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecurities>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTItNC0xLTEtMA_46d49b2e-4ac5-466a-b8cc-8f14d8d93036"
      unitRef="usd">255000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTItNi0xLTEtMA_caa88a3e-a472-49d8-ba14-32685ffabd28"
      unitRef="usd">17000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjJiYTM3YWQ0ZjI4NTRmNjBhNzQ0NGIyMzQzMTkxMDYxL3RhYmxlcmFuZ2U6MmJhMzdhZDRmMjg1NGY2MGE3NDQ0YjIzNDMxOTEwNjFfMTItOC0xLTEtMA_bfc455f4-82d4-436c-bf38-40b14c4a59d0"
      unitRef="usd">452740000</fold:CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMTY3MQ_6a80f878-f332-4508-9fc2-4cc47645c5b2"
      unitRef="usd">9500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMTgzNA_b02bf94a-6c93-4ff8-9e41-59fa4634fafa"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="iaae514757a6c44d4a4b8a4a9a318e979_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMTkwNQ_b24b5e76-7b81-4a50-99f4-b9f971121dd0"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMjM0Mg_c6b13708-4668-4fb6-83ef-206d9eddd64c"
      unitRef="usd">99500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMjM1MA_4e25378e-9686-4f4f-889f-13ccffaddfe6"
      unitRef="usd">42600000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RleHRyZWdpb246NTJmYmZkNDNjMThlNDE5M2FlOGQ5Y2VmNGVkMzg0ZDVfMjYzNA_9282eb89-b77e-438b-b391-6b5cd9f9d99e">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:68.175%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.181%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.530%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.184%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;123,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;96,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:9pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;125,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;98,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjc1MWI4ZjgxOWViMjQ5ZmNiZmMyMTE1MjhhOGY4OWIxL3RhYmxlcmFuZ2U6NzUxYjhmODE5ZWIyNDlmY2JmYzIxMTUyOGE4Zjg5YjFfMS0yLTEtMS0w_f97bd11a-7640-4099-8f8a-edde3dd024ae"
      unitRef="usd">123231000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjc1MWI4ZjgxOWViMjQ5ZmNiZmMyMTE1MjhhOGY4OWIxL3RhYmxlcmFuZ2U6NzUxYjhmODE5ZWIyNDlmY2JmYzIxMTUyOGE4Zjg5YjFfMS02LTEtMS0w_cd921979-27ab-4b96-9881-a0afbb9cb831"
      unitRef="usd">96349000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjc1MWI4ZjgxOWViMjQ5ZmNiZmMyMTE1MjhhOGY4OWIxL3RhYmxlcmFuZ2U6NzUxYjhmODE5ZWIyNDlmY2JmYzIxMTUyOGE4Zjg5YjFfMi0yLTEtMS0w_5f628b7a-8a9e-49fa-8a14-2d3a2d2f6fb7"
      unitRef="usd">2662000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjc1MWI4ZjgxOWViMjQ5ZmNiZmMyMTE1MjhhOGY4OWIxL3RhYmxlcmFuZ2U6NzUxYjhmODE5ZWIyNDlmY2JmYzIxMTUyOGE4Zjg5YjFfMi02LTEtMS0w_ee7f5a22-124e-461c-9632-c4a970c413eb"
      unitRef="usd">2579000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjc1MWI4ZjgxOWViMjQ5ZmNiZmMyMTE1MjhhOGY4OWIxL3RhYmxlcmFuZ2U6NzUxYjhmODE5ZWIyNDlmY2JmYzIxMTUyOGE4Zjg5YjFfMy0yLTEtMS0w_8247003d-4ef6-4332-a097-8d63eb2fcc94"
      unitRef="usd">125893000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181Mi9mcmFnOjUyZmJmZDQzYzE4ZTQxOTNhZThkOWNlZjRlZDM4NGQ1L3RhYmxlOjc1MWI4ZjgxOWViMjQ5ZmNiZmMyMTE1MjhhOGY4OWIxL3RhYmxlcmFuZ2U6NzUxYjhmODE5ZWIyNDlmY2JmYzIxMTUyOGE4Zjg5YjFfMy02LTEtMS0w_3ff1b3d6-fb1e-49de-a4e0-8a49088b22a0"
      unitRef="usd">98928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RleHRyZWdpb246NzFkNzA4ZTFiZTBlNGJlNmJmZTI0MDI1NTk5ZmFjZjBfMjgw_713baf54-0e14-46cd-b2b7-f67e73c886ef">Inventories&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Inventories consist of raw materials, work-in-process, and finished goods related to the manufacture of Galafold&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;&#xae;&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;. The following table summarizes the components of inventories: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.648%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company recorded a reserve for inventory of $0.2 million as of March 31, 2020 and December 31, 2019.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RleHRyZWdpb246NzFkNzA4ZTFiZTBlNGJlNmJmZTI0MDI1NTk5ZmFjZjBfMjgz_56894f5c-b0da-4b3e-a6cc-984127a8e647">The following table summarizes the components of inventories: &lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.648%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.809%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.077%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;14,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfMS0yLTEtMS0w_48f9c47e-6d38-4032-8525-0bd387929b64"
      unitRef="usd">5322000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfMS00LTEtMS0w_855695b6-3a6f-4fed-a15d-15f5deda91d3"
      unitRef="usd">6544000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfMi0yLTEtMS0w_19c194ef-d2da-40d1-ba01-e8699faad7b1"
      unitRef="usd">2900000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfMi00LTEtMS0w_bd6ff3bc-98b1-4a7c-84df-d2c1d16bf842"
      unitRef="usd">3660000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfMy0yLTEtMS0w_e9688249-d45c-4f3d-9fa0-bf3b6ca8f1c0"
      unitRef="usd">4609000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfMy00LTEtMS0w_f0975bff-b4ac-4825-b6da-c7f631d5ee4e"
      unitRef="usd">3837000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfNC0yLTEtMS0w_5ef91bc6-e587-4171-b797-d6542ed899fc"
      unitRef="usd">12831000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RhYmxlOmRlY2U2YTE1MTRhNTRjM2FhNWM0N2ViMGQ1NzUzODI4L3RhYmxlcmFuZ2U6ZGVjZTZhMTUxNGE1NGMzYWE1YzQ3ZWIwZDU3NTM4MjhfNC00LTEtMS0w_80427761-fce0-4699-9acb-bb423e4407b6"
      unitRef="usd">14041000</us-gaap:InventoryNet>
    <us-gaap:InventoryValuationReserves
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RleHRyZWdpb246NzFkNzA4ZTFiZTBlNGJlNmJmZTI0MDI1NTk5ZmFjZjBfMjU0_52a568ed-089c-4280-80ad-48faf13c4f25"
      unitRef="usd">200000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY181NS9mcmFnOjcxZDcwOGUxYmUwZTRiZTZiZmUyNDAyNTU5OWZhY2YwL3RleHRyZWdpb246NzFkNzA4ZTFiZTBlNGJlNmJmZTI0MDI1NTk5ZmFjZjBfMjU0_5d1f35e8-2341-453f-8361-9a5f20a9892d"
      unitRef="usd">200000</us-gaap:InventoryValuationReserves>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfNzA5NQ_423c5aaf-3a82-4098-9bc2-1552fd09f824">Debt &lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's debt consists of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.208%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.662%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.664%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"&gt;Senior Secured Term Loan due 2023:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;Less: debt discount &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;Less: deferred financing &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(289)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(311)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net carrying value of the Senior Secured Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;147,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;147,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"&gt;Convertible Notes due 2023 &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;Less: debt discount &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(625)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(659)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;Less: deferred financing &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net carrying value of the Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:3pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt; Included in the Consolidated Balance Sheets within Convertible Notes and Senior Secured Term Loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:3pt;margin-bottom:15pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt; The Convertible Notes are currently convertible as the last reported sale price of the Company's common stock was equal to or more than 130% of the conversion price for at least 20 trading days of the 30 consecutive trading days ending on the last day of the quarter. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;During the first quarter of 2019, the Company entered into separate, privately negotiated Exchange Agreements with a limited number of holders ("the Holders") of the unsecured Convertible Senior Notes due in 2023 ("the Convertible Notes"). Under the terms of the Exchange Agreements, the Holders agreed to exchange an aggregate principal amount of $219.3&#160;million of Convertible Notes held by them in exchange for an aggregate of approximately 39.0&#160;million shares of Company common stock, par value $0.01 per share. In addition, pursuant to the Exchange Agreements, the Company made aggregate cash payments of $1.0&#160;million to the Holders to satisfy accrued and unpaid interest to the closing date of the transactions, along with cash in lieu of fractional shares. These transactions resulted in $190.4&#160;million in additional paid-in-capital and common stock of $0.4&#160;million on the Consolidated Balance Sheets as of March 31, 2019. Additionally, the Company recognized a net loss on the exchange of debt of $36.1&#160;million on the Consolidated Statements of Operations for the three months ended March 31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;text-align:justify;margin-top:1pt;margin-bottom:1pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;"&gt;During the first quarter of 2019, the Company terminated the Capped Call Confirmations related to the exchange of the Convertible Notes for proceeds of approximately $14.6&#160;million.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth interest expense recognized related to the Company's debt for the three months ended March 31, 2020 and 2019, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.140%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.049%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.052%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of deferred financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ConvertibleDebtTableTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NzU1NQ_041acc10-2206-4216-8814-768cee5ccd82">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's debt consists of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:67.208%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.662%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:12.664%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"&gt;Senior Secured Term Loan due 2023:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;150,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;Less: debt discount &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(2,315)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;Less: deferred financing &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(289)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(311)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net carrying value of the Senior Secured Term Loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;147,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;147,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"&gt;Convertible Notes due 2023 &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;vertical-align:top;"&gt;(2)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;Less: debt discount &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(625)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(659)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div style="padding-left:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;Less: deferred financing &lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(33)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net carrying value of the Convertible Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-top:3pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt; Included in the Consolidated Balance Sheets within Convertible Notes and Senior Secured Term Loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;(2) The Convertible Notes are currently convertible as the last reported sale price of the Company's common stock was equal to or more than 130% of the conversion price for at least 20 trading days of the 30 consecutive trading days ending on the last day of the quarter.</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i140e72212c4a4bfb81bf6148fb2aa0a6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMS0yLTEtMS0xNTQ4_e6f093e5-ba3a-4ba8-a725-1eb10dfe11ac"
      unitRef="usd">150000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i3674ca7debaf4f0aafd63c83f885edf1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMS00LTEtMS0xNTQ4_2503493e-d784-4420-b999-285f035f8597"
      unitRef="usd">150000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i140e72212c4a4bfb81bf6148fb2aa0a6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMi0yLTEtMS0xNTQ4_22a1f5fc-5500-4815-8954-8fbd1a56e694"
      unitRef="usd">2142000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i3674ca7debaf4f0aafd63c83f885edf1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMi00LTEtMS0xNTQ4_c7d09e6f-cc3e-4bca-aaf5-6b1e14d75759"
      unitRef="usd">2315000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts
      contextRef="i140e72212c4a4bfb81bf6148fb2aa0a6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMy0yLTEtMS0xNTQ4_6a36cd3f-9b40-4652-9b99-db84d597684f"
      unitRef="usd">289000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i3674ca7debaf4f0aafd63c83f885edf1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMy00LTEtMS0xNTQ4_5c28a506-6ecd-4ff3-a6fa-ac8295b507d4"
      unitRef="usd">311000</us-gaap:DeferredOfferingCosts>
    <us-gaap:LongTermDebt
      contextRef="i140e72212c4a4bfb81bf6148fb2aa0a6_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfNS0yLTEtMS0xODY4_18dee782-024e-4ff0-92c0-cc1b3df49e32"
      unitRef="usd">147569000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i3674ca7debaf4f0aafd63c83f885edf1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfNS00LTEtMS0xODcx_a950364c-894b-4e08-aab4-ee7e8ce7730c"
      unitRef="usd">147374000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="icb44be7fb6564606a0f40b69c09e76c5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfOC0yLTEtMS0xNTg3_1b23aa7a-8b3b-46c5-a3f3-ce80012d3243"
      unitRef="usd">2825000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i0b34927c8eaa48f08e87f87c3ed7a95c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfOC00LTEtMS0xNTg3_a45b2876-5c2f-4d43-baa9-65d7ce09ed44"
      unitRef="usd">2825000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="icb44be7fb6564606a0f40b69c09e76c5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfOS0yLTEtMS0xNTg3_371904bf-bdaa-4b07-9572-1175b5379e1d"
      unitRef="usd">625000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i0b34927c8eaa48f08e87f87c3ed7a95c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfOS00LTEtMS0xNTg3_be423ecd-6045-4635-9c7f-d293df6aa061"
      unitRef="usd">659000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredOfferingCosts
      contextRef="icb44be7fb6564606a0f40b69c09e76c5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMTAtMi0xLTEtMTU4Nw_2c4365b6-86d5-422f-b4c1-5e581185f34e"
      unitRef="usd">33000</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i0b34927c8eaa48f08e87f87c3ed7a95c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMTAtNC0xLTEtMTU4Nw_0582d845-0417-4bcb-9f24-063cebb17f73"
      unitRef="usd">35000</us-gaap:DeferredOfferingCosts>
    <us-gaap:LongTermDebt
      contextRef="icb44be7fb6564606a0f40b69c09e76c5_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMTEtMi0xLTEtMTg3NQ_fe575413-c583-4288-9d31-9c9a3879286e"
      unitRef="usd">2167000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i0b34927c8eaa48f08e87f87c3ed7a95c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOjMwMWM1OGJkMmIyNzRhNjFiNjk2N2FkZDc0ZGNjODNiL3RhYmxlcmFuZ2U6MzAxYzU4YmQyYjI3NGE2MWI2OTY3YWRkNzRkY2M4M2JfMTEtNC0xLTEtMTg3Nw_0b5cb4b9-b805-4c86-a69d-595bdaffe7d9"
      unitRef="usd">2131000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger
      contextRef="ic6b8135fdb4c48c0a197d684b3bef8b9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTgwOQ_05de4854-adec-404f-972a-1ceac3ff5a0c"
      unitRef="number">1.30</us-gaap:DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger>
    <fold:DebtInstrumentsConvertibleThresholdTradingDays
      contextRef="i44debd31ac6748d0a90567edb19522f6_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTgxOA_074e3aa5-40b5-4b50-9324-36632e187b96">P20D</fold:DebtInstrumentsConvertibleThresholdTradingDays>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="ic6b8135fdb4c48c0a197d684b3bef8b9_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTgxNA_8d4802c0-0140-4522-ac0c-84f904e7603b"
      unitRef="day">30</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount
      contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTgyNA_c1a36763-9044-42dd-905d-ac4b11afe670"
      unitRef="usd">219300000</fold:DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount>
    <fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance
      contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NzQzMA_260a698c-0dd5-4db1-823f-e4a2c16e27be"
      unitRef="shares">39000000.0</fold:DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTg3NQ_dd3b03f6-622b-4056-8697-d22a038c068c"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <fold:DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NzQ1Nw_c3edef25-4151-4a94-a5be-3c4ac29dacc8"
      unitRef="usd">1000000.0</fold:DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest>
    <fold:GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NzQ4Ng_ec83c8af-9333-49e9-979d-14dab2833a81"
      unitRef="usd">190400000</fold:GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital>
    <fold:GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTg0NA_7888916e-8638-40e6-97ed-b395cc0eddca"
      unitRef="usd">400000</fold:GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NTkxNA_9976abf7-ed7b-4690-94ba-c5661cc65add"
      unitRef="usd">-36100000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NzQwMg_07f25940-3dac-4880-be72-8ebca00a7c84"
      unitRef="usd">14600000</fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt>
    <fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfODI0NjMzNzI0NzQwMg_b51394c2-cd4f-403c-86a6-230530bf6b95"
      unitRef="usd">14600000</fold:ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RleHRyZWdpb246NWYxMTIzNjBjMWM0NDhhN2EzN2NkOWJiMGUxY2UxNDRfNzA5MA_257a8583-0a43-416d-bf2b-cad01ee827c1">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table sets forth interest expense recognized related to the Company's debt for the three months ended March 31, 2020 and 2019, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:70.140%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.533%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.049%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.826%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:11.052%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contractual interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Amortization of deferred financing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOmRiODY5OTE3NDg1ZDQ1Y2RiZjY0ODNiYWI5NDExMzY0L3RhYmxlcmFuZ2U6ZGI4Njk5MTc0ODVkNDVjZGJmNjQ4M2JhYjk0MTEzNjRfMi0yLTEtMS0w_f90051bd-d381-4613-ada4-9775570d02c5"
      unitRef="usd">3585000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOmRiODY5OTE3NDg1ZDQ1Y2RiZjY0ODNiYWI5NDExMzY0L3RhYmxlcmFuZ2U6ZGI4Njk5MTc0ODVkNDVjZGJmNjQ4M2JhYjk0MTEzNjRfMi00LTEtMS0w_0592166e-6668-4e69-993d-7d877f9866dc"
      unitRef="usd">4813000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOmRiODY5OTE3NDg1ZDQ1Y2RiZjY0ODNiYWI5NDExMzY0L3RhYmxlcmFuZ2U6ZGI4Njk5MTc0ODVkNDVjZGJmNjQ4M2JhYjk0MTEzNjRfMy0yLTEtMS0w_67835fbf-b59d-40d4-96ca-6952bbeb0b5d"
      unitRef="usd">206000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOmRiODY5OTE3NDg1ZDQ1Y2RiZjY0ODNiYWI5NDExMzY0L3RhYmxlcmFuZ2U6ZGI4Njk5MTc0ODVkNDVjZGJmNjQ4M2JhYjk0MTEzNjRfMy00LTEtMS0w_8d4859f3-6a4a-4e97-ba46-f15731a0ca5c"
      unitRef="usd">1559000</us-gaap:AmortizationOfDebtDiscountPremium>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOmRiODY5OTE3NDg1ZDQ1Y2RiZjY0ODNiYWI5NDExMzY0L3RhYmxlcmFuZ2U6ZGI4Njk5MTc0ODVkNDVjZGJmNjQ4M2JhYjk0MTEzNjRfNC0yLTEtMS0w_3cfd38a5-c349-4e0c-9f83-cd9c8a89493d"
      unitRef="usd">25000</fold:AmortizationDeferredFinancingCosts>
    <fold:AmortizationDeferredFinancingCosts
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY182MS9mcmFnOjVmMTEyMzYwYzFjNDQ4YTdhMzdjZDliYjBlMWNlMTQ0L3RhYmxlOmRiODY5OTE3NDg1ZDQ1Y2RiZjY0ODNiYWI5NDExMzY0L3RhYmxlcmFuZ2U6ZGI4Njk5MTc0ODVkNDVjZGJmNjQ4M2JhYjk0MTEzNjRfNC00LTEtMS0w_c37a4188-c375-4a54-8ca1-2a3d913d5892"
      unitRef="usd">83000</fold:AmortizationDeferredFinancingCosts>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMjgzOA_41c66156-8d80-4333-a2a6-5f08d02434a3">Share-Based Compensation&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's Equity Incentive Plans consist of the Amended and Restated 2007 Equity Incentive Plan (the "Plan") and the 2007 Director Option Plan (the "2007 Director Plan"). The Plan provides for the granting of restricted stock units and options to purchase common stock in the Company to employees, directors, advisors, and consultants at a price to be determined by the Company's Board of Directors. The Plan is intended to encourage ownership of stock by employees and consultants of the Company and to provide additional incentives for them to promote the success of the Company's business. The 2007 Director Plan is intended to promote the recruiting and retention of highly qualified eligible directors and strengthen the commonality of interest between directors and stockholders by encouraging ownership of common stock of the Company. The Board of Directors, or its committee, is responsible for determining the individuals to be granted options, the number of options each individual will receive, the option price per share, and the exercise period of each option. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Stock Option Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;Expected life of options (years)&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected annual dividend per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;______________________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:15pt;"&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"&gt; The average expected life is determined using actual historical data. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the Company's stock options for the three months ended March 31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise&#160;&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Remaining &lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(968)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(355)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and unvested expected to vest, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;As of March 31, 2020, the total unrecognized compensation cost related to non-vested stock options granted was $42.8 million and is expected to be recognized over a weighted average period of three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Restricted Stock Units&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;and Performance-Based Restricted Stock Units (collectively "RSUs")&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;RSUs awarded under the Plan are generally subject to graded vesting and are contingent on an employee's continued service. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. A summary of non-vested RSU activity under the Plan for the three months ended March 31, 2020 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.029%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.384%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.569%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.384%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.569%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.384%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.569%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.465%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&#160;Shares&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted &lt;br/&gt;Average Grant  &lt;br/&gt;Date Fair  &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted&#160;&lt;br/&gt;Average&lt;br/&gt;Remaining&#160;&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-vested units as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-vested units as of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;All non-vested units are expected to vest over their normal term. As of March 31, 2020, there was $73.4 million of total unrecognized compensation cost related to unvested RSUs with service-based vesting conditions. These costs are expected to be recognized over a weighted average period of three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Compensation Expense Related to Equity Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity compensation expense recognized in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total equity compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMjgyOA_7a8148b7-fb05-4911-a6c7-e52ac5935af0">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The fair value of the stock options granted is estimated on the date of grant using a Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.792%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;74.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;div&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;"&gt;Expected life of options (years)&lt;/span&gt;&lt;sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.67&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expected annual dividend per share&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;______________________________&lt;/span&gt;&lt;/div&gt;(1) The average expected life is determined using actual historical data.</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfMi0xLTEtMS0w_eefd62d2-21b1-45ea-a99c-266a1401d6fb"
      unitRef="number">0.752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ibe7c67f71a114f90ae76db8af5fe4c45_D20190101-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfMi0zLTEtMS0w_a06fce9b-ebc1-4977-ae36-bbc4d88f2e18"
      unitRef="number">0.742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfMy0xLTEtMS0w_5b29e8ed-31f5-4a0a-82c2-676fed00f0cf"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ibe7c67f71a114f90ae76db8af5fe4c45_D20190101-20190331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfMy0zLTEtMS0w_d0a92e46-b1d9-4d5b-9100-191363697c0b"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfNC0xLTEtMS0w_0f80a3d6-80f2-44a4-8e1b-3265d3d9f6c8">P5Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ibe7c67f71a114f90ae76db8af5fe4c45_D20190101-20190331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfNC0zLTEtMS0w_5292e98e-ae6f-4b29-83ed-2875b44099fb">P5Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfNS0xLTEtMS0w_3aa0e066-09e4-4e22-8234-83ebe556867a"
      unitRef="usdPerShare">0</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare
      contextRef="ibe7c67f71a114f90ae76db8af5fe4c45_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjQzOTA1NmJiYThjOTQzMDc5ZDIzOWViMWQwNjUzYjA3L3RhYmxlcmFuZ2U6NDM5MDU2YmJhOGM5NDMwNzlkMjM5ZWIxZDA2NTNiMDdfNS0zLTEtMS0w_2860d561-a07f-4ad8-905b-cf2129aa6ce8"
      unitRef="usdPerShare">0</fold:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPerShare>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMjgzMA_9f99352e-16ee-4759-b167-dcdc2ce17ce9">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the Company's stock options for the three months ended March 31, 2020 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:44.852%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.741%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Exercise&#160;&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted Average Remaining &lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding, December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;16,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(968)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(355)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(259)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;13.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options outstanding, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested and unvested expected to vest, March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;17,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Exercisable at March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3357c282064f406dac5037a4c2b21d13_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfMi0xLTEtMS0w_df430cb9-a2fd-4644-bbfb-43cf0a95db0f"
      unitRef="shares">16724000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3357c282064f406dac5037a4c2b21d13_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfMi0zLTEtMS0w_3573c2bd-febb-4021-8a4b-484b6f63706f"
      unitRef="usdPerShare">9.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfMy0xLTEtMS0w_24ccacd1-bf03-4e90-a6f8-1a23d1369b33"
      unitRef="shares">3944000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfMy0zLTEtMS0w_dfe5c22f-4445-46e4-9dba-c9ae34b4cf52"
      unitRef="usdPerShare">9.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNC0xLTEtMS0w_dc89c84c-94ec-4e0e-a6e5-5d32ac71f9db"
      unitRef="shares">968000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNC0zLTEtMS0w_f61a4750-ae16-4c25-b92d-2712f63804e3"
      unitRef="usdPerShare">6.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNS0xLTEtMS0w_fdf645b9-3937-4e26-a98a-ca438bea5cd6"
      unitRef="shares">355000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNS0zLTEtMS0w_8370fe45-6e05-4b52-b763-a866912fee74"
      unitRef="usdPerShare">10.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNi0xLTEtMS0w_a4e1fcc2-a1d9-4c2a-815b-c2d55b48a587"
      unitRef="shares">259000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNi0zLTEtMS0w_c35d9e92-bd37-454f-96c4-6bf15553a7d6"
      unitRef="usdPerShare">13.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNy0xLTEtMS0w_1a20d2e7-c9c4-4436-b76e-69ad40280b6d"
      unitRef="shares">19086000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNy0zLTEtMS0w_2148bd22-ca59-4619-be53-0752d310dab3"
      unitRef="usdPerShare">9.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNy01LTEtMS0w_07b431ea-a9ee-4467-8a5e-9066297cec1d">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfNy03LTEtMS0w_1c08cb53-8cab-43f7-948e-e7aecbbc3caa"
      unitRef="usd">23500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOC0xLTEtMS0w_568883d0-64bf-4bc1-a8ce-2015d95e211e"
      unitRef="shares">17629000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOC0zLTEtMS0w_746f9897-c0e0-4c96-a9c4-9b38c15ddcab"
      unitRef="usdPerShare">9.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOC01LTEtMS0w_5fb009e3-0393-4fce-b381-4efb1000c086">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOC03LTEtMS0w_d2d7211e-a082-4bdc-be01-d7936ad99e2c"
      unitRef="usd">23400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOS0xLTEtMS0w_bcc93c4b-501c-4d34-ad46-1ea912ef8e81"
      unitRef="shares">10808000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOS0zLTEtMS0w_6c4e5a4b-436a-48ae-ad3b-cd5c3dc02ecd"
      unitRef="usdPerShare">8.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOS01LTEtMS0w_a556446a-d670-4090-922c-0be4dd557302">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmU0M2VmZjUwNzJlMjQyNDM5OTk0ZjZkZjBjYzc3NzQ5L3RhYmxlcmFuZ2U6ZTQzZWZmNTA3MmUyNDI0Mzk5OTRmNmRmMGNjNzc3NDlfOS03LTEtMS0w_b05db707-a4c2-4bb8-a691-006e8f6dc8d5"
      unitRef="usd">21400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i3b6358ff594f435b8c28ece99c733032_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMTYwMw_2acdcdf0-d4ee-4245-9ee8-e211753e502e"
      unitRef="usd">42800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="iefbade6a3ddf41debb536dbe5e907135_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMzg0ODI5MDcwMDI3OQ_e3ebdd5a-1953-421a-b0cf-30ffe2ad6455">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMjg1MQ_904474bf-5c0b-4558-8acd-d7c555994f2e">A summary of non-vested RSU activity under the Plan for the three months ended March 31, 2020 is as follows:&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.029%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:39.076%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.384%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.569%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.384%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.569%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.384%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.569%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:8.465%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Number&#160;of&#160;Shares&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted &lt;br/&gt;Average Grant  &lt;br/&gt;Date Fair  &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted&#160;&lt;br/&gt;Average&lt;br/&gt;Remaining&#160;&lt;br/&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-vested units as of December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(1,600)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;8.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;10.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Non-vested units as of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;69.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id011b45be10140f38519fd2adf3253d2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfMi0xLTEtMS0w_4cd8c5f2-fd2c-45f5-a663-cf434d434921"
      unitRef="shares">5792000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="id011b45be10140f38519fd2adf3253d2_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfMi0zLTEtMS0w_423b6eef-9832-4bfb-88ce-779a0fd46434"
      unitRef="usdPerShare">11.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfMy0xLTEtMS0w_460d0f7c-32c3-465e-9b0e-829d6beee274"
      unitRef="shares">3600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfMy0zLTEtMS0w_ccc2ffa8-26a7-413e-ae03-a652e78f7699"
      unitRef="usdPerShare">10.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNC0xLTEtMS0w_1bb347af-bb01-4e3e-81c8-ada271047c94"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNC0zLTEtMS0w_879be6be-893e-4d96-b329-4fa5d173b596"
      unitRef="usdPerShare">8.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNS0xLTEtMS0w_b5347ed2-d6f2-4a62-a2f3-3c9d177c75ed"
      unitRef="shares">230000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNS0zLTEtMS0w_57db7763-3488-462b-89d3-9291ddac34a3"
      unitRef="usdPerShare">10.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i086ab493f15f4e6680cd436cde171e07_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNi0xLTEtMS0w_6c9d1e8b-cb99-456b-afe9-be6a5f15c9cf"
      unitRef="shares">7562000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i086ab493f15f4e6680cd436cde171e07_I20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNi0zLTEtMS0w_da33bae7-5f45-440a-90a2-32c9a9e450fd"
      unitRef="usdPerShare">11.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNi01LTEtMS0w_82af1f4f-ae7b-41f6-8d23-8f66084e9b17">P2Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
      contextRef="i086ab493f15f4e6680cd436cde171e07_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOjVhZDhhYTc5NGRkNzRlMzI4YzdjNGFmNDQxNzBjYThiL3RhYmxlcmFuZ2U6NWFkOGFhNzk0ZGQ3NGUzMjhjN2M0YWY0NDE3MGNhOGJfNi03LTEtMS0w_9cad8159-49e3-4d26-aa41-2665bbf157a3"
      unitRef="usd">69900000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i086ab493f15f4e6680cd436cde171e07_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMzg0ODI5MDcwMDI4NQ_b2d06d45-53d7-4396-a639-0e68701e3811"
      unitRef="usd">73400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i16020fa576b847e0be1314bfb846de53_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMzg0ODI5MDcwMDMwMQ_8dfe4dbb-5ee9-474d-a6da-afe17dd7e05f">P3Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RleHRyZWdpb246NmZjNzliYzg4NDc0NDlkZTg3ZjQwMWUzZjk5OWQ4ZGRfMjgzNA_fbfac799-1332-4ae9-a9dd-b38c8a13b2a5">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table summarizes information related to compensation expense recognized in the Consolidated Statements of Operations related to the equity awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:12pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Equity compensation expense recognized in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Selling, general, and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total equity compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;12,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie57efb8719074ac89dbe8b6a28e6d637_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmFlNjZlOGIwNzg2NTQ5OGE5ZWQxZTM5MzhlY2VjYzU2L3RhYmxlcmFuZ2U6YWU2NmU4YjA3ODY1NDk4YTllZDFlMzkzOGVjZWNjNTZfMy0yLTEtMS0w_8da76768-7bcb-4897-adac-4d1eb2e20194"
      unitRef="usd">5253000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1bddcfce942349258e4cb92f5ce02164_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmFlNjZlOGIwNzg2NTQ5OGE5ZWQxZTM5MzhlY2VjYzU2L3RhYmxlcmFuZ2U6YWU2NmU4YjA3ODY1NDk4YTllZDFlMzkzOGVjZWNjNTZfMy00LTEtMS0w_c4cc99d1-85ce-45b0-9018-d98d108a4b59"
      unitRef="usd">5032000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib0c9afa9ca0b4b35bab63830db5c839b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmFlNjZlOGIwNzg2NTQ5OGE5ZWQxZTM5MzhlY2VjYzU2L3RhYmxlcmFuZ2U6YWU2NmU4YjA3ODY1NDk4YTllZDFlMzkzOGVjZWNjNTZfNC0yLTEtMS0w_7405b71b-5293-435c-8579-267cdcf85ee5"
      unitRef="usd">7343000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1dc1a4e6d9264abd9af1dd18a8a59526_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmFlNjZlOGIwNzg2NTQ5OGE5ZWQxZTM5MzhlY2VjYzU2L3RhYmxlcmFuZ2U6YWU2NmU4YjA3ODY1NDk4YTllZDFlMzkzOGVjZWNjNTZfNC00LTEtMS0w_59ecb9c5-db41-4b6d-8178-6be02e9b873e"
      unitRef="usd">7712000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmFlNjZlOGIwNzg2NTQ5OGE5ZWQxZTM5MzhlY2VjYzU2L3RhYmxlcmFuZ2U6YWU2NmU4YjA3ODY1NDk4YTllZDFlMzkzOGVjZWNjNTZfNS0yLTEtMS0w_9ddbdb44-6738-4e22-807f-782caf59de53"
      unitRef="usd">12596000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183MC9mcmFnOjZmYzc5YmM4ODQ3NDQ5ZGU4N2Y0MDFlM2Y5OTlkOGRkL3RhYmxlOmFlNjZlOGIwNzg2NTQ5OGE5ZWQxZTM5MzhlY2VjYzU2L3RhYmxlcmFuZ2U6YWU2NmU4YjA3ODY1NDk4YTllZDFlMzkzOGVjZWNjNTZfNS00LTEtMS0w_29e02b5f-41a7-470b-a7fc-425551702732"
      unitRef="usd">12744000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RleHRyZWdpb246MWUyYzhmMjE0MzQ4NGIyODkxODg4YTViOGM2YWVhMDBfNTYxNw_01811006-6a97-47b7-84b0-3c10ef37eb4d">Assets and Liabilities Measured at Fair Value&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's financial assets and liabilities are measured at fair value and classified within the fair value hierarchy, which is defined as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level 1&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2014; Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level 2&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2014; Inputs other than quoted prices in active markets that are observable for the asset or liability, either directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;"&gt;Level 3&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt; &#x2014; Inputs that are unobservable for the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of March 31, 2020 are identified in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;107,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;107,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;218,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;218,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.058%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.481%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.775%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.484%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2019 are identified in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;314,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;314,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.876%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.306%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.306%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.310%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's Convertible Notes fall into the Level 2 category within the fair value level hierarchy. The fair value was determined using broker quotes in a non-active market for valuation. The fair value of the Convertible Notes at March 31, 2020 was $4.7 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company's Senior Secured Term Loan fall into the Level 2 category within the fair value level hierarchy and the fair value was determined using quoted prices for similar liabilities in active markets, as well as inputs that are observable for the liability (other than quoted prices), such as interest rates that are observable at commonly quoted intervals. The carrying value of the Senior Secured Term Loan approximates the fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company did not have any Level 3 assets as of March 31, 2020 or December 31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Cash, Money Market Funds, and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Company classifies its cash within the fair value hierarchy as Level&#160;1 as these assets are valued using quoted prices in an active market for identical assets at the measurement date. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and the money market funds within the fair value hierarchy as Level&#160;2 primarily utilizing broker quotes in a non-active market for valuation of these securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Contingent Consideration Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The contingent consideration payable resulted from the acquisition of Callidus Biopharma, Inc. ("Callidus") in November 2013. The most recent valuation was determined using a probability weighted discounted cash flow valuation approach. Gains and losses are included in the Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The contingent consideration payable for Callidus has been classified as a Level 3 recurring liability as its valuation requires substantial judgment and estimation of factors that are not currently observable in the market.&#160;If different assumptions were used for the various inputs to the valuation approach, the estimated fair value could be significantly higher or lower than the fair value the Company determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.567%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.625%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.581%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.468%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.581%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.625%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.581%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.625%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.581%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.533%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent&#160;Consideration&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value as of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation&#160;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unobservable&#160;Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Clinical and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probability weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probability of achievement of milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75% - 78%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021 - 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Contingent consideration liabilities are remeasured to fair value each reporting period using discount rates, probabilities of payment, and projected payment dates. Projected contingent payment amounts related to clinical and regulatory based milestones are discounted back to the current period using a discounted cash flow model. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. There is no assurance that any of the conditions for the milestone payments will be met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table shows the change in the balance of contingent consideration payable for the three months ended March 31, 2020 and March 31, 2019, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Changes in fair value during the period, included in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustment for contingent consideration paid in stock &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(316)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;"&gt;Deferred Compensation Plan - Investment and Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The Deferred Compensation Plan (the "Deferral Plan") provides certain key employees and members of the Board of Directors with an opportunity to defer the receipt of such participant's base salary, bonus, and director's fees, as applicable. Deferral Plan assets are classified as trading securities and recorded at fair value with changes in the investment's fair value recognized in the period they occur. The asset investments consist of market exchanged mutual funds. The Company considers its investments in marketable securities as available-for-sale and classifies these assets and related liability within the fair value hierarchy as Level 2, primarily utilizing broker quotes in a non-active market for valuation of these securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RleHRyZWdpb246MWUyYzhmMjE0MzQ4NGIyODkxODg4YTViOGM2YWVhMDBfNTYxOA_57c2d3dd-83e8-43fa-b2a7-7129f1611ad1">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of March 31, 2020 are identified in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;35,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;68,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;107,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;107,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;218,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;218,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:12pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:58.058%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.481%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.775%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.484%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;3,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;26,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;A summary of the fair value of the Company's recurring assets and liabilities aggregated by the level in the fair value hierarchy within which those measurements fall as of December 31, 2019 are identified in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;73,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;77,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;145,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;U.S. government agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;11,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;314,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;314,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:6pt;"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:61.876%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.306%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.306%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:9.310%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent consideration payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Deferred compensation plan liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;4,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;27,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i69ecdce58c8e44a7b7446b787e6b5571_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfMi0yLTEtMS0w_ef703aff-c724-4ddf-bad9-c41648099ae4"
      unitRef="usd">35348000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i76dd233dc95c43edb284968ccf887232_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfMi00LTEtMS0w_af7e8dfc-676c-4ee5-aa84-b4d374e267b6"
      unitRef="usd">35348000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib14953c89ea842048d571e925165ae39_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfMy0yLTEtMS0w_4bed404c-81d2-4a8c-80f4-a8a0afe6344f"
      unitRef="usd">68795000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i79d9f3582ceb4f39b144041e9d62cd8f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfMy00LTEtMS0w_edd1eea0-8228-45dc-893a-1c423fb758c9"
      unitRef="usd">68795000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifd85987fc9fb44248ab3d5d19af0664e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNC0yLTEtMS0w_a455e2c3-8be6-4545-9e5c-78221150c971"
      unitRef="usd">107098000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic98cbd8bf78c4e479a4b68211ebe7595_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNC00LTEtMS0w_d901e0f3-3f42-4a9f-8e10-7971d99a55bd"
      unitRef="usd">107098000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9850e46e79c9490ca6d79c93c720720b_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNS0yLTEtMS0w_f381f781-1e22-423c-86db-4b982f054f30"
      unitRef="usd">4000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6e582d44c1854742ab6c8ed5ee290d43_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNS00LTEtMS0w_d37f4241-5a05-4f81-bde3-ea3e2dfb54d2"
      unitRef="usd">4000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if74e828956b7436da5162de1eb41377f_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNi0yLTEtMS0w_317ea01e-0ffe-45ba-8671-2280e7757d34"
      unitRef="usd">3378000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i14951a04eb4e4b7b9d35f47bed16e634_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNi00LTEtMS0w_cb2f79fa-edc3-4908-929c-d9628ea86066"
      unitRef="usd">3378000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i975aba94542c4c2988e78b6ee343ef08_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNy0yLTEtMS0w_2e89e1d4-5a84-4e65-9894-e7700d1f43d9"
      unitRef="usd">218619000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIyNDJlNjk2MzNlMDRiODU5NmU5OTMyMGIwODdhMmQ2L3RhYmxlcmFuZ2U6YjI0MmU2OTYzM2UwNGI4NTk2ZTk5MzIwYjA4N2EyZDZfNy00LTEtMS0w_410d3ca3-b717-4f66-9aae-16bd56e9d009"
      unitRef="usd">218619000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i975aba94542c4c2988e78b6ee343ef08_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfMi0yLTEtMS0w_a3c2e703-38bd-449d-8de4-e9f6205398b2"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4a2116def0d444d1b2c560065e4d05c1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfMi00LTEtMS0w_0399c9d7-3333-4c0d-96d0-bbe551663f20"
      unitRef="usd">23612000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfMi02LTEtMS0w_3822536a-fb74-4398-88cd-131b36ec9c6b"
      unitRef="usd">23612000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i975aba94542c4c2988e78b6ee343ef08_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfMy0yLTEtMS0w_dbc87e55-e15a-415d-bdc3-fea84a0d3c62"
      unitRef="usd">3055000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i4a2116def0d444d1b2c560065e4d05c1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfMy00LTEtMS0w_7a0caf99-b8d2-4e7d-a4fe-7746646716c6"
      unitRef="usd">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfMy02LTEtMS0w_36e28429-081b-4a13-8154-fb0d80614efd"
      unitRef="usd">3055000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i975aba94542c4c2988e78b6ee343ef08_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfNC0yLTEtMS0w_68861b7f-ed1b-4a7d-944e-9e64f4c58e8f"
      unitRef="usd">3055000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4a2116def0d444d1b2c560065e4d05c1_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfNC00LTEtMS0w_2e7b6a2e-1777-4606-8611-191435696f43"
      unitRef="usd">23612000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmIwYWI5MWQwNjNlODRhYjA4ZGEwMGI4MGVjYjlhY2MxL3RhYmxlcmFuZ2U6YjBhYjkxZDA2M2U4NGFiMDhkYTAwYjgwZWNiOWFjYzFfNC02LTEtMS0w_b2a5f13f-5cd9-4218-961d-6a32e8f5efcf"
      unitRef="usd">26667000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i41235f69acc344c2ab91f52c5639a874_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfMi0yLTEtMS0w_6a37de9f-8308-4fa7-a347-c895c6365d02"
      unitRef="usd">73710000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i69bfb02d155d46d7a1e1ec0c33f195ca_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfMi00LTEtMS0w_a56cff80-cdab-46a5-bf9e-c8354d2d3c76"
      unitRef="usd">73710000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i00deaed1957b488787cdaa82dc50e59b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfMy0yLTEtMS0w_fe5538af-4b8b-45ae-8d8e-b9454e264f76"
      unitRef="usd">77810000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i780f97fa745c46f2a97bd268ba15bc18_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfMy00LTEtMS0w_84bd759d-9420-4ec1-9fe8-95c3716151da"
      unitRef="usd">77810000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i65b648c925e740579dcae60193ae3051_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNC0yLTEtMS0w_dffdb00c-2b5a-445a-bb3a-856cbc33c1cb"
      unitRef="usd">145991000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7fa313342b3241bba30e7d90a90214b9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNC00LTEtMS0w_b3e0e405-8a15-4986-9b2b-f7dfbc32ed0d"
      unitRef="usd">145991000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib5ecdd9caab3473cb281d4bc13e0eca9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNS0yLTEtMS0w_7028d06f-7abc-4c04-a1b6-8110e39fce97"
      unitRef="usd">11991000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia1cd03431da34173829810953c60ca83_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNS00LTEtMS0xMzk0_c288d20e-ab55-4e39-a36c-0de56263a934"
      unitRef="usd">11991000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2e7a3776ad894ab5b362c7b3cf1a371c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNi0yLTEtMS0w_fc42ed4e-79c8-4080-937a-f1359ea8cba1"
      unitRef="usd">4768000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i87a274e586cf4c16a08587c4031550b4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNi00LTEtMS0w_ab5bc5f3-ea6d-4135-9342-7fab65889851"
      unitRef="usd">4768000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia1230a6c7511406892e2964d9334d607_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNy0yLTEtMS0w_3608c32d-ef4e-4c57-a75e-979a193a6123"
      unitRef="usd">314270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjhhMzAwN2VkZjViNzRkMDVhNDRkMGI4OTA3ODQ2MTEwL3RhYmxlcmFuZ2U6OGEzMDA3ZWRmNWI3NGQwNWE0NGQwYjg5MDc4NDYxMTBfNy00LTEtMS0w_ba333d2a-4879-4a9b-9b96-87ed3ae52458"
      unitRef="usd">314270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia1230a6c7511406892e2964d9334d607_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfMi0yLTEtMS0w_c770a46e-20d0-44c6-9e0f-7eb8e91365fd"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i55f9cd444bfc49af80a93225821ade9c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfMi00LTEtMS0w_e291a435-cca1-45d8-9a04-5c642e9a2264"
      unitRef="usd">22681000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfMi02LTEtMS0w_4b940054-7252-4c1a-b930-eae125903ef1"
      unitRef="usd">22681000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="ia1230a6c7511406892e2964d9334d607_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfMy0yLTEtMS0w_551bfa9a-7d1c-4046-9800-d05544a2f4ec"
      unitRef="usd">4419000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i55f9cd444bfc49af80a93225821ade9c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfMy00LTEtMS0w_9f80545a-4cea-40e4-b307-62a515b0d47f"
      unitRef="usd">0</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfMy02LTEtMS0w_1b9ef1be-acb4-430c-a0ac-265089d1fab5"
      unitRef="usd">4419000</us-gaap:DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia1230a6c7511406892e2964d9334d607_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfNC0yLTEtMS0w_cd60df51-7967-474a-9b10-b3fccaa4f032"
      unitRef="usd">4419000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i55f9cd444bfc49af80a93225821ade9c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfNC00LTEtMS0w_f2690a29-7575-4bac-85e7-867498aaad69"
      unitRef="usd">22681000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOjJlMjM3NDg2YjFmYzQ5NjZhZjE4NzgxZDNhMzkzY2ViL3RhYmxlcmFuZ2U6MmUyMzc0ODZiMWZjNDk2NmFmMTg3ODFkM2EzOTNjZWJfNC02LTEtMS0w_b251fc2d-9e83-4eaa-ae2e-9834933ee152"
      unitRef="usd">27100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ConvertibleDebtFairValueDisclosures
      contextRef="i975aba94542c4c2988e78b6ee343ef08_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RleHRyZWdpb246MWUyYzhmMjE0MzQ4NGIyODkxODg4YTViOGM2YWVhMDBfMTI0NQ_fe5b20bc-eef4-43af-855f-b6118ab58342"
      unitRef="usd">4700000</us-gaap:ConvertibleDebtFairValueDisclosures>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RleHRyZWdpb246MWUyYzhmMjE0MzQ4NGIyODkxODg4YTViOGM2YWVhMDBfNTYyMQ_7ccd3f27-0b5d-4b66-9594-cb12929a9be6">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following significant unobservable inputs were used in the valuation of the contingent consideration payable of Callidus for the ATB-200 Pompe program: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:93.567%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.625%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.581%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:13.468%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.581%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.625%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.581%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:18.625%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.581%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:17.533%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Contingent&#160;Consideration&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Fair Value as of March 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Valuation&#160;Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unobservable&#160;Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;9.4%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Clinical and regulatory milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:middle;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:middle;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probability weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Probability of achievement of milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;75% - 78%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:18pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Projected year of payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:center;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2021 - 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <fold:ContingentConsiderationMeasurementInput
      contextRef="ib43a922550c542ecb66e87e81bc9113b_I20200331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmU5MjEzNzRjOTZiZTRmZDQ5NzU4YTRjMjhhNTBmYWQyL3RhYmxlcmFuZ2U6ZTkyMTM3NGM5NmJlNGZkNDk3NThhNGMyOGE1MGZhZDJfMy04LTEtMS0w_af2ce1a8-e5eb-40bd-b7fa-a8312c78836d"
      unitRef="number">0.094</fold:ContingentConsiderationMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i44733de43da34221b7d954e41f00c039_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmU5MjEzNzRjOTZiZTRmZDQ5NzU4YTRjMjhhNTBmYWQyL3RhYmxlcmFuZ2U6ZTkyMTM3NGM5NmJlNGZkNDk3NThhNGMyOGE1MGZhZDJfNS0yLTEtMS0w_1f5ca1cc-62e4-4727-a869-1b1373e94317"
      unitRef="usd">22985000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RleHRyZWdpb246MWUyYzhmMjE0MzQ4NGIyODkxODg4YTViOGM2YWVhMDBfNTYyNw_9581939f-ca73-4e3b-8cec-9df11f1529bf">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table shows the change in the balance of contingent consideration payable for the three months ended March 31, 2020 and March 31, 2019, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;22,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Changes in fair value during the period, included in the Consolidated Statements of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;1,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Adjustment for contingent consideration paid in stock &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(316)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Balance, end of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;23,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;20,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i196c9221c6d643fdaa0ea733f27450c9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfMi0yLTEtMS0w_100c73c6-ffff-4d5e-af41-178438bffae2"
      unitRef="usd">22681000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="icab07bfc15ea4b0a9b2e3d5dfe987d2a_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfMi00LTEtMS0w_bac453c8-19f6-445f-9850-942f388d3a41"
      unitRef="usd">19700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfNC0yLTEtMS0w_3b0b7a16-4c7c-4028-ae9f-684ff0695812"
      unitRef="usd">-931000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfNC00LTEtMS0w_0e00226d-18dd-47d4-a167-c56193de086b"
      unitRef="usd">-1383000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <fold:ContingentConsiderationPaidInStockAdjustment
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfNS0yLTEtMS0w_ab2012f7-588b-4c97-8009-8e6c9adfcc69"
      unitRef="usd">0</fold:ContingentConsiderationPaidInStockAdjustment>
    <fold:ContingentConsiderationPaidInStockAdjustment
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfNS00LTEtMS0w_d23c1713-491e-4175-861c-243ccf40e4f9"
      unitRef="usd">-316000</fold:ContingentConsiderationPaidInStockAdjustment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3f47f80cc42645f4afb99b7ca72c39f8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfNi0yLTEtMS0w_ffe22b93-1352-4fcb-b020-6e70e188b2c3"
      unitRef="usd">23612000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia85c7d4cee774ba29ddedfa2ec518587_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY183My9mcmFnOjFlMmM4ZjIxNDM0ODRiMjg5MTg4OGE1YjhjNmFlYTAwL3RhYmxlOmY1NmE0ZWQxNTg1OTQxMGE4ZjgxNzg5ODUxZDAxOTRlL3RhYmxlcmFuZ2U6ZjU2YTRlZDE1ODU5NDEwYThmODE3ODk4NTFkMDE5NGVfNi00LTEtMS0w_09ae966e-9c78-4f20-9273-61f2f7c5e99d"
      unitRef="usd">20767000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RleHRyZWdpb246ZWZiYTIwNTc1YTRlNDUwNGEwYTE1ZDI5YTE2MmJiODBfNzMy_e8a05faf-0bc4-4365-9c2c-b3070a41cbf3">Basic and Diluted Net Loss per Common Share&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.568%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.481%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.483%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(88,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(120,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average common shares outstanding&#160;&#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;256,968,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;213,519,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs, and warrants for common stock equivalents.&#160;Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding warrants, convertible to common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RleHRyZWdpb246ZWZiYTIwNTc1YTRlNDUwNGEwYTE1ZDI5YTE2MmJiODBfNzI4_5e8d29c2-0e0e-46d6-aa13-3a3745b13c93">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.568%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.481%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.534%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.483%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(88,948)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(120,299)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Weighted average common shares outstanding&#160;&#x2014; basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;256,968,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;213,519,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjEwZDk0YTdiMDA0YzQxMTNhOTY5MmVkOGE3OTkwMWFlL3RhYmxlcmFuZ2U6MTBkOTRhN2IwMDRjNDExM2E5NjkyZWQ4YTc5OTAxYWVfMy0yLTEtMS0w_f2a176be-4499-4379-b40d-e7e500746d09"
      unitRef="usd">-88948000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjEwZDk0YTdiMDA0YzQxMTNhOTY5MmVkOGE3OTkwMWFlL3RhYmxlcmFuZ2U6MTBkOTRhN2IwMDRjNDExM2E5NjkyZWQ4YTc5OTAxYWVfMy00LTEtMS0w_94e82d8c-02ee-4739-b976-bf47dcd3a508"
      unitRef="usd">-120299000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjEwZDk0YTdiMDA0YzQxMTNhOTY5MmVkOGE3OTkwMWFlL3RhYmxlcmFuZ2U6MTBkOTRhN2IwMDRjNDExM2E5NjkyZWQ4YTc5OTAxYWVfNS0yLTEtMS0w_0e3b1d5d-9e82-4845-9439-7f823a1104fc"
      unitRef="shares">256968248</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjEwZDk0YTdiMDA0YzQxMTNhOTY5MmVkOGE3OTkwMWFlL3RhYmxlcmFuZ2U6MTBkOTRhN2IwMDRjNDExM2E5NjkyZWQ4YTc5OTAxYWVfNS00LTEtMS0w_36072e4a-ba19-4933-a774-fcda33e14f27"
      unitRef="shares">213519287</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RleHRyZWdpb246ZWZiYTIwNTc1YTRlNDUwNGEwYTE1ZDI5YTE2MmJiODBfNzM2_1395b538-9e39-4188-9119-f5d5bea87e17">&lt;div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"&gt;&lt;span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"&gt;The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;margin-bottom:15pt;"&gt;&lt;table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"&gt;&lt;tr&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:71.060%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.737%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:0.532%;"/&gt;&lt;td style="width:0.1%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;td style="width:10.739%;"/&gt;&lt;td style="width:1.0%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;td colspan="3" style="display:none;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;(in&#160;thousands)&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;19,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;18,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Convertible notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;5,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Outstanding warrants, convertible to common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;2,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;6,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;Total number of potentially issuable shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;29,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/&gt;&lt;td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;31,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"&gt;&lt;span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia053dc80670e4de08f203297971a38ee_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfMi0yLTEtMS0w_a0144aeb-7111-4ec9-bf56-58256543f79d"
      unitRef="shares">19086000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibd00e196fb5248c38c3a76f7e124b8ff_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfMi00LTEtMS0w_883dbcbb-b89c-4b78-81db-41dbd43f32c3"
      unitRef="shares">18331000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic483241cafdd4ff19dea8e3ded6ae7c9_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfMy0yLTEtMS0w_7074614a-aefe-4b46-92ae-e1d90a933e2b"
      unitRef="shares">462000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie9fe2af9630e470c8859c9adef1e1816_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfMy00LTEtMS0w_6d4a7d45-b5a0-40c6-ba39-94b1928a64d2"
      unitRef="shares">5017000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i208a59305dc0405a95804c555ac42287_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfNC0yLTEtMS0w_075f1557-6e6d-4e42-bbe6-0b74ecc911fc"
      unitRef="shares">2554000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2456a772e9a5467790859303b3e7e057_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfNC00LTEtMS0w_35d6f150-dbaf-4642-85be-a82c28679090"
      unitRef="shares">2554000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id8d7af76424f479fa3108e53610e4c9a_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfNS0yLTEtMS0w_f085e826-8afd-49ac-bc6c-9fdc560c88a6"
      unitRef="shares">7562000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i41dc54a86052461baed38b6ea6e9142a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfNS00LTEtMS0w_4980bdfb-3f22-4718-8949-7498a3f47dc1"
      unitRef="shares">6010000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i01fb21a8f0124a93b9f3ab260b56d28d_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfNy0yLTEtMS0w_ed4ed9e5-b412-4eb3-8dd8-25da1347e1e4"
      unitRef="shares">29664000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7bc85b6348df4edfb7ceaa7fd48590ac_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjM3YTYxNzc4MTczODQwZmM4MTFkNTY3ZDg2MjRjZmFjL3NlYzozN2E2MTc3ODE3Mzg0MGZjODExZDU2N2Q4NjI0Y2ZhY184Mi9mcmFnOmVmYmEyMDU3NWE0ZTQ1MDRhMGExNWQyOWExNjJiYjgwL3RhYmxlOjIxNDk3ZmY1Y2EwMTRhNjc4ODJhODA1ZTRlY2VmYTM2L3RhYmxlcmFuZ2U6MjE0OTdmZjVjYTAxNGE2Nzg4MmE4MDVlNGVjZWZhMzZfNy00LTEtMS0w_0350b0dd-266b-435e-92fd-eec0fad722f3"
      unitRef="shares">31912000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6837609984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 5,322<span></span>
</td>
<td class="nump">$ 6,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">3,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">4,609<span></span>
</td>
<td class="nump">3,837<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">12,831<span></span>
</td>
<td class="nump">14,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Reserve for inventory</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6634982272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (1,857,558)<span></span>
</td>
<td class="num">$ (1,768,610)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6774848496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of liability components of long term debt</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company's debt consists of the following: </span></div><div style="text-align:center;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.208%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.662%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.664%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Senior Secured Term Loan due 2023:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">150,000&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Less: debt discount </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,142)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,315)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Less: deferred financing </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(289)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(311)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net carrying value of the Senior Secured Term Loan</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">147,569&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">147,374&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="height:14pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-align:justify;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Convertible Notes due 2023 </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;vertical-align:top;">(2)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">:</span></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td><td style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Principal</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,825&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,825&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Less: debt discount </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(625)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(659)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-left:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Less: deferred financing </span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(33)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(35)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net carrying value of the Convertible Notes</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,167&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"/></span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,131&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">______________________________</span></div><div style="text-align:justify;margin-top:3pt;"><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;vertical-align:top;">(1)</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;"> Included in the Consolidated Balance Sheets within Convertible Notes and Senior Secured Term Loan and amortized to interest expense over the remaining life of the Convertible Notes and Senior Secured Term Loan using the effective interest rate method.</span></div>(2) The Convertible Notes are currently convertible as the last reported sale price of the Company's common stock was equal to or more than 130% of the conversion price for at least 20 trading days of the 30 consecutive trading days ending on the last day of the quarter.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Components of total interest expense</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table sets forth interest expense recognized related to the Company's debt for the three months ended March 31, 2020 and 2019, respectively:</span></div><div style="text-align:center;margin-bottom:12pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:70.140%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.049%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.826%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:11.052%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contractual interest expense</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,585&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,813&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of debt discount</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">206&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,559&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of deferred financing</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">83&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6730524544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (88,948)<span></span>
</td>
<td class="num">$ (120,299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average common shares outstanding - basic and diluted (in shares)</a></td>
<td class="nump">256,968,248<span></span>
</td>
<td class="nump">213,519,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">29,664,000<span></span>
</td>
<td class="nump">31,912,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_EmployeeAndDirectorsStockOptionsMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">19,086,000<span></span>
</td>
<td class="nump">18,331,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">462,000<span></span>
</td>
<td class="nump">5,017,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Outstanding warrants, convertible to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">2,554,000<span></span>
</td>
<td class="nump">2,554,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">7,562,000<span></span>
</td>
<td class="nump">6,010,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6640812208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of reconciliation of the numerator and denominator used in computing basic and diluted net loss per common share</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:71.568%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.481%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.483%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(88,948)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(120,299)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">256,968,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">213,519,287&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method</a></td>
<td class="text"><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,331&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible notes</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">462&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding warrants, convertible to common stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,554&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,554&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,010&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,664&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,912&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615795760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories for the period</a></td>
<td class="text">The following table summarizes the components of inventories: <table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.648%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,544&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,660&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,831&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,041&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6767995616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 123,231,000<span></span>
</td>
<td class="nump">$ 142,837,000<span></span>
</td>
<td class="nump">$ 96,349,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">215,642,000<span></span>
</td>
<td class="nump">309,903,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesRealizedGainLoss', window );">Realized gain (loss) on debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair value of available-for-sale debt securities in unrealized loss positions</a></td>
<td class="nump">99,500,000<span></span>
</td>
<td class="nump">42,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">2,662,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,579,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash shown in the Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 125,893,000<span></span>
</td>
<td class="nump">$ 146,341,000<span></span>
</td>
<td class="nump">$ 98,928,000<span></span>
</td>
<td class="nump">$ 82,375,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>98</ContextCount>
  <ElementCount>315</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>37</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2107103 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2111104 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2114105 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119106 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2126107 - Disclosure - Assets and Liabilities Measured at Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2130108 - Disclosure - Basic and Diluted Net Loss per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCash</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2312303 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Inventories</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2315304 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/Debt</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2320305 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/ShareBasedCompensation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2327306 - Disclosure - Assets and Liabilities Measured at Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueTables</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValue</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2331307 - Disclosure - Basic and Diluted Net Loss per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShare</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DescriptionofBusinessDetails</Role>
      <ShortName>Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/DescriptionofBusiness</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashComponentsDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/CashCashEquivalentsMarketableSecuritiesandRestrictedCashAdditionalInformationDetails</Role>
      <ShortName>Cash, Cash Equivalents, Marketable Securities, and Restricted Cash - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/InventoriesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2416406 - Disclosure - Debt - Summary of Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtSummaryofLongTermDebtDetails</Role>
      <ShortName>Debt - Summary of Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2417407 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/DebtInterestExpenseDetails</Role>
      <ShortName>Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2421409 - Disclosure - Share-Based Compensation - Weighted-average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationWeightedaverageAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Weighted-average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2422410 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2423411 - Disclosure - Share-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2424412 - Disclosure - Share-Based Compensation - RSUs and PBRSUs Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationRSUsandPBRSUsSummaryDetails</Role>
      <ShortName>Share-Based Compensation - RSUs and PBRSUs Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2425413 - Disclosure - Share-Based Compensation - Expense Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/ShareBasedCompensationExpenseSummaryDetails</Role>
      <ShortName>Share-Based Compensation - Expense Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2428414 - Disclosure - Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueComponentsbyHierarchyLevelDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Components by Hierarchy Level (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2429415 - Disclosure - Assets and Liabilities Measured at Fair Value - Level 3 Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/AssetsandLiabilitiesMeasuredatFairValueLevel3RollforwardDetails</Role>
      <ShortName>Assets and Liabilities Measured at Fair Value - Level 3 Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="fold-20200331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2432416 - Disclosure - Basic and Diluted Net Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareDetails</Role>
      <ShortName>Basic and Diluted Net Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.amicustherapeutics.com/role/BasicandDilutedNetLossperCommonShareTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="fold-20200331.htm">fold-20200331.htm</File>
    <File>exhibit101.htm</File>
    <File>exhibit102.htm</File>
    <File>fold-03312020xex311.htm</File>
    <File>fold-03312020xex312.htm</File>
    <File>fold-03312020xex321.htm</File>
    <File>fold-20200331.xsd</File>
    <File>fold-20200331_cal.xml</File>
    <File>fold-20200331_def.xml</File>
    <File>fold-20200331_lab.xml</File>
    <File>fold-20200331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6789839152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 123,231<span></span>
</td>
<td class="nump">$ 142,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments in marketable securities</a></td>
<td class="nump">215,642<span></span>
</td>
<td class="nump">309,903<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">40,555<span></span>
</td>
<td class="nump">33,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">12,831<span></span>
</td>
<td class="nump">14,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">15,690<span></span>
</td>
<td class="nump">20,008<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">407,949<span></span>
</td>
<td class="nump">520,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, less accumulated amortization of $6,260 and $5,342 at March 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">32,501<span></span>
</td>
<td class="nump">33,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, less accumulated depreciation of $19,260 and $17,604 at March 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">47,688<span></span>
</td>
<td class="nump">47,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">In-process research&#160;&amp; development</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">197,797<span></span>
</td>
<td class="nump">197,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">29,414<span></span>
</td>
<td class="nump">28,317<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">738,349<span></span>
</td>
<td class="nump">850,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">16,239<span></span>
</td>
<td class="nump">21,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">66,722<span></span>
</td>
<td class="nump">98,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent', window );">Deferred reimbursements</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">7,503<span></span>
</td>
<td class="nump">7,189<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">91,714<span></span>
</td>
<td class="nump">128,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent', window );">Deferred reimbursements</a></td>
<td class="nump">8,906<span></span>
</td>
<td class="nump">8,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible notes</a></td>
<td class="nump">2,167<span></span>
</td>
<td class="nump">2,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuredLongTermDebt', window );">Senior secured term loan</a></td>
<td class="nump">147,569<span></span>
</td>
<td class="nump">147,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration payable</a></td>
<td class="nump">23,612<span></span>
</td>
<td class="nump">22,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">5,051<span></span>
</td>
<td class="nump">5,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">52,522<span></span>
</td>
<td class="nump">53,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">4,214<span></span>
</td>
<td class="nump">5,296<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">335,755<span></span>
</td>
<td class="nump">373,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 500,000,000 shares authorized, 257,449,955 and 255,417,869 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">2,607<span></span>
</td>
<td class="nump">2,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">2,238,346<span></span>
</td>
<td class="nump">2,227,225<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract', window );"><strong>Accumulated other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">6,981<span></span>
</td>
<td class="nump">2,785<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized (loss) gain on available-for-sale securities</a></td>
<td class="num">(169)<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants</a></td>
<td class="nump">12,387<span></span>
</td>
<td class="nump">12,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,857,558)<span></span>
</td>
<td class="num">(1,768,610)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">402,594<span></span>
</td>
<td class="nump">476,425<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 738,349<span></span>
</td>
<td class="nump">$ 850,207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=116690757&amp;loc=SL116692626-108610<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income during the current period and current obligations not separately disclosed in the balance sheet (other liabilities, current).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income after one year or beyond the normal operating cycle, if longer and noncurrent obligations not separately disclosed in the balance sheet (other liabilities, noncurrent).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuredLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuredLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6782990928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, tax expense (benefit)</a></td>
<td class="nump">$ 1,536<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Available-for-sale securities, tax expense (benefit)</a></td>
<td class="num">$ (56)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6633033904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Basic and Diluted Net Loss per Common Share</a></td>
<td class="text">Basic and Diluted Net Loss per Common Share<div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss attributable to common stockholders per common share:</span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.561%;"><tr><td style="width:1.0%;"/><td style="width:71.568%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.481%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.534%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.483%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands,&#160;except&#160;per&#160;share amounts)&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net loss attributable to common stockholders</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(88,948)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(120,299)</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:6.75pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Weighted average common shares outstanding&#160;&#8212; basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">256,968,248&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">213,519,287&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Dilutive common stock equivalents would include the dilutive effect of common stock options, convertible debt units, RSUs, and warrants for common stock equivalents.&#160;Potentially dilutive common stock equivalents were excluded from the diluted earnings per share denominator for all periods because of their anti-dilutive effect.</span></div><div style="text-indent:18pt;text-align:justify;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The table below presents potential shares of common stock that were excluded from the computation as they were anti-dilutive using the treasury stock method:</span></div><div style="text-align:justify;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.853%;"><tr><td style="width:1.0%;"/><td style="width:71.060%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.737%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.532%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:10.739%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">As of March 31,</span></td><td colspan="3" style="display:none;"/><td colspan="3" style="display:none;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in&#160;thousands)&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,086&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">18,331&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Convertible notes</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">462&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,017&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Outstanding warrants, convertible to common stock</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,554&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,554&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Unvested restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,562&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,010&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total number of potentially issuable shares</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,664&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,912&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6774784576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="text-indent:18pt;text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Inventories consist of raw materials, work-in-process, and finished goods related to the manufacture of Galafold</span><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;vertical-align:top;">&#174;</sup><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">. The following table summarizes the components of inventories: </span></div><div style="text-align:center;margin-bottom:15pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:99.707%;"><tr><td style="width:1.0%;"/><td style="width:67.648%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.809%;"/><td style="width:1.0%;"/><td style="width:0.1%;"/><td style="width:0.533%;"/><td style="width:0.1%;"/><td style="width:1.0%;"/><td style="width:12.077%;"/><td style="width:1.0%;"/></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(in thousands)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,322&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,544&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Work-in-process</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,900&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,660&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,609&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#cceeff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,837&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#cceeff;text-align:right;vertical-align:bottom;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><span style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,831&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td><td colspan="3" style="background-color:#ffffff;text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"/><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">14,041&#160;</span></td><td style="padding-top:2px;padding-bottom:2px;background-color:#ffffff;text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><span style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</span></td></tr></table></div>The Company recorded a reserve for inventory of $0.2 million as of March 31, 2020 and December 31, 2019.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6633155280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Assets and Liabilities Measured at Fair Value - Level 3 Rollforward (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of the period</a></td>
<td class="nump">$ 22,681<span></span>
</td>
<td class="nump">$ 19,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value during the period, included in the Consolidated Statements of Operations</a></td>
<td class="nump">931<span></span>
</td>
<td class="nump">1,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ContingentConsiderationPaidInStockAdjustment', window );">Adjustment for contingent consideration paid in stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of the period</a></td>
<td class="nump">$ 23,612<span></span>
</td>
<td class="nump">$ 20,767<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ContingentConsiderationPaidInStockAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration Paid In Stock, Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ContingentConsiderationPaidInStockAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6716556640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands, shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount', window );">Exchange agreement, aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 219,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance', window );">Shares authorized for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest', window );">Exchange agreement, accrued and unpaid interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital', window );">Gain (loss) on extinguishment of debt, additional paid-in capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued', window );">Gain (loss) on extinguishment of debt, fair value of common shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on exchange of convertible debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">36,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt', window );">Proceeds from termination of capped call confirmations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Exchange Agreement, Accrued And Unpaid Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Exchange Agreement, Aggregate Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible Debt, Exchange Agreement, Shares Authorized For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Extinguishment Of Debt, Additional Paid-In Capital</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Extinguishment Of Debt, Fair Value Of Common Shares Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Capped Call Confirmations, Exchange Of Convertible Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">fold_ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>fold_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6630163024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs</a></td>
<td class="nump">$ 42.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units | Stock Option Plan Amended Restated 2007 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized compensation costs</a></td>
<td class="nump">$ 73.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation costs, period for recognition (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=fold_EmployeeAndDirectorsStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=fold_StockOptionPlanAmendedRestated2007EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
